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Abstract 
Background 
Studies which have sought to explore the associations between diabetes and cancer have produced 
heterogeneous results and there is a paucity of evidence related to glycated haemoglobin (HbA1C) 
and cancer risk.  
 
Methods 
Initial analyses utilised data from the Health Survey for England (HSE) and SHeS combined linked to 
mortality and Cancer Registry data (n=204,533, including 7,199 with diabetes)  to explore the 
associations between diabetes, HbA1C and cancer incidence and mortality. Additional analyses used 
linked Whitehall I data (n= 19,019, including 237 with diabetes). Odds Ratios (ORs), Hazard Ratios 
and 95% Confidence Intervals (CI) were estimated adjusted for a range of confounding factors using 
logistic, multinomial and Cox regression.  
 
Results 
18,310 deaths occurred within the HSE/SHeS follow-up period (4,997 from cancer). The adjusted OR 
for cancer among those with diabetes was 1.27, CI 1.12-1.43.  Raised HbA1C was associated with an 
excess risk of dying/developing cancer; diabetes and HbA1C were associated with a number of site-
specific cancers. When analyses were stratified by cardiovascular disease (CVD) baseline status, only 
those with diabetes who did not report CVD had a statistically significant excess in cancer mortality 
(adjusted OR: 1.27, 1.08-1.48). There were also sex differences in cancer incidence and mortality 
risk. 
81% of Whitehall I participants died during follow-up (including 4,076 from cancer). These results did 
not replicate the initial analyses in finding no association between diabetes and cancer mortality -
this is likely to relate to the age of the two cohorts and the differences in CVD mortality and 
incidence. 
Conclusion 
The association of diabetes and HbA1C with increased cancer incidence and mortality was not 
consistent across studies or population groups. Differences in risk by sex and CVD status suggest the 
need for health professionals to tailor services to take account of the individual circumstances of 
their diabetic patients. 
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1. Chapter 1: Introduction 
1.1 Diabetes and cancer: diseases of increasing public health concern 
In both developed and developing countries, diabetes is now being viewed as an emerging and 
serious public health issue. Zimmet concluded that diabetes was a major threat to public health 
currently and that, for an approach to successfully reduce the morbidity and mortality caused by 
diabetes, it would need to be focussed upon producing change in behaviour at an individual and 
societal level.(1) 
The financial cost to the NHS of each disease is increasing: 10% of the total NHS budget, and 9% of 
hospital budgets, are being spent on diabetes, (2,3) In the year 2010/2011 the direct costs of 
diabetes were £9.8 billion, with this figure expected to increase to 16.9 billion in 2035/2036.(4) The 
Cancer Reform Strategy (2007) stated that the NHS spent £4.35 billion a year on treating individuals 
with cancer, and that this amounted to over 5% of NHS spending.(5) In total 15% of the NHS budget 
is currently spent on treating the two diseases, with this figure expected to rise as incidence of the 
two diseases increases. A report by Livestrong and the American Cancer Society put the global cost, 
in terms of the economic value of the Disability Adjusted Life Years (DALY’s) lost due to diabetes, at 
around $204 billion, while for cancer the figure was $895 billion; diabetes ranked fifth while cancer 
ranked first in terms of their cost in this respect.(6)  
Diabetes and cancer are having a growing impact upon both the health of individuals, in terms of 
mortality and morbidity, and placing an increasing financial burden upon health care systems. If an 
association were found between diabetes and cancer, then an increased prevalence of the former 
would impact upon the financial cost of the latter. Supporting this is the growing amount of 
evidence which suggests a causal relationship between diabetes and cancer incidence and mortality. 
Because of the number of individuals with diabetes, if diabetes were found to be the cause of only a 
small percentage increase in the incidence of cancer, this could amount to a large number of cases 
nationally and internationally. There is also a clear need for a better understanding of the link 
between the two diseases in order to enable the prevention of cancers attributable to diabetes. If an 
association were to be found between the two diseases, this would also enable evidence-based 
public health messages to be developed in order to facilitate increased awareness of the factors 
related to diabetes which impact upon an individual’s risk of developing cancer. 
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1.2 Diabetes and cancer: background to the current study 
There is a growing body of epidemiological evidence which has investigated the associations 
between diabetes and incidence of and mortality from cancer. Within such studies there is 
heterogeneity of results related to: 
 the methods used within the study, 
 the population under investigation,  
 the method used to identify the diabetic cohort, 
 the end-point under investigation (for example cancer incidence, cancer mortality, all-
cancers or site-specific cancers).  
There is also a limited amount of evidence related to whether raised glycated haemoglobin, both 
among those with and without diagnosed diabetes, increases an individual’s risk of developing or 
dying from cancer. The issue of whether or not any associations between glycated haemoglobin and 
cancer relate to over-all cancer incidence and mortality or particular site-specific cancers also 
requires further investigation. 
A number of the factors related to diabetes (such as adiposity) have also been linked to cancer 
outcomes; the role that these confounding factors may play within the associations between 
diabetes  and cancer has yet to be conclusively assessed.  
1.3 Diabetes Mellitus 
Diabetes mellitus is a chronic and progressive condition which currently has no cure.  The term is 
used to describe a number of conditions, which have different clinical outcomes and aetiologies, 
related to hyperglycaemia (elevated blood glucose)(7). Although the disorder has traditionally been 
classified into three different forms (type-1, type-2 and gestational)  although commentators such 
Tuomi et al. argue that type-1 and type-2 diabetes are likely to represent only two extreme points 
along a spectrum of diabetic conditions.(8) Further to this a number of commentators have argued 
that diabetes mellitus should be regarded as a syndrome rather than a specific disease.(9) Within the 
following section type-1, type-2, gestational, Maturity Onset Diabetes of the Young and, because of 
their similarities with diabetes, pre-diabetes and the metabolic, are detailed. 
 
Within this thesis diabetes mellitus will be referred to as ‘diabetes’. The term will relate to type-1 
and type-2 diabetes; when the discussion includes gestational diabetes this will be made clear. For a 
lay definition of diabetes please turn to Appendix Two. 
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1.3.1 Classification and diagnosis of diabetes 
In the body of a non-diabetic individual, insulin is created in the β-cells islets of Langerhans within 
the pancreas and the hormone controls the level of glucose in the blood to within very narrow 
physiological boundaries. There also occurs a cyclical process within which the β-cells and the insulin 
sensitive tissue found within the liver, muscles and adipose tissue interact with each other in order 
to supply the required amount of insulin.(7) Within the body of an individual with diabetes, 
deficiencies within insulin secretion and reduced responses to insulin, within insulin sensitive tissue, 
produce hyperglycaemia. Both may occur within the diabetic body and it is often difficult to clearly 
understand which is the primary cause of the subsequent hyperglycaemia is.(10)  
There are a number of different measurements used to test the level of glucose within the blood. 
Currently the World Health Organization supports the measuring of glycated haemoglobin (HbA1C) 
as an appropriate method for diagnosing diabetes at an individual level.(11) Glycated haemoglobin is 
used as a measure of plasma glucose concentration over a two to three month period. An HbA1C 
measurements of 48mmol/mol (6.5%) or above is currently considered indicative of the presence of 
diabetes; measurements below this level have the potential to conceal the condition and could be 
followed up with further blood tests (such as a fasting plasma glucose or oral glucose tolerance test 
(GTT)).(12) Impaired Fasting Glucose (IFG), also known as pre-diabetes, occurs when blood glucose 
level are raised, but not at a level considered indicative of the presence of diabetes. An HbA1C level 
between 6.1% and 6.49% is currently used to diagnose IFG (IFG is discussed in more detail 
below).(13) Among those with diagnosed diabetes the American Diabetes Association suggests an 
HbA1C level of 7.0% as optimal for reducing the risk of microvascular and macrovascular 
complications, although they further suggest that the characteristics of the individual should be 
considered when agreeing the level.(14) Current NICE recommendations are that, for those with 
type-2 diabetes and taking one glucose lowering drug, an HbA1C of 6.5% should be aimed for. While 
for those taking two or more glucose lowering oral medication or those on insulin the target should 
be 7.5%.(15) 
1.3.2 Type-1 diabetes 
Type-1 diabetes (also referred to as insulin-dependent diabetes or juvenile onset-diabetes) usually 
occurs in childhood and accounts for around 10% of all cases of diabetes.(16) Globally, diagnosed 
type-1 diabetes in children is increasing by around 3% annually.(17)  Although the causes of this are 
not fully understood, contributing factors may relate to the interplay between genes and the 
environment, and to better diagnosis of the disease within countries that previously did not 
undertake service provision.(17,18)  Individuals with type-1 diabetes have an excess in mortality at 
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every age, with some estimates placing it at five to ten times higher.(19)  This excess in mortality is 
related primarily to the metabolic complications caused by type-1 diabetes, which result in increased 
rates of cardiovascular and renal disease.(20) 
In an individual with type-1 diabetes, an autoimmune response destroys the β-cells within the 
pancreas and leaves the body deficient of insulin.(21) Type-1 diabetes is characterised by a rapid 
increase in glucose in the blood and severe symptoms which, if left untreated, would almost 
certainly result in death. Individuals with this form of the disease must therefore take exogenous 
insulin in order to prevent ketoacidosis, a life threatening complication characterised by acidic 
ketones and glucose in blood and urine.(22) Within type-1 diabetes, the rate at which β-cells are 
destroyed can vary, but it usually occurs more rapidly in children with this form of the disease than 
adults. Adults with this form of the disease may continue to produce limited amounts of insulin for a 
number of years before levels are reduced enough that they require insulin to prevent 
ketoacidosis.(10) 
Among those who are 10 years old or younger, autoantibody-positive, normal weight and present 
with ketoacidosis, the diagnosis of type-1 diabetes is often clear-cut, although ketoacidosis is 
present in nearly 20% of young people with type-2 diabetes.(8) The diagnosis of type-1 diabetes 
among adults is more complex, as they may still have residual insulin production, although the 
presence of autoantibodies may assist in this regard. 
1.3.3 Type-2 diabetes 
Type-2 diabetes accounts for around 90% of all cases of diabetes mellitus.(16) The condition is 
characterised by either decreased β-cell production of insulin or decreased insulin sensitivity within 
peripheral tissue.(21) This reduction in insulin sensitivity, otherwise referred to as insulin resistance, 
is characterised by tissue in the body being less responsive to insulin in terms of uptake of glucose. 
Within the bodies of those with type-2 diabetes the ‘feedback loop’ also malfunctions.(7) The result 
is that the body cannot compensate for reduced insulin sensitivity with increased insulin production. 
Initial treatment of type-2 diabetes includes changes in lifestyle behaviours followed by the 
introduction of hypoglycaemic medications. Insulin may be introduced to treat the condition; within 
the UK, this occurs on average 10-15 years after diagnosis.(23)  
Type-2 diabetes was traditionally, almost exclusively, found among adults (hence also being referred 
to as adult-onset diabetes) but with rising rates of obesity in the young, children are now being 
diagnosed with the disease in increasing numbers. A report by Diabetes UK in 2005 found that all the 
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reported cases of type-2 diabetes in the UK among children had been among those who were 
overweight.(24) Even though there have been observed increases in the incidence of type-2 diabetes 
in childhood, the disease is still predominantly age related and therefore relatively rare among 
children. Age is also strongly associated with the risk of developing the disease. Data from the Health 
Survey for England 2009 showed that prevalence of doctor-diagnosed diabetes increased with age, 
from a low of <1% within the youngest adults (16-34) to a high of 19.5% of men and 12.7% of 
women aged 75 years and older.(25) By 2011, up to one in 12 adults overall in England were thought 
to live with the disease (either diagnosed or undiagnosed); this figure increased to one in four men 
and one in five women aged 75 and over.(26) 
1.3.4 Gestational diabetes 
During pregnancy, a woman’s body creates a certain amount of insulin resistance in order to enable 
the delivery of nutrients to the foetus via the placenta.(27) Gestational diabetes develops when the 
body is unable to produce enough insulin to control glucose levels in the body. Prevalence of 
gestational diabetes varies by location; a literature review focussed upon developed countries found 
that prevalence ranged from 1.7-11.6%.(28) Risk factors for gestational diabetes include being 
overweight or obese, increased age at pregnancy, previous gestational diabetes, a family history of 
the disease and having given birth to a high weight baby in the past (possibly indicating undiagnosed 
gestational diabetes).(29,30) Gestational diabetes may also be indicative of previously undiagnosed 
type-2 diabetes and has been found to increase the risk of type-2 diabetes later in life.(31) Women 
who have gestational diabetes are at an increased risk of requiring a caesarean section, delivering 
early or needing to be induced. Further to this, the babies of women with diabetes are at an 
increased risk of dying before birth and once born, being high weight or having neonatal 
complications.(32,33) 
 
1.3.5 Maturity Onset Diabetes of the Young 
Although the majority of cases of diabetes are currently diagnosed as type-1, type-2 or gestational, 
there are several forms of diabetes which are related to monogenetic defects within the function of 
the β-cells. These defects are thought to account for around 1-2% of all cases of diabetes. Referred 
to as Maturity-Onset Diabetes of the Young (MODY), this form of diabetes is often diagnosed during 
young adulthood and is characterised by hyperglycaemia caused by deficits within insulin 
secretion.(34) Differentiating between MODY and type-1 and type-2 diabetes is complicated by the 
fact that they all share similar characteristics clinically. 
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1.3.6 Pre-diabetes and the metabolic syndrome 
If type-1 and type-2 diabetes are the two extremes along a spectrum of diseases, then pre-diabetes 
(also referred to as Impaired Fasting Glucose or Impaired Glucose Tolerance) is considered the 
precursor for type-2 diabetes. It is found within individuals who have increased blood glucose levels 
that are not at a high enough level to warrant a diagnosis of diabetes, but are raised compared with 
those who are normoglycaemic.(35) If changes in behaviour and lifestyle are not made, individuals 
with pre-diabetes are at increased risk of their condition progressing and developing into type-2 
diabetes, as well as at an increased risk for cardiovascular complications.(36)  
Similarly to pre-diabetes, the metabolic syndrome is a group of factors related to insulin resistance 
which increase an individual’s risk of getting type-2 diabetes; it also increases their risk of other 
diseases associated with atherosclerosis.(37) Although a single definition of the syndrome is 
controversial and its clinical utility has not been agreed,(38,39) the World Health Organisation 
(WHO) define the syndrome as the presence of glucose intolerance, Impaired Glucose Tolerance 
(IGT) or diabetes mellitus and/or insulin resistance together with at least two of the following:  
 Insulin resistance (under hyperinsulinaemic, euglycaemic conditions, glucose uptake below 
lowest quartile for background population under investigation), 
 Raised arterial pressure ≥140/90 mmHg, 
 Raised plasma triglycerides (≥1.7 mmol l–1; 150 mg/dl) and/or low HDL–cholesterol (< 0.9 
mmol/l, 35 mg/dl men; < 1.0 mmol/l, 39 mg/dl women), 
 Central obesity (males: waist to hip ratio > 0.90; females: waist to hip ratio > 0.85) and/or 
BMI > 30 kg/m2, 
 Microalbuminuria (urinary albumin excretion rate ≥ 20 μg/mg/min or albumin: creatinine 
ratio³ 30 mg/g).(40) 
 The National Cholesterol Education Program (NCEP)’s Adult Treatment Panel (ATP) III report also 
identified six factors related to the metabolic syndrome that increase an individual’s risk of 
developing cardiovascular disease: abdominal adiposity, dyslipidaemia, high blood pressure, insulin 
resistance and/or glucose intolerance, inflammation and being prothrombotic.(41)  
1.3.7 Incidence and prevalence of the metabolic syndrome and diabetes 
There is no single definition of the metabolic syndrome and, as discussed in the previous section, a 
number of different definitions have been used. This has resulted in a wide range of estimates in 
relation to the prevalence of the syndrome; with some commentators suggesting that a significant 
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proportion of the population meet the criteria for the condition. For example, eight pooled studies 
in Europe found that among men and women aged 40-55, 7-36% and 5-22% respectively could be 
considered to have the condition.(42) Results from NHANES 1999-2006 indicated that, within the US, 
age-adjusted prevalence of the metabolic syndrome was increasing and stood at 34.2% (± 0.7%).(43)  
Globally it is estimated that 347 million individuals are currently living with diabetes mellitus, with 
this figure expected to rise to 552 million by 2030.(44,45) The World Health Organization estimates 
that around 3.4 million deaths occur per year as a result of hyperglycaemia,(45) while 2010 study 
estimated that 3.96 million deaths were caused by diabetes in 2010.(46) The large number of 
individuals with diabetes means that if the disease contributes even a small percentage increase in 
mortality, this would result in large numbers of deaths. 
Information gathered between April 2011 and March 2012 in England as part of the Quality and 
Outcomes Framework (QOF) indicated that, among those over 16 years of age, around 2.5 million 
individuals had diagnosed diabetes, equating to a prevalence of 5.8%.(47) In England around 23% of 
those with diabetes are thought to be undiagnosed,(48) equating to a further 850,000 individuals in 
the UK living with diabetes who are either undiagnosed or unregistered.(16) Prevalence of 
diagnosed diabetes within the other countries of the UK was: 4% within Northern Ireland(49), 4.4% 
within Scotland(50) and 5.3% within Wales.(51) The APHO Diabetes Projection Model estimated that 
by 2025 five million individuals will be living with diabetes in the UK.(52) In terms of incidence, the 
latest estimates suggest that around 145,000 individuals are diagnosed with diabetes each year.(53) 
Although the prevalence of type-1 and type-2 diabetes is increasing, the pattern and cause of the 
increase differs. Incidence trends analysis utilising Europe-wide data suggest that the former is 
increasing by around 3.9% (95% CI 3.5-4.2) each year(54); globally, type-1 diabetes increased by 
3.4% (95% CI 2.7-4.3).(17) The cause of these increases remains unclear, although contributing 
factors are thought to relate to the interaction between the environment and genes, and to 
improvements in the monitoring and diagnosis of the disease within some countries.(55) The 
increase in type 2 diabetes is thought to relate to an ageing of the population and rapid increases in 
overweight/obesity.(56) Hart et al. estimated that around 60% of cases of diabetes could be 
prevented if the population were to maintain a normal weight.(57) 
1.4 Cancer 
The causes of cancer are complex, interlinked and include an individual’s genetic predisposition to 
the disease, their age and lifestyle behaviours.(58,59) Analyses by Doll and Peto, carried out in the 
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1980s, suggested that around half of all cancers could be prevented by changes in lifestyle 
(particularly in relation to smoking).(60)  
 There are over 200 different types of cancer, each with its own aetiology, incidence and mortality 
rate. In England around 275,00 individuals were diagnosed with the disease in 2011.(61) Among 
men, the three most common incident cancers are prostate, lung and colorectum (accounting for 
53% of all cancers diagnosed among men within England).(61) For women the three most commonly 
diagnosed cancers are those of the breast, lung and colorectum. Within both sexes these three 
cancers accounted for around 53% of all diagnosed cancers in 2011. 
Of the 139,951 recorded cancer deaths in England and Wales in 2011, over half (56%) were from 
cancers of the lung, colorectum, breast, prostate, pancreas and oesophagus (Table 1-1 details the 
number of deaths from these site-specific cancers and the total number of cancer deaths in 2011). 
2008 data indicates that there were 12.7 million new cases of cancer globally and 7.6 million 
deaths.(62) 
Table 1-1: Six most common causes of site-specific cancer mortality, England and Wales 
Cancer Site Sex  
Male Female Total 
Lung 16,881 13,267 30,148 
Colorectum 7,578 6,428 14,006 
Breast 69 10,328 10,397 
Prostate 9,671 0 9,671 
Pancreas 3,748 3,686 7,434 
Oesophagus 4,488 2,147 6,635 
TOTAL 42,435 35,856 78,291 
All deaths from 
cancer 
73,709 66,242 139,951 
a
 This information is taken from ONS data for 2011.(63)  
 
1.5 A brief overview of the epidemiological evidence related to the 
associations between diabetes and cancer  
The earliest documents to mention either diabetes or cancer came from Egypt around 1600BC. As 
early as 1885, Freund(64) had begun to document the presence of hyperglycaemia within cancer 
patients. This was followed by the work of Tuffier(65) which sought to explore a potential correlation 
between diabetes and cancer. Maynard, who undertook analysis of cancer death rates within the 
United States, found that a key limitation of research within this area was the inconsistent recording 
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of deaths caused by cancer or diabetes. Despite this, he reported a correlation between the two 
diseases.(66)  
The discovery of insulin by Banting and Best(67) in the laboratories of JJR Macleod in 1921, and its 
purification for use as a treatment for type-1 diabetes by James Collip, enabled increases in life 
expectancy among those with the disease that had been inconceivable in the preceding years; up to 
this point life expectancy was between one and two years from diagnosis.(68) Cancer being a 
disease positively correlated with age(69), intuitively it would be expected that an increase in life 
expectancy would bring about a corresponding increase in cancer incidence and mortality among 
those with diabetes. The work of Joslin et al. supported this conclusion; they found that in 1900 
(before the introduction of insulin) the incidence of cancer among diabetics was 1.5%, while in 1940 
(after the introduction of insulin) the figure was 8.9%.(70) However, other researchers found no 
increase in site-specific cancers among diabetic cohorts(71); such varied conclusions may elicit more 
about the different methods of research, than the actual rates of cancer among those with diabetes. 
An extensive review of the literature relating to the relationship between diabetes and cancer by 
Kessler(72) in 1971 concluded that studies undertaken using clinical evidence were likely to show a 
positive relationship between diabetes and cancer, while those that used autopsy data showed a 
negative relationship. He also found that studies which used a measure of proportionate mortality 
from cancer (comparing a diabetic sub-group with the general population) supported a negative 
relationship between diabetes and cancer; this was in all cancers other than pancreatic which was 
consistently found at higher rates among those with diabetes. 
The 1980s began to see studies investigating the link between diabetes and cancer that were 
methodologically more rigorous than those undertaken previously. It was also at this time that 
studies began to focus more upon specific cancer sites and their link to diabetes. However, some of 
these studies still suffered from methodological problems, particularly: 
 sample sizes that lacked the power to derive statistically significant conclusions about the 
association between diabetes and cancer or were dependent on relatively unreliable data 
sources(73,74), 
 a lack of assessment of the role of confounding factors(75), 
 a small number of concurrent cases of diabetes and site-specific cancers, and/or  
 utilised study populations from homogenous populations (such as patient information from 
a single hospital).(76) 
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These weaknesses within the studies may partially explain why, in relation to cancer mortality, some 
found mortality rates similar to those within the general population,(20,77) while others 
demonstrated an increase(78–80) or decrease(81,82) among people with diabetes. These studies are 
discussed in full in the literature review (Chapter 2); the following section gives a brief overview of 
the key pieces of research (post-1980) that explored the associations between diabetes and cancer. 
A study using the American Cancer Society Prevention Study II cohort investigated the risk of cancer 
mortality among those with diabetes. The study was one of the largest to specifically investigate the 
risk of cancer mortality among diabetics (the cohort included 467,992 men and 588,321 
women).(83) The study found no increased mortality risk for a number of cancers including for men 
those of the oesophagus (RR=1.20, CI 0.94-1.53), stomach (RR=0.99, CI 0.77-1.27) and kidney 
(RR=0.82, CI 0.61-1.10) and for women those of the stomach (RR=1.25, CI 0.90-1.73), liver (RR=1.37, 
CI 0.94-2.0) and kidney (RR=1.12, CI 0.80-1.58). The study also investigated the role BMI might play 
within the relationship between diabetes and cancer mortality and found that it had little impact. 
A 2010 meta-analysis and systematic review undertaken in Japan sought to explore whether those 
with diabetes had an increased risk of cancer compared with non-diabetics.(84) After adjustment for 
confounding factors, the meta-analysis of five studies found an increased risk that was significant for 
diabetic men (RR= 1.25, 95% CI = 1.06-1.46) but not for diabetic women (RR 1.23, 95% CI 0.97-1.56). 
This point is noteworthy in that a second study undertaken in Japan found the reverse: only women 
with diabetes were at an increased risk of cancer.(85) Within their systematic review the former 
researchers found consensus across studies - none of the studies included found a decreased risk of 
cancer among diabetic patients compared with non-diabetics. Although the meta-analysis utilised a 
large data-set of just over 250,000 individuals there are a number of issues in terms of extrapolating 
its findings to a wider population. All the studies were undertaken in Japan and although the 
aetiology and pathophysiology of diabetes is likely to be the same globally, the population of Japan is 
very demographically homogenous compared with the UK and so the results may not be the same 
for these different populations.  
The Emerging Risk Factors Collaboration (ERFC) study analysed pooled data from 97 prospective 
studies (including >800,000 participants) and found increased cancer mortality among those with 
diabetes (hazard ratio (HR) 1.25, 95% CI 1.19-1.31).(86) A 2008 systematic review and meta-analysis 
also found an increased risk of cancer mortality among those with diabetes (HR 1.41, 95% CI 1.28-
1.55) compared with those without the disease.(87) Studies focussed upon site-specific cancers also 
demonstrate differences in mortality risk among those with diabetes(78,88,89); the most consistent 
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results are related to site-specific cancers of the pancreas, but whether this is due to reverse 
causality is still uncertain.(90) Evidence also demonstrates increased risks for bladder, liver and 
breast cancer mortality.(83) Analysis of Whitehall I data found significant associations between 
diabetes and pancreatic and liver cancer, but none of the other 13 cancers analysed.(89) Chia et al. 
found that women with diabetes subsequently diagnosed with endometrial cancer experienced a 
70% increase in all-cause mortality but not mortality from endometrial cancer.(91) There are also 
mixed findings related to cancer incidence (all-cause and site-specific).(92,93)  
Recent investigations related to the biological plausibility between diabetes and cancer have 
focussed upon hyperglycaemia, hyperinsulinaemia, the use of diabetes related drugs and/or 
exogenous insulin, although a definitive pathway has yet to be established.(94–97)  
The uncertainty surrounding the epidemiological associations between diabetes and cancer 
incidence and mortality (as well as the impact that confounding factors have upon the associations), 
in terms of all-cause and site-specific incidence and mortality, suggests the need for further research 
which utilises nationally representative data to explore the associations further.  
Chapter one concludes with an outline of the rest of the thesis. 
 
 
1.6 Outline of thesis 
The thesis consists of 12 chapters, detailed below. 
 
Chapter One 
The introduction introduces why diabetes and cancer are increasingly being viewed as diseases of 
public health concern. Chapter One also gives an overview of the study aims, the background to the 
study and information concerning the aetiology, diagnosis, prevalence and consequences (in terms 
of morbidity and mortality) of diabetes and cancer. The chapter concludes with a brief overview of 
the current epidemiological evidence in relation to an association between diabetes and cancer. 
 
Chapter Two 
The focus of the literature review in Chapter Two is to explore the research related to the 
associations between diabetes and cancer. The review also details previous investigations of the 
confounding factors within, and biological plausibility of, the potential associations between the two 
diseases. The chapter also details the gaps in our current knowledge in terms of the associations 
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between diabetes and cancer and how this information has been used to develop the research 
questions, hypotheses and aims of the current study. 
 
Chapter Three 
The chapter introduces the Health Survey for England, Scottish Health Survey and Whitehall I data. 
The methods used to ensure variable conformity, link the datasets and identify a number of cohorts 
within the data are also addressed. 
 
Chapter Four 
Chapter Four explores the data issues that were encountered within the analyses and the methods 
used to analyse the data in relation to diabetes and cancer incidence and mortality. 
 
Chapters Five to Eleven 
Within these chapters the results of the analyses are explored. Chapter Five details the associations 
between diabetes and cancer incidence. Chapter Six includes the results related to HbA1C and cancer 
incidence. Chapter Seven is focussed upon diabetes and cause-specific mortality, with a particular 
focus upon cancer. Chapter Eight details the findings related to diabetes and site-specific cancer 
mortality. Chapter Nine examines the impact HbA1C has upon mortality. Chapter Ten examines the 
impact that diabetes and glycated haemoglobin have upon all-cause mortality and Chapter 11 details 
the results of the analyses of Whitehall I. 
 
Chapter Twelve 
A detailed discussion of the results is given in Chapter Twelve. The chapter is divided into sections 
related to diabetes and HbA1C and incidence of and mortality from cancer, as well as mortality from 
other causes. The thesis draws to a close with the conclusions that can be drawn from the research 
study overall and implications for further research. 
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2. Chapter 2: Literature review 
2.1 Methods  
The aim of the literature review was to identify the literature related to the associations between 
diabetes, HbA1C and cancer and amalgamate the results. This would enable clarity in relation to the 
current evidence, and identification of gaps in knowledge, which would then facilitate the 
formulation of the study’s research aims, objectives and hypotheses.  
 
2.1.1 Literature review: research questions 
The literature review had a number of overarching questions within it. Primarily, it sought to answer 
a number of questions related to what evidence exists: 
 
 in relation to the associations between diabetes and cancer mortality 
 to support a link between diabetes and overall cancer incidence, 
 in terms of a link between diabetes and site-specific cancer incidence and mortality, 
 that supports an association between glycated haemoglobin and incidence of and mortality 
from cancer, 
 that indicates the impact that confounding factors (such as obesity and comorbidities) have 
upon the associations between diabetes and/or glycated haemoglobin and cancer incidence 
and mortality. 
 
In order to answer these questions the framework for causality proposed by Bradford-Hill(98) was 
utilised and this elicited further questions: 
 
 Is there homogeneity (consistency and coherence) within epidemiological study results 
related to diabetes/glycated haemoglobin and cancer incidence and mortality? If so, what is 
the strength of the association? 
 Is diabetes associated with mortality from other causes? Although the evidence related to 
an association between diabetes and CVD is strong, what evidence exists for diseases of the 
respiratory system and other causes of death? Within the Bradford-Hill criteria it was 
suggested that the evidence related to rubella increases the robustness of the results related 
to the possibility that other viral diseases during pregnancy affect foetal outcomes. In the 
same way, if diabetes were to impact upon mortality from and incidence of other diseases, 
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this could be used as evidence with which to support the associations between diabetes and 
an increased risk of cancer incidence and mortality. 
 What does current research advance as the biologically plausible pathways between 
diabetes and incidence of and mortality from cancer and other causes? 
 Is there evidence of reverse-causality within any of the associations? 
 Within the associations between glycated haemoglobin and cancer (incidence and 
mortality), is there a dose-response effect? 
 
An initial broad search within Pubmed (www.ncbi.nlm.nih.gov/pubmed/) using the words “cancer” 
and “diabetes” elicited 15,052 articles. A similar search of Google Scholar produced >2.5 million hits, 
while a search of the terms ‘diabetes and cancer mortality’ and ‘diabetes and cancer incidence’ both 
generated around 1.5 million hits. In order to check the sensitivity of the Pubmed search strategy, 
the first twenty pages of each of these were reviewed for relevant literature.  
 
2.1.2 Literature review: inclusion/exclusion criteria 
A number of criteria were used to assess a study’s suitability for inclusion within the literature 
review. These were: 
 If two studies utilised the same dataset or sample, the earlier study was excluded from the 
review.  
 If a study detailed the excess mortality of a diabetic cohort but did not specifically analyse 
one of the outcomes of interest for this study (all-cause, cause-specific, site-specific 
mortality or all-cause cancer or site-specific cancer incidence) compared with the general 
population, or other specified control group, reports without an appropriate comparison 
group were excluded. 
 A study was excluded if it did not give point estimate information about the association or 
precision of their measurement, such as 95% Confidence intervals (CI) or p-values. 
Analysis of the titles and abstracts of the studies found within the initial search elicited a further 
question: 
 What evidence exists of a relationship between treatments for diabetes and cancer 
incidence? 
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Using the inclusion criteria above, studies were then moved into a number of categories depending 
upon their focus. Studies which sought to explore the biological plausibility of a link between 
diabetes and cancer, those which investigated diabetes treatments and their link to cancer, and 
those specifically focussed upon other confounding factors (such as overweight and obesity) were 
also selected from the initial list. Similarly to the initial search of the broad terms of ‘diabetes’ and 
‘cancer’, secondary searches of Google Scholar were undertaken. Table 2-1 below gives information 
about these categories and the number of hits produced by each Pubmed search term and the 
number of studies that remained after an initial sift of the titles and abstracts. (ordered in 
descending order). Reference and author searches were also undertaken after each stage of the 
search process and relevant articles were added to the total number of hits so that their titles and 
abstracts could be sifted through. 
 
Table 2-1: Search categories within the literature review 
Category No. of total hits No. after 
title/abstract 
sifting 
“Diabetes” and “cardiovascular”a and “disease” 2,745 84 
“Diabetes” and “cancer” 1,141 71 
“Diabetes” and “all-cause mortality” 453 65 
“Diabetes” and “cancer mortality” 247 57 
“Metabolic syndrome”b and “cancer” 140 23 
“Diabetes” and “cancer incidence” 95 43 
“Obesity”c and “cancer” 73 41 
“Insulin” or “hyperglycaemia” and “cancer” 60 27 
“Glycated haemoglobin” and “mortality” 52 21 
“Diabetes treatment” and “cancer” 43 27 
“Glycated haemoglobin” and “cancer” 36 12 
“Diabetes” and “respiratory” and “disease” 27 4 
a
 Searches within this category also included the terms “heart disease” “stroke” “CHD” “CVD” and “Ischaemic 
heart disease”. 
b 
The results in this section of the table also include those for searches using the terms “metabolism” and 
“fasting glucose”. 
c
 The results given also include those for searches utilising the terms “BMI” “overweight” and “adiposity”. 
 
 
Articles within each of these categories were then separated out (using title, abstract and article) 
into 1) highly relevant, 2) possibly relevant and 3) unlikely to be relevant. Articles within categories 
one and two were then considered for inclusion within the literature review; they were also moved 
to category 3, at this stage, if found not to be relevant. This left  57 articles that included information 
about the associations between diabetes and overall cancer incidence and/or mortality  (but not a 
specific cancer type) which have been used for the literature review section focussed upon 
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associations between diabetes and cancer in general. There were over 80 articles that included 
information about diabetes and mortality from all-causes and causes other than cancer and these 
have also been used to inform the appropriate sections of the literature review. 
 
Articles were also selected, and moved into separate categories, if they focussed upon the 
associations between diabetes and site-specific cancers. The table below (Table 2-2) lists the cancers 
for which papers were found (the table is ordered in descending order by the number of studies 
found). As above, studies were included in the literature review if they met the inclusion criteria and 
were relevant to the literature review. 
 
Table 2-2: Site-specific search categories within the literature review 
Category Number of 
studies found 
No. after 
title/abstract 
sifting 
“Diabetes” and “pancreas” and “cancer” 195 22 
“Diabetes” and “breast” and “cancer” 138 12 
“Diabetes” and (“colorectal” OR “bowel” OR “rectum” OR 
“colon”) and “cancer” 
121 19 
“Diabetes” and (“endometrial” OR “womb” “uterus”) and 
“cancer” 
107 7 
“Diabetes” and “prostate” and “cancer” 102 10 
“Diabetes” and (“liver” OR “hepatocellular”) and “cancer” 77 14 
“Diabetes” and (“gastrointestinal” OR “gastric” OR “stomach”) 
and “cancer” 
27 9 
“Diabetes” and “bladder” “cancer” 25 12 
“Diabetes” and (“kidney” OR “renal”) and “cancer” 17 9 
“Diabetes” and “lung” and “cancer 13 4 
“Diabetes” and “non-Hodgkins lymphoma” 11 7 
“Diabetes” and “oral” and “cancer” 11 3 
“Diabetes” and “ovarian” and “cancer” 7 2 
“Diabetes” and (“haematopoietic” OR “leukaemia”) and 
“cancer” 
3 3 
“Diabetes” and (“skin” OR “melanoma”) and “cancer” 1 1 
 
 
The associations between diabetes and some site-specific cancers were explored within studies 
looking at a number of site-specific cancers simultaneously, but were not the primary focus of a 
single study. These cancers, although not included in the table above, were included within the 
literature review (as long as the studies met the inclusion criteria). In total around 90 studies were 
used to support the sections of the literature review related to diabetes and site-specific cancer 
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incidence and mortality. Around 30 studies were also used to garner information about the 
associations between diabetes treatments and cancer risk. 
 
The literature searches undertaken above highlighted the fact that the majority of studies either did 
not focus upon type-1 diabetes specifically, or did not differentiate between type-1 diabetes and 
cancer. Because of this a separate search of the literature in this area was undertaken within 
PubMed and Google Scholar. Searches utilised the terms “diabetes”, “type 1 diabetes”, “insulin 
treated diabetes mellitus” “IDDM”, “early onset diabetes”, “juvenile onset”, “young onset”, or  
“type-1 diabetes mellitus” “T1DM”,  and “cancer”, “neoplasm”, “malignancy”, “incidence” or 
“mortality”. The references cited within each article were then reviewed in order to elicit further 
relevant articles. Although a meta-analysis was considered, it became apparent that the diversity of 
endpoints (all-cause and cause-specific incidence and mortality), and the heterogeneity of findings 
and of study cohorts would make this method inappropriate. Therefore a narrative review was 
undertaken, plus a visual display of the findings of each included study. 
 
A large number of reports detailed evidence relating to the excess all-cause mortality experienced by 
those with type-1 diabetes; the references for these reports were also reviewed. Studies were 
excluded in instances when they did not analyse the two different types of diabetes separately, or 
when it was unclear which type of diabetes was under analysis. The only instances where studies of 
this nature have been included in the review is when the focus of the study was upon insulin use and 
the age group of the cohort was young enough to be composed mainly of those with type-1 
diabetes. In total 1,736 hits were produced within the searches, with 43 full-text reviews being 
undertaken which resulted in 22 studies being included within the review. For a discussion of the 
results of this literature search see Section 0. 
 
The literature review begins with an exploration of the evidence related to the associations between 
diabetes, HbA1C and related factors and cancer incidence and mortality. As mentioned previously, 
studies were also included in the literature review if they focussed upon diabetes and all-cause and 
non-cancer cause-specific mortality; epidemiological studies of this nature are discussed at the end 
of the chapter.   
 
The literature review was updated throughout the PhD to take into consideration new research; the 
most recent update took place at the end of November, 2013. 
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2.2 Epidemiological evidence: associations between diabetes and cancer 
(1880s-present) 
The first part of the literature review has been split into three time periods: 
 the pre-insulin era, 
 the insulin era, 
 studies undertaken after 1980.  
For the third section, the year 1980 was chosen because it was during this time-period that studies 
began to utilise methodologically more rigorous techniques than had previously been employed. For 
example, studies begun to use a range of data sources to confirm the presence of diabetes and 
incidence of and mortality from cancer. 
 
2.2.1 The pre-insulin era 
It was not until the 1920s that Warburg introduced the idea that tumour cells may have higher rates 
of glucose utilisation than normal cells and that they produce more lactic acid.(99) Even before the 
first use of insulin to treat diabetes mellitus in 1922, and a clear understanding of the pathologies of 
diabetes and cancer had been developed, researchers had begun exploring the potential link 
between diabetes and cancer. In 1885, Freund documented hyperglycaemia in cancer patients and 
as early as 1888(64), Tuffier begun to explore the correlation between the two diseases.(65) His 
research devised a framework which sought to address the following three interrelated research 
questions: 1) how diabetes might affect the incidence of cancer; 2) how diabetes might affect the 
course of a case of cancer; and 3) how cancer might affect the course of diabetes. Following his 
study, he further concluded that diabetes was the antecedent, followed by an incident cancer. 
 
In the early part of the twentieth century, large increases in mortality from both cancer and diabetes 
were reported. Increases in cancer mortality continued throughout the first half of the 20th century, 
with a consensus being formed that this was due, to a certain extent, to improved diagnosis of 
cancer as a cause of death and recognition of it within medical records.(66) One of the key 
limitations of research, undertaken within this period, which sought to explore the link between 
diabetes and cancer was that the recording of deaths caused by either disease were often 
inconsistent. Maynard undertook a statistical study reporting cancer death rates using data from the 
United States and concluded that although he was presenting results, he was aware that the use of 
death-rates could result in result errors and false conclusions.(66) Despite this, he reported both a 
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marked increase in cancer and diabetes death rates and a correlation between cancer and diabetes 
which required further analysis. 
 
2.2.2 The insulin era (1920s-1970s) 
Although a number of studies were undertaken between the introduction of insulin and 1980, they 
were often methodologically flawed, making it difficult for statistically rigorous conclusions to be 
drawn. This also resulted in inconsistent findings, with some studies finding strong positive 
correlations between the two diseases and others finding similarly strong negatives ones. 
 
The discovery of insulin in 1921,(67) and its use as a treatment for diabetes, enabled increases in life 
expectancy among those with diabetes. As was mentioned in chapter one, the increase in life 
expectancy was associated with a corresponding increase in cancer incidence and mortality among 
diabetics: the incidence of cancer among this group was 1.5% in 1900 but 8.9% in 1940.(70)  
Marble used detailed mortality data from the Metropolitan Life Insurance Company, taken from the 
George F. Baker Clinic in Boston.(100) He found an increased rate of cancer among his diabetic group 
of 256 cases in 10,000 diabetics. Marble acknowledged that his findings should be treated with 
caution and that, by only investigating cases among those attending hospital, he may have biased 
the results.  
 
A 1940 study by Kruger, using 5,844 autopsies between 1934 and 1938, sought to examine the 
occurrence of cancer and diabetes combined.(101) Within the study population 731 cases of cancer 
were found, ten within those with concurrent diabetes (n=122). The pathological, anatomical and 
medical histories of the cases did not allow the researcher to further analyse why the diseases 
occurred together at this rate. Further to this, he found no links between severity of the metabolic 
disorder and that of the cancer and concluded that severe diabetes may actually be linked to having 
a less severe tumour - what he referred to as the ‘cancer-inhibiting tendency’ of diabetes and the 
‘diabetes-inhibiting’ tendency of cancer. Kruger stated that: 
 
 “an explanation of the infrequent co-occurrence of cancer and diabetes is provided by the 
metabolic change that takes place when either of these diseases develops, creating 
unfavourable conditions for the development of the other disease.”(101, p12) 
 
Kruger went on to postulate that, although the small sample size did not allow for the drawing of 
any general conclusions, it did appear that the two conditions together did not lead to increased 
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morbidity or earlier mortality, and did not increase the chances of metastases. As mentioned 
previously, the small number of concurrent diabetes and cancer cases makes this research merely 
indicative of an association between the two diseases. 
 
Jacobson (1948) was cautious about the use of hospital data within this area of research because he 
believed that diabetics utilising hospital services would not be representative of those within the 
general population. He postulated this was because: 
 
“a) these diabetics may be different from others who are not under care by the very fact that 
they are under care and (b) some of the diabetics found to have cancer may have sought care 
because the coexistence of the latter condition aggravated the diabetic symptoms.”(102, p.91) 
 
Further to this, Berkson in his article Limitations of the Application of the Fourfold Table Analysis to 
Hospital Data illustrated that the use of hospital data to explore correlations between diseases could 
overemphasise the correlation(103); the crux of his argument was that the more diseases a patient 
had, the more likely each disease’s symptoms would be to be noted by the patient and make the 
patient attend hospital. The result would be an over-correlation within the hospital population that 
did not match that found in the general population. Berkson noted that: 
 
“its effect would be to increase relatively the representation of multiple diagnoses in the 
hospital, and in general to increase the discrepancy between hospital and parent population” 
(103, p.50) 
 
Jacobson also concluded that “death certificates are probably not yet sufficiently complete to 
warrant critical studies of associated causes of death solely on the basis of data from death 
certificates.”(102, p.97) Despite this, the work of Jacobson is of particular note because he 
undertook a number of studies, using a variety of data sources, in order to explore the link between 
diabetes and cancer. He was also one of the first researchers to use health survey data (questions 
were asked of family members in relation to their health and key socioeconomic factors in a way 
similar to the Health Survey for England and Scottish Health Survey data used within this thesis) to 
explore the potential link between diabetes and cancer. He also agreed with the earlier work of 
Tuffier in concluding that an individual’s diabetes preceded the development of cancer, and not vice 
versa. Table 2-3 gives an overview of his key pieces of research and the conclusions that he drew. 
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Table 2-3: The research of Jacobson in relation to diabetes and cancer 
Data Source Results Conclusions 
Mortality data (1929-1938) from the George 
F. Baker Clinic Boston. 25 per cent sample of 
diabetic cohort at the clinic. 
83 cancer deaths among the sample, equivalent to 5.3 cancer deaths per 
1,000 years of life exposed. The number of expected cancer deaths within 
the same time-frame was 62.  
He believed this study confirmed the hypothesis of a 
positive association between diabetes and cancer. 
U.S census data on causes of death as 
recorded on death certificates in 1940. 
11.6 per cent of non-diabetics are recorded as having died from cancer, 
compared with 4.0 per cent of diabetics. Cause of death was recorded as 
diabetes and cancer of the digestive organs and peritoneum (which 
includes the pancreas) 35 times more than expected. 
Negative correlation between diabetes and cancer, 
but not among diabetes and a specific cancer. 
Cautious of findings considering that in the U.S. in 
the 1940s only around half of all death certificates 
included more than one cause of death. 
New York City mortality data from proprietary 
and municipal hospitals between 1937-1939 
and 1941. 
Cancer reported as the cause of death among male diabetics as 12.3 and 
non-diabetics as 18.4 per 100. For women the same figures were 10.3 and 
19.8. Further to this, pancreatic cancer was found to constitute a larger 
percentage of all cancer deaths among diabetics than non-diabetics (6.8 
per cent and 3.9 per cent respectively). 
The figures indicate a lower rate of cancer among 
diabetics than non-diabetics, but a similar rate 
among diabetics as among individuals with diseases 
associated with cancer (tuberculosis and syphilis). 
Thus diabetes is still associated with cancer. 
U.S population data from 1940 and numbers 
of deaths from cancer and diabetes in the 
same period. 
Expected number of deaths from both causes was 275. Actual number of 
deaths from both was 1348.  
Positive association between the diabetes and 
cancer. 
New York cause of death data Actual number of deaths with both causes reported 74 compared with 2.4 
expected. 
As above. 
National Health Survey data; morbidity data 
taken from 83 cities covering 703,092 families 
(1,310,051 individuals) over the winter of 
1935-1936. U.S. Data was collected on socio-
economic factors and general household 
illness. 
2,912 males and 5,278 females were found to have diabetes. Among this 
group 18 and 37 cases of cancer were reported (0.6 and 0.7 per cent) 
respectively. Among those under 65 for men and 75 for women diabetics 
were found to have more cancer. Over these ages they were found to 
have less than the general population. Within the diabetic group and 
including all ages the ratio of observed to expected cases of cancer was 
1.26 among men and 1.43 among women. 
Among women (but not men), and both genders 
combined, the observed: expected ratio was found 
to be statistically significant.  
Case-control study of individuals with 
diabetes and those with sinusitis (control 
group). The study sought to explore whether 
those who are using health services have 
higher rates of cancer diagnosed; or whether 
diabetes specifically is associated with cancer. 
The observed to expected ratio among diabetes among both sexes was 
1.37 compared with 0.90 for the same figure among those with sinusitis. 
Cancer of the digestive organs and peritoneum (which includes the 
pancreas) occurred more than would be expected among female 
diabetics but not for male diabetics. But neither of these findings were 
considered statistically significant. 
Cancer is more prevalent among diabetics compared 
with the general population but not among those 
with sinusitis. 
Therefore there was found to be a relationship 
between diabetes and cancer. 
a
 The information within this table was adapted from an article by Jacobson.(102)
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Tichy analysed autopsy results from 6,571 cases of benign and malignant neoplasm.(104) Among 
3,525 men, 85 (2.4%) were found to be diabetic, while among 3,000 women, 126 (4.2%) were. 
Further to this it was found that there was a lower rate of observed than expected cancers among 
those with diabetes. For men the figures were 28.8 (expected), 9 (observed) and for women 46.1 
(expected), 11 (observed). Tichy concluded that the diabetic cohort had a three to four times 
reduced risk of developing cancer than those without the disease. 
 
Glicksmann and Rawson undertook a case-control study with 950 patients to explore the presence of 
the diabetic glucose curve among those with cancer.(105) Within the study design, diabetic glucose 
curve was considered present when a patient had one of the following 1) a blood-sugar level above 
200 mg per 100cc (11mmol/l) any time during the test; 2) a blood-sugar level of more than 100 mg 
per 100cc (5.5mmol/l) 2 hours into the test; or 3) a blood sugar level that remained above fasting 
level for over three hours. They found the presence of this in 36.7% of those with cancer compared 
with 9.3% of those with benign conditions. Within the study, 13.3% of individuals with cancer had 
diabetes compared with 4% of the control group. Unfortunately this finding was not explored any 
further in the research. The diabetic group was also on average 8 years older than the control group; 
this is likely to increase the incidence of cancer in the former independently of their diabetes status. 
Confounding factors which may have impacted upon an individual’s glucose tolerance, such as liver 
function, were not considered. Finally, they reported that adjustment for confounding factors such 
as sex, weight and religion, had occurred but details were not given. 
Within this period, other researchers also explored the glucose tolerance of those with cancer; their 
use of small sample sizes made robust conclusions hard to draw, particularly in terms of 
understanding the mechanism which created such a decrease in glucose tolerance among those with 
cancer.(106) 
 
A study using autopsy and morbidity data from Bristol Royal Infirmary found that cancer incidence 
was lower among those with diabetes compared with non-diabetics; the former had a ratio of 0.50 
in the morbidity data and 0.53 in the autopsy data compared with the general population.(107) The 
study also noted that there were differences between diabetic men and women - men had a cancer 
occurrence of 87% that of the total autopsy population, with the corresponding figure for women 
was lower, at 37%. They concluded that the negative association between diabetes and cancer was 
statistically significant only for women. 
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Caution should be used when making generalisable conclusions about the association between 
diabetes and cancer from any study utilising autopsy data for a number of reasons. Within earlier 
studies, confirmation of primary carcinoma could be imprecise and often only one disease was 
recorded on an autopsy. This made correlations between diseases liable to statistical error.(72,108) 
There were also a large number of undetected cases of diabetes within the general population and 
there was no clear consensus on what constituted a death from diabetes, therefore the disease 
would often go unreported within autopsy and post mortem records. Mainland also found that there 
was bias within the selection of cases to undergo autopsy: it was dependent upon the diseases of 
interest to the individual doctor undertaking the autopsy, the wishes of the family, hospital policies 
and practices, and wider legal requirements.(108) As with the work of Jacobson mentioned above, 
the use of hospital data was unlikely to be representative of the wider population. 
  
An extensive review of the literature relating to a correlation between diabetes and cancer 
undertaken by Kessler in 1971 concluded that studies undertaken using clinical evidence were likely 
to show a positive relationship between diabetes and cancer, while those that used autopsy data 
showed a negative relationship.(72) He also found that studies which used a measure of 
proportionate mortality from cancer (comparing individuals with diabetes with the general 
population) supported a negative relationship between diabetes and cancer; this was in all cancers 
other than pancreatic which was consistently found at higher rates among the former (an issue 
which will be further addressed in a later section of this review). This latter point he also found to be 
true among studies exploring cancer risk among diabetic cohorts.  
 
A prospective study, tracking mortality among members of the British Diabetic Association (BDA), 
followed 5,971 individuals and found an excess of deaths relating to diabetes and ischaemic heart 
disease.(109) The reverse was found to be true for cancer; the expected number of deaths was 
calculated as 168 while the observed number was 128. The authors concluded that this was due to a 
lower rate of smoking among BDA members compared with the general population as there were 
fewer than expected deaths related to this activity, such as lung, pharynx and bladder cancer. When 
specific tumour sites were investigated they found an excess of death from that of the liver 
(expected=0.5, observed=4) among both sexes and pancreatic cancer among men (expected=8.1, 
observed=12) while a lower than expected death rate from cancer of the rectum (observed=4, 
expected=8.9) was observed. 
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2.2.3 1980s-present 
The 1980s began to see studies investigating the link between diabetes and cancer that were 
methodologically more rigorous than those undertaken previously, although some studies still used 
sample sizes that were too small to be able to make statistically significant inferences about the 
relationship between diabetes and cancer or were dependent on relatively unreliable data sources. 
It was also at this time that studies began to focus more upon specific cancer sites and their link to 
diabetes.  
 
The 1982 cohort study by Ragozzino et al. sought to investigate relative cancer risk among 
individuals with diabetes.(75) Those diagnosed with diabetes within the study were followed for an 
occurrence of cancer. The study utilised a range of data sources to confirm a diagnosis of cancer 
(death certificates, autopsies, hospital records, outpatient, clinic visits and nursing home care). 
Diagnoses of cancer were included in the study only when they were histologically confirmed and 
occurred after a diagnosis of diabetes; cases were also excluded from the study when both diseases 
were diagnosed in the same month. Within the study, a total of 1,135 individuals were diagnosed 
with diabetes and 120 cases of cancer were detected. For all of the cancer sites found, the relative 
risk was greater than 1.0 (1.2 among men and 1.1 for women), but it only reached statistical 
significance for women with adenocarcinoma of the pancreas, melanoma and lymphoma. For 
pancreatic cancer, the study found that around half the cases (four out of nine) were diagnosed in 
the first year of a diagnosis of diabetes. Although the researchers considered whether the incidence 
of diabetes occurred before cancer or vice-versa, they concluded that the relationship between the 
two conditions “was probably real”. The small number of concurrent cases of diabetes and cancer 
meant that statistical significance was not reached and no exploration of the effect of confounding 
factors upon the relationship between diabetes and cancer was undertaken. Overall, the study 
concluded that the relative risk of cancer among those with diabetes was statistically similar to that 
of the general population. 
 
O’Mara et al. undertook a multisite case-control study of the relative risk of cancer among diabetics. 
Using data collected between 1957 and 1965, a total of 8,220 men and 6,690 women between the 
ages of 30-89 with a diagnosis of cancer were investigated.(76) The study was one of the first to 
specifically differentiate between type-1 and type-2 diabetes. As with the above study, those whose 
cancer had been diagnosed within the same year as their diabetes were excluded from the study to 
reduce the number of cases within which diabetes was merely an outcome of cancer. The study 
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found the relative risk of cancer was increased among women more than men and gave the 
following risk ratios: 
 
 2.0 for uterine cancer among those with adult-onset diabetes; this increased risk remained 
even after adjustment for obesity and parity, with thinner women being found to have an 
increased risk compared with overweight and obese women); 
 2.0 for non-melanoma skin cancer among women; and 
 3.0 for kidney cancer among women. 
 
For other cancers, women with diabetes had a lower relative risk than the general population, for 
example 0.8 for cancer of the cervix. Contradicting the majority of earlier studies, no increased risk 
was found for diabetes with respect to pancreatic cancer and the study concluded that this type of 
cancer was likely to induce the occurrence of diabetes. The study further concluded that it was the 
diabetes, in and of itself, that was increasing the risk of cancer and not the treatment of the disease.  
A methodological weakness of this research lay in the fact that it only investigated white individuals 
and the cohort investigated was made up exclusively of individuals attending a single hospital. This 
would reduce the generalisability of the findings if the hospital was utilised by a homogenous socio-
economic/ demographic community. The study did not undertake any analysis of the socio-
economic or demographic backgrounds of those involved in the study. 
 
A meta-analysis and systematic review sought to explore whether diabetes conferred an increased 
risk of cancer.(84) The meta-analysis included five reports (one case-control and four cohort studies) 
and established an odds ratio of 1.70 (CI 1.38-2.10) among those with diabetes compared with their 
non-diabetic counterparts. When the analysis adjusted the risk ratio for confounders, the attenuated 
increased risk was similar in both sexes but was significant only for diabetic men (RR= 1.25, 95% CI = 
1.06-1.46) but not for diabetic women (RR 1.23, 95% CI 0.97-1.56). Within the systematic review and 
meta-analysis, the researchers found consensus across studies - none of the studies included found a 
decreased risk of cancer among diabetic patients compared with non-diabetics. As mentioned in 
section 1.8, the meta-analysis was large but was limited to Japanese populations.  
 
In the first decade of the 21st century, researchers began to conclude that in order to understand 
better any potential relationship between the two diseases it would be necessary to focus either 
upon 1) type-1 or type-2 diabetes (or measures of blood glucose) or 2) site-specific cancers. A report 
by the American Diabetes Association and the American Cancer Society in 2010, which aimed to 
38 
 
assess all the evidence relating to diabetes and its link to cancer, stated that “In view of the variable 
associations between diabetes and cancer risk at specific sites, we discourage studies exploring links 
between diabetes and risk of all cancers combined.” (37, p.209) With this in mind the following 
section of the literature review details the epidemiological evidence pertaining to the associations 
between diabetes and site-specific cancers. 
 
Two recent studies also found increased all-cause and site-specific cancer mortality among those 
with diabetes. The Emerging Risk Factors Collaboration utilised data from around 850,000 
participants from 97 pooled prospective studies; within the study all-cause cancer mortality among 
those with diabetes was increased (HR 1.25, 1.19-1.31), while site-specific mortality was only 
moderately associated with cancers of the colon and rectum, liver, breast, ovary, pancreas, lung and 
bladder.(86) The second study utilised data from over 1 million participants, with this study allowing 
for an evaluation of a mortality from a range of site-specific cancers.(110) Table 2-4 details the 
results. 
 
Table 2-4: Results diabetes and cause-specific mortality in a prospective cohort of one million U.S 
adults 
Site-specific cancer Relative Risk, 95% CI 
 
All-cause mortality 1.90, 1.87-1.93 (women) 
1.73, 1.70-1.75 (men) 
Liver 1.40, 1.05-1.86 (women) 
2.26, 1.89-2.70 (men) 
Pancreas 1.31, 1.14-1.51 (women) 
1.40, 1.23-1.59 (men) 
Endometrium 
 
1.33, 1.08-1.65 (women) 
Colon 1.18, 1.04-1.33 (women) 
1.15, 1.03-1.29 (men) 
Breast 1.16, 1.03-1.29 (women) 
4.20, 2.20-8.04 (men) 
Oral cavity and pharynx 
 
1.44, 1.07-1.94 (men) 
Bladder 
 
1.22, 1.01-1.47 (men) 
Prostate 
 
0.88, 0.79-0.97 (men) 
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2.3 Diabetes and site-specific cancer  
The following sections detail the evidence related to the associations between diabetes and site-
specific cancers. 
 
2.3.1 Lung cancer 
Lung cancer causes the greatest number of cancer deaths within the UK (around one in five cancers 
among men and women combined).(111) Only a small number of studies have explored the 
association between diabetes and lung cancer, with heterogeneity within results. The case-control 
study undertaken by Hall et al. involved 66,848 cases with diabetes and 267,272 controls.(112) They 
found that, among all those with diabetes, deaths from primary lung cancer were 1.63 per 1000 
patient years (95%CI 1.48-1.79) and among those followed after a diabetes diagnosis the 
corresponding rate was 2.05 (1.76-2.38). For non-diabetics the rate was 2.04 (1.96-2.13). The hazard 
ratio among diabetics was 0.8 (0.79-0.97) among all diabetics compared with non-diabetics and 1.12 
(0.95-1.34) among those with incident diabetes. The study concluded that there was not an 
increased risk of lung cancer among those with diabetes and that this may be due to a reduction in 
life expectancy among this group, which prevented the consequences of smoking increasing lung 
cancer cases. Ehrlich et el. supported this finding: they found an increased risk of diseases such as 
asthma and pneumonia but not lung cancer.(113) The age, sex and ethnicity-adjusted hazard ratio 
among diabetics was 1.05 (CI 0.94-1.17) compared with non-diabetics; further adjustment, for 
factors such as BMI, revealed a non-significantly raised hazard ratio of 1.10 (CI 0.96-1.26). A study of 
postmenopausal women, comparing risk of lung cancer diagnosis between those with and without 
diabetes, found that the former were at an increased risk (HR 1.27, 95% CI 1.02-1.59) and that this 
further increased among women who required exogenous insulin (1.71, 1.15-2.53).(114) 
 
In terms of life expectancy among those who have been diagnosed with lung cancer, Bartling et al. 
found increased life expectancy at 20 months among those with diabetes (76% survived to this point 
among diabetics compared with 59% among non-diabetics, p=0.048).(115) When survival was 
measured at 60 months, there was not a statistically significant difference between the groups (35% 
and 32%). This study involved a relatively small sample size of 55 cases with diabetes and 111 
controls. 
 
A meta-analysis including 34 studies found that diabetes was associated with lung cancer when 
studies that included adjustment for tobacco consumption were included (Relative Risk (RR)): 1.11, 
CI 1.02-1.20). There appeared to be no increased risk when studies that did not adjust for smoking 
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were considered (RR: 0.99, CI 0.88-1.11). When analysis was stratified by gender, only among 
women was there a statistically significant increased risk (1.14, CI 1.09-1.20).(116) 
 
2.3.2 Colorectal and other gastrointestinal cancers 
Colorectal cancer includes those of the colon and rectum and is the second largest site-specific cause 
of cancer mortality in the UK, killing over 16,000 individuals in 2008.(117) Globally, 1.28 million 
individuals were diagnosed with the disease in 2008.(118) The majority of studies have found an 
increased risk of developing colorectal cancer among those with diabetes compared with those 
without the disease. A case-control study of 14,916 male doctors followed for 13 years found a 
positive relationship between c-peptide level (a marker of insulin levels within the body) and risk of 
developing colorectal cancer.(119) Those in the highest quintile of c-peptide level had an increased 
risk of developing the disease compared with those in the lowest quintile, after adjusting for a 
number of factors including BMI, alcohol consumption and age (RR=2.7, 95% CI 1.2-6.2). Among 
patients with colorectal cancer, diabetes was associated with greater all-cause mortality (HR 1.41, CI 
1.18-1.70) and mortality from colorectal cancer (1.36, 1.11-1.67).(120) 
 
A meta-analysis utilising a large cohort of over 2.5 million individuals found an increased risk of 
colorectal cancer among those with diabetes compared with those without the disease (RR=1.30, 
95% CI 1.20-1.40).(121) A systematic review and meta-analysis, undertaken up to October 2008, 
included 15 articles and found that those with concurrent diabetes and colorectal cancer had an 
increased risk of mortality. Both short-term and long-term mortality was increased among those 
with diabetes (the latter by around 32%, 95% CI 24-41%).(87) Findings, in terms of increased 
mortality when both diseases are present, are inconsistent: some studies do not find an increase 
among those with diabetes compared with those without the disease. 
 
Other gastrointestinal cancers include those of the oesophagus, stomach, liver, biliary system, 
pancreas, bowel and anus. A number of these cancers are discussed individually in other sections of 
the literature review. Each year in the UK cancers of the pancreas and oesophagus each cause over 
7,000 deaths; while those of the stomach cause over 5000.(117) 
 
2.3.3 Pancreatic cancer 
The association between diabetes and pancreatic cancer appears to be the most established of all 
the site-specific cancers. In an early piece of research, Marble found an increased incidence of the 
disease among diabetics.(100) He noted that 13% of all tumours among the group were pancreatic, 
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while U.S data from the same time period showed that, for all cancers diagnosed in the general 
population, pancreatic cancer accounted for between 3 and 5%. A meta-analysis of 36 cohort and 
case-control studies found that the odds ratio for developing pancreatic cancer among those with 
diabetes was 1.8 (95% CI 1.7-1.9) compared with the general population.(122) At the same time, 
some researchers have argued that this represents reverse causality, that diabetes is merely an 
indicator of the presence of occult pancreatic cancer: among those who are aged 45-50, lean and 
have no history of diabetes within the family it is suggested that diabetes should be considered a 
marker of the presence of pancreatic cancer.(123,124) This finding is supported by an increased 
incidence of the cancer among those who have had diabetes for the shortest amount of time. For 
example within the meta-analysis by Huxley et al., those who had had diabetes for less than 4 years 
were twice as likely to be diagnosed with pancreatic cancer, while those who had the disease for 
longer had an excess risk of 50% compared with those without diabetes.  
 
2.3.4 Other gastrointestinal cancers 
Svacina et al. found no increased risk of developing gastrointestinal cancer among those with type-1 
diabetes.(125) A case-control study (311 cases and 10,154 controls) also found no increase in 
adenocarcinomas of the oesophagus and gastric cardia (OR 1.1, 95% CI 0.8-1.5) among 
diabetics.(126) Among those with type-2 diabetes, a case-control study utilising 1,172 cases and 496 
controls, found an increased odds ratio among diabetics for cancers of the pancreas (OR 3.22, 95% CI 
3.03-3.42), biliary system (2.10, CI 1.61-2.53) and gallbladder (2.20, CI 1.56-3.0).(127) A large cohort 
study (including 113,347 and 131,573 diabetic men and women respectively followed for over 10 
years) found an increase in mortality from gastric cancer.(128) For men and women the mortality 
rate ratio changed with age: among men the figure was 4.49 (95% CI 3.93-5.12) among those aged 
25-64, 1.58 (1.40-1.78) among those aged 65-74 and 1.52 (1.31-1.77) among those >74. For women, 
the same figures were 3.65 (CI 3.11-4.28), 1.95 (1.67-2.27) and 1.58 (1.32-1.90) respectively. A 2013 
cohort study supported an increase in gastric cancer among those with diabetes; four years after 
diabetes diagnosis increased hazard ratio was 1.76, CI 1.06-2.91.(129) 
 
An increased odds ratio was found in relation to oesophageal cancer among those with diabetes (OR 
1.59, 95% CI 1.04-2.43).(130) This figure was reduced, to a non-statistically significant level after 
adjustment for BMI (OR 1.32, CI 0.85-2.05). A cohort study of 469,448 cases found no association 
between adenocarcinoma of the oesophagus (HR 0.98, CI 0.73-1.31), oesophageal squamous cell 
carcinoma (HR 1.02, CI 0.60-1.74) and gastric non-cardia adenocarcinoma (HR 0.98, CI 0.70-1.37) but 
42 
 
did find an association with gastric cardia adenocarcinoma (1.89, CI 1.43-2.50).(131) The latter 
association remained after BMI was taken into account (1.70, CI 1.28-2.26).  
 
2.3.5 Kidney cancer 
A Swedish cohort study involving a sample of 153,852 individuals with diabetes and comparing renal 
cell cancer incidence and mortality among this group with that of the general population found an 
increase among those with diabetes.(132) A larger than expected number of kidney cancers were 
diagnosed among the diabetic cohort (267 occurred, while 182 were expected). Standardized 
Incidence Ratios were also increased among those with diabetes (1.7 (CI 1.4-2.0) among women and 
1.3 (1.1-1.6) among men). Mortality from kidney cancer was also found to be higher among this 
group (1.9 (1.7-2.2) among women and 1.7 (1.4-1.9) among men) compared with the general 
population. Svacina et al. supported the finding(133), while a non-significant increase in risk was 
found in a further study (OR 1.3, CI 0.9-1.7).(134) A large cohort study (46,462 men and 64,326 
women) found no statistically significant relationship between diabetes and kidney cancer. This 
appeared to be due to the small number of concurrent cases: in total, there were eight deaths from 
kidney cancer among those with diabetes.(135)  
 
A 2013 meta-analysis that included data from 24 studies found that diabetes was associated with an 
increased incidence of kidney cancer (RR 1.40, CI 1.16-1.69); each of the studies included showed an 
increased risk of developing the cancer among those with diabetes.(136) However the analysis did 
not indicate a statistically significant association between diabetes and mortality from kidney cancer 
(RR 1.12, CI 0.99-1.20). 
 
2.3.6 Liver cancer 
A case-control study (420 patients with hepatocellular carcinoma and 1,104 healthy controls) found 
an increased prevalence of diabetes among those with cancer (OR 4.2, CI 3.0-5.9).(137) In the 
majority of cases (87%), diabetes preceded the onset of cancer (OR 4.4, CI 3.0-6.3). For both men 
and women, diabetes was found to be associated with an increased risk of liver cancer (men: 1.63, CI 
1.06-2.51, women: 1.64, 1.03-2.61); the highest risk occurred during the first five years following the 
diabetes diagnosis.(138) A systematic review and meta-analysis involving 26 studies found an 
increased risk of hepatocellular cancer among those with diabetes.(139) Of the 13 case control 
studies included in the analysis, nine found a significant association, while among 13 cohort studies, 
seven found a significant association. This equated to a relative risk of 2.5 within both study types 
(RR=2.5, 95% CI 1.8-3.5 and RR=2.5, 95% CI 1.9-3.2 respectively). A systematic review and meta-
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analysis found an odds ratio for hepatocellular cancer of 3.64, 2.61-5.07; when adjusted for 
confounding factors the OR was only slightly attenuated (2.38, 2.01-2.81). (84) 
 
2.3.7 Haematopoietic cancers 
 A small number of studies have investigated the relationship between diabetes and haematopoietic 
cancers (non-Hodgkins lymphoma, leukaemia, and multiple myeloma). A case-control study found 
that diabetes was a risk factor for incident non-Hodgkins lymphoma (OR 1.88, CI 1.22-2.89).(140) A 
cohort study of 35,420 participants found an increase in mortality from non-Hodgkins lymphoma 
among men with a BMI in the highest quartile compared with the lowest  (HR 2.57, CI 1.24-5.34) and 
among men with the highest post-load glucose compared with the lowest (HR 2.86,1.35-6.06).(141) 
The corresponding figures for leukaemia were HR 1.98, CI 1.07-3.69 for BMI; an association was not 
found for post-load glucose. Among women, BMI was associated with leukaemia mortality only (HR 
2.47, CI 0.96-6.36), while post-load glucose was associated with multiple myeloma only (HR 3.06, CI 
1.05-8.93). 
 
A 2008 meta-analysis, focussing upon diabetes and non-Hodgkins lymphoma, included 16 papers (5 
detailing a cohort study and 11 a case-control study) and showed a slightly increased risk ratio 
among diabetics of 1.19 (95% CI 1.04-1.35) compared with non-diabetics.(142) In the same year, a 
meta-analysis and systematic review found an association between diabetes and non-Hodgkins 
lymphoma within both case-control studies (OR 1.18, CI 0.99-1.42) and prospective cohort studies 
(RR 1.79, CI 1.30-2.47). The most recent meta-analysis investigated the association between type-2 
diabetes and non-Hodgkins lymphoma, leukaemia and myeloma.(143) In the majority of cases there 
was a significantly increased odds ratio for incident cancer: non-Hodgkin lymphoma 1.22 (1.07-1.39); 
leukaemia 1.22 (1.03-1.44); and myeloma 1.22 (0.98-1.53). The authors concluded that future 
analysis should also consider the impact of confounding factors upon associations between diabetes 
and these site-specific cancers. 
 
2.3.8 Bladder cancer 
Mortality from bladder cancer is the eighth leading cause of cancer death within the UK, equating to 
around 10,000 deaths each year.(144) A 1988 case-control study found a substantially increased 
overall relative risk for bladder cancer mortality among those with diabetes of 2.18 (1.75-2.72); 
among men and women >75 years of age RR=2.18, CI 1.75-2.72 and RR=1.34, CI=0.96-1.89 
respectively; while for men and women aged 25-64 the corresponding figures were RR=5.95, CI 4.57-
7.74 and RR=7.44, CI 5.46-10.15, respectively. The study further concluded that this excess in risk 
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was unrelated to diabetes-related medication usage.(145) A case-control study found that diabetes 
duration was associated with bladder cancer risk (OR for those with diabetes for a duration >16 
years was 3.6, CI 1.1-11.2 compared with 2.2, CI 1.3-3.8 overall).(146) 
 
Only one study was focused exclusively upon diabetic women and their risk of bladder cancer. The 
Iowa Women’s Health Study found that diabetic women had, after multivariate adjustments, a 
relative risk of 2.46, CI=1.32-4.59.(147) A study carried out in an ethnically diverse cohort of 186,000 
participants, followed for over 10 years, found an increased risk of urothelial cancer, the majority of 
which were located in the bladder, among self-reported diabetics (RR=1.25, CI 1.04-1.50).(148) 
Further analysis suggested that confounding factors such as overweight and obesity did not explain 
the increased risk. A meta-analysis found an increased risk of bladder cancer among those with 
diabetes (RR 1.24, 1.08-1.42),(149) while a second, utilising data from 36 studies, resulted in a RR of 
1.35, CI 1.17-1.56.(150) These were consistent within results for case-control (RR 1.37, CI 1.04-1.80) 
and cohort studies (RR=1.43, CI 1.18-1.74). 
 
2.3.9 Breast cancer 
Among a cohort of 1,248 Asian-American women, diabetes was found to be associated with a risk of 
developing breast cancer (OR 1.68, CI 1.15-2.47); the increased risk remained unchanged when 
factors such as BMI were adjusted for.(151) Of note is the finding that the association was stronger 
among women with a low BMI (<22.7) (OR 3.50, 1.32-9.24) than in those with a BMI above this 
threshold (OR 1.39, 0.81-2.36) although this was not statistically significant. Postmenopausal women 
were found to have an increased, but not statistically significantly raised, risk of incident breast 
cancer (1.35, CI 0.99-1.85) but not mortality from the cancer.(152) 
 
A meta-analysis of 20 studies found an increased risk of breast cancer among diabetics (RR=1.20, 
95% CI 1.12-1.28).(153) Among the case-control studies, the relative risk for incident breast cancer 
among those with diabetes was 1.18 (CI 1.05-1.32), while for the cohort studies was 1.20 (1.11-1.30). 
Within the meta-analysis, five cohort studies focussed upon mortality from breast cancer and found 
a combined RR of 1.24 (CI 0.95-1.62) among those with diabetes compared with those without.  
 
2.3.10 Endometrial cancer 
Over 1,900 women each year die of endometrial cancer in the UK, with similar numbers newly 
diagnosed.(154) A 2013 cohort study found an increased HR of 1.71 (CI 1.48-1.97) of developing 
endometrial cancer.(155) A meta-analysis, including 16 studies, found an increased risk of 
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endometrial cancer among women with diabetes (RR=2.10, 95% CI 1.75-2.53) compared with the 
general population. Further analysis indicated a stronger relationship among women with type-1 
diabetes (RR=3.15, 95% CI 1.07-9.29). When analysis utilised data only from studies focussed upon 
type-1 diabetes, a statistically significant increased risk among those with diabetes remained (RR 
3.15, CI 1.07-9.29).(156) An odds ratio of 3.43 (1.53-7.72) was found within a systematic review and 
meta-analysis exploring incident endometrial cancer; following further adjustment for confounders 
the OR was 2.71, 1.19-6.19. 
 
2.3.11 Prostate cancer 
Prostate cancer is the only site-specific cancer for which research suggests a reduced incidence 
among those with diabetes. A meta-analysis of 14 studies found a negative relationship between 
diabetes and the disease (RR=0.91, 95% CI 0.86-0.96).(157) A second meta-analysis, involving a total 
of 19 studies published between 1971 and 2005, supported this finding. They found an inverse 
association between diabetes and prostate cancer (RR=0.84, 95% CI 0.76-0.93).(158) Within the case 
control studies, they found a relative risk of 0.89 (CI 0.72-1.11), while for cohort studies the relative 
risk was 0.81 (CI 0.71-0.92). 
 
A meta-analysis involving 11 studies focussing specifically upon prostate cancer mortality found a 
small increase in prostate cancer mortality among those with diabetes; compared with those 
without diabetes, the pooled hazard ratio was 1.57 (CI 1.12-2.20).(159)  
 
2.3.12 Other cancers and their link to diabetes 
As can be seen from the sections above, even when cancers occur relatively frequently it is still 
difficult to draw firm conclusions in terms of their link to diabetes. This situation is made even more 
difficult when the cancers occur infrequently and research is therefore restricted in terms of the 
methods that can be used to explore any potential relationships. There is a limited amount of 
evidence for a number of other cancers. For example, a 2013 study did not find an association 
between diabetes and oral cancer, instead the authors called for further research to investigate the 
associations between the two diseases.(160) An exploration of survival among women with ovarian 
cancer found that those with diabetes had a shorter survival time compared with those without 
diabetes (HR 2.04, 1.31-3.17).(161)  
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2.4 Type-1 diabetes and cancer 
The majority of the studies mentioned above either do not differentiate between type-1 and type-2 
diabetes or were focussed upon type-2 diabetes. Some commentators have questioned the validity 
of extrapolating to type-1 diabetes the results of studies focussed upon type-2. (162)  Therefore a 
review which specifically focussed upon research which explored the relationship between type-1 
diabetes and cancer was undertaken as part of this thesis. This then formed a paper which was 
published in the International Journal of Cancer.(163) The following section details the results of this 
literature review; the published paper is available at the back of this thesis. 
 
As can be seen from Table 2-5, there were mixed results in terms of whether or not those with type-
1 diabetes were at greater risk of developing and dying from cancer. Mixed results were found 
among cohort studies. None of the case-control studies found a statistically significant link between 
the two diseases, while both of the meta-analyses (which included both study designs) did. There 
were also mixed findings among research that defined type-1 diabetes in the same way. For 
example, three studies used diagnosis before the age of 30 as being indicative of the disease: two 
found no statistically significant relationship, while one did. The rest of this section explores the 
results of the research found within this review, based upon the method used within the study. 
Mention has been made of the country in which the study was undertaken as an exploration of the 
potential geographical differences in the strength of the association between type-1 diabetes and 
cancer may be beneficial to our understanding of the associations between the two diseases. 
 
Only a small number of cohort studies focussed on type-1 diabetes and overall cancer incidence; 
only one gave the information required for inclusion in this review. A Swedish study found a 17% 
increase in cancer among those with type-1 diabetes compared with the general population 
(RR=1.17 (95% CI 1.04-1.33).(164) At the same time, if analysis excluded specific time periods after 
diagnosis (based on either one or five years) no significant increase in standardized incidence ratio 
(SIR) was found. Exclusion of the first year (SIR 1.07, 95% CI 0.94-1.22) was similar to analysis for 
exclusion of first five years (SIR 1.09, 95% CI 0.96-1.25). This finding may support the reverse 
causality hypothesis—that diabetes is the result of an undiagnosed cancer rather than the other way 
round, or it could be the consequence of small numbers within the study. A further cohort study 
undertaken in Denmark found no overall increase in cancer cases among those with type-1 diabetes 
compared with the general population; although among men with insulin-treated diabetes, there 
was an increase in overall cancer incidence (RR= 1.37, 95% CI 1.03-1.83); however, this was not 
found to be the case for women (RR=1.08, 95% CI 0.77-1.51).(165) Although this study only used 
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insulin use as a proxy for type-1 diabetes, it has been included within this review because the follow-
up years within which the study was undertaken (1973-1981) were such that the majority of those 
using insulin were likely to have had type-1 diabetes. 
 
A Swedish cohort study found a standardized mortality ratio (SMR) of 1.73 (95% CI 1.45-2.05) among 
its type-1 diabetic cohort compared with the general population.(166) In support of this, a New 
Zealand study found an SMR for cancer of 12.96 (95% CI 3.36-22.57) among those diagnosed with 
type-1 diabetes compared with the general population.(78)The CI is wide and this may be due to 
there being only seven observed cases of cancer among those diagnosed with diabetes under the 
age of 30 (the measure used within the study as indicative of type-1 diabetes).  
 
A case-control study (7,713 cases, 38,518 controls) undertaken in the UK explored all-cause and 
cause-specific mortality among those with type-1 diabetes compared with the general 
population.(167) They found no statistically significant difference in the hazard ratios (HR) for cancer 
mortality between the two groups (HR=1.05, 95% CI 0.72-1.52). A second UK study also found no 
increase in cancer mortality among those with type-1 diabetes. For all-cause cancer mortality the 
SMR was 0.90 (95% CI 0.75-1.08).(168) A key limitation of this study was that a large proportion of 
their subjects (20,676 of 28,900) were under the age of 50 at follow-up. This is known to be a period 
when cancer incidence is lower than in later life; 63% of cancers are diagnosed in those over the age 
of 65 and only 5.4% of cancer in men, and 8.9% of those in women, occur under the age of 
45.(169,170) The US Allegheny County Type-1 Diabetes Registry cohort study investigated cause-
specific mortality among its cohort of those with type-1 diabetes (n=1,043). They found no 
statistically significant association between the two diseases (SMR= 1.2, 95% CI 0.5-2.0) compared 
with the general population.(171) The lack of statistical significance in this study is likely to be 
heavily influenced by the small number of cancer deaths and the consequent effect on statistical 
power.  
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Table 2-5: Key findings of research exploring the relationship between type-1 diabetes and cancer by outcome measure 
Study 
method  
Country Sample  Case definition (type-1 diabetes) Outcome 
measure 
Risk of cancer among 
T1DM participants (95% 
CI or p-value)  
Risk of site-specific cancers  
(95% CI or p-value) 
Cohort(165) Denmark 1,499 insulin treated individuals  Insulin use Incidence Men RR=1.37 (1.03-
1.83), Women RR=1.08 
(0.77-1.51),  
Pancreas RR=2.53 (1.17-5.47); RR=1.69 
(p=0.29) once cases excluded where 
diabetes an indicator of cancer 
Cohort (172) Denmark 109,581 individuals with 
diabetes 
Hospitalised with diabetes <age 50 Incidence SIR 1.1 (1.0-1.2) Liver SIR= 4.8 (2.8-7.7), mouth and pharynx 
SIR=1.8 (1.2-2.6) 
Cohort(164) Sweden 24,052 type-1 diabetic patients  Diagnosis <age 21 Incidence RR=1.17 (1.04-1.33),  Stomach RR=3.36 (1.44-6.66), skin RR=4.96 
(2.83-8.07), leukaemia RR=2.02 (1.15-3.29) 
Cohort(173) Sweden 29,187 diabetes patients Hospitalisation for diabetes <age 
30 
Incidence SIR=1.2 (1.0-1.3) N/A 
Case-
control(174) 
Italy 752 diabetic women with 
endometrial cancer and 2,606 
admitted to the same hospitals  
Diagnosis <age 40 Incidence OR=1.0 (0.3-3.4) N/A 
Case-
control(76) 
USA 14,000 participants with 
diabetes aged 30-89 
Diagnosed with diabetes  
<age 29 
Incidence Not significant (at the 
p<0.05 level) 
N/A 
Meta-analysis(156) I case-control and 2 cohort studies (168,173,175) Incidence N/A Endometrial RR=3.15 (1.07-9.92) 
Meta-analysis(176) 3 cohort and 6 case-control studies Incidence N/A Pancreatic RR=2.00 (1.37-3.01) 
Cohort(166) Sweden 144,427 participants with 
diabetes  
Hospitalisation for diabetes <age 
40 
Mortality RR=1.73 (1.45-2.05) N/A 
Cohort(78) New 
Zealand 
966 insulin treated participants 
including 427 with type-1 
diabetes 
Diagnosis <age 30 Mortality SMR=12.96 (3.36-22.57) N/A 
Case-
control(167) 
UK 7,713 cases of type-1 diabetes 
and 38,518 controls  
Those currently on insulin and 
aged <35 at treatment or <35 
years at diagnosis of diabetes 
Mortality HR=1.05 (0.72-1.52) N/A 
Cohort(171) USA 1,043 type-1 diabetic patients  Diagnosis <age 18 Mortality SMR=1.2 (0.5-2.0) N/A 
Cohort(168) UK 28,900 insulin treated diabetics 
including 23,834 with type-1 
diabetes 
Diagnosis <age 30 Mortality SMR=0.90 (0.75-1.08),  Ovarian SMR=2.90, (1.45-5.19) 
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In terms of site-specific cancers the study by Shu et al. found increased SIRs for those of the stomach 
(3.36, 95% CI 1.44-6.66), squamous cell carcinoma of the skin (4.96, 95% CI 2.83-8.07) and leukaemia 
(2.02, 95% CI 1.15-3.29).(164) These SIRs were those which excluded the first five years of follow-up 
after diagnosis of type-1 diabetes, with significance remaining stable across all the three follow-up 
intervals of all cases, one year follow-up exclusion, and five years’ exclusion. Gender was a key factor 
in excess cancer incidence. After exclusion of the first year following type-1 diabetes diagnosis, SIR 
remained increased only among women.  This statistical significance was also only for cancers of the 
skin (SIR 9.40, 95% CI 5.12-15.82) and leukaemia (2.55, 95% CI 1.26-4.57). The number of visits an 
individual made to hospital was also found to be a risk factor for cancer, but the researchers were 
unsure whether this was due to the increased chance of a cancer being diagnosed within more 
frequent visits to hospital or because there was an association between type-1 diabetes and cancer.  
More detailed analysis, undertaken by Green and Jensen, showed that, for site specific cancers, only 
that of the pancreas had a statistically significant increase (RR=2.53, 95% CI = 1.17-5.47).(165) 
However, further analysis showed that, once cases were excluded where diabetes was an early 
indication of the presence of cancer, the relationship was no longer statistically significant (RR= 1.69, 
p=0.29). In terms of age and gender, only men between the ages of 0-54 had an increased risk of 
cancer (RR=2.04, 95% CI= 1.11-3.74), although this result may reflect the small numbers within the 
studies rather than the real effect type-1 diabetes has upon cancer incidence.  
 
A Danish cohort study found mixed results depending on cancer site.(172) Among those defined as 
having type-1 diabetes (hospitalised for diabetes within the study period before the age of 50) the 
SIR for all cancers was 1.1, 95% CI 1.0-1.2; only cancers of the mouth and pharynx (SIR 1.8, 95% CI 
1.2-2.6) and liver (SIR 4.8, 95% CI 2.8-7.7) were increased among this group. For cancers of the 
pancreas, lung and kidney non-statistically significant increases were found (SIR 1.4, 95% CI 0.7-2.3, 
SIR 1.3, 1.0-1.6 and 1.6, 1.0-2.4, respectively). A third Swedish cohort study found an overall SIR for 
cancer of 1.2 (95% CI 1.0-1.3) among those with type-1 diabetes compared with the general 
population.(173) For site-specific cancers significant increases in SIR were found for those of the 
stomach (2.3, 95% CI 1.1-4.1), cervix (1.6, CI 1.1-2.2), and endometrium (2.7, CI 1.4-4.7). 
An Italian case-control study exploring the link between endometrial cancer incidence and diabetes 
(type-1 diabetes and type-2 diabetes, assessed separately) found no link between type-1 diabetes 
and the disease (odds ratio (OR)=1.0, 95% CI 0.3-3.4) but only four cases with type-1 diabetes were 
included in the study.(174) In support of this finding, a second study that included 14,000 individuals 
aged 30-89 with diabetes, found no statistically significant association (at the 5% level) between a 
range of site- specific cancers and the disease.(76)  
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A meta-analysis of the link between diabetes and endometrial cancer found an association between 
the two diseases (RR=3.15, 95% CI 1.07-9.29).(177) This was based on three studies, one of which 
was a Swedish case-control study which had few women with type-1 diabetes (<10) and found a 
relative risk (RR) of 13.3, with a wide CI of 3.1-56.4.(178) The other two studies are those of 
Swerdlow et al. (UK) and Zendehdel et al. (Sweden), mentioned earlier in this review.(168,173) 
 
A systematic review and meta-analysis focussed upon type-1 diabetes and the incidence of 
pancreatic cancer.(176) Within the meta-analysis, a RR of 2.00 (95% CI 1.37-3.01) was found for 
pancreatic cancer among those with type-1 diabetes. The meta-analysis was based on 39 concurrent 
cases of the two diseases. The researchers themselves reported that the study was limited by the 
small number of studies published in this area; there were an even smaller number that were 
published with sufficient concurrent cases of type-1 diabetes and pancreatic cancer: Ekoe et al. 
found only one case while La Vecchia found three.(179,180) Only two studies had more than five 
cases among those with type-1 diabetes; the first of these is the Wideroff study mentioned above 
and the second found an increased RR of pancreatic cancer among those with type-1 diabetes (RR 
2.23, 95% CI 1.08-4.58.(181) Three of the studies included in the analysis had no concurrent cases of 
type-1 diabetes and pancreatic cancer.(76,182,183)  
 
Only a few reports have focussed on cause-specific mortality among those with type-1 diabetes; 
among these a smaller number still investigated cancer mortality. The reason for this is likely to be 
the excess of mortality among those with type-1 diabetes caused by complications of the disease 
itself, such as renal disease and cardiovascular disease.(184) A UK study linked cause of death data 
to a register of those with diabetes and found that those with type-1 diabetes only accounted for 18 
(5%) of all deaths within the study; because of this they did not undertake separate analysis for 
cause of death among those with this form of diabetes.(185) Other studies were characterised by 
their inclusion of numbers of concurrent type-1 diabetes and cancer too small to elicit statistically 
viable results.(186–189) The study mentioned previously by Swerdlow et al. found increased 
mortality among women with type-1 diabetes for ovarian cancer (SMR 2.90, 95% CI 1.45-5.19); the 
same was not found to be true for any other cancer sites.(168)  
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Figure 2-1: Risk estimates for all-cause cancer incidence and mortality among those with diabetes 
 
 
2.5 Glycated haemoglobin (HbA1c) and cancer 
The evidence related to glycated haemoglobin and cancer risk is currently limited and the strength of 
the association remains unclear. A case control study (cases were those who developed cancer after 
a diagnosis of diabetes, n=53) found that the incidence of cancer was highest among those with an 
HbA1C level ≥8% (OR 3.16, CI 1.34-7.44).(190)
 The study also found that mean HbA1C was higher 
among those who had cancer compared with the control group (7.83 vs 7.30, p=0.02) and that there 
was a dose-response effect in cancer risk with each step-increase in HbA1C measurement (OR 1.61, 
CI 1.09-2.36). This association was accentuated when adjustment was made for a range of 
confounding factors including overweight/obesity, duration of the presence of diabetes, 
comorbidities and smoking status (OR 1.67, CI 1.10-2.53). Joshu et al. found that raised glycated 
haemoglobin was associated with incidence of and mortality from cancer among women, but not 
men, who were non-diabetic but were not normoglycaemic (HR 1.24, CI 1.07-1.44 and 1.58, CI 1.23-
2.05).(191) However, a third study found no association between raised HbA1C and cause-specific 
cancer risk (HR 1.02, CI 0.95-1.10) and no association between HbA1C and a range of site-specific 
cancers.(192) There also appeared to be no association when HbA1C was explored as a continuous 
variable or when quartiles were used. In terms of site-specific cancer incidence, evidence suggests 
that raised glycated haemoglobin is associated with cancers of the colorectum(193), pancreas(194) 
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and liver(195). It was also found to be associated with the nature of localised prostate and colorectal 
cancer; among those with a raised HbA1C their cancer was more likely to be aggressive in 
nature.(196,197) 
 
Glycated haemoglobin has also been found to be associated with endpoints related to cardiovascular 
disease. Elley et al. found that a 1% increase in HbA1C increased the risk of CVD (HR 1.08, CI 1.06-
1.10), myocardial infarction (1.08, 1.04-1.11) and stroke (1.09, 1.04-1.13)(198); an earlier 
investigation of data from the European Prospective Investigation of Cancer and Nutrition (EPIC)-
Norfolk found similar results.(199) 
 
There appears to be heterogeneity within findings related to the association between HbA1C and all-
cause mortality. A 2013 study found that, among those without diabetes, there was a non-significant 
association (HR 1.21, 95% CI 0.99-1.47) between raised HbA1C and all-cause mortality; the study 
found no association among those with diabetes.(200) However a number of studies contradict this 
result.(201,202) A Danish study found increased all-cause mortality among those with an HbA1C 
measurement ≥ 7% HR 1.26 (95% CI 1.15, 1.39) and a U-shaped relationship between increasing 
HbA1C and all-cause mortality.(203) A number of studies have highlighted the dangers posed, for 
example by hypoglycaemia, to the health of individuals with diabetes in seeking to maintain strict 
control of blood glucose.(204–206)  
 
2.6 The biological pathway between diabetes and cancer 
As yet there is no definitive explanation for the possible link between diabetes and cancer and a 
number of unexplained biochemical factors still elude researchers. Despite this, a number of 
theories have begun to dominate the research, in both biochemistry and epidemiology, seeking to 
explain the potential pathway between the two diseases. The two charts below highlight the two 
overarching hypotheses.  
 
2.6.1 Hypothesis one 
Hypothesis one suggests that insulin is the main cause of the relationship between diabetes and 
cancer. When type-2 diabetes first occurs hyperinsulinaemia occurs in an attempt to overcome the 
occurrence of insulin resistance in tissue. Insulin and insulin-like growth factor (IGF), along with their 
receptors, are also known to have both proliferative and mitogenic effects upon normal and 
cancerous cells.(207,208) Substances that are mitogenic are usually proteins that trigger mitosis via 
signal transduction and the involvement of mitogen-activated protein kinase. Insulin has also been 
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found to be anti-apoptotic (a substance that reduces cell suicide).(209) A number of studies have 
found that high levels of insulin were positively correlated with a range of site-specific 
cancers.(97,210–212) 
 
IGF-1 is very similar to insulin in being a mitogen and having anti-apoptotic properties. It also shares 
many of its signalling pathways with the protein. The majority of IGF-1 in circulation is produced by 
the liver and only a small proportion of it is unbound, the majority of it being bound to IGF-binding 
proteins (IGFBP). Research has found that high levels of insulin were associated with an increase in 
risk of cancers of the endometrium; while free IGF-1 levels were associated with a decrease, total 
IGF-1 and IGFBP were not associated with this type of cancer.(213) IGF-1 and insulin receptors have 
also been found to be produced, and in some instances over-produced, by cancer cells.(214) Figure 
2-2 details the role of insulin within the biologically plausible relationship between diabetes and 
cancer development. 
 
Figure 2-2: Hypothesis one: a key role for insulin 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.6.2 Hypothesis two 
Hypothesis two takes a broader approach to the relationship between diabetes and cancer, 
suggesting that factors related to diabetes, as well as confounding factors, are involved. Figure 2-3 
demonstrates the influence and interaction of all of these factors within the relationship between 
diabetes and cancer. At around the same time that Tuffier was exploring a potential link between 
diabetes and cancer, other researchers had begun to observe increased rates of hyperglycaemia 
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among those with cancer (for a more detailed investigation of the associations between 
hyperglycaemia and cancer, see section 0 above). Warburg also found that cancer cells could live 
without oxygen if they were in serum that contained glucose and that tumour cells utilised glucose 
at higher rates than normal cells.(99) As in vivo and in vitro research has developed in this field, it 
has been observed that cancer cells take up glucose independently of the presence of insulin and 
that they constitutively take up glucose at near full-capacity. Therefore, some commentators have 
argued that hyperglycaemia is likely to be of less importance, in terms of explaining the relationship 
between diabetes and cancer, than the role of insulin and IGF-1. Because of the Warburg effect it 
has been postulated that inducing hypoglycaemia could induce cancer remission, although the 
research in this area is in its preliminary phase.(215) 
 
During the early part of the 21st century, researchers began to explore the underlying factors that 
could explain the possible link between diabetes and cancer. This research was predominantly 
focussed upon attempts to unravel the influence that obesity might have over any potential 
increased incidence of cancer among diabetics. This was perhaps because, as mentioned previously, 
being overweight or obese increases an individual’s risk of developing type-2 diabetes. Being 
overweight or obese has also been found to increase the risk of developing cancer and mortality 
from the disease(216,217); evidence indicates that, in developed countries, around one in 20 deaths 
from cancer are associated with overweight and obesity,(218) and that its presence may increase 
the risk of cancers of the gallbladder, bowel, womb, breast, oesophagus, pancreas and kidney.(219) 
There are a number of interrelated biological factors which may explain the inter-play between 
overweight and obesity, diabetes and cancer. These are: 
 
 Adipose tissue has been found to be an endocrine organ which releases a range of 
inflammatory cytokines (such as IL-6 which has been found to reduce cell apoptosis) and can 
predispose the body to insulin resistance and hyperinsulinaemia.  
 Adiposity has been found to be related to cancers such as leukaemia and non-Hodgkin 
lymphoma. 
 Lower levels of adiponectin (an insulin sensitiser) are found among those with type-2 
diabetes, obese individuals and those with insulin resistance. Adiponectin is a substance 
which has been found to regulate insulin sensitivity (reducing an individual’s risk of 
developing typ-2 diabetes), down-regulate TNF-α and increase cell apoptosis.  
 Abdominal obesity has been found to reduce the levels of leptin (another cytokine) within 
the body, a substance which encourages insulin sensitivity and reduces free fatty acid levels. 
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There is also a small amount of evidence that leptin may have a role in the metastasis of 
some tumours.(216,220,221)  
 
Figure 2-3: Hypothesis two: the influence of factors related to diabetes and obesity 
 
 
 
 
 
 
 
 
 
 
 
 
 
2.7 Biological pathway between diabetes and site-specific cancers 
Because of the diverse aetiologies for individual cancer, a number of factors have been investigated 
in relation to the association between diabetes and site-specific malignancies. These include: 
 the impact that the slower transit time within the colon, found among diabetics, has upon 
risk of colon cancer(222),  
 evidence of increased incidence of bladder and urinary tract infections among diabetics 
(both factors may increase the risk of these cancers)(147), 
 the influence upon prostate cancer of lower levels of testosterone among men with diabetes 
compared with those without the disease(223), and 
 the increased rate of cirrhosis of the liver caused by non-alcoholic steatohepatitis (for which 
diabetics are at an increased risk).(224) There is also an increased rate of non-alcoholic fatty 
liver disease among those with type-2 diabetes; around 80% of those with type-2 diabetes 
are thought to have it, and this may contribute to increased rates of liver cancer among this 
group. 
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2.8 Diabetes therapies and their role in the associations between diabetes 
and cancer 
The impact of individual anti-diabetic drugs upon cancer risk is difficult to explore because 
individuals may change drug regimen over time, may combine drugs or may stop drug use 
altogether. It may also take a long time for the carcinogenic effect of some drugs to be uncovered, or 
the carcinogenic effect may disappear with drug cessation. Certain treatments may also be used at 
different stages of diabetes, for example the use of exogenous insulin is likely to occur at a later 
stage of type-2 diabetes compared with the use of metformin, with different risks relating to cancer. 
Finally, different anti-diabetic drugs work differently within the body, in relation to their impact 
upon hyperglycaemia and hyperinsulinaemia. Because of all these factors, the following section 
discusses anti-diabetic drugs in relation to their expected impact upon the different elements of the 
diabetic state. 
 
2.8.1 Sulphonylureas and insulin 
In non-diabetic individuals, insulin is produced by the pancreas in the beta-cells. It then travels to the 
liver via the portal vein where a large proportion is used and degraded; because of this, other organs 
receive around one-third to one-tenth the amount of insulin received by the liver.(225) In diabetic 
individuals, who receive their insulin exogeneously, all the organs and tissue receive the same 
amount of insulin. The issue is therefore whether or not these two different forms of insulin 
distribution impact upon the proteins influence over cancer incidence and mortality.  
 
Sulphonylureas are a type of secretagogue and work by activating endogenous secretion of insulin. If 
insulin is the biological mechanism that explains the relationship between diabetes and cancer, then 
a drug which increases hyperinsulinaemia may, hypothetically, increase the risk of cancer among its 
users. However, within the research the evidence is mixed; this may relate to the comparison group 
utilised within the study.(226–228) For example, studies that use individuals taking metformin (as 
the comparison group) may show an increased cancer risk that is caused more by the putative 
protective effects of metformin rather than the deleterious effects of sulfonylureas.  
 
2.8.2 Biguanides and thiazolidinediones 
These types of drugs increase tissue sensitivity to insulin and therefore reduce hyperinsulinaemia. 
The most researched of the biguanides, in terms of its anti-carcinogen properties, is metformin. This 
drug has been found to reduce the risk of cancer among diabetics by around 15%, compared with 
those with diabetes who are not being treated with metformin.(229–231) Metformin also stimulates 
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activated protein kinase (AMPK) which stimulates uptake of glucose by muscle, thus lowering 
hyperglycaemia. A systematic review and meta-analysis found that those being treated with 
metformin for diabetes did have a lower risk of cancer, but that there was a need for further 
research which utilised a range of research methods.(232) 
 
The evidence relating to thiazolidinediones is mixed, in terms of cancer risk among users, and 
commentators have called for further research in this regard.(233–237) 
 
2.9 Evidence from recent studies 
In order to ensure that this literature review included information from the most recent studies, a 
number of searches of PubMed were undertaken throughout the study period (Jan, 2010-November, 
2013). The last of these was performed on the 30th of November, 2013. The key results of these, 
more recent, studies were: 
 
 Those with diabetes were at an increased risk of mortality from all-causes, cardiovascular 
disease and all-cause cancer after adjusting for a range of confounding factors.(238) 
 A consistent association between diabetes and increased risk of developing pancreatic 
cancer.(239) The evidence also supports the hypothesis that diabetes causes pancreatic 
cancer, instead of there being ‘reverse causality’.(240)  
 A reduced risk of developing prostate cancer among men with diabetes, related to a 
protective effect of hyperglycaemia.(241,242) 
 Heterogeneous results related to the associations between diabetes and site-specific 
cancers other than those of the pancreas.(243–246) Meta-analyses found increased risks, 
among those with diabetes compared with the general population, for incidence of and 
mortality from cancers of the stomach, bladder, breast, colorectum, lung, ovary and 
endometrium.(116,247–251)  
 Studies seeking to assess the impact of diabetes treatments upon cancer risk continued to 
be limited by factors such as short follow-up times and the changing treatment regimens of 
those with diabetes.(252) Perhaps because of this, such studies produced mixed results 
when investigating whether specific drugs, such as metformin, had a deleterious or 
protective effect in relation to cancer incidence and mortality.(253–258) A meta-analysis 
explored the impact of insulin upon cancer risk and concluded that the use of the drug was 
associated with increased cancer risk, but that a number of the studies (n=42) included 
within the analysis had methodological limitations.(259) Thiazolidinediones were also found 
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not to be associated with overall cancer risk, (260) while a third meta-analysis found that 
metformin was associated with reduced risk of cancer development and mortality.(261)  
 Within studies which explored the associations between diabetes treatments and cancer 
risk, there were also mixed results depending upon whether cancer in general or site-specific 
cancers were under investigation.(262) 
 Those with diabetes, receiving treatment for cancer, have differing outcomes compared with 
the general population, although the results of these more recent studies were not 
conclusive. These differences in cancer outcome were related not only to the presence of 
diabetes but a number of other factors (such as the use of metformin), and whether the 
focus of the study was all-cancers combined or site-specific cancers.(263–266) 
 The key role that insulin and IGF-1 play in the biological plausibility of an association 
between diabetes and cancer risk among those with diabetes by encouraging cancer cell 
proliferation and reducing cell apoptosis (242,267) 
 
In support of the conclusions of earlier studies, the majority of the most recently published papers 
called for further research to explore the associations between diabetes and cancer incidence and 
mortality. 
 
2.10 All-cause and cardiovascular disease mortality among those with 
diabetes 
There is strong evidence that diabetes negatively impacts upon rates of all-cause mortality among 
those with the disease; 3.96 million deaths are estimated to have been caused by diabetes in 
2010.(46) The biological impact that the disease has upon the body is also associated with an 
increased risk of mortality from a range of conditions and diseases, including cardiovascular and 
renal disease.(268,269) Because of the inter-related nature of the increased all-cause and CVD-
specific mortality experienced by those with diabetes, the following section details the causes 
together in instances where studies produced results for both. 
 
Research exploring the relationship between diabetes and  cardiovascular disease has a history 
dating back to 1965; Ostrander et al. noted that the improving life-span experienced by those with 
diabetes was accompanied by a sharp increase in death from cardiovascular disease.(270) Since 
then, the majority of studies exploring cause-specific mortality and diabetes have found that the 
complications of diabetes and CVD were the main causes of the excess mortality experienced among 
59 
 
those with diabetes; those with diabetes have been found to have up to a fourfold increase risk of 
dying from cardiovascular disease.  
 
An early study found age-standardised all-cause mortality among those with insulin-treated diabetes 
to be 50% higher than those without the disease. For women the relative risk (RR) was 1.77 (95% 
confidence interval (CI) 1.51-2.06) and for men 1.49 (1.29-1.71).(185) They also found excess 
mortality relating to ischaemic heart disease and cerebrovascular disease but not cancer (women RR 
for cancer 0.98, 0.61-1.48; men 0.82, 0.55-1.18). A study published in 1998 found increased 
mortality from all causes after adjusting for age, serum cholesterol, systolic blood pressure, smoking, 
BMI and coronary disease at baseline among those with diabetes (RR 2.50, 2.11-2.95). The RR for 
CVD death among men with diabetes was 2.87 (2.31-3.57).(271) Lotufo et al. found an age-adjusted 
relative risk of all-cause mortality among men with diabetes of 2.3 (2.0-2.6).(272) It is noteworthy 
that after adjusting for age, BMI, alcohol intake, smoking and exercise status the increased risk did 
not change significantly (RR 2.1, CI 1.9-2.4) The same study found an increased risk of mortality from 
coronary heart disease (CHD) among those with diabetes (RR 3.3, CI 2.6-4.1). Guzder et al. found an 
increased odds ratio for all-cause mortality among those with diabetes compared with the general 
population (OR 2.47, CI 1.74-3.49).(79) A study of those with Type-2 diabetes found a SMR of all-
cause mortality among diabetic women of 1.83, CI 1.51-2.16 and 1.43, CI 1.18-1.67 among men.(273) 
The majority excess was driven by diseases of the circulatory system (SMR women 1.94, CI 1.52-2.36, 
men 2.09, CI 1.67-2.51) and not cancer (women 1.09, CI 0.56-1.62, men 0.79, 0.41-1.17) or other 
causes (women 1.70, CI 1.06-2.34, men 0.99, CI 0.56-1.42). 
 
Barr et al. found that all-cause mortality hazard ratios decreased among those with newly diagnosed 
diabetes compared with those with known diabetes (HR 1.3, CI 0.9-2.0 and 2.3, CI 1.6-3.2 
respectively in comparison with the general population).(269) Panzram et al. also found that age-at-
onset of type-1 diabetes was the key factor in determining the excess of all-cause mortality 
experienced by those with this form of diabetes.(19) Gu et al. found an increase in the relative risk of 
all-cause mortality among their diabetic cohort, which decreased with age (25-44 RR 3.6, p<0.05, 45-
64 RR 2.2, p<0.05, 65-74 RR 1.5, p<0.05).(274) A number of studies supported this finding: Bertoni et 
al. found that, among those over the age of 65 (receiving Medicare) with diabetes, excess mortality 
decreased with increasing age but the excess persisted even among the oldest age group (65-69 RR 
2.59, CI 2.37-2.82, >85 RR 1.46, CI 1.43-1.49).(73) Swerdlow and Jones also found that all-cause 
Standardized Mortality Ratios (SMR) were greatest within the youngest age group among those with 
60 
 
diabetes, compared with the general UK population, and decreased significantly as age increased (p< 
0.001).(275) 
 
An Italian cohort study found an all-cause SMR of 1.42, CI 1.35-1.50 among those with diabetes 
compared with those without the disease.(276) For CVD the SMR was 1.34, CI 1.23-1.44. This study 
found that, although raised, the excess CVD mortality was not as high as that found within American 
diabetic cohorts. Related to this they noted that this may be due to the severity of the diabetes 
within different countries, or the differing treatment cultures, for example within the US >25% of 
those with type-2 diabetes are treated within insulin compared with <10% of those in Italy. 
However, it was also found that mortality from cancer, respiratory disease and injury and poisoning 
were not significantly raised. They also found differences in all-cause mortality related to the 
diabetes treatment being used: those who were treated with diet alone had an increased survival 
compared with those treated with insulin or oral diabetic drugs (potential confounding factors are 
discussed in greater detail in later sections of this chapter). The study also proposed that there was a 
latency period between the onset of type-2 diabetes and its diagnosis of 7-10 years, within which 
mortality may be higher than once the disease had been diagnosed. 
 
Koskinen et. al. found increased relative mortality among diabetic women of 3.39 (CI 3.30-3.49); for 
men the corresponding figures were 2.41 (CI 2.34-2.48).(277) Circulatory diseases were found to be 
driving this excess in mortality, with over half of all deaths being recorded as ischaemic heart 
disease. Skrivarhaug et al. found an excess in CVD mortality of 4.0, 95% CI 3.2-4.8 among those with 
type-1 diabetes.(184) The Barr et al. study discussed previously found that those with known 
diabetes had an increased hazard ratio for CVD mortality, after adjustment for age, sex and other 
CVD risk factors (HR 2.6, CI 1.4-4.7).(269) They postulated that increased glycaemia may start to 
impact upon mortality before it reaches a level that would be diagnosed as diabetes. A study 
focussed upon mortality from CVD among those with diabetes found that those with the disease had 
the same risk of dying of CVD as those who had already experienced a myocardial infarction (MI) and 
that once an individual with diabetes experienced a MI they were more likely to die of it than those 
without diabetes(278); this result was supported by other studies utilising different 
populations.(279) 
 
The WHO Multinational Study of Vascular Disease in Diabetes found that CVD was the main cause of 
death among those with type-1 and type-2 diabetes (44% and 52% respectively).(280) They also 
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found differing SMRs between international study sites; for example women and men in Tokyo who 
had type-2 diabetes had a very low excess mortality compared with the general population.  
A 2009 paper utilised the large sample within The Framingham Heart Study and found that the all-
cause and cause-specific mortality excess experienced among their diabetic cohort had begun to 
decline between the period 1950-1975 and 1976-2001.(281) Despite this, an increase in all-cause 
mortality persisted among those with diabetes within both time periods (HR, 2.44; P<0.0001 and 
1.95; P<0.0001 respectively). Cardiovascular mortality was reduced from fourfold to threefold 
between the two time periods. This suggests that, within the Framingham study, much of the 
reduction in excess was caused by lower rates of CVD mortality within the second time period.  
In summary, those with diabetes have increased all-cause mortality. Although the majority of this 
excess mortality appears to relate to the increased risk of cardiovascular disease caused by the 
consequences of diabetes itself, there is also some evidence of differences in the mortality rate from 
other causes. Heterogeneity between study results, utilising data from national studies, further 
suggests that need for research exploring the associations between diabetes and all-cause and 
cause-specific mortality which utilise data from UK-based, nationally representative samples. 
 
2.10.1 Respiratory disease 
Although the evidence related to mortality from respiratory disease among those with diabetes is 
limited, Dawson et al. found increased SMRs among women and men with type-1 diabetes (SMR 
3.31, CI 1.98-4.63 and 2.32, CI 1.41-3.23 respectively).(78) There is a limited amount of evidence 
relating to the biological plausibility of a relationship between diabetes, obesity and respiratory 
disease. Zammit et al. postulate that obesity may alter lung physiology, cause inflammation (both 
systemic and within respiratory organs(282) but this requires further exploration with regard to its 
potential as a confounding factor between diabetes and such diseases. 
 
2.10.2 Renal disease 
One of the key complications of diabetes, which is found at low rates among the general population, 
is renal disease. A report from the Pittsburgh Epidemiology of Diabetes Complications Study found 
that, among those with type-1 diabetes who maintained normoalbuminuria (an indicator of kidney 
function), mortality rates were similar to those for the general population (SMR 1.3, CI 0.2–2.5).(283) 
Secrest et al. found that the leading cause of death, within the first ten years following diagnosis of 
diabetes, was complications related to the diabetes itself (renal, CVD, infections); this accounted for 
73.6% of all deaths within this time period within their type-1 diabetic cohort.(171) Within the next 
ten years, mortality was split almost evenly between renal diseases, CVD, acute causes and 
62 
 
infections. After 20 years, the leading cause of death returned to being complications of diabetes; 
within this, around 40% related to CVD complications. The study also found that women and those 
from black and minority ethnic (BME) communities had significantly higher diabetes-related 
mortality compared with men and those from white communities. Of note, the study found that 
deaths not related to diabetes did not differ between those with diabetes and those without.  
 
2.11 Conclusion 
To conclude this chapter the following section discusses the evidence related to the associations and 
relationships between diabetes and cancer within the context of proving causality. 
 
Diabetes and cancer: assessing causation 
In his seminal address on the subject of causality, Bradford Hill listed a number of the components 
that he considered key to assessing causation.(98) Based on the evidence considered within the 
above literature review, the following section discusses these components in the context of the 
potential causal relationship between diabetes and cancer. 
 
Strength 
The strength of the evidence relating to the association between diabetes and cancer is mixed. This 
is dependent upon a number of factors including the research method used, the definition of 
diabetes within the study and the cancer focussed upon (whether the research explores cancer in 
general or a site-specific cancer).  
 
Consistency 
Similarly to strength, findings within the research relating to the association between diabetes and 
cancer have been inconsistent. The key areas of inconsistency are related to research method used 
and cancer site and type of diabetes analysed. For example, within the literature relating to type-1 
diabetes, mixed results were found depending upon which method was used. The country within 
which the study occurred also appears to influence the strength of the association between diabetes 
and cancer. This suggests that, in order to understand the excess mortality among those with 
diabetes in a particular country, it is necessary to undertake research within that country. 
 
Specificity 
Diabetics have increased mortality across all ages, the majority of which is caused by cardiovascular 
diseases, as well as neuropathy, nephropathy and retinopathy. Therefore the relationship between 
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diabetes and cancer is weak in terms of specificity, in that diabetes increases the risk of a number of 
other diseases. 
 
Temporality 
Temporality refers to the order in which diseases occur. The evidence found within this literature 
review suggests that diabetes precedes cancer in all but one case, that of cancer of the pancreas, 
where evidenced is mixed as to ‘reverse causality’ caused by an occult malignancy.  
 
Biological gradient 
Again the evidence is mixed as to a dose-response effect within the relationship between diabetes 
and cancer incidence and/or mortality. There does appear to be some evidence to suggest that 
cancer risk is increased among those with a raised glycated haemoglobin measurement but that the 
association may be strongest among those with a measurement between 6 and 7% and tails off 
above this level. 
 
Plausibility 
The biological evidence relating to the association between the two diseases is strong: 
hyperinsulinaemia and hyperglycaemia appear to be associated with an increased risk of cancer 
development, both within epidemiological and biological research. Other factors present within 
diabetes, and overweight and obesity, also contribute to the strength of this evidence. 
 
Coherence, experiment and analogy 
Exogenous insulin, insulin sensitivity, Insulin-like Growth Factor-1 (IFG-1) and obesity have all been 
found to mediate and/or encourage the increased growth of cancer within rat and mouse 
models.(284–286) Current knowledge relating to cancer suggests that its development is related to 
factors present within both the metabolic syndrome and diabetes. An analogous example that may 
relate to the association of diabetes and cancer may be cirrhosis of the liver, found at increased 
rates among those with diabetes, as well as being a known risk factor for malignancies of the liver. 
At the same time, as mentioned above, increased hyperinsulinaemia and hyperglycaemia have been 
found to be related to cancer development. 
 
While a number of interventions have attempted to reduce the rate of diabetes, such as those 
relating to lifestyle changes and tight glycaemic control, the impact this has upon cancer risk is, as 
yet, unclear. Thus the experimental evidence relating to a link between the two diseases, and the 
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prevention of cancer among those with diabetes, is currently mixed. The evidence relating to the use 
of anti-diabetic drugs which reduce hyperinsulinaemia and hyperglycaemia, specifically metformin, 
suggests that lowering the occurrence of these factors can reduce the risk of the development of 
cancer.  
 
A number of diseases have been found to increase the risk of site-specific cancers, but evidence is 
limited in relation to diseases that have similar characteristics to those of diabetes. Therefore, 
analogous evidence in this area is limited. 
 
2.12 Literature review: gaps in our current knowledge 
A number of issues make it difficult to draw statistically robust conclusions about the relationship 
between diabetes and cancer, based on current findings. The overarching issue is the heterogeneity 
of findings. Even though research undertaken post-1980 utilised more rigorous research methods 
than before, studies continued to draw mixed conclusions. The result is that no clear consensus has 
been reached regarding the relationship between the two diseases. Up to the present time, research 
that has focussed upon the relationship between diabetes and cancer has elicited a number of 
broad, overarching and often contradictory results. The majority of the more recent studies support 
an association between diabetes and overall cancer mortality, although the magnitude of the effect 
differs between studies and whether or not there are associations between diabetes and site-
specific cancers has yet to be clarified. Previous studies also demonstrate a number of gaps in our 
knowledge related to: 
 
 the extent to which confounding factors (in particular overweight and obesity) explain the 
associations between diabetes and cancer, 
 how the risk of cancer differs between those with type-1 and type-2 diabetes, 
 the impact diabetes has upon the risk of developing and/or dying from site-specific cancers, 
 whether or not the impact that diabetes has upon cancer risk differs between the sexes, 
 how comorbidities, particularly CVD, impact upon the associations between diabetes and 
cancer, 
 whether or not there is an association between glycated haemoglobin and cancer incidence 
and mortality, 
 how the use of medications impact upon the cancer risk among those with diabetes, 
 the biological pathway between diabetes and site-specific cancers. 
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These findings suggest the need for further research which explores the association between 
diabetes and cancer incidence and mortality, the role of confounding factors (specifically overweight 
and obesity) within the associations and the dose effect of glycated haemoglobin upon cancer risk. 
The next section details the study aims, objectives and hypotheses that were developed after a 
consideration of the above gaps in our knowledge.  
 
2.13 Hypotheses, aims and objectives 
Following on from the literature review, a number of research questions were developed for the 
study and these were accompanied by specific aims and objectives. The following sections detail 
how the research questions, and hypotheses, at the heart of the research were developed and 
informed. 
 
2.13.1 Development of the research question and hypotheses 
As discussed above, there is heterogeneity within current results related to the associations 
between diabetes, glycated haemoglobin and incidence of and mortality from cancer and there are a 
number of gaps within our current knowledge related to this research area. Through the use of 
Health Survey for England and Scottish Health Survey linked to Cancer Registry and mortality data it 
was felt that this study could overcome some of the issues that had hindered previous studies; for 
example the utilisation of large enough datasets, or datasets with sufficient data related to potential 
confounders, to appropriately assess any potential associations.  At this juncture a number of more 
detailed objectives were developed, related to an exploration of: 
 
 the relationship between diagnosed diabetes and cancer incidence and death (all-cause and 
site-specific), 
 the impact of glycated haemoglobin upon the risk of cancer incidence and mortality among 
those with and without diabetes, 
 the impact that overweight and obesity have upon the associations between diabetes and 
cancer, 
 the effect of lifestyle and socio-economic/demographic factors upon the above association.   
With the data available in the Health Survey for England, Scottish Health Survey and also an 
occupational cohort, Whitehall I, it was also possible to assess the impact that diabetes had upon 
mortality from other causes including cardiovascular and respiratory disease and ‘other’ causes. The 
review of the literature demonstrated that the extent to which diabetes impacted upon mortality 
from other causes, particularly within a nationally representative UK-based dataset linked to up-to-
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date mortality data, had not been fully explored. Further to this, if diabetes were found to increase 
mortality from other diseases, this result would complement those which found associations 
between diabetes and cancer. Because of this, analyses of the associations between diabetes, HbA1C 
and all-cause and cause-specific mortality form part of the analyses undertaken within this thesis.  
The literature review highlighted the strong associations between diabetes and CVD, although there 
was a limited amount of evidence related to how comorbid CVD might impact upon the associations 
between diabetes and cancer. The recording of CVD as a longstanding illness within the HSE and 
SHeS meant that it was possible to include an exploration of this matter within the analyses 
undertaken in support of this PhD.  
 
Based upon the results of the literature review and a consideration of the aims of the study, a 
number of research questions and  hypotheses were developed.  
 
Research Questions 
Does the presence of diabetes, or a raised glycated haemoglobin measurement, alter the risk of 
incident cancer (both all-cause and site-specific) and/or mortality (all-cause, cause-specific and site-
specific cancer mortality) among the general population? 
 
Previous research has found a substantial association between diabetes and cardiovascular disease 
mortality; does this study support this association? Does the presence of diabetes, or raised glycated 
haemoglobin, impact upon mortality from other causes (including respiratory disease)? 
 
 
Null Hypotheses 
HØa 
Individuals with diabetes do not have an increased risk of developing cancer compared with the 
general population. 
AND 
Individuals with diabetes do not have an increased risk of dying from cancer compared with the 
general population 
 
HØb 
A raised glycated haemoglobin measurement is not associated with an increased risk of incident 
cancer nor mortality from the disease. 
 
The following hypothesis was developed in relation to the impact that diabetes might have upon 
mortality from diseases other than cancer.  
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HØc 
Diabetes is not associated with mortality from other causes (cardiovascular and respiratory disease 
and ‘other’ causes). 
 
Alternative Hypotheses 
H1 
The specifics of having diabetes directly increase the risk of an individual developing cancer. This 
increase in cancer incidence is above that caused by related factors such as adiposity. 
 
H2 
Individuals with diabetes are more likely to die of cancer than individuals who do not have diabetes.  
 
H3  
An increased glycated haemoglobin level is associated with an increased risk of developing cancer 
and of mortality from the disease.  
 
H4 
Diabetes is associated with an increased risk of mortality from other causes (specifically 
cardiovascular and respiratory disease). 
 
Following an introductory investigation into the variables that were available within the HSE, SHeS 
and Whitehall I as well as an assessment of the gaps in current research within this area, further 
hypotheses were added which took into account the presence of cardiovascular disease (CVD) as a 
comorbidity.  
 
Null Hypothesis 
HØd 
The presence of comorbid CVD has no impact upon the associations between diabetes and cancer 
incidence or mortality.  
 
H5 
Comorbid CVD alters the strength of the association between diabetes and incidence of and 
mortality from cancer. 
 
1.1.1 Aims 
The key aim of the study was to utilise data from the HSE, SHeS and Whitehall I to assess the 
associations between diabetes and incidence of and mortality from cancer. The breadth of the 
nationally representative HSE and SHeS datasets, also enabled an investigation of the effects of 
confounding factors such as overweight and obesity, the presence of CVD as a comorbidity and 
socio-economic and demographic factors. The age of the Whitehall I cohort further enabled analyses 
of a dataset with around 80% mortality and a follow-up period of 40 years. 
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Among Health Survey for England and Scottish Health Survey participants who had a valid 
measurement for glycated haemoglobin (HbA1c) level, the study also sought to explore if an 
association exists between raised HbA1c level and incidence of and mortality from cancer.  
 
1.1.2 Objectives 
The research objectives were to: 
 
 Establish if there are differences in the relative risk of developing cancer between those with 
and without diabetes. 
 Assess how much of this relationship is explained by a range of confounding factors and the 
extent to which diabetes is an independent risk factor for incidence of and mortality from 
cancer. 
 Investigate the relationship between HbA1c level and cancer incidence and mortality among 
the general population. 
 Assess the impact that comorbid CVD has upon the associations between diabetes and 
cancer incidence and mortality. 
 Establish the strength of the associations between diabetes and mortality from CVD, 
respiratory disease and ‘other’ causes. 
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3. Chapter 3: Data sources 
Three different datasets were used within this study to explore the associations between diabetes, 
glycated haemoglobin and incidence of and mortality from cancer (as well as all-cause and cause-
specific mortality) – the Health Survey for England, the Scottish Health Survey, and the Whitehall I 
cohort. Each of these is detailed below. 
 
3.1 The Health Survey for England  
The Health Survey for England (HSE) began in 1991 and is a cross-sectional survey which utilises a 
large, nationally representative new random sample each year, currently commissioned by the 
Health and Social Care Information Centre; until 2004, the survey was commissioned by the 
Department of Health. Since its inception, the survey has covered the adult population living in 
private households, with children being included from 1995. The survey collects a wealth of socio-
economic and demographic information, as well a range of objective health measurements. A 
number of the stated aims of the survey specifically relate to this research and these are monitoring 
the nation’s health; the prevalence of specific diseases and lifestyle risk factors associated with them 
(such as overweight and obesity); and the differences in the health of specific populations.(287) 
 
Each year the survey includes core topics related to health and lifestyle behaviours (for example 
long-standing illnesses, smoking and drinking) as well as physical measurements (blood pressure, 
height and weight) and biological samples (blood and saliva). Added to this are topics related to 
specific issues, such as cardiovascular disease (CVD), lung function and physical activity. The health 
of specific communities or sections of society, such as black and minority ethnic communities or 
older people, have also been focussed upon.  
 
3.1.1 Design of HSE 
Sampling 
The survey utilises a two-stage stratified multi-cluster design with random probability sampling. This 
approach sees the population divided into non-overlapping postcode areas (the Primary Sampling 
Units); following this, a second stage of sampling occurs to select the addresses to participate in the 
survey. This results in the survey using a nationally representative sample of all adults (16+) living in 
private accommodation. The survey utilises a new sample drawn from the general population each 
year. Through the use of the Postcode Address File, a random sample of postcode sectors are 
selected; the number selected changes by year. Within these, a further random sample of ‘delivery 
points’ (addresses) are selected, which makes up the sample size. For example within the HSE 2005, 
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the total number of addresses selected was 18,720 made up from 26 addresses within each of the 
720 postcode sectors.(288) To ensure that each address in England has an equal probability of being 
selected (even though the sample is clustered) postcode sectors are in the sampling frame in 
proportion to the number of addresses they contain. Among adults, a total of 10 can be interviewed 
within any single household, while for children only two can be included in the core survey, to 
reduce participant burden on parents. 
 
In some years of the HSE boost samples were used in order to increase the number of individuals 
from specific groups within the HSE cohort, these were:  
 
 1999 and 2004 included boosts of individuals from ethnic minority communities. 
 2005 included one boost of those aged 65+ and one of children between the ages of 2-15. 
 
Within the HSE there are certain core questions that are asked each year, there are also boost 
samples which enable the monitoring of specific areas of interest and comparisons to be drawn 
across years (for an overview of the focus of each year of the HSE see Appendix Six: Focus of the 
Health Survey for England 1991-2010). The data used within this research includes only the core 
sample of adults; children under the age of 16 were excluded from the analyses, primarily because 
they could not give consent for their data to be linked to mortality and Cancer Registry data. In 2006, 
because of the length of the survey, only a 50% sub-sample of those aged 65+ were asked to 
complete the module of the survey related to CVD (which included specific questions related to 
diabetes).  
 
3.1.2 Data collection 
The HSE utilises a two-stage, computer assisted personal interviewing (CAPI) process for data 
collection. The first of these is a face-to-face interview which consists of the core questions, detailed 
below, as well as those within the specific issue section.  
 
Core modules within the Health Survey for England interviewer visit: 
 household level information,  
 demographic and socio-economic information, 
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 health-related questions, for example the presence of longstanding illnesses, such as 
diabetes and cancer (for further information about how these variables were used in the 
current study see section 3.8.1.), 
 lifestyle behaviours, such as smoking and alcohol consumption, fruit and vegetable 
consumption since 2001, and physical activity in some years, 
 height and weight measurements.(287) 
 Within this study, information gathered at this stage of the survey process enabled an exploration of 
those who indicated doctor-diagnosed diabetes and/or volunteered the disease as a longstanding 
condition. 
If an individual agrees, the interview is then followed by a nurse visit; between 1994 and 2008, 66% 
of interviewed participants took part in the nurse visit. The following are examples of questions and 
measurements either asked/collected each survey, or in particular years, of the survey: 
 Which prescribed medications are used by the individual, coded to categories of drug; asked 
within each year of the HSE and SHeS, the information gathered from this question has been 
used within this thesis to create the variables relating to the use of anti-diabetic drugs 
(variables medbi1-medbi22). 
 Which vitamins are taken by the individual. 
 Measurements of the hip and waist circumference and blood pressure.  
 Saliva samples to measure cotinine levels (assessment of exposure to tobacco). 
 Urine sample which allows for the measurement of creatinine, potassium, sodium and/or 
albumin.  
 Blood sample which allows for the measurement of a number of analytes, which have varied 
over time. Relating specifically to this study, the taking of blood samples enables 
measurements of glycated haemoglobin to be taken.(289) 
3.2 The Scottish Health Survey  
The Scottish Health Survey (SHeS) took place in the years 1995, 1998, 2003, and 2008-2013; the 
survey is also running for the years 2014-2015. Within this study, data from SHeS 1995, 1998 and 
2003 were utilised. 
 
3.2.1 Design of the SHeS 
Sampling 
72 
 
All private households within Scotland were eligible to be included in the SHeS; a maximum of three 
households per address could be included. Similarly to the HSE, the SHeS utilised the Postcode 
Address File and a random sample approach. For the SHeS 1995, one person aged 16-64 within each 
household was eligible for inclusion. In 1998 all adults (aged 16-74) were eligible but only one was 
selected for interview. Within the years 2003 and 2008 onwards all adults and up to two children 
were eligible; boosts samples were also taken within these years to ensure that sufficient numbers 
of children were included in the survey.(290,291)  
 
As mentioned previously this study is limited to the adult sample of the HSE and SHeS. Therefore no 
further mention will be made of child-specific aspects of either dataset. Because this study only 
included HSE data up to 2008, no mention will be made of the datasets, nor changes to the surveys, 
from 2008 onwards. See section 3.8 for a discussion of the size of the overall sample, and the 
method for identifying those with diabetes.  
 
3.2.2 Data collection 
The design of the SHeS was similar to that of the HSE in that it is formed of a two-stage process, both 
of which collect the required information via the use of a CAPI.(292) 
The HSE and SHeS are general population health examination surveys combining survey interview 
data with measurements and biological samples taken from participants. Because the surveys utilise 
samples of the whole non-institutionalised population, they are better able to produce information 
related to the prevalence of a specific disease or lifestyle behaviour and the rates of undiagnosed 
disease, than surveys carried out with self-selecting cohorts such as those undertaken within health 
care settings. Within this study, data from the HSE to 2008 are used; the 1994, 1998, 2003 and 2006 
surveys asked specifically about doctor-diagnosed diabetes within the cardiovascular interview 
schedule (similar questions were asked in each year of the SHeS). More information about the focus 
of each year of the HSE is provided in Appendix Six. 
3.3 Whitehall I 
Whitehall I is a cohort study of male civil servants. Originally the data was used to explore the 
associations between employment grade and health outcomes and inequalities; early publications 
focussed upon areas related to cardiovascular disease.(293,294) 
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3.3.1 Data collection 
Collection of baseline data for Whitehall I occurred between the years 1967 and 1970.(295) In total, 
19,019 male civil servants working in London and aged 40-69 were surveyed to gather information 
related to health, socio-demographic information and lifestyle factors related to health. The 
participants also underwent a clinical examination.  Subsequent data collection waves were also 
undertaken, including a re-survey of participants in 1997-1998 (see section 3.5.1), as well as data 
linkage to mortality records. 
 
3.4 Amending variables to achieve conformity and appending the datasets 
An initial exploration of the 15 datasets within the HSE and three within the SHeS illustrated 
inconsistencies within variable values and coding, even where they were based on identical 
questions. These inconsistencies were addressed by the production of syntax for each survey year to 
recode the variables in a uniform manner. Table 3-1 (below) details each variable, within the 
minimum dataset used within this research, and when recoding was required.  
One of the key issues was lack of uniformity across datasets in relation to the ‘Missing values’; these 
were different both within and across the HSE and SHeS. To remedy this, further syntax was created 
for each year. For each variable, the missing values were re-coded as follows:  
 
 -9.00 ‘Not answered’ 
 -8.00 ‘Don’t know’ 
 -6.00 ‘Schedule not obtained’ 
 -2.00 ‘Schedule not applicable’ 
 -1.00 ‘Item not applicable’ 
 
It was also necessary to recode a number of the dichotomous variables included within each year of 
the HSE and SHeS. This ensured that across all of the survey years ‘1’ indicated the presence of a 
disease or occurrence of an event (for example diabetes or death) and ‘0’ indicated the absence of 
disease or that an event had not occurred. 
 
A string variable was then created which included information related to survey (whether HSE or 
SHeS), survey year and the serial ID for each case: this ensured that each case had a unique identifier 
when the survey datasets were appended. Cases from each year of the HSE and SHeS were then 
appended to the 1994 HSE dataset until all survey years were included.
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Table 3-1: Recoding of variables within the minimum dataset 
Year Variables 
HSE Longill
a 
Illsm  
1-6
b
 
diabete2
c 
everdi ageinfo1 medbi 01-
22
d 
medcindi advicedi docinfo1 insulin age sex height weight 
1994  Ills 1-6 diabdef  ageinfdi med 1-16   docinfdi   gender   
1995   N/A N/A N/A medbi 1-
15 
N/A N/A N/A N/A     
1996   N/A N/A N/A medbi 1-
15 
N/A N/A N/A N/A     
1997   N/A N/A N/A  N/A N/A N/A N/A     
1998 *              
1999 *  N/A N/A N/A  N/A N/A N/A N/A  *   
2000   N/A N/A N/A  N/A N/A N/A N/A  *   
2001   N/A N/A N/A  N/A N/A N/A N/A     
2002   N/A N/A N/A  N/A N/A N/A N/A     
2003 *   *   * * * *     
2004 *  N/A N/A N/A  N/A N/A N/A N/A     
2005 *  N/A N/A N/A  N/A N/A N/A N/A     
2006 *  * * *  * * * *     
2007 *  N/A N/A N/A  N/A N/A N/A N/A     
2008 * * N/A N/A N/A  N/A N/A N/A N/A     
SHeS 
1995 *  * cvd8* diage* medbi 01-
16 
dimed* othdi* diabetes* * respage respsex   
1998 * * * * * medbia 1-
18 
* * * * ageyrs    
2003 *  *   Medbi 
1-18 
* * * *  *   
a longill – Presence of a longstanding illness 
b illsm1-6 – Detailed information about the longstanding illness (up to a total of six) 
c diabete2, everdi, ageinfo1, medcindi, advicedi, docinfo1 and insulin – Each of these variables gives information related to diabetes 
d medbi1-22 – Detailed information about the medications that the participant is taking 
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Table 3-1: Recoding of variables within the minimum dataset (continued) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
*  Denotes that it was necessary to produce syntax to create uniformity across variable values (including missing values). 
Year Variables 
Household 
social 
class 
Individual 
social 
class 
Age at 
leaving 
education 
Highest 
qualification 
Cigarette 
smoking 
status 
BMI Waist: hip 
ratio 
Waist 
circumference 
Blood 
sample 
taken 
Ethnicity 
HSE sclasshoh sclass educend edugrouped cigsta3 Bmi waisthip Allwaist Samptak ethnic 
1994 schhstu1 scallx  topqual cigsmkng  alwhipra   * 
1995 scchstx1   quala 1-11 current  N/A N/A  * 
1996 schhstx1   quala 1-11 cigsmk2  N/A N/A  * 
1997 hsclass   topqual2* cigst1  whval Wstval * * 
1998 hsclass scallx  topqual3* cigst1  whval Wstval  nethnic 
1999 hsclass scallx  topqual3*   whval Wstval Samptakb ethnich 
2000 schrpg7 scallx  topqual3*   whval Wstval  ethnici* 
2001 schrpg7 scallx  topqual3*   whval Wstval  ethnici 
2002 schrpg7 scallx  topqual3*   whval Wstval  ethnici 
2003 schrpg7 scallx  topqual3*   whval Wstval  ethnici 
2004 schrpg7 scallx  topqual3*   whval Wstval  dmethn04 
2005 schrpg7 scallx  topqual3*   whval Wstval  ethinda* 
2006 schrpg7 scallx*  topqual3*   whval Wstval  ethinda 
2007 schrpg7 scallx*  topqual3*   whval Wstval  ethinda* 
2008 schrpg7 scallx*  topqual3*   whval Wstval  ethinda* 
SHeS 
1994 ciesc soccls*  topqual* cigmk2  alwhipra waistc1 & 2   
1998 soc2 sc  topqual* cigst1  whval wmeas1, 2 & 3   
2003 sccieg7  * hedqual cigst1   Wstval  ethnicl* 
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3.5 Creation of variables within the HSE and SHeS 
A number of variables were required that were not available within the baseline survey datasets, but 
could be created from the variables provided. Table 3-2 below details these variables. 
 
Table 3-2: Variables produced as part of this study 
Variable  Variables available within 
HSE and SHeS 
Region (South, Midlands, North, Scotland) 
 
NHS region and GORa 
All Diabetes (Diabetes: Yes/No) (see section 
3.8.1) 
illsm 1-6, medbi 1-22, 
diabete2 
Glycated Haemoglobin (<6.5%/≥6.5%) 
 
Glyhbval 
Diabetes and Glycated haemoglobin 
combined 
illsm 1-6, medbi 1-22, 
diabete2 & glyhbval 
Waist-hip ratio all (Waist/Hip raised: Men 
≥=0.95, Women ≥0.85) 
Waisthip 
Waist raised all (Waist raised: Men >102cm, 
Women> 88cm) 
Allwaist 
Ethnicity (White/Black/South Asian/Other) 
 
Ethnic 
BMI Grouped (<20/20-24.9, 25-29.9, 
≥30kg/m2) 
Bmi 
All Cancer Mortality (Yes/No/Died of 
another cause) 
CauseDeath 
Site-Specific cancer mortality 
 
CauseDeath 
Cause-Specific mortality (Cancer, CVD, 
Respiratory and ‘other’ causes) 
CauseDeath 
Age Grouped (16-64/65-75/75+) 
 
Age 
Cardiovascular Disease at Baseline 
 
illsm 1-6 
Cancer at Baseline 
 
illsm 1-6 
a 
Government Offices for the Regions (South West, South East and East Anglia=South, West Midlands and East 
Midlands=Midlands, North West, Yorkshire and Humberside, and North =North and cases from SHeS = 
Scotland). 
 
 
3.5.1 Variables within Whitehall I 
Although not as extensive as the HSE and SHeS, in terms of the scope of baseline variables available, 
Whitehall I included a number of variables related to this study. These were: 
 Employment grade 
 Date of birth/Age 
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 Smoking (Current/Ex/Never) 
 Diabetes status (+Age at diagnosis + Insulin use) 
 Medications 
 BMI 
 Weight 
 Height 
 Waist circumference 
 Waist to hip ratio 
 Fasting blood glucose 
 Serum cholesterol 
 Cause of death (all-cause, CVD, coronary heart disease (CHD) and cancer (all-cause and site-
specific)) 
 Variables required to undertake survival analysis (date of interview, date of death, length of 
time within study) 
A re-survey of original Whitehall I participants was undertaken in 1997-1998; the sample size within 
the re-survey totalled 7,033 participants. Those involved completed a postal questionnaire and 
visited their general practitioner in order to have health-related measurements taken. Variables 
within the re-survey, related to this study, included: 
 Age 
 Height (self-reported) 
 Weight (self-reported) 
 Smoking (Current/Ex/Never) 
 Alcohol 
 Self-rated health 
 Grouped medication 
 Grouped longstanding illness 
 Grouped cause of death 
 Diabetes status 
 BMI  
 Variables related to survival analysis (date of original survey, date of resurvey, date of death 
and time within the survey) 
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3.6 Creation of variables within Whitehall I 
The Whitehall I dataset required less manipulation, as the variables mentioned above were already 
available. In order to be able to compare results of the analyses of the HSE and SHeS with Whitehall I 
results, categorical variables were produced that matched those within the former dataset in 
relation to: 
 BMI (<20/20-24.9, 25-29.9, ≥30 kg/m
2
) 
 Age (16-64/65-75/75+) 
 The presence of comorbid CVD 
3.7 Research ethics 
Research ethics approval was gained for each year of the HSE and SHeS from relevant Research 
Ethics Committees prior to the undertaking of the each year’s survey. Approval to link this data to 
health outcomes data (Cancer Registry and mortality data, via the National Health Service Central 
Register (NHSCR)) was gained from the NHS Information Centre. From 2003 onwards, each adult 
participant was asked for their consent to link their HSE data to health outcomes data (the consent 
form explicitly mentioned the Cancer Registry and mortality data). In the years 1994-2002, 
participants were asked for consent for data linkage to mortality records but were not asked about 
data linkage to the Cancer Registry so, for the purposes of the analyses required for this research, 
the issue arose as to whether it was ethically and legally appropriate to seek the linking of data for 
years when individuals did not give their consent. Within both time periods around 90% of 
participants agreed to their data being linked, suggesting that those who agreed to their data being 
linked to mortality data would also have agreed to their data being linked to the Cancer Registry (if 
they had been asked). On the 27th of October, 2010, ONS who at that time held both of the 
outcomes datasets agreed that consent for data linkage for mortality would also cover the Cancer 
Registry data.  
 
ONS, and those linking the data at Natcen, agreed that the legal basis for the release of mortality 
data from ONS via MRIS was covered by S42(4) of the Statistics and Registration Service Act 2007, 
while cancer data was covered by S251 Class Action (pre 2003) and consent (post 2003). Therefore, 
even though participants had not explicitly given their consent for the linking of their data to the 
Cancer Registry - it was appropriate to analyse data linked to the Cancer Registry pre-2003.This 
information has been amended from a correspondence with ONS. 
This meant that accessing the linked Cancer Registry data would require a data release request being 
made to NatCen Social Research in the same way as accessing the linked mortality dataset would. 
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For Whitehall I, ethical approval had been given for the linking of data with mortality records prior to 
this study, therefore after agreeing the remit of this study (with PhD supervisors and the Whitehall I 
data holders at UCL) it was decided that no further ethical approval was required.  
 
3.8 Identifying the diabetic cohort within the data 
The following section details the questions within the datasets which enabled the identification of 
the diabetic cohort. 
 
3.8.1 HSE and SHeS 
Within the HSE and SHeS surveys there are three different variables relating to diabetes. Two of 
them are asked within the initial interview. 
 
Do you have any long-standing illness, disability or infirmity?  
 
Among those who answer yes to this question, the interviewer then asks the participant which 
illness or illnesses they have. Unlike the diabetes specific question below, this question is open and 
requires the participant to volunteer the illnesses they have. All of the long-standing illnesses the 
individual has, up to a maximum of six (variable names illsm1-illsm6), are coded to a high level of 
disease or group of diseases. Within the longstanding illness code-frame, diabetes is represented by 
the number 2, cardiovascular disease by 15, 16, 17, 18 and cancer by the number 1. It may be that 
some cases of diabetes are missed due to six other conditions being volunteered before diabetes, 
although analysis suggests that a very small number of individuals volunteer six conditions. 
 
Do you now have, or have you ever had diabetes (Variable name ‘everdi’)? 
 
This closed question was asked in each year of the SHeS but only within the surveys years 1994, 
1998, 2003 and 2006. Among those who answered yes to this question, further questions were 
asked relating to whether or not their diabetes had been diagnosed by a doctor, whether or not they 
injected insulin or took any other medications or treatments for the disease and whether their 
diabetes occurred only during pregnancy.(296) For the purposes of this research, the derived 
variable which includes only those who indicated doctor-diagnosed diabetes (and excludes those 
with only gestational diabetes) was used. 
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The third method of identifying those with diabetes occurs within the nurse visit and entails the 
question: 
 
Are you taking or using any medicines, pills, syrups, ointments, puffers or injections 
prescribed by a doctor? Could I take down the names of the medicines, including pills, 
syrups, ointments, puffers or injections prescribed by a doctor? (Variable names medbi01-
22) 
 
The nurse records all the prescribed medications which the individual is taking. From 1995 onwards, 
the same six digit codes were used, based on the sub-sections of the British National Formulary 
(BNF), and for diabetes whether the medication was insulin or orally taken was recorded. For the 
HSE 1994, only a 2 digit BNF code was used and the survey did not differentiate between the type of 
diabetic drug being taken. The BNF codes used within the HSE and SHeS enabled the creation of 
derived variables in order to select individuals who were taking prescribed medication for diabetes. 
These new variables were: 
 
 Meddiab1- This includes all individuals who were currently taking medications related to 
diabetes (insulin: BNF Code 060101, Anti-diabetic drugs: BNF Code 060102, Drugs for 
diabetic ketoacidosis: BNF Code 060103). 
 Meddiab2- This includes all individuals who were currently taking insulin (060101). 
 Meddiab3- This includes all individuals who were currently taking oral hypoglycaemic drugs 
(060102). 
 
 Figure 3-1 below details the three ways that an individual case could be identified for inclusion in 
the diabetic cohort within the HSE and SHeS data, as well as the question related to glycated 
haemoglobin. The numbers included within the figure relate to the 2003 HSE sample. 
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Figure 3-1: Pathways to identifying those with diabetes within the HSE and SHeS (illustrative example from HSE 2003) 
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3.8.2 Whitehall I 
There were a number of questions related to diabetes within the original Whitehall I survey. The first 
of these was: 
Are you or have you been diabetic? (Answer: Yes/No) 
If the participant gave a positive response, they were then asked a series of follow-on questions 
related to the age at which they were diagnosed with the disease, what their symptoms were, 
whether they were injecting insulin and if any of their relatives had diabetes. The survey also asked 
participants: 
Are you taking any medications, pills or on a diet? (Answer: Yes/No) 
They were then asked to list the medications they were taking and what these medications were for. 
A measurement of blood glucose was also taken, but the boundaries for this (in relation to what is 
considered a raised blood glucose threshold) are inconsistent with those used in more recent studies 
(this issue is discussed in more detail in Section 3.10). 
Within the follow-up resurvey, participants were asked the following yes/no question: 
Has a doctor ever told you that you had any of the following conditions? 
A number of disease options were then listed, including diabetes and cancer, to which the 
respondent could answer yes or no. This was followed by: 
Please list the names of all medications (tablets, capsules, liquids or injections etc), including 
over the counter preparations, (such as vitamins and aspirin) that you have taken during the 
last month? 
The key difference between the HSE/SHeS and Whitehall I, related to this second question, was that 
for the former a nurse would request all the medications being taken and then record them, 
whereas for Whitehall I the respondent was responsible for documenting their own medication use.  
3.9 The use of self-reported survey data 
The majority of the information gathered within the HSE and SHeS is self-reported, exceptions to this 
include height and weight (measured within the interview) and information gathered during the 
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nurse visit, such as medication use and specific measurements. A study by Okura et al. sought to 
understand how the use of self-reported data would impact upon the recorded prevalence of a 
number of diseases, including diabetes, and how much agreement there was between questionnaire 
data and medical records.(297) The study found strong agreement between the two forms of data 
for diabetes, with a kappa coefficient of 0.71-0.80. The factors associated with this agreement were 
being in the younger age group; being female; and increased levels of education.  
 
The study also found sensitivity of 66% for the self-reported questionnaire, which produced a lower 
prevalence of diabetes compared with medical records, prevalence of 5.2% and 7.4% respectively. 
Specificity was found to be 99.7% for the self-reported data. This issue will be explored further in the 
following sections of this thesis. 
 
3.10 Blood glucose within Whitehall I 
For glycated haemoglobin (HbA1C) a cut-off point of 6.5% (48mmol/mol) is currently considered 
indicative of the presence of undiagnosed or uncontrolled diabetes; this was used within the 
analyses of the association between HbA1C described within this thesis.(298) Within Whitehall I data 
participants were recorded as diabetic if, two hours after having drunk a 50g anhydrous dextrose 
drink, their glucose load was ≥11.1 mmol/l (≥200 mg/100ml).(89) Those with a glucose load of 
between 5.4 and 11.0 mmol/l (96-199 mg/100ml) were considered to have impaired glucose 
tolerance. The normoglycaemic group consisted of all those with a measurement below 5.4 mmol/l. 
As a consequence of this although blood glucose could be adjusted for within the regression models, 
it would not be possible to directly compare the results of the analyses which explored the 
association of this variable with all-cause and cause-specific mortality within the Whitehall I data 
with the results of the HSE and SHeS dataset analyses.  
 
3.11 Sensitivity and specificity analysis 
In the first year of the study, and in order to undertake sensitivity analysis, new variables were 
created which: 
 
 investigated the number of individuals who indicated diabetes in more than one variable 
(through the use of the logical ‘And’), 
 investigated the total number of diabetics (through the use of logical ‘Or’). 
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The following section details these variables and the initial analyses that were undertaken in order 
to identify the diabetic cohort. The second of these variables was also required in order to undertake 
the power calculations detailed in Section 3.15. 
 
The three different methods of identifying the diabetic sub-group within the HSE and SHeS required 
an investigation of sensitivity and specificity of each variable. Therefore, initial analysis focussed 
upon the years that included a question related to doctor-diagnosed diabetes, which was deemed to 
be the ‘gold standard’ for identifying people with diagnosed diabetes. The data produced was used 
to create the four sub-groups required for further analysis within this research. The sub-groups 
were: 
 
 Individuals who could be considered part of the ‘gold standard’ in terms of identifying 
diagnosed diabetes (this group comprised those who indicated the presence of doctor-
diagnosed diabetes in response to direct questioning). 
 Those who only indicated diabetes elsewhere within the survey. 
 Those who indicated that they had diabetes at any stage of the survey process (this would 
include those in group one and group two). 
 Those who responded negatively to the diabetes-specific question, did not mention diabetes 
when asked about the presence of any longstanding illnesses and those who did not appear 
to be taking diabetes-related medication. 
 
Analysis was undertaken to calculate the total number of people with diagnosed diabetes within the 
HSE and SHeS, via the different pathways, and the predictive value of each variable. As can be seen 
from Table 3-3, few participants indicated diabetes in either the longstanding illness or the 
prescribed medication variables but not within the doctor-diagnosed variable. In total (in the four 
HSE years), 97 cases were in this group (2.9% of the total number of people with diagnosed 
diabetes): 31 cases (0.9% of total diabetics) recorded prescribed medications, 43 (1.3%) volunteered 
diabetes and 23 (0.7%) indicated both. There are a number of factors which explain the occurrence 
of this group: 
 
 Cases that had diabetes only during pregnancy and were taking diabetic medication or 
indicated that their diabetes was longstanding (three women were found within the former 
and five within the latter group). In total 196 women indicated that they had only 
gestational diabetes. 
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 Cases that indicated the presence of diabetes but had not had their disease diagnosed by a 
doctor (as can be seen from Table 3-3 a total of 95 cases indicated that they had, or 
previously had, diabetes but that it was not doctor-diagnosed). 
 Individuals who were taking prescribed medication for diabetes, but were not aware that 
they had the disease.  
 
Further to this there were a small number of cases that indicated: 
 
 Diabetes within the longstanding illness variable and were taking prescribed diabetic 
medication but did not indicate diabetes within the doctor-diagnosed variable (Group D). 
 Doctor-diagnosed diabetes and were taking diabetic medication but did not volunteer 
diabetes as a longstanding illness (Group E). 
 Diabetes only within the longstanding illness question (Group I). 
 Taking prescribed medication for diabetes only (Group J). 
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Figure 3-2: Diabetes within the HSE and SHeS 
 
 
 
 
 
 
 
 
 
 
 
Key 1: The diabetic cohort identified within each area of the Venn diagram 
A: Cases who indicated doctor-diagnosed diabetes (=E+F+G+H)  
B: Cases who volunteered diabetes within the longstanding illness question (=D+F+G+I)  
C: Cases who were recorded as taking diabetic medications (insulin, oral and drugs for diabetic ketoacidosis) (=D+E+G+J)  
D: Cases who volunteered diabetes AND were taking diabetic medications but did not indicate doctor-diagnosed diabetes (=BnC not A: where 
n=intersect or ‘AND’)  
E: Cases who indicated doctor-diagnosed diabetes, AND were taking diabetic medications but did not volunteer diabetes (=AnC not B)  
F: Cases who indicated doctor-diagnosed diabetes AND volunteered diabetes but were not recorded as taking diabetic medications (=AnB not C)  
G: Cases who indicated doctor-diagnosed diabetes AND volunteered diabetes AND were taking diabetic medications (=AnBnC). 
H: Cases who only indicated doctor-diagnosed diabetes (=A-CuB: where u= union or ‘AND/OR’). 
I: Cases who only volunteered diabetes (=B-AuC) 
J: Cases who were only taking diabetic medication (=C-AuB) 
A, E, F, G and H utilise the doctor-diagnosed (excluding pregnant) variable: diabete2. 
 B  
F 
D 
J 
H 
G E 
 B C 
A 
I 
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Table 3-3: Number of participants within each area of the Venn diagram  
YEAR GROUP
 
 A %  B %  C % D  E  F  G  (%) H I J 
HSE 
1994 377 2.4 308 1.9 227 1.4 6 27 103 189 1.2 58 10 5 
1998 452 2.8 360 2.3 283 1.8 3 42 109 237 1.5 64 11 1 
2003 611 4.1 540 3.6 354 2.4 4 23 206 323 2.2 59 7 4 
2006  562 4.5 482 3.8 352 2.8 5 36 168 299 2.4 59 10 12 
SHeS 
1995 140 1.8 116 1.5 87 1.1 1 6 36 79 1.0 19 0 1 
1998 256 2.8 210 2.3 153 1.7 3 17 72 131 1.4 36 4 2 
2003 344 4.2 267 3.3 181 2.2 1 23 114 151 1.9 56 1 6 
TOTAL 2,742 N/A 2,283 N/A 1,637 N/A 23 174 808 1,409 N/A 351 43 31 
 A: Doctor-diagnosed diabetes; B: Diabetes as a longstanding illness; C: On diabetic medication; D: B or C, not 
A; E: A or C, not B; F: A or B, not C; G: Those reporting diabetes in all three ways; H: Doctor-diagnosed but 
neither B nor C; I: Diabetes as a longstanding illness but neither A nor C; J: Diabetic medication but neither A 
nor B. 
 
Around half (46%) of those who indicated diabetes within the doctor-diagnosed variable also 
indicated diabetes within both of the two derived variables. New variables were created to 
investigate the number of individuals who indicated diabetes within more than one variable 
(Table 3-4). Numbers within groups that include the diabetic medication variable are likely to be 
smaller than groups that exclude it because only a proportion of the entire survey cohort 
participated in the nurse visit each year.  
 
Table 3-4: Individuals who indicated diabetes within more than one variable 
 
 
 
 
 
 
 
Year VARIABLE 
A and B % A and C % B and C % A and B 
and C 
% 
HSE 
1994 293 1.9 217 1.4 195 1.2 189 1.2 
1998 347 2.2 280 1.8 240 1.5 237 1.5 
2003 530 3.6 347 2.3 327 2.2 323 2.2 
2006 468 3.7 336 2.7 304 2.4 299 2.4 
SHeS 
1995 115 1.4 85 1.1 80 1.0 79 1.0 
1998 205 2.3 150 1.7 134 1.5 131 1.4 
2003 265 3.3 174 2.1 152 1.9 151 1.9 
2008 N/A N/A 64 1.0 N/A N/A N/A N/A 
TOTAL 2,223 2.6 1,653 1.8 1,432 1.7 1,409 1.7 
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Derived variables were used to investigate the total number of those with diabetes within each year 
of the survey. This further illustrated the strong sensitivity of the doctor-diagnosed variable for 
identifying the total number of diabetics within the sample. Using this information it was also 
possible to calculate the number of individuals who did not indicate the presence of diabetes at any 
stage of the survey process (see Table 3-5). 
 
Table 3-5: Total number of cases who did/did not indicate diabetes 
a
 This number only includes those who responded to the diabetes specific question or were taking prescribed 
medication for diabetes because at the time of writing the longstanding illness variable was unavailable for 
SHeS 2008. 
 
Key 2: Total number with/without diagnosed diabetes 
 
3.12 Sensitivity of diabetes-related variables 
Using this information it was then possible to calculate the sensitivity (what proportion of those with 
the disease were correctly identified) for each of the diabetes related variables. The total number of 
those with diabetes within each year was taken to be any case that gave a positive response to any 
of: the doctor-diagnosed diabetes variable; volunteered the disease within the longstanding illness 
Year VARIABLE 
A or B % A or C % B or C % A or B 
or C 
% Did not indicate 
diabetes 
HSE 
1994 419 2.7 414 2.6 340 2.2 424 2.7 15,381 
1998 508 3.2 498 3.1 403 2.5 509 3.2 15,399 
2003 669 4.5 666 4.5 567 3.8 673 4.5 14,163 
2006 623 5.0 625 5.0 530 4.2 635 5.1 11,915 
SHeS 
1995 150 1.9 151 1.9 123 1.6 151 1.9 7,781 
1998 271 3.0 269 3.0 229 2.5 273 3.0 8,774 
2003 358 4.4 363 4.5 296 3.6 364 4.5 7,784 
2008 N/A N/A 356 5.5 N/A N/A 356a N/A 6,109 
Total 2,998 3.5 3,342 3.8 2,488 2.9 3,385 3.6 87,306 
A or B: Cases who indicated doctor-diagnosed diabetes OR volunteered diabetes (= (AuB).  
A or C: Cases who indicated doctor-diagnosed diabetes OR were taking diabetic medications (= (AuC). 
B or C: Cases who volunteered diabetes OR were taking diabetic medications (= (BuC). 
A or B or C: Cases who indicated doctor-diagnosed diabetes OR volunteered diabetes OR were taking 
diabetic medication (=AuBuC).  
Did not indicate diabetes: Cases who did not state that they were diabetic when asked the diabetic specific 
question, did not give diabetes as a longstanding illness and were not recorded as taking any prescribed 
diabetes medication within the nurse visit. 
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variable; or were taking any medication for diabetes, as recorded during the nurse visit. Analysis 
demonstrated that the doctor-diagnosed diabetes variable had good sensitivity (Table 3-6). 
Sensitivity for this variable ranged from 89% to 95%; mean sensitivity across all years was 90% (95% 
CI 89%-91%). Sensitivity for the longstanding illness variable ranged from 71% to 80%, with mean 
sensitivity across all years of 75% (95% CI 74%-76%). Sensitivity for the diabetic medication variable 
was lower, in part, because not every individual with diabetes participated in the nurse visit. 
Sensitivity ranged from 50%-58% (mean sensitivity=55%, 95 CI 52-56). Because of this, sensitivity 
was also calculated for the prescribed medication variable only among the sub-sample of cases that 
completed the nurse visit schedule. This increased the sensitivity of this variable to around 70%. 
 
Because the diabetes-specific variable was available only in certain years, sensitivity analysis was 
undertaken within each year to identify the total number of cases identified as diabetic (either via 
the longstanding illness derived variable or the prescribed diabetic medication derived variable). This 
enabled a better understanding of how well these two variables captured the diabetic cohort who 
might also have positively responded to the doctor-diagnosed variable if they had been asked it. 
Using a combination of the two derived variables achieved a sensitivity of just over 94% (95% CI 93-
94%). This suggested that, in years within which the diabetes-specific variable was not available, 
around 94% of those with diabetes would be positively identified using the two other variables in 
combination. 
 
Table 3-6: Sensitivity (%) of diabetes variables 
YEAR Total 
no. DMa 
Doc. 
diagnosed 
(excl. 
pregnant) 
Sensitivity 
% 
Longstanding 
illness: DM 
Sensitivity 
% 
Prescribed 
medication 
for DM 
Sensitivity 
% 
HSE 
1994 424 377 89 308 73 227 54 
1998 509 452 89 360 71 283 56 
2003 673 611 91 540 80 354 53 
2006 635 562 89 482 76 352 55 
SHeS 
1995 151 140 93 116 77 87 58 
1998 273 256 94 210 77 153 56 
2003 364 344 95 267 73 181 50 
TOTAL 3,029 2,742 91 2,283 75 1,637 55 
a DM – Diabetes mellitus 
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Table 3-7 indicates the number of cases with diabetes that were identified within each survey year 
using either the two variables (column: ‘Variables: B or C’) or the three diabetes variables, where 
available (column: ‘Variables: A or B or C’). Further analysis of the sensitivity of the two individual 
variables found that the longstanding illness variable (B) achieved an overall sensitivity of 93% (95% 
CI 92.6-93.3%). For the prescribed medication variable (C), sensitivity was 63% (95% CI 62-64%).  
 
Table 3-7: Utilising the three diabetes variables to identify those with and without diabetes 
Year Variables:  
B or C 
Variables:  
A or B or 
C 
Variables:  
B 
Sensitivity: 
B (%) 
Variables:  
C 
Sensitivity:  
C (%) 
Did not 
indicate DM 
(n) 
HSE     
1994 340 424 308 91 277 81 14,661 
1995 364 364 342 94 246 68 15,691 
1996 383 383 361 94 265 69 16,060 
1997 231 231 217 94 138 60 8,351 
1998 403 509 360 89 283 70 15,399 
1999 232 232 229 99 26* 11 7,566 
2000 476 476 424 89 239 50 10,005 
2001 531 531 506 95 322 61 15,116 
2002 254 254 240 94 163 64 10,007 
2003 567 673 540 95 354 62 14,163 
2004  295 295 293 99 25* 8 6,409 
2005  331 331 312 95 189 57 7,299 
2006  530 635 482 91 461 66 13,507 
2007 389 389 351 90 243 62 6,493 
2008 786 786 728 93 454 58 14,316 
SHeS 
1995 123 151 116 94 87 71 7,781 
1998 229 273 210 92 153 67 8,774 
2003 296 364 267 90 181 61 7,784 
TOTAL  6,760 7,301 6,286 93 4,106 63 199,382 
*The 1999 and 2004 HSEs were focussed upon the health of those from Black and Minority Ethnic 
communities. Within the overall sample from these years a substantially reduced percentage completed a 
nurse visit, with a corresponding reduction in the number indicating the use of diabetic medication compared 
with samples from other years. 
 
91 
 
 
3.13 Specificity of diabetes variables 
Sensitivity analysis enabled a better understanding of how effective the three variables, both 
independently and combined, were at capturing all cases with diabetes. It was also important to 
understand how effectively those without the disease were identified, to ensure that the non-
diabetic cohort included, as far as possible, only those who did not have diagnosed diabetes. 
Therefore the specificity of the diabetes variables was also analysed. 
 
Specificity relates to the number of cases without the disease who are correctly identified as such. 
The diabetes-specific variable utilised within this research considered those who stated that they 
had diabetes, but that it was not doctor-diagnosed (n=95), as not having diabetes. This group may 
include those who have had their diabetes diagnosed but made a mistake in responding to the 
question, were incorrectly coded, or who correctly identified that they had diabetes without the 
involvement of a doctor. Using the above figure, relating to the total number of cases who did not 
indicate diabetes, it was possible to calculate a specificity >99.9% for the percentage of diagnosed 
diabetics included in the non-diabetic cohort. This suggests that the majority of those who indicated 
diabetes but, within this research, will be identified as non-diabetic are those who had not had their 
diabetes diagnosed by a doctor. 
 
Within the analyses of Whitehall I, only the variable specifically related to the presence of diabetes 
was used to identify the diabetic cohort. One of the reasons for this is that it enabled results from 
the current study to be compared with those previously undertaken. Because of this, no sensitivity 
or specificity analyses were undertaken. 
 
3.14 Exclusion criteria for cases 
Because only those aged 16 and over were able to give consent for their data to be flagged within 
mortality and Cancer Registry data, children were excluded from the dataset used for this study. To 
address the issue of the temporality of an association between diabetes and cancer, those reporting  
cancer at baseline (identified using the longstanding illness questions, Section 3.8) were excluded 
from further analyses, leaving a sample size of 204,537, including 7,199 with diabetes. 
 
Following advice from NatCen Social Research and discussing the process with members of the 
Health and Social Surveys Research Group (HSSRG) at UCL, it was decided that certain site-specific 
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cancer groups were inappropriate for inclusion within the analyses. Skin cancer was excluded as it 
was not possible with the grouped data provided for this study to distinguish between the different 
types of skin cancer, while benign tumours were excluded as they are not cancerous (the nature of 
these types of growth renders them unable to metastasise). Because the specifics of the cancers of 
uncertain or unknown behaviour could not be ascertained this group was also excluded from 
becoming a case within the mortality and Cancer Registry variables. Thus once the HSE and SHeS 
data were linked with mortality and Cancer Registry data, participants with any of the following 
registered diagnoses were excluded from the analyses: 
 Benign growths, 
 Cancers of uncertain or unknown behaviours, 
 In situ neoplasms, 
 Skin. 
After cases that matched any of the above criteria had been excluded, the dataset included 204,533 
participants. Table 3-8 details the sample and the number of those with diabetes from each survey 
year. 
Table 3-8: Final study sample 
Year Total sample Participants indicating 
diabetes (%) 
Participants not 
indicating diabetes 
(%) 
HSE  
1994 15,599 393 (2.5) 15,206 (97.5) 
1995 15,807 351 (2.2) 15,456 (97.8) 
1996 16,215 382 (2.4) 15,833 (97.6) 
1997 8,432 223 (2.6) 8,209 (97.4) 
1998 15,686 461 (2.9) 15,225 (97.1) 
1999 7,666 223 (2.9) 7,443 (97.1) 
2000 10,246 463 (4.5) 9,783 (95.5) 
2001 15,359 507 (3.3) 14,852 (96.7) 
2002 10,192 243 (2.4) 9,949 (97.6) 
2003 14,545 575 (4.0) 13,970 (96) 
2004 6,558 286 (4.4) 6,272 (95.6) 
2005 10,023 586 (5.8) 9,437 (94.2) 
2006 13,847 703 (5.1) 13,144 (94.9) 
2007 6,752 373 (5.5) 6,379 (94.5) 
2008 14,790 747 (5.1) 14,043 (94.9) 
SHeS  
1995 7,300 122 (1.7) 7,178 (98.3) 
1998 8,212 241 (2.9) 7,971 (97.1) 
2003 7,304 320 (4.4) 6,984 (95.6) 
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TOTAL 204,533 7,199 (3.5) 197,334 (96.5) 
 
3.15 Power calculations 
The three factors of sample size, magnitude of the effect of interest and the statistical significance 
level used determine statistical power. Traditionally it has been considered unethical to undertake 
research either with a sample size too small to be able to produce clinically relevant results or so 
large that the study includes an unnecessary number of participants.(299) In order to decrease the 
chance of a type II error, that a null hypothesis is not rejected when it is actually false, and to 
understand the minimum effect size that could be detected within the analysis, a power calculation 
was undertaken. The power calculation utilised the total number of those with diabetes, found by 
combining the three diabetes-related variables discussed above. This sample size of 7,199 was 
inputted into the sample size estimation tool created by Wade and Koutoumanou.(300) The 
programme ‘Sample Size Estimation’ includes a ‘Spreadsheet for calculation of sample size: Detecting 
a difference between two rates with specified power and significance’ and this was used to 
undertake the power calculations. At the significance level of 0.05, the effect size set at 0.2 and the 
prevalence of cancer within the general population of three percent the power of the study was 
found to be >95%. Cancer prevalence of three percent was based upon analyses by Maddams et 
al.(301) 
 
For the analyses utilising measurements of glycated haemoglobin (HbA1C), a sample size of 1,459 
was inputted into the sample size estimation tool (this is the number of participants with an HbA1C 
measurement ≥6.5%), along with a significance level of 0.05 and the prevalence of cancer set at 3%. 
Following an assessment of the results of earlier studies which explored the associations between 
glycated haemoglobin and cancer incidence and mortality, the difference to be detected was set at 
0.2. Using all of this information, the power for this particular element of the analyses was found to 
be >95%. 
 
Cancer incidence was set at 0.5% of the total population based upon the latest figures from the 
Office for National Statistics (ONS).(61) The diabetic sample of 7,199 was inputted, with a 
significance level of 0.05, difference to be detected of 0.2. This gave power of > 95% within the 
analyses of the associations between diabetes and overall cancer incidence. For the analyses of 
glycated haemoglobin and overall cancer incidence, the power of the study was >90%. 
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3.16 Identifying longstanding illnesses at baseline (HSE and SHeS) 
In order to be able to exclude those with cancer at baseline from the study, the variable ‘longcancer’ 
was derived, using data from the variables ‘illsm1-6’ (codeframe number: 1). Table 3-9 below 
indicates the number (and percentage) of individuals who indicated that they had the disease. 
 
Similarly to the variable related to cancer at baseline, ‘cvdall’ was created using data from the 
longstanding illness variables (illsm 1-6). Any case that mentioned cardiovascular disease (CVD) 
within these variables (codeframe: 15, 16, 17, 18) was identified as having CVD at baseline. Table 3-9 
also details the number within this variable from each year of the HSE and SHeS. 
 
Table 3-9: Cases with cancer and CVD at baseline 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This CVD at baseline variable was then used to analyse the impact that the presence of the disease, 
as a comorbidity, had upon the associations between diabetes and cancer mortality and incidence. 
The results of these analyses are explored in later chapters of this thesis. 
Year Total Sample Cancer 
(%) 
CVD 
(%) 
HSE  
1994 15,599 206 (1.3) 1,179 (7.6) 
1995 15,807 248 (1.5) 1,352 (8.6) 
1996 16,215 228 (1.4) 1,484 (9.2) 
1997 8,432 150 (1.7) 833 (9.9) 
1998 15,686 222 (1.4) 1,450 (9.2) 
1999  7,666 132 (1.7) 773 (10.1) 
2000 10,246 235 (2.2) 1,454 (14.2) 
2001 15,359 288 (1.8) 1,736 (11.3) 
2002 10,192 139 (1.3) 790 (7.8) 
2003 14,545 291 (2.0) 1,724 (12.5) 
2004 6,558 146 (2.2) 822 (12.5) 
2005 10,023 280 (2.7) 1,708 (17) 
2006  13,847 295 (2.1) 1,727 (12.5) 
2007 6,752 130 (1.9) 856 (12.7) 
2008 14,790 312 (2.1) 1,940 (13.1) 
SHeS  
1995 7,300 63 (0.9) 445 (6.1) 
1998 8,212 93 (1.1) 777 (9.5) 
2003 7,304 126 (1.2) 842 (11.5) 
TOTAL  204,533 3,584 (1.7) 21,892 (10.7) 
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3.17 Analysing the impact of diabetes medications upon cancer incidence 
and mortality 
The use of diabetes-related medications was used to identify the diabetic cohort within the HSE and 
SHeS combined dataset. Within the majority of years within the HSE and SHeS it was not possible to 
differentiate between those taking insulin and those taking oral medications. At the same time, the 
often changing treatment regimens of those with diabetes (in terms of the different oral 
medications available and the introduction of exogeneous insulin as diabetes progresses) makes it 
difficult for any analyses to unravel the influence of one treatment over another in relation to cancer 
outcomes. Because of this the decision was made to not include the use of treatments for diabetes 
within any of the regression models utilised within these analyses. This issue will be addressed 
within the discussion section. 
 
3.18 Linking the survey datasets with mortality and cancer registry data 
In the first instance, the linking of the HSE to mortality data occurred in the secure data enclave at 
NatCen (see Chapter 4 for further information about the process of accessing the mortality and 
Cancer Registry data). The following variables were available within the mortality data: 
 An anonymised ID for matching with HSE data, 
 Consflag (Participant gave consent for mortality data linkage), 
 Agedied (Age respondent died), 
 doDyr (Year of death), 
 QRTdeath (Quarter of year died), 
 CauseDeath (Cause of death of interest, in broad categories). 
The last of these variables was a broad cause of death variable. Table 3-10 below details the 
numbers of cases that died of each cause. 
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Table 3-10: Total number of deaths within the HSE (1994-2008) linked to mortality data 
Cause of Death Number 
Ischaemic heart disease 3,032 
Stroke 1,468 
Other cardiovascular disease 2,433 
All cardiovascular disease 6,933 
Lung cancer 1,117 
Colon cancer 490 
Breast cancer 327 
Prostate cancer 282 
Other cancer 2,781 
All cancer 4,997 
Respiratory 2,650 
Other non-traumatic 3,227 
External causes 503 
TOTAL 18,310 
 
Once a minimum dataset was created, which included all the required HSE variables but no other 
variables, both this and the mortality datasets were ordered by the matched ID. The variables from 
the mortality dataset were then merged with the HSE data. In 2013, access to the site-specific cancer 
mortality data was granted: this meant that it was also possible to create a more detailed variable 
based upon deaths from the site-specific cancers shown in Table 3-11 (ordered by descending 
frequency). 
 
Table 3-11: Site-specific cancer mortality within the HSE (1994-2008) 
Site-specific cancer Number 
Trachea, bronchus and lung 1,111 
Colorectal 493 
Lymphoid, haematopoietic and related tissue 343 
Prostate 334 
Breast 324 
Pancreatic 297 
Oesophagus 221 
Stomach 188 
Bladder 152 
Ovarian 149 
Kidney 129 
Liver 73 
Cervix, uterus and endometrium 70 
Lip, oral cavity and pharynx 61 
Other cancer not specified 936 
All cancers 4,881 
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Because the original site-specific mortality variable was string in nature, the production of the syntax 
to create this grouped variable was very time-consuming. An example of this syntax is given in 
Appendix One: Syntax for the creation of the site-specific cancer variables. An advantage of this 
syntax was that, once it had been written, it (and its corresponding coding framework) could be used 
to produce variables related to the Cancer Registry, and mortality and incidence variables within the 
SHeS. This ensured uniformity across the HSE and SHeS and expediency within analyses. 
 
As can be seen from comparing the information in Table 3-11 with that in Table 3-10, there are small 
differences in the number of deaths from the site-specific cancers; these differences are probably 
caused by slight differences in the syntax used by NatCen Social Research to produce the original 
variable compared with the syntax used within this study. The syntax produced for this study was 
checked by a number of members of the HSSRG at UCL, so it was decided that all site-specific cancer 
mortality and Cancer Registry variables used within future analyses would be based upon it; while 
the original variable produced by NatCen Social Research would be used within the all-cause and 
cause-specific analyses. Table 3-12 details the final number of cause-specific deaths in the HSE data 
(ordered by number of deaths) within the variable derived by NatCen Social Research. At the time 
that this data became available it was not possible to check the syntax used to produce this variable. 
 
Table 3-12: Cause-specific mortality in the HSE (1994-2008) 
Cause of death Number 
CVD 
 
6,933 
Cancer 
 
4,997 
Respiratory 
 
2,650 
Other 
 
3,730 
TOTAL 
 
18,310 
 
The information included in this variable was then used to create a binary variable which indicated 
whether or not an individual had died (0=Alive, 1=Died) following participation in the HSE. The same 
variable was created within the SHeS and Whitehall I datasets. 
 
The merging of the HSE Cancer Registry data was a more complex process. As a number of 
participants had more than one cancer registration, a variable was created that included only a first 
registration of a cancer of interest (in total there were 10,721 participants in this group). Earlier 
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studies investigating the associations between diabetes and cancer had considered only the first 
incidence of cancer and the decision was taken to do the same within this study. This issue will be 
addressed in more detail in the discussion chapter. Table 3-13 below indicates those cancers 
included and excluded from this variable (ordered by descending frequency). 
 
Table 3-13: Registrations for cancer included/excluded in the HSE 
Includeda 
 
Number Excluded Number 
Breast 2,053  
Skin 
 
4,112 
Prostate 1,299 In situ neoplasms 2,908 
Trachea, bronchus and lung 1,203 
Colon 926 Uncertain/unknown behaviour 648 
Lymphatic and hematopoietic 822 
Uterus and cervix 553 Benign 170 
Bladder 492 
Pancreas 271 Missing  39 
Stomach 264 
Kidney 241 Incorrectly coded 34 
Oesophagus 235 
Lip 205   
Liver 74 
TOTAL 7,911 
Other cancers 2,083 
TOTAL 10,721 
a After concerns were raised that the small number of cases of incident ovarian cancer might be 
disclosive, registrations for this cancer were merged into the ‘other cancers’ group. 
 
Once the linking of the HSE and Cancer Registry data had been completed, it became apparent that 
either all or some of the Cancer Registry data from HSE 2008 had been incorrectly linked at NatCen 
Social Research (sex-specific cancers were appearing in the incorrect sex – for example 8 men were 
found to have cervical cancer and 8 women were found to have prostate cancer). Following 
discussions with colleagues at UCL and NatCen Social Research, and the time constraints of the study 
(given the delays in receiving the site-specific Cancer Registry data), it was decided that the most 
appropriate action would be to exclude cancer registrations from HSE 2008 in the analyses. 
Therefore the table above excludes those registrations. This issue will be addressed in greater detail 
in the discussion chapter. 
3.19 Identifying cancer within linked SHeS data  
The SHeS datasets included the variable ‘cause’ which detailed cause of death by International 
Classification of Disease (ICD) 10 code. Using this variable two mortality variables were derived 
which detailed:  
99 
 
 Cause-specific mortality (cancer, respiratory disease, cardiovascular disease and other 
causes) 
 Site-specific cancer mortality (this variable matched the one produced within the HSE data). 
Table 3-14 details the number of cause-specific deaths within the Scottish Health Surveys (survey 
years: 1993, 1998 and 2003) while Table 3-15 gives the number of site-specific cancer deaths within 
the dataset (ordered by descending number of deaths by cause). 
 
Table 3-14: Cause-specific mortality in the SHeS  
Cause 
 
Number 
Cancer 574 
 
CVD 
 
556 
Other 
 
423 
Respiratory 
 
188 
TOTAL 1,741 
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Table 3-15: Site-specific cancer mortality within the SHeS  
Site-specific cancer 
 
Number 
Trachea, bronchus and lung 186 
 
Colorectal 59 
 
Oesophagus 
 
40 
Breast 30 
 
Lymphoid, haematopoetic and related tissue 30 
 
Pancreatic 
 
24 
Stomach 23 
 
Bladder 
 
16 
Ovarian* 16 
 
Prostate 13 
 
Cervix, uterus and endometrium 
 
11 
Kidney  11 
 
Liver and hepatocellular <10 
 
Lip, oral cavity and pharynx <10 
 
Other cancer not specified 102 
 
TOTAL 574 
 
*In order to match the site-specific cancer variable derived within the HSE data, deaths from ovarian cancer 
were included in the ‘other’ cancer category in the variable used within the analyses. 
 
Within the linked SHeS datasets, there were a number of variables which garnered information 
about cancer registration. In order to undertake initial exploratory analysis of this data the variable 
‘ICD10crshe’ was created that matched that produced for the HSE dataset. SHeS participants could 
be identified as having a registration within Cancer Registry data up to 2008.  
Table 3-16 details the incidence of the site-specific cancers of interest within the SHeS cohort. 
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Table 3-16: Site-Specific cancer incidence in the SHeS 
Site-specific cancer Number 
 
Trachea, bronchus and lung 170 
 
Breast 156 
 
Prostate 63 
 
Colon 63 
 
Lymphatic and hematopoietic 53 
 
Uterus and cervix 32 
 
Stomach 28 
 
Oesophagus 27 
 
Bladder 24 
 
Pancreas 21 
 
Lip, oral cavity and pharynx 20 
 
Kidney 20 
 
Liver <10 
 
Other cancers 173 
 
TOTAL 857 
 
Excluded 
Skin 268 
 
 
The cancer incidence variable within the linked SHeS data did not include information about cancers 
of uncertain or unknown behaviours, in situ or benign neoplasm or those that were incorrectly 
coded as these were not required for the analyses. 
 
3.20 Cancer variables within Whitehall I 
Within the Whitehall I dataset made available for this project, variables related to all-cause, cause-
specific and site-specific mortality had already been derived. In order to enable a comparison of the 
results of this analysis with those of earlier studies, that had utilised shorter follow-up periods, these 
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variables were used in each of the Whitehall I analyses detailed within this thesis. Information is 
given in relation to the descriptive analysis of this dataset in the results sections. 
As can be seen from the sections above, a considerable amount of time was spent: 
 
 ensuring that sub-groups within the dataset were identified as accurately as possible, 
 producing correctly derived variables to enable the analyses required for this study,  
 ensuring uniformity across the survey years. 
 
The following chapter details the methods that were used to analyse the associations between 
diabetes, glycated haemoglobin and all-cause, cause-specific and site-specific (cancer) mortality and 
incidence of cancer using data from the HSE and SHeS (combined) and Whitehall I datasets. 
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4. Chapter 4: Methods 
4.1 Data issues 
A number of factors impacted upon the availability of the linked HSE and mortality/Cancer Registry 
data and these are described in the following sections. 
4.1.1 NatCen Social Research data release requests 
In order to access the mortality and Cancer Registry data it was necessary to submit a Data Release 
Request to NatCen. This request was then discussed by a panel and a decision made as to whether 
or not data would be made available for the purposes of this research, and whether or not access 
would be granted outside the NatCen offices. NatCen makes data available to researchers within the 
data enclave (a computer not connected to a network). Any output from the analyses is then sent to 
the researcher, reducing the potential for data leaving NatCen that is disclosive. An initial Data 
Release Request, for linked HSE and cancer mortality and registry data was submitted on the 23rd of 
September 2010, with the Data Release Panel (DRP) meeting on the 10th of October 2010. Following 
this, access was granted to data already held by UCL, which included a broad perspective mortality 
variable (mortality data for HSE participants were updated to the first quarter of 2011) which 
included information related to the following causes of death: 
 
 Non-traumatic, not including other sub-groups of interest 
 Cardiovascular 
 Stroke 
 Ischaemic heart disease 
 Respiratory 
 Cancer, not including other sub-groups of interest 
 Lung cancer 
 Colon cancer 
 Breast cancer 
 Prostate cancer 
 Other cause of death. 
 
Concurrently the panel concluded that allowing access to more detailed data (in relation to site-
specific cancer mortality and cancer registrations) would be inappropriate without an initial 
descriptive exploration of the data, in order to assess whether or not the small number of deaths (or 
incidents of cancer) from these detailed causes would make the data disclosive. As the data became 
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available a number of Data Release Requests (related to cancer incidence and mortality) were 
submitted that related to the following site-specific cancers (ICD 9 and 10 Codes):  
 
 oral cavity and pharynx (ICD-9 140-149 ICD-10C00-C149) 
 Oesophagus (ICD-9 150, ICD-10 C15) 
 Stomach (ICD-9 151, ICD-10 C16) 
 Colorectal (ICD-9 153-154, ICD-10 C18-C21) 
 Bladder (ICD-9 188, ICD-10 C67) 
 Breast (ICD-9 174, ICD-10 C50) 
 Cervix/Uterus/Endometrium (ICD-9 179, 180, 182, ICD-10 C53 C54-C55) 
 Liver (ICD-9 155, ICD-10 C22) 
 Trachea, bronchus and lung (ICD-9 162, ICD-10 C33-C34) 
 Kidney/Renal (ICD-9 189, ICD-10 C64-C66) 
 Lymphoid, haematopoietic and related tissue: includes non-Hodgkins Lymphoma, Leukaemia 
and Hematopoietic (ICD-9 200-208, ICD-10 C81-C96) 
 Prostate (ICD-9 185, ICD-10 C61) 
 Other cancers (this group is made up of all those cancers not included in the above). 
 
It was decided that these cancers should be focussed upon because previous research suggested an 
association with diabetes (based upon results from the literature review) and they occurred at high 
enough rates that including them in a linked dataset would not negatively impact upon the 
disclosivity of the study dataset. 
 
4.1.2 Delays in data acquisition 
There were significant delays in accessing the mortality (detailed site-specific cancer mortality 
variables) and Cancer Registry data linked to the HSE. The key cause of the delay related to concerns 
NatCen had in relation to the disclosive nature of the linked data; it was felt that linking detailed 
mortality data to the variables within the HSE would enable the identification of individual 
participants. In relation to the mortality data there were also considerable delays in the provision of 
the data to NatCen initially from the ONS and subsequently from the Health and Social Care 
Information Centre. This was followed by further delays caused by a lack of staff available to 
undertake the data linkage. Following the submission of a Data Release Request, the panel meeting 
at NatCen decided that the most appropriate course of action was for the data to be made available, 
for linking and analyses, only within the NatCen enclave. Availability of the enclave was restricted 
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both by renovations to the building and its use by NatCen staff. Because of these delays, initial 
linking and analyses of the detailed mortality data took place in December 2012, with a minimum 
dataset being made available outside of the enclave on the 18th of December 2012. 
 
There were longer delays in gaining access to the Cancer Registry data, caused by delays in NatCen 
receiving the data and the availability of staff to link the data. A dichotomous Cancer Registry 
variable (cancer registration: yes or no) was made available at the start of 2013. Following this an 
initial exploration of the site-specific Cancer Registry data was possible, within the enclave, at the 
start of 2013; this data was then made available outside of the enclave on the 17th of April 2013.  
 
In order to reduce the disclosive nature of the HSE linked data (mortality and cancer incidence) it 
was agreed that two of the continuous variables would be replaced with categorical grouped 
variables. These were: 
 
 Age (replaced with grouped: 16-64, 65-75, 75+) 
 BMI (grouped: <20, 20-24.99, 25-<30, ≥30kg/m2). 
 
4.2 SHeS 
Accessing the linked SHeS data was unproblematic; the data was already available to members of 
the HSSRG team at UCL and informing the Health Information Group within the NHS National 
Services Scotland of the nature of the research and any publications that would result from it 
enabled access to the data for the purposes of this research. Access to the linked SHeS data (for 
SHeS years 1995, 1998 and 2003) was granted on the 21st of April 2011.  
 
4.3 Whitehall I 
Held within the Department of Epidemiology and Public Health at UCL, the data became available (in 
September 2012) following a discussion of the aims and potential outcomes of the current study 
with Dr David Batty and Dr Martin Shipley. Through the analyses of Whitehall I data, it was possible 
to further test the hypotheses of this current study using a dataset with exceptionally long follow-up 
and within which around 80% of the study population had died within the 40 year follow-up period.  
4.4 Analyses 
To assess the associations between diabetes and cancer incidence and mortality a range of statistical 
methods were utilised; the following sections details the analyses that were undertaken. 
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4.5 HSE and SHeS 
4.5.1 All-cause mortality: logistic regression  
Using the binary variables related to the presence of diabetes and all-cause mortality, a logistic 
regression was undertaken in order to explore the risk of an individual with diabetes dying of any 
cause compared with those without the disease and produce Odds Ratios (ORs)and 95% Confidence 
Intervals (CI) for the association. Within all of the analyses undertaken the reference group consisted 
of those who had not indicated the presence of diabetes or who had a glycated haemoglobin 
measurement of <6.5% (48mmol/mol). In order to assess the impact of confounding factors upon 
the associations between diabetes and all-cause mortality a number of variables were entered into 
the regression model. Age and sex were included in every regression model, with the following 
variables added at consecutive steps of the regression model: 
 
 Basic model: age and sex plus Smoking status (Current, Ex-regular, Never-regular)  
 Advanced model: Basic model plus BMI (<20, 20-24.9, 25-29.9, 30+) 
 CVD model: Advanced model plus CVD status (CVD at baseline: Yes/No). 
 
To explore the impact of socio-economic/demographic factors upon the association between 
diabetes and all-cause mortality further adjustment included the advanced model plus: 
 
 Education: degree/other/none (educend) 
 Social class: I-VII (sclass) 
 Region: south/midlands/north/Scotland (region) 
 HbA1C: Normal/Raised (≥6.5%) and continuous (glyhbval2 and glyhbval respectively) 
 
To establish how measurements of overweight and obesity impact upon the association between 
diabetes and all-cause mortality, the following variables were also added to the basic model: 
 
 Waist-hip ratio (Normal/raised)  
+ CVD status 
 Waist circumference (Normal/raised) 
+ CVD status 
 Education 
 Social Class 
 Region  
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 HbA1C 
 
Progressive adjustment then took into account a number of these variables: 
 
 Advanced model + Social class, region and CVD 
 + HbA1C 
 Advanced model + Education, region and CVD 
+ HbA1C 
 Basic model + Waist-hip ratio, social class, region and CVD 
+HbA1C 
 Basic model + Waist-hip ratio, education, region and CVD 
+ HbA1C 
 Basic model + Waist circumference, social class, region and CVD 
+ HbA1C 
 Basic model + Waist circumference, education, region and CVD 
+ HbA1C 
 
CVD status was then removed from the above models and the syntax re-run. Initially analyses 
utilised the whole sample. Following this, the above analyses were re-run with the data stratified by 
CVD status and then by sex; sensitivity analysis, among those who indicated that they had never 
been a regular smoker, was then undertaken using the models above. 
 
The analyses described below follows the schedule detailed within this section, unless otherwise 
stated. 
 
4.5.2 Cause-specific and site-specific cancer mortality: multinomial logistic regression 
Both the cause-specific and site-specific cancer mortality variables were categorical; because of this, 
initial analyses of these variables utilised multinomial logistic regression to produce ORs and CIs. 
Within the analyses the reference category was ‘alive’ and the association of diabetes with the 
specific causes of death was estimated. The regression model framework followed the same 
pathway as that undertaken for the all-cause mortality analyses mentioned above. 
 
In order to perform the multinomial logistic regression within SPSS, dummy variables were produced 
for the following variables: 
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 Smoking status (current smoker/everyone else, ex-smoker/everyone else) 
 Grouped BMI (<20kg/m2/everyone else, 25-29.9 kg/m2/everyone else, 30+ kg/m2/everyone 
else) 
 Region (midlands/everyone else, north/everyone else, Scotland/everyone else) 
 Education (other qualification/everyone else, no qualifications/everyone else) 
 Social class (II/everyone else, NMIII/everyone else, MIII/everyone else, IV/everyone else, 
V/everyone else, other/everyone else). 
 
The syntax required to undertake the multinomial logistic regression was then written, for both the 
cause-specific and site-specific cancer mortality variables, this followed the analyses schedule 
detailed within the all-cause mortality methods section above.  
 
Survival analysis and Cox regression were undertaken to further explore the associations between 
diabetes and cancer mortality by adding a time to event element to the analyses. It was necessary to 
create a number of variables in order to undertake this method of analysis. This included: 
 
 A binary ‘cancer/everyone else’ variable.  
 
All cases who were alive at the end of the follow-up period and those who died of a cause, other 
than cancer, were included in the latter group. 
 
 An interview date and censor date variable. 
 
The interview date variable was computed within SPSS by combining the three date variables within 
the HSE and SHeS datasets (dintb = day of interview, mintb = month of interview, yintb = year of 
interview). The censor date refers either to the date that the event of interest (in this instance 
mortality from cancer) or when an observation is right censored (the follow-up period ended and the 
observation had not experienced the event). This variable was produced using either death date 
variables (doDyr = year of death, QRTdeath = Quarter of year of death) for cases who were flagged 
within the mortality data or a censor date (this was set as the end of the first quarter of 2011 – the 
last available date a case could be flagged within mortality data) for those who had not died within 
the study time-period. These variables enabled the computation of a variable that included 
information about the duration of time cases had spent in the study, this variable was then used 
within the survival analysis and Cox regression. Because of the issue of disclosivity a day of death 
109 
 
variable was unavailable within the HSE and SHES data. The day of death was therefore set to 16 for 
all cases that died of cancer (the middle of the month). 
 
Following survival analysis and a Cox regression which analysed all-cause cancer mortality, variables 
were then computed for each site-specific cancer mortality category. For example a binary variable 
(cases who died of pancreatic cancer/died of another cause or were alive). The syntax utilised within 
the initial survival analysis and Cox regression was then adapted to assess the associations between 
diabetes and these site-specific cancers. 
 
4.5.3 Cancer incidence 
A binary variable (participant experienced an incident cancer: yes/no) was created within the 
dataset. This enabled a logistic regression to be undertaken which would detailed whether or not 
those with diabetes had an increased risk of incident cancer compared with those without diabetes 
(through the generation of ORs and CIs).  
 
The primary approach to assessing the associations between diabetes and site-specific cancer 
incidence utilised multinomial logistic regression. The estimates, within these analyses, were ORs 
and 95% CI. The dummy variables required to perform these analyses had already been computed 
for the cause-specific mortality analyses. The syntax produced for the latter were therefore adapted 
to undertake the site-specific incidence analyses. Further to this, survival analyses and Cox 
regression were undertaken, to explore whether or not those with diabetes had differing risks of 
developing incident cancer. The date variables computed for the all-cause mortality survival analyses 
were also utilised in this section. The analyses described above were then re-run utilising three 
diabetes-related variables: 
 
 Glycated haemoglobin (normal/raised ≥ 6.5%) 
 Glycated haemoglobin (continuous) 
 
The analyses of HSE and SHeS were performed using SPSS version 20. 
 
4.6 Whitehall I: logistic regression and survival analysis 
4.6.1 All-cause mortality 
Initial analyses of Whitehall I data utilised logistic regression to estimate the increased risk of all-
cause mortality among those with diabetes compared with the general population. The analyses 
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schedule matched the one developed for analysing the HSE and SHeS datasets, where corresponding 
variables were available. The Whitehall I data included only men who worked in London, so sex and 
region were not adjusted for.  
 
Whitehall I data were analysed using STATA 11. Within STATA dummy variables are produced by the 
programme as part of the analyses, therefore it was not necessary to produce them for the 
categorical independent variables. 
 The following logistic regression models were developed: 
 
 Age 
 Basic model: Age and smoking status (current, ex-regular, never-regular) 
 Advanced model: Age, smoking status and BMI (grouped the same as the HSE and 
SHeS variable or continuous) 
 
Cardiovascular disease status was only available within the resurvey dataset as a question related to 
the presence of the disease was not asked within the original dataset. Therefore it was only possible 
to produce a model which included this variable within the analyses of the resurvey data. 
 
The ‘basic model’ within these analyses referred to adjustment for age and smoking status, while the 
‘advanced model’ included BMI (grouped). Additional adjustment was made for variables related to: 
 
 Position within the civil service (social class) 
 Blood glucose measurement 
 
All cause-specific, survival analysis and Cox regression follows this schedule. 
 
4.6.2 Cause-specific mortality 
Within the Whitehall I data, binary variables had been computed for cause-specific mortality prior to 
the current study. In order to compare the results of the current analyses, which included 40 years 
of follow-up, with those of an earlier study with 27 years of follow-up logistic, rather than 
multinomial, regression for the following causes of death was performed: 
 
 Cancer 
 CVD 
111 
 
 CHD 
 Stroke 
 Other causes 
 
Survival analysis and Cox regression were performed to explore the association between diabetes 
and mortality from all-causes and cancer overall. This utilised a ‘time in study’ variable that was 
already available in the dataset. Analyses of the associations between diabetes and the following 
site-specific cancers were also undertaken: 
 
 Pancreas 
 Liver 
 Colon 
 Lung 
 Melanoma 
 Skin 
 Oesophagus 
 Bladder 
 Brain 
 Leukaemia 
 Myeloid leukaemia 
 Prostate 
 Stomach 
 
Although analyses of some of the site-specific cancers above were not undertaken using the HSE and 
SHeS datasets, it was agreed that analysing them within Whitehall I data would enable comparison 
with earlier results which utilised a shorter follow-up time. Regression analysis was not performed 
for the following site-specific cancers because descriptive analysis indicated that there were no cases 
among those who reported diabetes.  
 Rectum 
 Lymphoma 
 Lymphoid leukaemia 
 Kidney 
 Other skin 
The following chapters detail the results of the above analyses. 
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5. Chapter 5: Results – diabetes and cancer incidence 
Chapter five begins with an exploration of the study sample by detailing the descriptive analysis 
undertaken using data from the whole sample as well as the diabetic and non-diabetic cohorts. The 
following section then details the results related to the association between diabetes and cancer 
incidence. 
 
All of the results chapters are focused upon assessing the associations between diabetes and/or 
glycated haemoglobin and cancer incidence and mortality; as well as all-cause and mortality from 
respiratory and cardiovascular disease and ‘other’ causes. In instances where a statistically 
significant association was found these will be discussed. Further to this, and to enable a better 
understanding of results that may be indicative of an association, when point estimates are 
consistently raised or reduced (but the results are not statistically significant) these will also be 
discussed.  
 
 
 
 
 
5.1 Models used within the analyses 
As discussed in the previous chapter, a number of models were consistently used within the study 
analyses. Each of these included the following covariates: 
 
 Basic model: Age, sex and smoking 
 Advanced model: Age, sex, smoking and BMI (categorical) 
 CVD model: Age, sex, smoking, BMI and Cardiovascular disease at baseline. 
 
When analyses were stratified by either sex or CVD status these variables were removed from the 
regression model. 
 
Further analyses included variables related to educational attainment; the region the participant 
lived in; socioeconomic status; and whether the participant had a raised glycated haemoglobin 
(HbA1C) measurement (≥6.5%). These models were used within the analyses related to the 
combined Health Survey for England and Scottish Health Survey dataset.  
The following models were used within the analyses of Whitehall I data: 
Each chapter includes tables of results and within these the Odds Ratios and Hazard Ratios 
given refer to the risk or excess among those with either diabetes or raised glycated 
haemoglobin compared to those who did not indicate the presence of either. 
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 Basic model: Age and smoking (all the participants of Whitehall I were male so the sex 
variable was redundant). 
 Advanced model: Age, smoking and BMI (categorical). 
 
Further models were developed which adjusted for grade of employment (used as a proxy for 
socioeconomic status) and blood glucose measurement (used as a proxy for glycated haemoglobin) 
but no variable related to CVD at baseline was available. 
 
5.2 Descriptive analysis 
Table 5-1 gives an overview of the HSE/SHeS study sample. Within the dataset there were 7,199 
cases with diabetes (3.5% of the total) and 197,334 controls without known diabetes. Those with 
diabetes were considerably older (mean age 63 years old (SD±15.1) p-value <0.01) than those 
without the disease (mean 47 years old (SD±19.1)) and within the former group a larger percentage 
were aged ≥75 years old (23% vs 9%). In relation to lifestyle factors, a smaller percentage of those 
with diabetes indicated that they were current smokers compared with those without diabetes (p-
value <0.01). Measurements related to overweight and obesity were raised among those with 
diabetes compared with those who did not have the disease. The p-values for the differences in BMI, 
waist circumference and waist-to-hip ratio means between the two groups were <0.01 (independent 
two-sample T-tests were performed). 
 
There were no significant statistical differences in the region in which they lived between the 
diabetic and non-diabetic groups (south (England), midlands (England), north (England), and 
Scotland). Social class was separated into seven groups based upon the Registrar-General’s Social 
Class Occupation bandings (I: Professional occupations, II: Managerial and technical, IIINM: Skilled 
non-manual, IIIM: Skilled manual, IV: Partly-skilled, V: Unskilled and other); there were no 
differences between those with and without diabetes in terms of the distribution between the 
classes. A higher percentage of those without diabetes had a degree or other qualification, while 
50% of those with diabetes were found to have no qualifications (compared with 28% of those who 
did not indicate the presence of the disease). 38% of those with diabetes indicated that they had 
comorbid cardiovascular disease, compared with 10% of those without diabetes. 
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Table 5-1: Characteristics of HSE/SHeS study cohort (by diabetes status) 
Characteristics Diabetes Did not 
indicate 
diabetes 
Total 
Demographic factors  
Total sample (%) 7,199 (3.5) 197,334 (96.5) 204,533 
Age-groups no. (%)    
16-64 3,448 (48) 156,816 (80) 160,264 (78) 
65-74 2,127 (30) 22,376 (11) 24,503 (12) 
75+ 1,624 (23) 18,142 (9) 19,766 (10) 
Sex - no. (%)    
Male 3,762 (52) 87,648 (45) 91,410 (45) 
Female 3,437 (48) 109,511 (55) 112,948 (55) 
Missing 36 139 175 (1) 
Lifestyle factors  
Smoking status-no. (%)  
Never 3,023 (43) 95,084 (48) 98,827 (48) 
Ex-regular smoker 2,828 (39) 47,515 (24) 50,343 (25) 
Current smoker 1,226 (17) 52,719 (27) 53,945 (26) 
Missing 122 (2) 2016 (1) 2,138 (1) 
Anthropometric measures  
BMI   
No. with data (%) 5,986 (84) 176,670 (90) 182,656 (89) 
Mean – kg/m2 (SD) 29.79 (5.5) 26.47 (4.8) 28.13 (5.4) 
BMI: <20 kg/m2 83 (1) 9,836 (6) 9,919 (5) 
BMI: 20-<25 kg/m2 1,019 (17) 64,310 (36) 65,329 (32) 
BMI: 25-<30 kg/m2 2,287 (38) 66,888 (38) 69,175 (34)  
BMI: ≥30 kg/m2 2,597 (43) 35,607 (20) 38,204 (19) 
BMI: Missing 1,213 (16) 20,693 (10) 21,906 (11) 
Waist circumference  
No. With data (%) 4,302 (59) 111,935 (57) 116,237 (57)  
Above threshold (Men: 
102cm, Women: 88cm) 
2,877 (67) 42,716 (38) 45,593 (39) 
Mean-cm (SD) 101.85 (14.4) 89.45 (13.7) 95.65 (14.1) 
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Waist-to-hip ratio  
No. with data (%) 4,291 (59) 111,785 (57) 116,076 (57) 
Above threshold (Men: 0.949, 
Women: 0.849) (%) 
2,804 (65) 31,503 (28) 34,307 (30) 
Mean (SD) 0.93 (0.09) 0.86 (0.09) 0.90 (0.09) 
Socio-demographic  
Region (%)  
South 3,067 (43) 86,611 (44) 89,678 (44) 
Midlands 1,341 (19) 35,389 (18)  36,730 (18) 
North 1,889 (26) 50,910(26) 52,799 (26) 
Scotland 683 (10) 22,133 (11) 22,816 (11) 
Education (%)  
Degree 595 (8) 28,361 (14) 28,956 (14) 
Other 2,886 (40) 111,443 (57) 114,329 (56) 
No qualifications 3,587 (50) 55,829 (28) 59,416 (29) 
Missing 131 (2) 1,701 (1) 1832 (1) 
Socio-economic class (%)  
I: Professional 222 (3) 8,591 (4) 8813 (4) 
II: Managerial 1,614 (22) 50,767 (26) 52,381 (26) 
III: Skilled Non-manual 1,319 (18) 45,614 (23) 46,933 (23) 
III: Skilled Manual 1,667 (23) 35,150 (18) 36,817 (18) 
IV: Semi-skilled Manual 1,363 (19) 32,779 (17) 34,142 (17) 
V: Unskilled manual 553 (8) 11,491 (6) 12,044 (6) 
Other 313 (4) 10,054 (5) 10,367 (5) 
Missing 148 (2) 2,888 (2) 3,036 (1) 
Comorbidity  
CVD reported at baseline (%) 2,722 (38) 19,170 (10) 21,892 (10) 
 
 
5.3 Descriptive statistics: cancer incidence 
Within the Health Survey for England (HSE) and Scottish Health Survey (SHeS) data linked to the 
Cancer Registry a string variable gave the three digit International Classification of Disease (ICD) code 
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(either from ICD 9 or 10). This chapter details the analyses related to the associations between 
diabetes and incidence of all-cancers combined and incidence of site-specific cancers.  
 
As mentioned previously, the inconsistencies within the Cancer Registry linked data for HSE 2008 
meant that participants from that year of the survey were excluded from the dataset used for this 
section of the thesis. This produced a reduced dataset including 189,743 cases, of which 6,488 
(3.4%) indicated the presence of diabetes at baseline. Table 5-2 details the number of incident 
cancers that were flagged among those within the HSE and SHeS appended dataset. 11% of those 
with diabetes had an incident cancer compared within 6% of those without diabetes.  
 
Table 5-2: Cancer Registrations (HSE and SHeS) 
Cancer Registration Diabetic 
(%) 
Did not indicate diabetes 
(%) 
Total 
Yes 679 (11) 10,899 (6) 11,578 (6) 
No 5,442 (89) 164,544 (94) 169,986 (94) 
 
Table 5-3 demonstrates the number of incident site-specific cancers registered during the follow-up 
period. 
 
Table 5-3: Site-specific cancer registrations (HSE and SHeS) 
Site-specific cancer 
registrations 
Diabetic Did not 
indicate 
diabetes 
Total 
Breast 100 2,109 2,209 
Lung 96 1,277 1,373 
Prostate 75 1,287 1,362 
Colorectal 68 921 989 
Lymphatica 39 836 875 
Cervixb 38 547 585 
Bladder 46 470 516 
Pancreatic 25 267 292 
Stomach 18 274 292 
Oesophagus 16 246 262 
Kidney/Renal 22 239 261 
Lipc 6 219 225 
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a
 Lymphatic group also includes haematopoietic and related tissue cancers. 
c
 Cervix also includes cancers of the uterus and endometrium. 
b 
Lip cancer group also contains those of the oral cavity and pharynx. 
d 
‘Other cancer’ category contains those cancers not specified in other groups.
 
 
 
Information was available for other cancers (skin, n=4,380) and types of neoplasms (benign, n=170; 
uncertain/unknown origin, n=648; in situ, n=2,908; incorrectly coded, n=34) that were excluded 
from the analyses as their type, site of origin and/or malignant nature could not be clarified. 
 
5.4 Overall cancer incidence 
Using the derived binary variable for cancer incidence, regression models were developed to assess 
the association between diabetes and any registration of cancer. The results given in Table 5-4 
demonstrate that, when analyses were focused upon the whole sample, within both the basic (OR 
1.13, CI 1.04-1.23) and advanced models (1.11, CI 1.01-1.21) those with diabetes were at a 
statistically significant increased risk of cancer incidence. This increase remained, but became non-
significant, when adjustment included CVD at baseline, education or glycated haemoglobin. When 
analyses were stratified by CVD status at baseline, those with diabetes but without comorbid CVD 
were found to have increased odds ratios in relation to cancer incidence while those with CVD did 
not. Within the sex-stratified analyses, women with diabetes were found to have a statistically 
significant increased risk of developing cancer, while for men only the point estimate was increased. 
Sensitivity analysis was performed (using cases who indicated that they had never been a regular 
smoker): among this group there were non-significant increases within each model, including those 
used within the additional adjustment, which appeared to be non-significant. 
 
Liver <5 77 81 
Other cancerd 126 2,130 2,256 
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Table 5-4: Cancer incidence ORs among those with diabetes compared with the general population 
 Progressive 
adjustment 
  
Whole 
sample 
Stratified by CVD status 
 
Stratified by sex Never 
smokers 
Only 
NO YES WOMEN MEN 
Age & sex 
  
1.15 1.21 0.92 1.22 1.06 1.20 
(1.05-1.25) (1.09-1.35) (0.80-1.06) (1.08-1.38) (0.94-1.19) (1.04-1.38) 
& Smoking  1.13 1.20 0.92 1.22 1.04 N/A 
  (1.04-1.23) (1.08-1.34) (0.80-1.06) (1.08-1.38 (0.93-1.17)  
& BMI  1.11 1.17 0.94 1.16 1.03 1.13 
  (1.01-1.21) (1.04-1.32) (0.81-1.09) (1.02-1.33) (0.91-1.17) (0.97-1.32) 
Basic & CVD 
Status 
1.10 
(1.00-1.20) 
N/A N/A 1.19 
(1.05-1.34) 
1.01 
(0.90-1.14) 
1.17 
(1.01-1.35) 
Additional adjustment (Advanced model + the following variables in turn) 
+ CVD 1.08 N/A N/A 1.14 1.00 1.11 
  (0.98-1.19)   (0.99-1.31) (0.88-1.14) (0.95-1.29) 
+ Education 1.08 1.14 0.94 1.12 1.01 1.11 
  (0.98-1.18) (1.02-1.28) (0.81-1.09) (0.98-1.29) (0.89-1.15) (0.95-1.30) 
+ Social Class 1.11 1.18 0.94 1.18 1.03 1.15 
  (1.01-1.22) (1.05-1.32) (0.81-1.09) (1.03-1.35) (0.91-1.17) (0.98-1.34) 
+ Region 1.11 1.18 0.94 1.17 1.03 1.13 
  (1.01-1.22) (1.05-1.32) (0.81-1.09) (1.02-1.34) (0.91-1.17) (0.96-1.32) 
+HbA1c 1.16 1.20 1.07 1.98 0.68 1.38 
  (0.86-1.58) (0.82-1.75) (0.63-1.82) (1.30-3.03) (0.43-1.06) (0.84-2.29) 
 
 
Models were then developed which included alternative measurements for overweight and obesity. 
As can be seen from the advanced model and the results given in Table 5-5 and Table 5-6, including a 
measurement of BMI, waist-to-hip ratio (WHR) or waist circumference (WC) did little to alter the 
excess risk of developing cancer among those with diabetes compared with those without diabetes. 
Further to this, when a combination of covariates were included in the models, and when analyses 
were stratified by either sex or baseline CVD status, this excess in risk of cancer incidence remained 
among those with diabetes compared with the general population. 
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Table 5-5: Cancer incidence ORs among those with diabetes (alternative measures of overweight 
and obesity) 
 Further 
adjustment 
  
Whole 
sample 
Stratified by CVD status 
 
Stratified by sex Never 
smokers 
Only NO YES WOMEN MEN 
& BMI  
  
1.11 1.17 0.94 1.16 1.03 1.13 
(1.01-1.21) (1.04-1.32) (0.81-1.09) (1.02-1.33) (0.91-1.17) (0.97-1.32) 
Basic & WHR 1.14 1.23 0.96 1.26 1.04 1.14 
(1.03-1.28) (1.07-1.41) (0.81-1.15) (1.08-1.48) (0.89-1.20) (0.95-1.37) 
Basic & WC 1.15 
(1.03-1.28) 
1.23 
(1.07-1.41) 
0.97 
(0.81-1.16) 
1.23 
(1.05-1.45) 
1.06 
(0.91-1.24) 
1.13 
(0.94-1.36) 
Basic + WHR 
& CVD 
1.12 N/A N/A 1.22 1.02 1.13 
(1.00-1.25)   (1.04-1.44) (0.88-1.19) (0.93-1.36) 
Basic + WC & 
CVD 
1.12 N/A N/A 1.20 1.05 1.12 
(1.00-1.26)   (1.02-1.41) (0.90-1.22) (0.93-1.35) 
 
Table 5-6: Cancer incidence ORs (measures of overweight and obesity removed) 
Further 
adjustment 
Whole sample Stratified by CVD status 
 
Stratified by sex Never smokers 
Only 
NO YES WOMEN MEN 
Basic + 
Education 
1.10 1.16 0.92 1.17 1.02 1.17 
(1.01-1.20) (1.04-1.30) (0.80-1.06) (1.03-1.32) (0.91-1.15) (1.02-1.35) 
Basic + 
Social Class 
1.13 1.21 0.93 1.23 1.04 1.21 
(1.04-1.24) (1.08-1.35) (0.81-1.07) (1.09-1.40) (0.92-1.17) (1.05-1.40) 
Basic + 
Region 
1.15 1.22 0.93 1.24 1.05 1.19 
(1.05-1.25) (1.10-1.36) (0.80-1.07) (1.09-1.41) (0.93-1.18) (1.03-1.38) 
Basic + 
HbA1c 
1.16 1.22 1.04 1.86 0.71 1.43 
(0.87-1.55) (0.86-1.74) (0.63-1.72) (1.25-2.77) (0.47-1.08) (0.90-2.27) 
 
5.5 Site-specific cancer incidence (HSE and SHeS) 
Using the categorical variable related to site-specific cancer incidence, multinomial logistic 
regression models were then developed to investigate whether those with diabetes had an 
increased risk of a range of incident site-specific cancers (information about the number of site-
specific cancers among those with and without diabetes is given in Table 5-3 above). Only for 
incident pancreatic cancer were those with diabetes at an increased risk within both the basic (1.58, 
CI 1.04-2.40) and advanced (1.60, 1.02-2.50) models compared with those without diabetes. For 
cancers of the kidney and lung there were statistically significant increases within the basic, but not 
advanced models, while for cancers that were sex-specific and those of the oesophagus, colorectum, 
bladder and other sites there were point estimates increases in risk among the former (Table 5-7). 
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Diabetes appeared to lower the risk of incident lip cancer, although this was a non-statistically 
significant reduction. These results remained when alternate measurements of overweight and 
obesity were included in further models and when adjustment was made for socio-demographic and 
economic factors (data not shown). 
 
The models developed above were then repeated stratified by baseline CVD status. The number of 
cancers within each of these groups can be found within Table 5-8. Among those with diabetes and 
comorbid CVD there were point estimate increases in risk for cancers of the oesophagus, liver, 
pancreas, lung and kidney (although none of these were statistically significant, Table 5-9). The 
results suggest that those with diabetes but without CVD had a statistically significant increase in the 
risk of developing ‘other’ cancers (Table 5-10), and there were point estimate increases for cancers 
of the oesophagus, stomach, colorectum, pancreas, lung, bladder, kidney, lymphatic system and sex-
specific sites (cervix, prostate and breast). 
 
Analyses were then performed stratified by sex. Table 5-11 details the number of site-specific 
cancers among men and women. Among men with diabetes, the results suggested a statistically 
significant risk for pancreatic and bladder cancer that remained consistent within each of the 
models. Further to this, within the BMI and CVD regression models the ORs were increased for 
cancers of the stomach, colorectum, lung, lymphatic, prostate and ‘other’ sites. Women with 
diabetes were found to have an increased risk of developing cancers of the lung (statistically 
significant increased risk in the basic and CVD models), breast and cervix (statistically significant 
increases for cervical cancer were found within the basic, but not advanced, models). There were 
also point estimate increases for cancers of the oesophagus, colorectum, pancreas and kidney 
among women with diabetes. 
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Table 5-7: Site-specific cancer incidence ORs among those with diabetes 
Progressive 
adjustment 
Lip Oesophagus Stomach Colorectal Liver Pancreas Lung Sex-
specific 
cancer 
Bladder Kidney Lymphatic Other 
cancers 
Age & sex 0.63 1.10 0.98 1.14 0.94 1.59 1.24 1.12 1.30 1.64 0.90 1.13 
 
(0.28-
1.42) 
(0.66-1.84) (0.60-
1.61) 
(0.88-
1.46) 
(0.34-
2.60) 
(1.05-
2.42) 
(1.00-
1.53) 
(0.97-
1.29) 
(0.95-
1.77) 
(1.05-
2.55) 
(0.85-
1.25) 
(0.94-
1.35) 
& Smoking  0.64 1.10 0.97 1.12 0.93 1.58 1.29 1.09 1.29 1.64 0.90 1.12 
 
(0.28-
1.45) 
(0.66-1.83) (0.59-
1.59) 
(0.87-
1.44) 
(0.34-
2.56) 
(1.04-
2.40) 
(1.04-
1.60) 
(0.94-
1.26) 
(0.95-
1.75) 
(1.05-
2.56) 
(0.65-
1.24) 
(0.93-
1.34) 
& BMI 0.84 1.10 0.93 1.12 0.92 1.60 1.25 1.05 1.19 1.55 0.88 1.11 
 
(0.37-
1.92) 
(0.63-1.91) (0.55-
1.59) 
(0.86-
1.46) 
(0.33-
2.57) 
(1.02-
2.50) 
(0.99-
1.58) 
(0.90-
1.22) 
(0.84-
1.68) 
(0.97-
2.49) 
(0.62-
1.24) 
(0.91-
1.35) 
& CVD 0.82 1.12 0.92 1.10 0.87 1.48 1.20 1.05 1.10 1.47 0.87 1.06 
 
(0.36-
1.87) 
(0.64-1.94) (0.53-
1.60) 
(0.84-
1.43) 
(0.31-
2.45) 
(0.93-
2.35) 
(0.94-
1.52) 
(0.90-
1.23) 
(0.77-
1.58) 
(0.91-
2.37) 
(0.61-
1.24) 
(0.86-
1.29) 
Table 5-8: Site-specific cancer incidence by CVD status  
Comorbid 
CVD 
Pancreas Colorectal Bladder Stomach Lip Liver Lung Lymphatic Kidney Oesophagus Other Sex-
specific
a 
Yes 66 232 118 58 31 19 293 136 63 50 400 684 
No 226 757 398 232 194 61 1,078 738 198 212 1,854 3,469 
a This category includes cancers that only occur in one gender (prostate and cervical) and those that are rarely found within a specific sex (breast). In the 
sex-stratified analyses the results are given for these cancers. 
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Table 5-9: Site-specific cancer incidence ORs among those with diabetes and comorbid CVD 
Progressive 
adjustment 
CVD indicated at baseline 
Lip Oesophagus Stomach Colorectal Liver Pancreas Lung Sex-spec 
cancer 
Bladder Kidney Lymphatic Other 
cancers 
Age, sex 0.72 1.09 0.50 0.91 1.29 1.62 1.14 0.93 0.83 1.22 0.72 0.76 
 
(0.22-
2.38) 
(0.49-
2.42) 
(0.18-
1.38) 
(0.61-1.36) (0.37-
4.43) 
(0.88-
2.99) 
(0.82-
1.58) 
(0.73-
1.18) 
(0.47-
1.45) 
(0.62-
2.40) 
(0.55-
1.27) 
(0.55-
1.06) 
& Smoking  0.73 1.08 0.50 0.91 1.34 1.59 1.18 0.92 0.82 1.21 0.71 0.77 
 
(0.22-
2.39) 
(0.48-
2.40) 
(0.18-
1.37) 
(0.61-1.36) (0.39-
4.62) 
(0.86-
2.93) 
(0.85-
1.64) 
(0.72-
1.17) 
(0.47-
1.44) 
(0.61-
2.38) 
(0.40-
1.26) 
(0.55-
1.07) 
& BMI 0.94 1.02 0.60 0.90 1.49 1.65 1.20 0.96 0.89 1.13 0.68 0.75 
 
(0.28-
3.16) 
(0.40-
2.63) 
(0.22-
1.69) 
(0.59-1.37) (0.42-
5.29) 
(0.85-
3.21) 
(0.83-
1.72) 
(0.75-
1.24) 
(0.49-
1.60) 
(0.55-
2.32) 
(0.36-
1.28) 
(0.53-
1.07) 
 
Table 5-10: Site-specific cancer incidence ORs among those with diabetes and without comorbid CVD 
Progressive 
adjustment 
CVD not indicated at baseline 
Lip Oesophagus Stomach Colorectal Liver Pancreas Lung Sex-spec 
cancer 
Bladder Kidney Lymphatic Other 
cancers 
Age, sex 0.51 1.05 1.27 1.18 0.42 1.36 1.17 1.18 1.58 1.63 1.01 1.30 
 
(0.16-
1.61) 
(0.54-2.07) (0.72-2.24) (0.85-
1.63) 
(0.06-
3.03) 
(0.75-
2.45) 
(0.88-
1.55) 
(0.99-
1.41) 
(1.10-
2.29) 
(0.90-
2.95) 
(0.68-
1.49) 
(1.04-
1.62) 
& Smoking  0.53 1.05 1.26 1.17 0.41 1.36 1.22 1.15 1.58 1.65 1.00 1.29 
 
(0.17-
1.66) 
(0.54-2.10) (0.71-2.22) (0.85-
1.62) 
(0.06-
2.95) 
(0.76-
2.46) 
(0.92-
1.63) 
(0.96-
1.38) 
(1.09-
2.29) 
(0.91-
2.99) 
(0.67-
1.49) 
(1.03-
1.61) 
& BMI 0.69 1.17 1.14 1.20 0.40 1.42 1.19 1.07 1.36 1.64 1.01 1.31 
 
(0.21-
2.18) 
(0.59-2.30) (0.61-2.11) (0.86-
1.69) 
(0.06-
2.94) 
(0.77-
2.64) 
(0.88-
1.63) 
(0.88-
1.31) 
(0.89-
2.08) 
(0.88-
3.05) 
(0.67-
1.53) 
(1.04-
1.65) 
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Table 5-11: Site-specific cancer incidence by sex 
Sex Pancreas Colorectal Bladder Breast Cervical Stomach Lip Liver Lung Lymphatic Kidney Oesophagus Prostate Other 
Male 140 491 377 0 0 185 141 43 787 479 169 159 1,361 1,114 
Female 152 498 139 2,196 585 105 84 37 584 395 92 103 0 1,140 
 
Table 5-12: Site-specific cancer incidence ORs among men with diabetes 
Progressive 
adjustment 
Lip etc Oesophagus Stomach Colorectal Liver Pancreas Lung Bladder Kidney Lymphatic Prostate Other 
cancers 
Age & sex 0.84 1.09 1.03 1.13 1.13 1.74 1.16 1.43 1.67 0.96 0.80 1.07 
(0.34-
2.08) 
(0.57-2.09) (0.57-
1.87) 
(0.81-
1.57) 
(0.34-
3.70) 
(1.01-
3.02) 
(0.88-
1.51) 
(1.02-
2.00) 
(0.99-
2.83) 
(0.64-
1.44) 
(0.63-
1.02) 
(0.83-
1.38) 
& Smoking 0.86 1.07 1.01 1.11 1.09 1.69 1.19 1.41 1.66 0.94 0.78 1.06 
(0.35-
2.13) 
(0.56-2.05) (0.56-
1.83) 
(0.79-
1.54) 
(0.33-
3.57) 
(0.98-
2.93) 
(0.91-
1.56) 
(1.01-
1.97) 
(0.98-
2.81) 
(0.63-
1.41) 
(0.61-
0.99) 
(0.82-
1.36) 
& BMI 1.03 1.06 1.07 1.05 1.05 1.11 1.10 1.11 1.00 1.05 1.05 1.07 
(0.96-
1.10) 
(1.02-1.11) (1.02-
1.12) 
(1.02-
1.09) 
(0.97-
1.14) 
(1.05-
1.16) 
(1.08-
1.13) 
(1.04-
1.18) 
(0.95-
1.06) 
(1.01-
1.09) 
(1.02-
1.09) 
(1.05-
1.10) 
& CVD 1.03 1.07 1.06 1.05 1.03 1.10 1.09 1.09 1.00 1.05 1.06 1.07 
(0.95-
1.11) 
(1.02-1.11) (1.01-
1.12) 
(1.01-
1.08) 
(0.95-
1.13) 
(1.04-
1.16) 
(1.07-
1.12) 
(1.02-
1.16) 
(0.94-
1.06) 
(1.01-
1.09) 
(1.03-
1.09) 
(1.05-
1.10) 
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Table 5-13: ORs site-specific cancer incidence among women with diabetes 
 
 
Progressive 
adjustment 
Lip Oeso-
phagus 
Stomach Colo-
rectal 
Liver Pancreas Lung Breast Cervix Bladder Kidney Ovarian Lymphatic Other 
cancers 
Age & sex 0.29 1.17 0.90 1.15 0.62 1.42 1.37 1.26 1.70 0.80 1.54 1.07 (0.80 1.18 
 
(0.04-
2.09) 
(0.51-
2.68) 
(0.37-
2.23) 
(0.78-
1.68) 
(0.08-
4.59) 
(0.74-
2.71) 
(0.97-
1.94) 
(1.03-
1.56) 
(1.21-
2.38) 
(0.35-
1.81) 
(0.67-
3.56) 
(1.02-
1.12) 
(0.46-
1.40) 
(0.90-
1.55) 
& Smoking  0.30 1.18 0.91 1.14 0.63 1.43 1.49 1.25 1.64 0.81 1.56 1.07 0.80 1.19 
 
(0.04-
2.14) 
(0.51-
2.71) 
(0.37-
2.25) 
(0.78-
1.66) 
(0.09-
4.64) 
(0.75-
2.73) 
(1.05-
2.12) 
(1.02-
1.54) 
(1.17-
2.30) 
(0.36-
1.85) 
(0.67-
3.60) 
(1.02-
1.12) 
(0.46-
1.40) 
(0.91-
1.56) 
& BMI  0.37 1.28 0.81 1.18 0.52 1.29 1.38 1.22 1.35 0.78 1.70 1.06 0.68 1.15 
 
(0.05-
2.67) 
(0.51-
3.20) 
(0.30-
2.24) 
(0.80-
1.76) 
(0.07-
3.87) 
(0.62-
2.67) 
(0.93-
2.05) 
(0.97-
1.53) 
(0.93-
1.95) 
(0.31-
1.91) 
(0.73-
3.98) 
(1.02-
1.11 
(0.36-
1.29) 
(0.86-
1.53) 
& CVD 0.96 1.07 1.06 1.06 1.09 1.07 1.07 1.04 0.99 1.03 1.13 1.06 1.03 1.04 
(0.84-
1.09) 
(1.00-
1.14) 
(0.99-
1.13) 
(1.02-
1.10) 
(0.97-
1.23) 
(1.01-
1.12) 
(1.04-
1.10) 
(1.00-
1.07) 
(0.93-
1.05) 
(0.96-
1.12) 
(1.02-
1.26) 
(1.02-
1.11 
(0.99-
1.08) 
(1.01-
1.07) 
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The results detailed within this chapter suggest that those with diabetes may be at an increased risk 
of cancer incidence, when all cancers are considered, compared with the general population. 
Concurrently, such risk appears dependent upon a number of factors related to the presence of CVD 
as a comorbidity, sex and smoking status. In terms of site-specific cancers, the presence or not of 
CVD as a comorbidity appears to alter an individual’s risk of incident cancer. Both men and women 
with diabetes appear to have an increased risk of lung cancer; at the same time the risk of 
developing a number of other site-specific cancers appears to differ between the sexes. 
 
The following chapter detail the association between glycated haemoglobin and cancer incidence.  
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6. Chapter 6: Results – glycated haemoglobin and cancer 
incidence 
6.1 Descriptive statistics: glycated haemoglobin 
In total, 28,754 participants had a valid glycated haemoglobin (HbA1C) measurement (14% of the 
total sample) at baseline. The mean HbA1C was 5.50 (SD 0.74), with 5% of the sample having a 
measurement of 6.5% (48mmol/mol) or above; this threshold indicates uncontrolled or undiagnosed 
diabetes (Table 6-1). The majority of the sample were in the 16-64 age group (75%), with slightly 
more women than men (15,541 and 13,213, respectively). 50% of the sample indicated that they had 
never been a regular smoker. In relation to the anthropometric measures, the mean BMI was 27.01 
(SD 4.85), 41% had a waist circumference above the threshold (102cm for men and 88cm for 
women) and 34% had a raised measurement for waist-to-hip ratio (WHR: 0.95 or above for men and 
0.85 or above for women). 42% of the sample lived in the South. A majority (42%) indicated that 
they had qualifications other than a degree (29% indicated no qualifications) and 5% were from the 
‘professional’ socioeconomic class. 3,539 (12%) indicated the presence of cardiovascular disease as a 
comorbidity: 32% of those with HbA1C ≥6.5% compared with 11% of those with a measurement 
below this. Among those with raised HbA1C, 57% indicated the presence of diabetes, compared with 
2% with a normal measurement. When HbA1C was divided into tertiles, the majority of those with 
diabetes (90%) were in the top tertile (indicating the highest measurements) compared with 34% of 
those who did not indicate the presence of diabetes. 
 
Table 6-1: Descriptive statistics – valid glycated haemoglobin sample 
Characteristics HbA1C sample 
Total sample (%) Raised Normal All 
 n=1,459 n=27,295 n=28,754 
Glycated haemoglobin    
Mean (SD) 7.81 (1.46) 5.37 (0.40) 5.50 (0.74) 
HbA1c Tertiles    
1  (lowest) 0 (0) 10,335 (38) 10,335 (35) 
2 0 (0) 7,956 (29) 7,956 (28) 
3 (highest) 1,459 (100) 9,004 (33) 10,463 (36) 
Age-groups no. (%) 
16-64 714 (49) 20,910 (77) 21,624 (75) 
127 
 
65-74 451 (31) 3,832 (14) 4,283 (15) 
75+ 294 (20) 2,553 (9) 2,847 (10) 
Sex - no. (%) 
Male 791 (54) 12,422 (46) 13,213 (46) 
Female 668 (46) 14,873 (55) 15,541 (54) 
Lifestyle factors 
Smoking status-no. (%) 
Never 620 (43) 13,713 (50) 14,333 (50) 
Ex-regular smoker 555 (38) 7,242 (27) 7,797 (27) 
Current smoker 283 (19) 6,291 (23) 6,574 (23) 
Missing 1 (<1) 49 (<1) 50 (<1) 
Anthropometric measures 
BMI  
No. with data (%) 1,316 (90)  25,795 (95) 27,111 (94) 
Mean – kg/m2 (SD) 29.88 (5.36) 26.87 (4.78) 27.01 (4.85) 
BMI: <20 kg/m2 12 (<1) 1,112 (4) 1,124 (4) 
BMI: 20-24.99 kg/m2 233 (17) 8,658 (33) 8,891 (31) 
BMI: 25-29.99 kg/m2 484 (36) 10, 318 (40) 10,802 (38) 
BMI: ≥30 kg/m2 587 (44) 5,707 (22) 6,294 (22) 
BMI: Missing 143 (10) 1,500 (6) 1,643 (6) 
Waist circumference 
No. With data (%) 1,388 (95) 26,429 (97) 27,817 (97) 
Above threshold (Men: 
102cm, Women: 88cm) 
953 (69) 10,875 (41) 11,828 (41) 
Mean-cm (SD) 102.74 (14.66) 90.87 (13.53) 91.46 (13.84) 
Waist-to-hip ratio 
No. with data (%) 1,385 (95)  26,402 (97) 27,787 (97) 
Above threshold (Men: ≥0.95, 
Women: ≥0.85) (%) 
942 (68) 8,830 (33) 9,772 (34) 
Mean (SD) 0.93 (0.07) 0.82 (0.07) 0.87 (0.09) 
Region    
South 625 (43) 11,349 (42) 11,974 (42) 
Midlands 283 (19) 4,678 (17) 4,961 (17) 
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North 387 (27) 7,444 (27) 7,831 (27) 
Scotland 164 (11) 3,824 (14) 3,988 (14) 
Education    
Degree 159 (11) 5,005 (18) 5,164 (18) 
Other 584 (40) 14,641 (54) 15,225 (53) 
No qualifications 714 (49) 7,624 (28) 8,338 (29) 
Missing 2 (<1) 25 (<1) 27 (<1) 
Socio-economic status    
I: Professional 59 (4) 1,439 (5) 1,498 (5) 
II: Managerial 371 (26) 8,109 (30) 8,480 (30) 
III: Skilled Non-manual 251 (17) 6,092 (23) 6,343 (22) 
III: Skilled Manual 329 (23) 4,805 (18) 5,134 (18) 
IV: Semi-skilled Manual 288 (20) 4,249 (16) 4,537 (16) 
V: Unskilled manual 106 (7) 1,417 (5) 1,523 (5) 
Other 44 (3) 941 (4) 985 (3) 
Missing 11 (<1) 243 (<1) 254 (<1) 
Morbidity and mortality 
Diabetes 827 (57) 415 (2) 1,242 (4) 
CVD reported at baseline (%) 462 (32) 3,077 (11) 3,539 (12) 
Vital status    
Alive 1,291 (89) 26,101 (96) 27,392 (95) 
Dead 168 (12) 1,194 (4) 1,362 (5) 
Cause of death    
Cancer 47 (28)  402 (34) 449 (33) 
Respiratory 19 (11) 154 (13) 173 (13) 
CVD 73 (43) 398 (33) 471 (35) 
Other 29 (17) 240 (20) 269 (20) 
 
The following chapter details the results related to glycated haemoglobin (HbA1C) and cancer 
incidence (all-cancers and site-specific) when analyses were undertaken using the combined HSE and 
SHeS dataset. Amongst those with a valid HbA1C measurement there were 1,137 recorded incident 
cancers within the follow-up period, including 103 among those with an HbA1C of ≥6.5%. The next 
section assesses the associations between raised HbA1C and overall cancer incidence. 
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6.2 Overall cancer incidence 
A binary variable was produced which included those with and without an incident cancer (0=no 
cancer, 1=cancer registration). This dependent variable was then used to assess the associations 
between HbA1C and cancer incidence. Within the whole sample, there were statistically significant 
increased ORs among those with a raised measurement within the basic (1.33, CI 1.07-1.66) but not 
advanced model, although within the latter there was a point estimate increase (1.22, 0.96-1.55). 
This point estimate increase remained when additional variables, related to socio-economic and 
demographic covariates, were added to the regression model. The analyses were then re-run with 
the data stratified by CVD status. As can be seen from Table 6-2, those without comorbid CVD but 
with a raised HbA1C measurement were at an increased risk of developing cancer within both the 
basic (1.44, 1.10-1.89) and advanced (1.34, 1.00-1.79) models, while those with CVD did not appear 
to have a statistically significant increased risk. When the data were stratified by sex, women with a 
raised HbA1C measurement had an increased risk at the point estimate, while men had statistically 
significant increased odds within the basic (1.44, 1.08-1.93) but not advanced models. Among those 
who indicated that they had never been a regular smoker, there were point estimate increases in 
the risk of incident cancer, but these were non-significant.  
 
Further analyses were undertaken which explored the impact of alternative measurements of 
overweight and obesity upon the association between raised HbA1C and overall cancer incidence. As 
can be seen from Table 6-3, the inclusion of these covariates had little impact upon the increased 
risk in odds found among those with raised HbA1C compared with those with a lower measurement. 
The exclusion of all the adiposity related variables, as well as the inclusion of a number of socio-
economic and demographic covariates, had little impact upon the results given below (results not 
shown). 
 
Table 6-2: Cancer incidence ORs among those with HbA1C ≥6.5% 
Progressive 
adjustment 
WHOLE 
SAMPLE 
STRATIFIED BY CVD STRATIFIED BY GENDER NEVER 
SMOKERS 
ONLY 
 
 NO YES WOMEN MEN  
Age & sex 1.34 1.45 1.12 1.20 1.45 1.31 
 
(1.08-1.67) (1.11-1.90) (0.76-1.65) (0.85-1.68) (1.09-1.95) (0.91-1.87) 
& Smoking 1.33 1.44 1.10 1.20 1.44 N/A 
 
(1.07-1.66) (1.10-1.89) (0.75-1.63) (0.85-1.69) (1.08-1.93) 
& BMI 1.22 1.34 0.99 1.10 1.31 1.13 
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(0.96-1.55) (1.00-1.79) (0.65-1.50) (0.77-1.59) (0.95-1.79) (0.76-1.69) 
Basic + 
CVD status 
1.32 
(1.06-1.65) 
N/A N/A 1.19 
(0.84-1.67) 
1.44 
(1.07-1.93) 
1.31 
(0.91-1.89) 
Additional adjustment (Advanced model + the following variables) 
+ CVD 1.21 
(0.95-1.54) 
N/A N/A 1.10 
(0.76-1.58) 
1.30 
(0.94-1.78) 
1.14 
(0.76-1.69) 
+ Education 1.19 1.30 1.03 1.08 1.27 1.12 
 
(0.94-1.52) (0.97-1.74) (0.68-1.60) (0.75-1.56) (0.93-1.75) (0.75-1.67) 
+ Social Class 1.20 1.30 1.01 1.06 1.30 1.09 
 
(0.95-1.53) (0.97-1.74) (0.67-1.54) (0.73-1.54) (0.95-1.78) (0.73-1.64) 
+ Region 1.22 1.32 0.99 1.10 1.31 1.13 
 
(0.96-1.55) (0.99-1.77) (0.65-1.51) (0.77-1.59) (0.96-1.80) (0.76-1.69) 
+ Diabetes 1.12 1.22 0.95 0.75 1.61 0.94 
 
(0.84-1.51) (0.86-1.73) (0.55-1.61) (0.48-1.18) (1.09-2.39) (0.56-1.55) 
 
Table 6-3: Cancer incidence ORs among those with raised HbA1C (including alternative measures of 
overweight and obesity) 
Additional 
adjustment 
WHOLE 
SAMPLE 
STRATIFIED BY CVD STRATIFIED BY GENDER NEVER 
SMOKERS 
ONLY 
  NO YES WOMEN MEN  
Basic +  
WHR 
1.23 
(0.98-1.55) 
1.28 
(0.96-1.69) 
1.16 
(0.78-1.72) 
1.09 
(0.76-1.55) 
1.35 
(0.99-1.82) 
1.15 
(0.79-1.68) 
Basic +  
WC 
1.26 
(1.00-1.58) 
1.32 
(1.00-1.74) 
1.14 
(0.77-1.70) 
1.11 
(0.78-1.58) 
1.38 
(1.02-1.86) 
1.16 
(0.79-1.69) 
Basic + 
 WHR & 
CVD 
1.23 
0.98-1.55) 
N/A N/A 1.08 
(0.76-1.55) 
1.35 
(1.00-1.83) 
1.16 
(0.79-1.69) 
Basic +  
WC & CVD 
1.26 
(1.00-1.58) 
N/A N/A 1.10 
(0.77-1.57) 
1.38 
(1.02-1.86) 
1.17 
(0.80-1.71) 
 
 
6.3 Site-specific cancer incidence 
Using the derived site-specific Cancer Registry variable (produced for the analyses related to 
diabetes and cancer incidence) it was possible to explore the associations between raised HbA1C and 
the risk of developing specific cancers. As can be seen from Table 6-4, for some of the site-specific 
incident cancers there was a small number registered among those with raised glycated 
haemoglobin during the follow-up period. This prevented the undertaking of analyses which 
stratified the sample by either sex or comorbid CVD; therefore the results given below are those for 
analyses of the whole HbA1C sample. 
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Table 6-4: Site-specific cancer registrations among those with a valid HbA1C sample 
Site-specific 
cancer 
Normoglycaemic Raised 
Lip 16 <5 
Oesophagus 25 <5 
Stomach 20 8 
Colon 93 11 
Liver 5 <5 
Pancreas 13 <5 
Lung 109 16 
Breast 227 12 
Cervix 66 6 
Bladder 47 <5 
Kidney 47 <5 
Lymphatic 77 <5 
Prostate 131 16 
Other 181 17 
TOTAL 1,034 103 
 
The only incident cancers that appeared to have a consistent, statistically significant, association 
with raised HbA1C were those of the stomach and lung; HbA1C was associated with a statistically 
significant increased odds of developing pancreatic cancer within the basic (3.40, 1.08-10.66) but not 
the advanced (2.95, 0.79-10.97) model. Other site-specific cancers (lip, colon, ‘other’ and sex-specific 
cancers) produced increases at the point estimate which were non-significant. The addition of 
variables related to region, socio-economic status and education level did not significantly alter the 
results given in Table 6-5. The analyses then explored the associations between HbA1C and sex-
specific cancer incidence.  
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Table 6-5: Site-specific cancer incidence ORs among those with raised HbA1C 
 
 
Progressive 
adjustment 
Site-specific cancer 
Lip Oesophagus 
 
Stomach Colon Liver Pancreas Lung Bladder Kidney Lymphatic Other 
cancers 
Sex- 
specific 
Age, sex 1.19 0.48 4.44 1.41 2.70 3.42 1.92 0.85 1.12 0.75 1.35 1.14 
 
(0.15-
9.20) 
(0.06-3.56) 1.91-
10.33) 
(0.75-
2.67) 
(0.30-
24.26) 
(1.09-
10.71) 
(1.12-
3.30) 
(0.30-
2.38) 
(0.26-
4.83) 
(0.27-
2.07) 
(0.81-
2.25) 
(0.79-
1.64) 
& Smoking 1.17 0.47 4.36 1.43 2.57 3.40 1.83 0.83 1.15 0.74 1.35 1.15 
 
(0.15-
9.05) 
(0.06-3.52) (1.87-
10.14) 
(0.76-
2.71) 
(0.29-
23.19) 
(1.08-
10.66) 
(1.06-
3.15) 
(0.30-
2.33) 
(0.27-
4.96) 
(0.27-
2.04) 
(0.81-
2.24) 
(0.80-
1.65) 
& BMI 1.67 0.55 4.07 1.21 N/A 2.95 1.99 0.67 0.99 0.73 1.32 1.03 
 
(0.21-
13.30) 
(0.07-4.13) (1.54-
10.76) 
(0.60-
2.45) 
 (0.79-
10.97) 
(1.12-
3.53) 
(0.20-
2.18) 
(0.23-
4.29) 
(0.26-
2.03) 
(0.77-
2.28) 
(0.70-
1.51) 
& CVD 1.79 0.58 4.80 1.11 N/A 2.76 2.00 0.65 0.96 0.71 1.34 1.03 
(0.22-
14.36) 
(0.08-4.41) (1.81-
12.73) 
(0.55-
2.24) 
 (0.74-
10.36) 
(1.12-
3.56) 
(0.20-
2.11) 
(0.22-
4.18) 
(0.26-
1.99) 
(0.77-
2.31) 
(0.70-
1.52) 
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Among men there were 16 cases of prostate cancer among those with a measurement of HbA1C 
≥6.5%. The ORs within the basic, advanced and CVD models indicated a non-significant increased 
odds and were: 1.30, 0.76-2.22; 1.29, 0.76-2.22; 1.03, 0.57-1.87, respectively. Among women there 
appeared to be no increased risk of incident breast cancer for those with raised HbA1C and a point 
estimate increase for cervical cancer (ORs 1.38, 0.59-3.25; 1.18, 0.46-3.01 and 1.24, 0.48-3.20, 
respectively). 
 
This chapter indicates that those with a raised glycated haemoglobin measurement appear to be at 
an increased risk of developing incident cancer. Concurrently, only those without comorbid CVD had 
a statistically significant increased risk of incident cancer. The risk also differed between the sexes, 
although only within the basic model were men found to have a statistically significant increased risk 
of developing cancer if they had an HbA1C measurement of 6.5% or above. Turning to site-specific 
cancer incidence, although the small number of cases prevented further analyses there appears to 
be a statistically significant association between HbA1C and cancers of the stomach and lung, as well 
as point estimate increases for a number of other site-specific cancers. The next chapter discusses 
the results of the analyses which were focussed upon the associations between diabetes and cause-
specific mortality. 
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7. Chapter 7: Results – diabetes and cause-specific mortality 
The following chapter details the results related to diabetes and mortality from cancer, CVD, 
respiratory disease and ‘other’ causes when analyses utilised data from the HSE and SheS combined 
dataset. 
 
7.1 Cause-specific mortality (with a particular focus upon cancer) 
As discussed in the literature review, the association between diabetes and cardiovascular disease is 
well established, although there are differences in the strength of the association dependent upon a 
number of factors - including the population being investigated and the covariates adjusted for. At 
the same time, there is a paucity of evidence related to the association between diabetes and 
respiratory disease. Therefore, in order to support the main aims of this research, to explore the 
associations between diabetes and cancer incidence and mortality, analyses were undertaken which 
explored the association between diabetes and four broad causes of mortality (including cancer). 
Within the linked HSE dataset, provided by NatCen Social Research, a variable was available that 
gave information about four broad, primary causes of death. These were:  
 
 cancer (ICD 10 C00-C97) 
 respiratory diseases (J00-J99) 
 CVD (ICD10 codes I00-I99)  
 ‘Other’ causes included all deaths not included in the three categories above.  
 
Because this variable was not available within the SHeS dataset it was necessary to create one that 
matched it. This was produced using the string mortality variable, which contained the ICD 10 codes 
related to cause of death, included within the linked SHeS dataset. Once this had been derived it was 
then possible to combine the two datasets and analyse the associations of diabetes with these broad 
causes of mortality. Table 7-1 details the number of cases that had died during the study follow-up 
period (up to the first quarter of 2011 for the HSE and 2008 for the SHeS). Among those with and 
without diabetes, cardiovascular disease (CVD) accounted for the largest number of deaths (45% 
among those with diabetes and 37% among those without). A higher percentage of those without 
diabetes died of cancer compared with those with diabetes (29% vs. 20%, respectively). Similar 
percentages within each group were recorded as having died of respiratory disease (12% among 
those with diabetes and 14% among those without diabetes). 
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Table 7-1: Cause-specific mortality among those with and without diabetes 
Cause of death (% of total 
deaths)a 
Diabetes Did not indicate 
diabetes 
Whole sample 
CVD 819 (45) 6,670 (37) 7,489 (37) 
 
Cancer 355 (20) 5,216 (29) 5,571 (28) 
 
Respiratory 212 (12) 2,626 (14) 2,838 (14) 
 
Other 428 (24) 3,725 (20) 4,153 (21) 
 
TOTAL 1,814     18,237 20,051 
 
a
 Percentages have been rounded so summed percentages may not add up to 100%. 
 
Initial analyses explored the associations between diabetes and cause-specific mortality using data 
from the whole sample. Table 7-2 details the excess mortality experienced by the diabetic cohort. 
The odds ratios (ORs) were increased among those with diabetes for each specific cause of death. 
The largest excess in mortality among those with diabetes was for cardiovascular disease (CVD); 
within the ‘basic model’ (age, sex and smoking) the OR for mortality from CVD was 1.96 (CI 1.80-
2.14). This increase remained unchanged after further adjustment for BMI (1.94, CI 1.76-2.13) and 
was attenuated at the point estimate following adjustment for CVD status (1.69, CI 1.54-1.86), 
although this decrease was not statistically significant. 
 
For cancer, the ORs for those with diabetes, compared with the general population, were also 
increased. Within the ‘basic model’ the OR was 1.26 (CI 1.13-1.42); this remained unchanged after 
further adjustment for BMI (1.27, CI 1.12-1.43) and CVD (1.21, CI 1.06-1.36). The corresponding 
estimates for respiratory disease were also increased (1.25, CI 1.08-1.46; 1.39, CI 1.18-1.64 and 1.34, 
CI 1.13-1.58, respectively. The ORs for ‘other’ causes were also increased within each model. 
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Table 7-2: Cause-specific mortality odds ratios (and 95% CI) among those with diabetes 
Progressive adjustment 
 
 
Cancer Respiratory CVD Other 
Age, sex 1.23 
(1.09-1.38) 
1.18 
(1.02-1.37) 
1.89 
(1.73-2.05) 
1.97 
(1.77-2.20) 
 & Smoking 1.26 
(1.13-1.42) 
1.25 
(1.08-1.46) 
1.96 
(1.80-2.14) 
2.06 
(1.84-2.30) 
 & BMI 1.27 
(1.12-1.43) 
1.39 
(1.18-1.64) 
1.94 
(1.76-2.13) 
2.09 
(1.85-2.37) 
 Basic + CVD status 1.20 1.22 1.71 2.00 
 (1.07-1.35) (1.05-1.41) (1.57-1.87) (1.79-2.24) 
Additional adjustment (Advanced model + the following variables) 
+ CVD 1.21 
(1.06-1.36) 
1.34 
(1.13-1.58) 
1.69 2.01 
 
(1.54-1.86) (1.78-2.28) 
+ Education 1.22 
(1.08-1.38) 
1.34 1.89 2.03 
 (1.14-1.59) (1.72-2.08) (1.79-2.30) 
+ Social Class 1.26 
(1.11-1.42) 
1.37 1.92 2.07 
 (1.16-1.62) (1.75-2.11) (1.83-2.34) 
+ Region 1.26 
(1.11-1.43) 
1.40 1.93 2.09 
 (1.18-1.66) (1.75-2.12) (1.85-2.37) 
+ HbA1c 1.19 
(0.74-1.89) 
1.46 2.22 3.39 
 (0.72-2.95) (1.52-3.25) (2.07-5.55) 
 
Additional covariates were added to the advanced model. Within each of these models the excess in 
mortality remained for CVD; those with diabetes had over double to the odds of dying of CVD, when 
the model included adjustment for glycated haemoglobin (HbA1C) (OR 2.22, CI 1.52-3.25), compared 
with those without diabetes. The increased ORs were also unchanged within the analyses of ‘other’ 
cause of mortality. For cancer the increased odds of cancer-specific mortality remained statistically 
significant after adjustment for education (1.22, CI 1.08-1.38), social class (1.26, CI 1.11-1.42), region 
(1.26, CI 1.11-1.43) but not HbA1C (1.19, CI 0.74-1.89). The same outcome was found for respiratory 
disease (education: 1.34, CI 1.14-1.59; social class: 1.37, CI 1.16-1.62; region: 1.40, CI 1.18-1.66 and 
HbA1C: 1.46, CI 0.72-2.95, respectively). 
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Table 7-3: Cause-specific mortality ORs (adjusting for alternative measures of overweight and 
obesity) 
Additional adjustment 
 
Cancer Respiratory CVD Other 
Basic + BMI 1.27 
(1.12-1.43) 
1.39 
(1.18-1.64) 
1.94 
(1.76-2.13) 
2.09 
(1.85-2.37) 
Basic + WHRa 1.22 1.28 1.78 1.87 
(1.05-1.42) (1.04-1.56) (1.58-1.99) (1.60-2.19) 
Basic + WCb 1.22 1.32 1.81 1.93 
 (1.05-1.42) (1.08-1.61) (1.62-2.04) (1.65-2.26) 
Basic + WHR & CVD 1.18 1.24 1.56 1.82 
(1.02-1.38) (1.01-1.52) (1.39-1.76) (1.55-2.13) 
Basic + WC & CVD 1.19 1.28 1.59 1.87 
(1.02-1.38) (1.05-1.57) (1.42-1.79) (1.6-2.19) 
a
 WHR – Waist-to-hip ratio 
b 
WC – Waist circumference 
 
 
In order to assess the impact of adjusting for different measurements of overweight and obesity, 
further models were developed which, in the first instance, excluded any measurement of adiposity 
then included either waist-to-hip ratio or waist circumference. Within these models the increased 
odds ratios for each cause of death, among those with diabetes, remained statistically significant. 
For cancer those with diabetes were consistently found to have around a 20% increased odds of 
mortality from this cause. For respiratory and cardiovascular disease there was a wider range in the 
ORs, which appeared to be dependent upon whether cardiovascular disease at baseline had been 
adjusted for.  
 
Table 7-4: Cause-specific mortality ORs among diabetic cases (without adjustment for overweight 
and obesity) 
Additional adjustment 
 Cancer Respiratory CVD Other 
Basic + Education 1.21 1.21 1.91 1.99 
(1.08-1.36) (1.04-1.40) (1.75-2.08) (1.78-2.22) 
Basic + Social Class 1.25 1.23 1.93 2.03 
(1.11-1.40) (1.06-1.43) (1.78-2.11) (1.81-2.26) 
Basic + Region 1.27 1.30 1.98 2.03 
(1.13-1.43) (1.11-1.51) (1.82-2.16) (1.81-2.27) 
Basic + HbA1c 1.20 1.25 2.33 3.31 
(0.78-1.85) (0.66-2.40) (1.64-3.31) (2.1-5.23) 
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Models were then developed which included the variables related to socioeconomic/ demographic 
information and HbA1C, but excluded measurements of overweight and obesity. As can be seen by 
comparing the results in Tables 7-3 and 7-4 which indicate that the inclusion or exclusion of 
measurements of overweight and obesity had little impact upon the excess in cause-specific 
mortality experienced by those with diabetes compared with those without diabetes. Similarly to the 
model that included BMI, the increase in cancer-specific mortality was not statistically significant 
when HbA1C was included in the model (1.20, CI 0.78-1.85) and the same was true for respiratory 
disease (1.25, CI 0.66-2.40). Further models were developed which took into account a number of 
the covariates of interest. As can be seen from tables 7-5 and 7-6, the diabetic cohort remained at 
an increased risk of cause-specific mortality within a variety of models; unless HbA1C was included 
(cancer and respiratory disease). For cardiovascular disease and mortality from ‘other’ causes the 
excess remained for those with diabetes within all of the models. 
Table 7-5: Cause-specific mortality ORs among cases with diabetes (further adjustment) 
Further adjustment Cancer Respiratory CVD Other 
Advanced Model + Sclass, Region & 
CVD 
1.19 1.33 1.67 1.99 
(1.05-1.35) (1.12-1.58) (1.51-1.84) (1.75-2.25) 
Advanced Model + Sclass, Region, CVD 
& HbA1c 
1.17 1.41 1.93 2.84 
(0.75-1.83) (0.71-2.77) (1.34-2.77) (1.79-4.52) 
Advanced Model + Education, Region & 
CVD 
1.16 1.31 1.65 1.96 
(1.03-1.32) (1.11-1.56) (1.50-1.81) (1.72-2.22) 
Advanced Model + Education, Region, 
CVD & HbA1c 
1.16 1.31 1.90 2.77 
(0.75-1.82) (0.65-2.61) (1.32-2.74) (1.74-4.40) 
Basic Model + Waist/Hip, Sclass, Region 
& CVD 
1.17 1.21 1.55 1.79 
(1.01-1.37) (0.99-1.48) (1.37-1.74) (1.53-2.10) 
Basic Model + Waist/Hip, Sclass, 
Region, CVD & HbA1c 
1.20 1.15 1.87 2.34 
(0.78-1.83) (0.59-2.23) (1.31-2.66) (1.44-3.80) 
Basic Model + Waist/Hip, Education, 
Region & CVD 
1.16 1.21 1.56 1.79 
(1.00-1.35) (0.99-1.48) (1.39-1.75) (1.53-2.10) 
Basic Model + Waist/Hip, Education, 
Region, CVD & HbA1c 
1.20 1.07 1.86 2.28 
(0.78-1.84) (0.54-2.10) (1.31-2.64) (1.41-3.69) 
Basic Model + Waist Circ, Sclass, Region 
& CVD 
1.17 1.24 1.57 1.84 
(1.01-1.36) (1.02-1.52) (1.39-1.76) (1.57-2.16) 
Basic Model + Waist Circ, Sclass, 
Region, CVD & HbA1c 
1.17 1.17 1.87 2.32 
(0.76-1.79) (0.60-2.28) (1.32-2.66) (1.43-3.77) 
Basic Model + Waist Circ, Education, 
Region & CVD 
1.16 1.24 1.58 1.84 
(1.0-1.35) (1.01-1.52) (1.40-1.78) (1.57-2.15) 
Basic Model + Waist Circ, Education, 
Region, CVD & HbA1c 
1.17 1.09 1.85 2.25 
(0.76-1.80) (0.55-2.14) (1.30-2.63) (1.39-3.65) 
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Table 7-6: Cause-specific mortality ORs (no adjustment for CVD at baseline) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
In order to explore potential differences in cause-specific mortality risk between the sexes, the 
above analyses were re-run stratified by sex. Within each of the models, women with diabetes had 
an excess in cancer-related mortality compared with women without diabetes (of particular note is 
that this increase remained even after adjustment for raised HbA1c: 2.45, CI 1.24-4.86). For men the 
increase in odds of dying from cancer persisted within each of the models (apart from the one which 
included adjustment for HbA1C). Among women with diabetes, an increased odds of dying of 
respiratory disease was found; within the model that adjusted for HbA1C there was an increase at 
the point estimate, but this was not statistically significant (1.58, CI 0.59-4.22). As can be seen from 
Table 7-7, for both men and women with diabetes the odds of mortality from CVD were substantially 
increased and close to doubled. For men the association between diabetes and mortality from 
Additional adjustment 
 
 
Cancer 
 
Respiratory CVD Other 
Advanced model + 
 Sclass & Region 
1.25 1.39 1.91 2.07 
(1.10-1.42) (1.17-1.64) (1.74-2.04) (1.83-2.35) 
Advanced model + 
Sclass, Region & HbA1c 
1.22 1.49 2.19 3.15 
(0.78-1.90) (0.76-2.95) (1.52-3.16) (1.98-5.00) 
Advanced model +  
Education, Region 
1.22 1.36 1.88 2.03 
(1.07-1.38) (1.15-1.61) (1.71-2.07) (1.79-2.31) 
Advanced model +  
Education, Region & HbA1c 
1.21 1.38 2.17 3.05 
(0.78-1.88) (0.69-2.76) (1.51-3.11) (1.93-4.84) 
Basic model + 
WHR, Sclass & Region 
1.21 1.24 1.75 1.85 
(1.04-1.40) (1.02-1.52) (1.56-1.97) (1.58-2.16) 
Basic model +  
WHR, Sclass, Region & HbA1c 
1.23 1.19 2.10 2.52 
(0.80-1.88) (0.61-2.31) (1.48-2.99) (1.55-4.08) 
Basic model +  
WHR, Education & Region 
1.20 1.24 1.76 1.84 
(1.03-1.39) (1.01-1.52) (1.57-1.98) (1.57-2.16) 
Basic model +  
WHR, Education, Region & HbA1c 
1.23 1.10 2.09 2.45 
(0.80-1.88) (0.56-2.17) (1.47-2.97) (1.51-3.95) 
Basic model +  
WC, Sclass, Region 
1.21 1.28 1.78 1.90 
(1.04-1.40) (1.05-1.57) (1.59-2.00) (1.62-2.22) 
Basic model +  
WC, Sclass, Region & HbA1c 
1.20 1.22 2.11 2.50 
(0.78-1.84) (0.63-2.37) (1.49-3.00) (1.55-4.05) 
Basic model +  
WC, Education & Region 
1.19 1.28 1.79 1.89 
(1.03-1.39) (1.04-1.56) (1.6-2.01) (1.62-2.21) 
Basic model +  
WC, Education, Region & HbA1c 
1.20 1.13 2.09 2.43 
(0.79-1.84) (0.57-2.21) (1.48-2.97) (1.50-3.91) 
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respiratory disease was increased within the vast majority of models; although within the basic, 
advanced and HbA1C models the increase was not statistically significant. The excess in mortality 
among those with diabetes from ‘other’ causes remained within each of the models for both men 
and women.  
 
Analyses then explored the impact that utilising different measurement of overweight and obesity 
(waist-to-hip ratio and waist circumference) would have upon the association. Table 7-7 illustrates 
that for women with diabetes, only within one of these models was the association with cancer 
mortality statistically significant (basic + CVD: OR 1.28, CI 1.07-1.53). However, for the other causes 
of mortality among women with diabetes, the excess remained within each of these models. Among 
men there was a point estimate increased odds of mortality from cancer and respiratory disease, but 
these were not statistically significant within any of these advanced models. The ORs for CVD and 
‘other’ causes remained substantially increased following adjustment for alternative measurements 
of overweight and obesity. Table 7-9 gives information pertaining to stratified analyses that excluded 
adjustment for measurements of overweight and obesity. For women the increased odds of cause-
specific mortality remained within each of these models, only for respiratory disease (and when the 
model included adjustment for HbA1C) was there an increased OR that appeared to be non-
significant. Among men there was an excess of mortality from cancer, although the confidence 
interval suggested that this was not statistically significant when adjustment included HbA1C. Further 
to this, there were point estimate increases for respiratory disease and statistically significant 
increased odds for mortality from cardiovascular disease and ‘other’ causes. 
 
Adjustment was then made which included a number of covariates within each model. As can be 
seen from Table 7-10 and Table 7-11, the increase in cancer-specific mortality differed between men 
and women with diabetes (as with the earlier models). For example, for women the ORs were 
increased within each of the models that adjusted for HbA1C, while for men with diabetes the 
majority of the models (that did or did not include comorbid CVD) found an increase at the point 
estimate that was not statistically significant. For the other causes of death, including a number of 
covariates had little impact upon the ORs that had been produced within the earlier models. 
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Table 7-7: Cause-specific mortality odds ratios (and 95% CI) among those with diabetes (stratified by sex) 
PROGRESSIVE 
ADJUSTMENT 
Women Men 
 
Cancer Respiratory CVD Other Cancer Respiratory CVD Other 
Age, sex 1.27 1.29 1.83 1.71 1.19 1.09 1.94 2.30 
 
(1.07-1.51) (1.05-1.60) (1.61-2.07) (1.46-2.00) (1.02-1.38) (0.89-1.34) (1.73-2.17) (1.98-2.68) 
& Smoking 1.33 1.38 1.92 1.80 1.21 1.14 1.99 2.36 
 
(1.12-1.59) (1.12-1.71) (1.69-2.18) (1.54-2.11) (1.03-1.40) (0.93-1.41) (1.78-2.24) (2.03-2.75) 
& BMI 1.27 1.41 1.92 1.72 1.25 1.37 1.95 2.51 
 
(1.05-1.54) (1.09-1.82) (1.67-2.22) (1.43-2.08) (1.10-1.47) (1.10-1.71) (1.72-2.22) (2.13-2.96) 
Basic + 
CVD status 
1.28 
(1.07-1.53) 
1.36 
(1.09-1.68) 
1.72 
(1.51-1.95) 
1.78 
(1.52-2.09) 
1.14 
(0.98-1.33) 
1.10 
(0.89-1.35) 
1.70 
(1.51-1.91) 
2.26 
(1.94-2.64) 
Additional adjustment (Advanced model + the following variables) 
+ CVD 1.22 
(1.00-1.48) 
1.36 
(1.05-1.76) 
1.72 
(1.49-1.99) 
1.68 
(1.39-2.03) 
1.18 
(1.01-1.39) 
1.31 
(1.05-1.64) 
1.67 
(1.47-1.90) 
2.39 
(2.02-2.82) 
+ Education 1.22 1.37 1.88 1.68 1.21 1.32 1.91 2.43 
 (1.00-1.48) (1.06-1.77) (1.63-2.16) (1.39-2.02) (1.03-1.43) (1.06-1.65) (1.68-2.16) (2.05-2.86) 
+ Social Class 1.26 1.37 1.88 1.69 1.25 1.37 1.94 2.49 
 (1.04-1.52) (1.06-1.77) (1.63-2.18) (1.40-2.04) (1.06-1.47) (1.09-1.70) (1.71-2.20) (2.11-2.94) 
+ Region 1.25 1.41 1.91 1.74 1.25 1.39 1.95 2.49 
 (1.03-1.52) (1.09-1.83) (1.65-2.21) (1.44-2.11) (1.06-1.47) (1.11-1.73) (1.72-2.21) (2.11-2.95) 
+ HbA1c 2.45 1.58 1.94 2.56 0.73 1.44 2.55 4.07 
 (1.24-4.86) (0.59-4.22) (1.08-3.50) (1.13-5.80) (0.39-1.35) (0.53-3.94) (1.56-4.17) (2.20-7.52) 
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Table 7-8: Cause-specific mortality ORs (adjusting for alternative measures of overweight and obesity) stratified by sex 
Additional adjustment Women Men 
 
Cancer Respiratory CVD Other Cancer Respiratory CVD Other 
Basic + BMI 
 
1.27 1.41 1.92 1.72 1.25 1.37 1.95 2.51 
(1.05-1.54) (1.09-1.82) (1.67-2.22) (1.43-2.08) (1.10-1.47) (1.10-1.71) (1.72-2.22) (2.13-2.96) 
Basic +  
WHR 
1.25 1.50 1.81 1.73 1.18 1.11 1.75 2.03 
(0.99-1.58) (1.12-2.01) (1.52-2.16) (1.37-2.19) (0.97-1.44) (0.84-1.46) (1.50-2.05) (1.64-2.51) 
Basic +  
WC 
1.25 
(0.99-1.58) 
1.50 
(1.12-2.02) 
1.83 
(1.53-2.18) 
1.76 
(1.39-2.22) 
1.20 
(0.99-1.46) 
1.15 
(0.88-1.52) 
1.81 
(1.55-2.10) 
2.10 
(1.70-2.59) 
Basic +  
WHR & CVD 
1.21 1.46 1.62 1.70 1.15 1.07 1.53 1.95 
(0.96-1.54) (1.09-1.97) (1.36-1.94) (1.35-2.15) (0.94-1.40) (0.81-1.42) (1.31-1.78) (1.57-2.41) 
Basic +  
WC & CVD 
1.21 1.47 1.64 1.73 1.16 1.11 1.56 2.00 
(0.96-1.53) (1.09-1.98) (1.37-1.96) (1.37-2.19) (0.95-1.41 (0.84-1.47) (1.33-1.82) (1.62-2.48) 
 
Table 7-9: Cause-specific mortality ORs among diabetic cases (without adjustment for overweight and obesity) stratified by sex 
Additional adjustment Women Men 
 
Cancer Respiratory CVD Other Cancer Respiratory CVD Other 
Basic +  
Education 
1.27 1.34 1.87 1.75 1.16 1.10 1.94 2.27 
(1.06-1.51) (1.08-1.66) (1.65-2.12) (1.49-2.05) (1.00-1.35) (0.89-1.35) (1.73-2.18) (1.95-2.65) 
Basic +  
Social Class 
1.31 1.33 1.86 1.75 1.20 1.13 1.98 2.34 
(1.10-1.57) (1.07-1.65) (1.64-2.12) (1.50-2.06) (1.03-1.39) (0.92-1.39) (1.76-2.22) (2.01-2.72) 
Basic +  
Region 
1.34 1.44 1.96 1.78 1.21 1.18 2.00 2.32 
(1.12-1.60) (1.15-1.79) (1.72-2.23) (1.51-2.11) (1.04-1.41) (0.96-1.45) (1.78-2.24) (1.98-2.71) 
Basic +  
HbA1c 
2.14 1.27 1.96 2.96 0.79 1.31 2.76 3.70 
(1.12-4.07) (0.52-3.09) (1.15-3.35) (1.48-5.91) (0.44-1.40) (0.51-3.33) (1.74-4.36) (2.02-6.77) 
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Table 7-10: Cause-specific mortality ORs among cases with diabetes (further adjustment) stratified by sex 
Additional adjustment Women Men 
 Cancer Respiratory CVD Other Cancer Respiratory CVD Other 
Advanced Model + Sclass, Region 
& CVD 
1.20 1.32 1.67 1.66 1.17 1.32 1.65 2.35 
(0.99-1.46) (1.02-1.72) (1.44-1.94) (1.37-2.01) (1.00-1.38) (1.06-1.65) (1.45-1.88) (1.98-2.78) 
Advanced Model + Sclass, Region, 
CVD & HbA1c 
2.29 1.69 1.95 2.49 0.73 1.30 1.98 3.02 
(1.19-4.41) (0.66-4.33) (1.11-3.44) (1.15-5.39) (0.40-1.33) (0.48-3.47) (1.23-3.20) (1.69-5.41) 
Advanced Model + Education, 
Region & CVD 
1.17 1.33 1.67 1.65 1.14 1.29 1.63 2.30 
(0.96-1.42) (1.03-1.73) (1.45-1.94) (1.36-2.00) (0.97-1.35) (1.03-1.61) (1.43-1.85) (1.94-2.72) 
Advanced Model + Education, 
Region, CVD & HbA1c 
2.27 1.64 1.94 2.49 0.73 1.17 1.95 2.91 
(1.18-4.36) (0.64-4.19) (1.10-3.42) (1.15-5.38) (0.40-1.33) (0.42-3.29) (1.21-3.14) (1.63-5.20) 
Basic Model + Waist/Hip, Sclass, 
Region & CVD 
1.19 1.38 1.58 1.66 1.15 1.07 1.52 1.96 
(0.94-1.51) (1.03-1.86) (1.32-1.89) (1.31-2.10) (0.94-1.40) (0.81-1.42) (1.30-1.77) (1.58-2.42) 
Basic Model + Waist/Hip, Sclass, 
Region, CVD & HbA1c 
1.91 1.24 1.78 2.17 0.84 1.13 2.01 2.49 
(1.01-3.60) (0.50-3.08) (1.03-3.08) (1.02-4.61) (0.47-1.49) (0.43-2.96) (1.27-3.20) (1.32-4.69) 
Basic Model + Waist/Hip, 
Education, Region & CVD 
1.19 1.43 1.62 1.68 1.13 1.05 1.52 1.94 
(0.94-1.51) (1.06-1.93) (1.36-1.94) (1.33-2.12) (0.93-1.38) (0.79-1.38) (1.30-1.77) (1.57-2.40) 
Basic Model + Waist/Hip, 
Education, Region, CVD & HbA1c 
1.93 1.23 1.77 2.16 0.84 1.01 1.99 2.39 
1.02-3.63) (0.50-3.05) (1.03-3.06) (1.02-4.56) (0.47-1.49) (0.37-2.77) (1.25-3.15) (1.28-4.49) 
Basic Model + Waist Circ, Sclass, 
Region & CVD 
1.18 1.39 1.59 1.69 1.16 1.10 1.54 2.00 
(0.93-1.50) (1.03-1.88) (1.33-1.90) (1.33-2.13) (0.95-1.41) (0.84-1.46) (1.32-1.80) (1.62-2.48) 
Basic Model + Waist Circ, Sclass, 
Region, CVD & HbA1c 
1.92 1.29 1.78 2.14 0.81 1.15 2.01 2.47 
(1.02-3.63) (0.52-3.20) (1.03-3.08) (1.01-4.54) (0.46-1.43) (0.44-3.00) (1.27-3.19) (1.32-4.64) 
Basic Model + Waist Circ, 
Education, Region & CVD 
1.18 1.43 1.63 1.70 1.14 1.08 1.54 1.98 
(0.93-1.50) (1.06-1.93) (1.37-1.96) (1.34-2.15) (0.93-1.39) (0.82-1.42) (1.32-1.80) (1.60-2.46) 
Basic Model + Waist Circ, 
Education, Region, CVD & HbA1c 
1.94 1.28 1.77 2.12 0.81 1.02 1.98 2.37 
(1.03-3.67) (0.51-3.17) (1.03-3.05) (1.00-4.48) (0.46-1.43) (0.37-2.81) (1.25-3.14) (1.27-4.44) 
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Table 7-11: ORs cause-specific mortality (no adjustment for CVD at baseline) stratified by sex 
Additional adjustment Women Men 
 Cancer Respiratory CVD Other Cancer Respiratory CVD Other 
Advanced model + 
 Sclass & Region 
1.24 1.37 1.87 1.71 1.25 1.39 1.94 2.48 
(1.02-1.51) (1.05-1.77) (1.62-2.17) (1.42-2.07) (1.06-1.47) (1.11-1.73) (1.71-2.20) (2.09-2.93) 
Advanced model + 
Sclass, Region & HbA1c 
2.31 1.77 2.09 2.58 0.78 1.40 2.34 3.51 
(1.21-4.44) (0.69-4.53) (1.18-3.69) (1.19-5.60) (0.43-1.42) (0.52-3.73) (1.46-3.76) (1.97-6.25) 
Advanced model + Education, Region 1.21 1.37 1.87 1.70 1.21 1.34 1.90 2.41 
(0.99-1.46) (1.06-1.78) (1.61-2.16) (1.41-2.05) (1.03-1.42) (1.07-1.67) (1.68-2.16) (2.04-2.86) 
Advanced model + Education, Region & HbA1c 2.29 1.72 2.07 2.58 0.78 1.25 2.30 3.36 
(1.20-4.39) (0.67-4.38) (1.18-3.65) (1.19-5.58) (0.43-1.41) (0.45-3.50) (1.44-3.69) (1.89-5.97) 
Basic model + 
WHR, Sclass & Region 
1.22 1.41 1.75 1.69 1.18 1.11 1.75 2.04 
(0.97-1.55) (1.05-1.90) (1.47-2.10) (1.34-2.13) (0.97-1.44) (0.84-1.47) (1.50-2.04) (1.65-2.52) 
Basic model + WHR, Sclass, Region & HbA1c 1.93 1.27 1.91 2.23 0.87 1.19 2.34 2.82 
(1.03-3.63) (0.51-3.14) (1.11-3.30) (1.05-4.72) (0.49-1.54) (0.45-3.09) (1.48-3.70) (1.51-5.28) 
Basic model +  
WHR, Education & Region 
1.22 1.46 1.80 1.70 1.16 1.08 1.74 2.01 
(0.97-1.54) (1.08-1.96) (1.51-2.16) (1.35-2.15) (0.96-1.42) (0.82-1.43) (1.49-2.03) (1.63-2.50) 
Basic model + WHR, Education, Region & 
HbA1c 
1.95 1.26 1.89 2.21 0.87 1.05 2.31 2.71 
(1.04-3.67) (0.51-3.11) (1.10-3.26) (1.05-4.66) (0.49-1.54) (0.39-2.87) (1.46-3.65) (1.45-5.06) 
Basic model + WC, Sclass, Region 1.21 1.42 1.77 1.71 1.19 1.15 1.79 2.10 
(0.96-1.54) (1.06-1.91) (1.48-2.11) (1.36-2.16) (0.98-1.45) (0.87-1.51) (1.54-2.09) (1.70-2.60) 
Basic model + WC, Sclass, Region & HbA1c 1.95 1.32 1.91 2.19 0.84 1.20 2.34 2.81 
(1.03-3.68) (0.53-3.28) (1.11-3.30) (1.03-4.66) (0.47-1.48) (0.46-3.15) (1.48-3.70) (1.50-5.24) 
Basic model + WC, Education & Region 1.21 1.46 1.81 1.73 1.17 1.12 1.78 2.07 
(0.96-1.53) (1.08-1.96) (1.52-2.17) (1.37-2.18) (0.96-1.43) (0.85-1.48) (1.53-2.08) (1.68-2.56) 
Basic model + WC, Education, Region & HbA1c 1.97 1.31 1.89 2.17 0.84 1.07 2.31 2.69 
(1.05-3.71) (0.53-3.25) (1.10-3.27) (1.03-4.58) (0.48-1.48) (0.39-2.92) (1.46-3.64) (1.44-5.00) 
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Analyses then explored whether or not those with diabetes and comorbid CVD had differences in 
cause-specific mortality risk compared to those without the former, but without the latter. As can be 
seen from Table 7-12, those with diabetes but not comorbid CVD had an excess risk of cancer 
mortality compared with those without diabetes. This increase remained statistically significant until 
HbA1C was adjusted for. The same was found for mortality from respiratory disease, while for CVD 
and ‘other’ causes of mortality the excess remained significant within each of the models. For those 
with diabetes and comorbid CVD there were point estimate increases in ORs for cancer and 
respiratory disease and statistically significant increases, within each of the models, for mortality 
from CVD and ‘other’ causes. When adjustment included different measurement of overweight and 
obesity (waist-to-hip ratio and waist circumference) the excess in mortality from cancer was raised 
at the point estimate, but appeared not to be significant. The excess mortality from respiratory 
disease remained when adjustment was made for waist circumference but not waist-to-hip ratio. For 
CVD and mortality from ‘other’ causes the ORs remained raised among those with diabetes and 
comorbid CVD compared with those with diabetes only. Among diabetics with comorbid CVD there 
were statistically significant increases for mortality from CVD and ‘other’ causes within each of the 
initial models. 
 
Covariates related to socioeconomic and demographic information were then adjusted for. The 
results are given in Table 7-14 and indicate that those with diabetes and comorbid CVD were found 
to have an excess in each of the specific causes of mortality; only within the model that adjusted for 
HbA1C did the ORs and/or confidence intervals suggest that the association was not statistically 
significant. Among those with diabetes, who also indicated comorbid CVD there were increased ORs 
for each cause but the association only appeared statistically significant for CVD and ‘other’ causes. 
Because the analyses were stratified by CVD, adjustment was not made for this variable within this 
section. Further analyses included a range of covariates within each model. As can be seen from 
Table 7-15, among those without comorbid CVD there was a point estimate increase for mortality 
from cancer and respiratory disease and statistically significant increases for CVD and ‘other’ causes. 
Among those with CVD, there were mixed results for each cause of mortality.  
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Table 7-12: Cause-specific mortality odds ratios (and 95% CI) among those with diabetes (stratified by CVD status)  
 
 
PROGRESSIVE 
ADJUSTMENT 
Did not indicate CVD at baseline Indicated CVD at baseline 
 
Cancer Respiratory CVD Other Cancer Respiratory CVD Other 
Age, sex 1.22 1.18 1.81 2.04 1.03 1.05 1.37 1.63 
 
(1.05-1.41) (0.97-1.42) (1.61-2.03) (1.77-2.34) (0.86-1.24) (0.83-1.33) (1.22-1.55) (1.36-1.96) 
& Smoking 1.26 1.26 1.90 2.13 1.06 1.09 1.40 1.67 
 
(1.09-1.46) (1.04-1.52) (1.69-2.14) (1.86-2.45) (0.88-1.27) (0.86-1.38) (1.24-1.59) (1.39-2.00) 
& BMI 1.27 1.40 1.91 2.18 1.11 1.23 1.45 1.71 
 
(1.08-1.48) (1.13-1.73) (1.67-2.17) (1.86-2.55) (0.91-1.35) (0.95-1.61) (1.26-1.66) (1.40-2.10) 
Additional adjustment (Advanced model + the following variables) 
+ Education 1.22 1.36 1.86 2.12 1.09 1.20 1.43 1.67 
 
(1.04-1.44) (1.10-1.69) (1.63-2.12) (1.81-2.49) (0.89-1.33) (0.92-1.57) (1.25-1.64) (1.37-2.05) 
+ Social Class 1.26 1.37 1.89 2.16 1.10 1.22 1.44 1.70 
 (1.07-1.48) (1.11-1.71) (1.66-2.15) (1.84-2.52) (0.90-1.34) (0.94-1.60) (1.26-1.65) (1.39-2.08) 
+ Region 1.25 1.42 1.92 2.18 1.11 1.23 1.42 1.70 
 (1.07-1.47) (1.15-1.77) (1.68-2.19) (1.86-2.56) (0.91-1.35) (0.94-1.61) (1.24-1.63) 1.39-2.09) 
+ HbA1c 1.02 2.09 2.70 2.75 1.33 0.74 1.42 3.51 
 (0.55-1.90) (0.86-5.07) (1.62-4.5) (1.39-5.42) (0.64-2.76) (0.24-2.27) (0.81-2.47) (1.71-7.2) 
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Table 7-13: Cause-specific mortality ORs (adjusting for alternative measures of overweight and obesity) stratified by CVD status 
 
Table 7-14: Cause-specific mortality ORs among diabetic cases (without adjustment for overweight and obesity) stratified by CVD status 
Additional adjustment Did not indicate CVD at baseline Indicated CVD at baseline 
 
Cancer Respiratory CVD Other Cancer Respiratory CVD Other 
Basic + 
Education 
1.21 1.22 1.85 2.08 1.04 1.06 1.39 1.63 
(1.04-1.41) (1.01-1.48) (1.64-2.09) (1.81-2.38) (0.87-1.25) (0.84-1.35) (1.23-1.57) (1.36-1.95) 
Basic +  
Social Class 
1.25 1.23 1.87 2.10 1.05 1.08 1.39 1.65 
(1.08-1.45) (1.01-1.49) (1.66-2.11) (1.83-2.42) (0.87-1.26) (0.85-1.37) (1.23-1.57) (1.38-1.98) 
Basic +  
Region 
1.27 1.34 1.95 2.07 1.07 1.07 1.39 1.68 
(1.09-1.47) (1.10-1.63) (1.73-2.20) (1.79-2.39) (0.89-1.28) (0.84-1.36) (1.23-1.57) (1.39-2.01) 
Basic +  
HbA1c 
0.99 1.74 2.85 2.78 1.45 0.65 1.44 3.47 
(0.58-1.77) (0.79-3.87) (1.78-4.57) (1.51-5.13) (0.74-2.83) (0.22-1.92) (0.86-2.41) (1.75-6.88) 
Additional adjustment Did not indicate CVD at baseline Indicated CVD at baseline 
 
Cancer Respiratory CVD Other Cancer Respiratory CVD Other 
Basic +  
WHR 
1.21 1.28 1.70 1.79 1.12 1.16 1.38 1.78 
(0.99-1.47) (0.98-1.66) (1.45-2.01) (1.46-2.20) (0.88-1.42) (0.84-1.58) (1.17-1.62) (1.39-2.28) 
Basic +  
WC 
1.21 1.33 1.76 1.86 1.13 1.15 1.38 1.81 
(0.99-1.47) (1.03-1.73) (1.49-2.07) (1.51-2.28) (0.89-1.43) (0.84-1.58) (1.17-1.62) (1.41-2.32) 
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Table 7-15: ORs cause-specific mortality (no adjustment for CVD at baseline) stratified by CVD status 
Additional adjustment Did not indicate CVD at baseline Indicated CVD at baseline 
 Cancer Respiratory CVD Other Cancer Respiratory CVD Other 
Advanced model + 
Sclass & Region 
1.25 1.40 1.90 2.16 1.10 1.22 1.41 1.69 
(1.06-1.47) (1.13-1.74) (1.66-2.17) (1.84-2.53) (0.90-1.34) (0.93-1.60) (1.23-1.62) (1.38-2.07) 
Advanced model + 
Sclass, Region & HbA1c 
1.07 2.03 2.63 2.68 1.23 0.76 1.28 2.96 
(0.59-1.93) (0.87-4.73) (1.62-4.27) (1.44-4.99) (0.61-2.49) (0.25-2.34) (0.75-2.20) (1.46-6.01) 
Advanced model + 
Education, Region 
1.21 1.39 1.88 2.12 1.09 1.20 1.41 1.67 
(1.03-1.43) (1.12-1.73) (1.64-2.14) (1.81-2.49) (0.90-1.33) (0.92-1.57) (1.23-1.61) (1.36-2.05) 
Advanced model + 
Education, Region & HbA1c 
1.07 2.03 2.57 2.63 1.23 0.64 1.29 2.88 
(0.59-1.93) (0.87-4.71) (1.59-4.18) (1.42-4.88) (0.61-2.48) (0.20-2.06) (0.75-2.22) (1.43-5.81) 
Basic model + 
WHR, Sclass & Region 
1.20 1.25 1.68 1.76 1.11 1.13 1.38 1.77 
(0.98-1.45) (0.96-1.62) (1.42-1.98) (1.43-2.16) (0.87-1.41) (0.82-1.56) (1.17-1.62) (1.38-2.27) 
Basic model + WHR, Sclass, 
Region & HbA1c 
1.06 1.66 2.49 2.10 1.38 0.59 1.29 2.68 
(0.60-1.87) (0.74-3.73) (1.56-3.99) (1.10-4.02) (0.70-2.72) (0.19-1.85) (0.77-2.19) (1.28-5.62) 
Basic model +  
WHR, Education & Region 
1.18 1.26 1.69 1.77 1.11 1.12 1.40 1.75 
(0.97-1.44) (0.97-1.64) (1.44-1.99) (1.44-2.17) (0.88-1.41) (0.81-1.54) (1.19-1.65) (1.37-2.25) 
Basic model + WHR, 
Education, Region & HbA1c 
1.07 1.66 2.49 2.07 1.38 0.46 1.31 2.56 
(0.61-1.89) (0.75-3.70) (1.56-3.98) (1.09-3.94) (0.70-2.69) (0.14-1.59) (0.78-2.20) (1.23-5.35) 
Basic model + WC, Sclass, 
Region 
1.19 1.30 1.72 1.82 1.12 1.12 1.37 1.79 
(0.98-1.45) (1.00-1.69) (1.47-2.03) (1.48-2.23) (0.88-1.42) (0.81-1.54) (1.17-1.62) (1.40-2.30) 
Basic model + WC, Sclass, 
Region & HbA1c 
1.03 1.69 2.49 2.10 1.37 0.60 1.29 2.63 
(0.58-1.81) (0.75-3.79) (1.56-3.99) (1.10-4.00) (0.70-2.69) (0.19-1.92) (0.76-2.17) (1.26-5.51) 
Basic model + WC, Education 
& Region 
1.18 1.31 1.74 1.83 1.12 1.11 1.39 1.77 
(0.97-1.43) (1.01-1.70) (1.48-2.04) (1.49-2.24) (0.88-1.42) (0.80-1.53) (1.18-1.64) (1.38-2.27) 
Basic model + WC, 
Education, Region & HbA1c 
1.04 1.69 2.48 2.06 1.36 0.78 1.30 2.51 
(0.59-1.83) (0.76-3.77) (1.55-3.96) (1.08-3.91) (0.70-2.65) (0.14-1.6) (0.77-2.19) (1.21-5.23) 
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To remove the impact of further confounding caused by smoking, sensitivity analysis was carried out 
which included only those cases who indicated they had never been a regular smoker (n=98,107). 
For cancer the OR was increased for those with diabetes within the ‘basic’ model (1.27, CI 1.02-1.59), 
but not when CVD was added (1.24, CI 0.99-1.55). The ‘advanced’ model was not utilised within the 
sensitivity analysis as it included adjustment for smoking status. The ORs for respiratory disease, CVD 
and ‘other’ causes, among those with diabetes, were significantly increased compared with those 
without the disease.  
Within the models that included education, socioeconomic class and region, those with diabetes had 
an increased risk for every cause of mortality. The multinomial logistic regression model, which 
included adjustment for HbA1C, resulted in mortality only from ‘other’ causes having a statistically 
significant increased OR (3.47, CI 1.50-8.02); although for respiratory disease and CVD there was an 
increase at the point estimate. 
Table 7-16: Cause-specific mortality odds ratios (and 95% CI) among those with diabetes 
(sensitivity analysis) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
Because the sensitivity analyses only included those who indicated never regular-smoking this variable was 
excluded from the analyses. 
PROGRESSIVE 
ADJUSTMENT 
Indicated never regular-smoker 
 
Cancer Respiratory CVD Other 
Age, sex 1.31 1.46 1.96 1.88 
 
(1.07-1.61) (1.12-1.90) (1.70-2.26) (1.58-2.25) 
& Smokinga N/A N/A N/A N/A 
 
    
& BMI 1.27 1.54 1.93 1.91 
 
(1.02-1.59) (1.14-2.08) (1.65-2.26) (1.57-2.33) 
Basic + 
CVD status 
1.28 
(1.04-1.57) 
1.46 
(1.12-1.90) 
1.78 
(1.54-2.05) 
1.90 
(1.59-2.27) 
Additional adjustment (Advanced model + the following variables) 
+ CVD 1.24 1.53 1.76 1.90 
 
(0.99-1.55) (1.13-2.08) (1.50-2.06) (1.56-2.22) 
+ Education 1.25 1.51 1.90 1.86 
 (1.00-1.57) (1.11-2.04) (1.62-2.22) (1.52-2.27) 
+ Social Class 1.26 1.50 1.90 1.87 
 (1.01-1.58) (1.11-2.03) (1.62-2.22) (1.53-2.28) 
+ Region 1.28 1.51 1.92 1.90 
 (1.02-1.60) (1.11-2.06) (1.64-2.25) (1.55-2.33) 
+ HbA1c 0.83 1.13 1.42 3.47 
 (0.33-2.10) (0.29-4.47) (0.75-2.71) (1.50-8.02) 
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The analyses then included the alternative measurements for overweight and obesity. Although the 
OR among diabetic never regular-smokers was raised compared with those without diabetes when 
the model included BMI, as can be seen from Table 7-17 this was not the case when either waist-to-
hip ratio or waist circumference were included. For each of the other causes of mortality the ORs 
were increased within each step of the additional adjustment. 
 
Table 7-17: Cause-specific mortality ORs (adjusting for alternative measures of overweight and 
obesity) 
Additional adjustment Indicated never regular-smoker 
 Cancer Respiratory CVD Other 
Basic + 
BMI 
1.27 1.54 1.93 1.91 
(1.02-1.59) (1.14-2.08) (1.65-2.26) (1.57-2.33) 
Basic +  
Waist-Hip Ratio 
1.23 1.58 1.78 1.91 
(0.94-1.62) (1.11-2.25) (1.46-2.16) (1.48-2.46) 
Basic + 
WHR & CVD 
1.21 1.55 1.63 1.89 
(0.92-1.60) (1.08-2.20) (1.34-1.98) (1.47-2.44) 
Basic +  
Waist Circumference 
1.19 1.57 1.78 1.91 
(0.90-1.57) (1.10-2.23) (1.46-2.16) (1.49-2.46) 
Basic +  
WC & CVD 
1.17 1.54 1.63 1.90 
(0.89-1.55) (1.08-2.20) (1.34-1.98) (1.47-2.45) 
 
As with the previous analyses undertaken, models were then utilised that took into account a range 
of socioeconomic/demographic covariates in order to understand whether they had an impact upon 
the association between diabetes and cause-specific mortality. Within Table 7-18 it can be seen that 
those with diabetes had a statistically significant excess in mortality from cancer when education, 
social class and region were added to the basic model. This excess disappeared when HbA1C was 
adjusted for. For the other causes of death there were point estimates increase, which within the 
majority of models were statistically significant; only the inclusion of HbA1C removed the 
significance. 
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Table 7-18: Cause-specific mortality ORs among diabetic cases (without adjustment for overweight 
and obesity) sensitivity analysis 
 
 
 
 
 
 
 
 
 
Table 7-19: Cause-specific mortality ORs among cases with diabetes (further adjustment) 
sensitivity analysis
Additional adjustment Indicated never regular-smoker 
 
Cancer Respiratory CVD Other 
Basic + Education 1.28 1.43 1.92 1.83 
(1.04-1.57) (1.10-1.86) (1.67-2.21) (1.54-2.19) 
Basic +  
Social Class 
1.29 1.42 1.91 1.84 
(1.05-1.59) (1.09-1.85) (1.66-2.21) (1.54-2.19) 
Basic +  
Region 
1.32 1.48 1.99 1.88 
(1.07-1.63) (1.12-1.94) (1.73-2.30) (1.56-2.26) 
Basic +  
HbA1c 
0.92 1.00 1.59 3.86 
(0.39-2.17) (0.27-3.78) (0.87-2.88) (1.84-8.10) 
Additional adjustment Indicated never regular-smoker 
 Cancer Respiratory CVD Other 
Advanced Model + Sclass, Region 
& CVD 
1.23 1.46 1.72 1.84 
(0.98-1.55) (1.07-2.00) (1.46-2.02) (1.49-2.26) 
Advanced Model + Sclass, Region, 
CVD & HbA1c 
0.82 1.19 1.40 3.14 
(0.33-2.02) (0.31-4.61) (0.75-2.63) (1.40-7.06) 
Advanced Model + Education, 
Region & CVD 
1.22 1.48 1.72 1.83 
(0.98-1.53) (1.08-2.03) (1.47-2.02) (1.49-2.25) 
Advanced Model + Education, 
Region, CVD & HbA1c 
0.82 1.09 1.34 3.18 
(0.33-2.03) (0.29-4.15) (0.71-2.52) (1.43-7.04) 
Basic Model + Waist/Hip, Sclass, 
Region & CVD 
1.20 1.46 1.58 1.84 
(0.91-1.58) (1.01-2.09) (1.30-1.93) (1.43-2.38) 
Basic Model + Waist/Hip, Sclass, 
Region, CVD & HbA1c 
0.92 1.14 1.49 2.97 
(0.40-2.12) (0.30-4.29) (0.81-2.75) (1.34-6.60) 
Basic Model + Waist/Hip, 
Education, Region & CVD 
1.22 1.51 1.62 1.88 
(0.93-1.61) (1.06-2.17) (1.33-1.97) (1.46-2.42) 
Basic Model + Waist/Hip, 
Education, Region, CVD & HbA1c 
0.95 1.05 1.46 2.99 
(0.42-2.19) (0.28-3.94) (0.79-2.70) (1.37-6.53) 
Basic Model + Waist Circ, Sclass, 
Region & CVD 
1.16 1.45 1.58 11.84 
(0.88-1.53) (1.01-2.08) (1.29-1.92) (1.43-2.38) 
Basic Model + Waist Circ, Sclass, 
Region, CVD & HbA1c 
0.87 1.12 1.48 2.93 
(0.38-2.02) (0.30-4.21) (0.81-2.72) (1.32-6.50) 
Basic Model + Waist Circ, 
Education, Region & CVD 
1.18 1.51 1.61 1.88 
(0.89-1.56) (1.05-2.16) (1.33-1.97) (1.46-2.42) 
Basic Model + Waist Circ, 
Education, Region, CVD & HbA1c 
0.91 1.04 1.44 2.92 
(0.40-2.10) (0.28-3.90) (0.78-2.66) (1.34-6.39) 
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 Table 7-20: Cause-specific mortality ORs (no adjustment for comorbid CVD) sensitivity analysis 
 
 
When analyses included a number of covariates within a single model it appeared that those with 
diabetes did not have a statistically significant increased excess in cancer mortality, with HbA1C 
producing substantial attenuation within each of the models. For respiratory disease and CVD the 
excess in mortality remained within each of the models that did not include HbA1C, although when 
HbA1C was included, the point estimates remained raised. Within each of the additional adjustment 
models, the ORs for ‘other’ causes of mortality remained increased. As can be seen from  Table 7-20, 
removing CVD at baseline from the models had little impact upon the ORs for mortality from each of 
the specific causes.  
 
Additional adjustment Indicated never regular-smoker 
 Cancer Respiratory CVD Respiratory 
Advanced model + Sclass & 
Region 
1.27 1.47 1.89 1.86 
(1.01-1.59) (1.07-2.00) (1.61-2.22) (1.52-2.28) 
Advanced model + 
Sclass, Region & HbA1c 
0.86 1.24 1.53 3.27 
(0.35-2.13) (0.32-4.80) (0.82-2.86) (1.46-7.32) 
Advanced model + Education, 
Region 
1.26 1.48 1.89 1.85 
(1.00-1.57) (1.09-2.02) (1.61-2.22) (1.51-2.27) 
Advanced model + Education, 
Region & HbA1c 
0.87 1.12 1.46 3.30 
(0.35-2.14) (0.29-4.31) (0.78-2.74) (1.49-7.31) 
Basic model + 
WHR, Sclass & Region 
1.22 1.48 1.73 1.85 
(0.92-1.61) (1.03-2.12) (1.42-2.10) (1.44-2.39) 
Basic model + WHR, Sclass, 
Region & HbA1c 
0.96 1.17 1.60 3.06 
(0.42-2.20) (0.31-4.42) (0.87-2.92) (1.38-6.77) 
Basic model +  
WHR, Education & Region 
1.24 1.54 1.77 1.89 
(0.94-1.64) (1.07-2.20) (1.45-2.15) (1.47-2.43) 
Basic model + WHR, Education, 
Region & HbA1c 
0.99 1.08 1.57 3.08 
(0.43-2.27) (0.29-4.06) (0.85-2.88) (1.41-6.72) 
Basic model + WC, Sclass, 
Region 
1.17 1.48 1.72 1.85 
(0.89-1.55) (1.03-2.11) (1.42-2.10) (1.44-2.39) 
Basic model + WC, Sclass, 
Region & HbA1c 
0.91 1.17 1.59 3.02 
(0.39-2.09) (0.31-4.37) (0.87-2.90) (1.36-6.68) 
Basic model + WC, Education & 
Region 
1.20 1.53 1.76 1.89 
(0.91-1.58) (1.07-2.19) (1.45-2.14) (1.46-2.43) 
Basic model + WC, Education, 
Region & HbA1c 
0.95 1.09 1.55 3.12 
(0.41-2.17) (0.29-4.05) (0.85-2.85) (1.38-6.57) 
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7.2 Diabetes and cancer-specific mortality (Cox regression and survival 
analysis) 
 
7.2.1 HSE and SHeS 
Binary variables were derived within the Health Survey for England and Scottish Health Survey 
dataset which included the following information: 
 
 Cancer mortality/Everyone else. 
 
These variables were then used to create survival analysis models in order to explore the 
associations between diabetes and mortality and produce the Hazard Ratios related to it. The 
variables required for survival analysis were also derived and these included: 
 
 A censor date variable (this either contained information about date of death or the end of 
the follow-up period). 
 A duration of time in study variable (derived from the baseline interview date and censor 
date). 
 
Table 7-21 indicates that, within all of the Cox regression models which used date from the HSE and 
SHeS appended dataset, those with diabetes were at an increased risk of mortality from cancer. The 
HRs for cancer were increased at the point estimate within each model, only when HbA1C was 
adjusted for did the association became statistically non-significant (HR 1.36, CI 0.95-1.94).  
 
Table 7-21: cancer-specific mortality HRs 
Progressive adjustment Cancer 
Age & sex 1.31 
(1.18-1.47) 
Age, sex & smoking 1.35 
(1.21-1.50) 
Age, sex, smoking & BMI 1.34 
(1.19-1.50) 
Age, sex, smoking, BMI & 
CVD 
1.28 
(1.14-1.44) 
Further adjustment 
Age, sex, smoking, BMI & 
Education group 
1.30 
(1.16-1.47) 
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Age, sex, smoking, BMI & 
social class 
1.34 
(1.19-1.50) 
Age, sex, smoking, BMI & 
Region 
1.34 
(1.19-1.50) 
Age, sex, smoking, BMI & 
Hba1c 
1.36 
(0.95-1.94) 
Age, sex, smoking & waist 
raised 
1.31 
(1.14-1.51) 
Age, sex, smoking & waist-
hip-ratio 
1.30 
(1.13-1.50) 
 
7.2.2 Survival curve (cancer mortality) 
Survival curves were produced for cancer mortality. The HRs and survival curves developed for these 
analyses further suggest that the association between diabetes and cancer-specific mortality is not 
significantly altered by a range of confounding factors related to overweight/obesity, socio-
demographic and economic confounding factors; although adjusting for HbA1C does appear to 
attenuate the association. Survival curves were produced for each of the above models: as the 
inclusion of other covariates did little to alter the associations between diabetes and all-cause 
mortality, only those showing the models adjusted for age and sex are shown below 
 
Figure 7-1: Cancer mortality: HSE/SHeS (age and sex) 
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The results presented within this chapter suggest that, even after adjustment for a range of factors, 
those with diabetes are at an increased risk of mortality from various different causes and, 
specifically, from cancer. Further to this, there are differences in the excess mortality experienced by 
the diabetic cohort dependent upon gender, the presence of comorbid CVD and smoking status. 
Within the basic and advanced models, those with diabetes were at an increased risk of cancer 
mortality when analyses included the whole sample, was stratified by either sex or CVD status and 
within the sensitivity analysis. The odds ratios produced for respiratory disease also suggest that 
those with diabetes are at an increased risk of mortality from respiratory causes. The results of this 
study further confirm the substantial increase in mortality from CVD among those with diabetes 
compared with the general population.  
 
The next section explores the associations between diabetes and site-specific cancer mortality. 
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8. Chapter 8: Results – diabetes and site-specific cancer mortality 
This chapter details the exploration of the associations between diabetes and mortality from site-
specific cancer. Utilising the string variable within the HSE and SHeS datasets which gave detailed 
information about cause of death, the ICD9 and 10 codes for each cause to three digits, it was 
possible to derive a variable that gave information about mortality from a range of site-specific 
cancers.  
 
8.1 Diabetes and site-specific cancers: HSE and SHeS 
Table 8-1 details the number of deaths from each cancer of interest (by descending order of number 
of deaths by cause). In total, of the 5,571 cancer deaths within the original all-cause and cause-
specific dataset, information about the cancer site was available for 5,455 cases (98% of the total 
cancer deaths).  
 
Table 8-1: Site-specific cancer mortality (HSE and SHeS) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
a 
Lymphatic includes haematopoietic cancers and leukaemia. 
b
 Cervix includes cancers of the endometrium. 
C
 Lip includes cancers of the oral cavity and pharynx. 
 
 
Initial analyses were performed using multinomial logistic regression with the alive cases comprising 
the reference category. As can be seen from Table 8-2 those with diabetes had a substantial increase 
Site-specific cancer mortality Diabetic Did not 
indicate 
diabetes 
Total 
Lung 88 1,209 1,297 
Colorectal 34 518 552 
Lymphatica 19 354 373 
Breast 22 332 354 
Prostate 20 327 347 
Pancreatic 26 295 321 
Oesophagus 15 246 261 
Stomach 19 192 211 
Bladder 12 156 168 
Ovarian 6 159 165 
Kidney 11 129 140 
Liver 3 79 82 
Cervixb 3 78 81 
Lip 3 62 65 
Other cancer 65 973 1,038 
TOTAL 346 5,109 5,455 
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in odds of dying of pancreatic cancer compared with those without diabetes. This increase remained 
after adjusting for a range of covariates. There were also point estimate increases for cancers of the 
colorectum, bladder, stomach, lymphoid, lung, kidney, oesophagus, lip and other cancers. There 
were also reduced point estimates among those with diabetes for cancers of the liver. Because of 
the small number of site-specific cancer deaths among those with a measurement of glycated 
haemoglobin there was insufficient power to detect the effect that diagnosed diabetes had upon 
mortality, when adjustment included HbA1C, and therefore glycated haemoglobin was not included 
within the regression models. Further analyses were undertaken which included waist circumference 
and waist-to-hip ratio as alternative measurements of overweight and obesity. Their inclusion had 
little impact upon the results (not shown). 
 
Analyses were then stratified by sex, to allow for an exploration of sex-specific associations between 
diabetes and cancer, as well as associations with sex-specific cancers. For men there was a 
substantial excess in the odds of dying of pancreatic cancer among those with diabetes; this increase 
was maintained within each of the regression models. There were also substantial increases in odds 
of dying of stomach cancer among men with diabetes, which became statistically significant within 
the advanced model. There were also raised point estimates for a number of other site-specific 
cancers, while those for liver, lymphoid and prostate cancer were indicative of a reduced risk of 
mortality from these causes among men with diabetes, although the results were statistically non-
significant. Women with diabetes were found to have an increased risk of mortality from breast 
cancer, which remained statistically significant within both the basic and advanced models. There 
were also raised point estimates for mortality from a number of other site-specific cancers among 
women with diabetes. The analysis detailed below includes only the basic and advanced models; 
further analyses were undertaken but had little impact upon the excess in site-specific cancer 
mortality found among men and women with diabetes compared with those without the disease. 
 
To assess the impact that comorbid CVD had upon the association between diabetes and site-
specific cancers the above analyses were repeated stratified by baseline CVD status. The point 
estimates for site-specific cancers among those with diabetes but without CVD were consistently 
increased, although the confidence intervals suggested that none of the associations were 
statistically significant. This was in contrast to those with diabetes who also had comorbid CVD: this 
group had a substantial increase in pancreatic cancer within the advanced model (1.88, 1.02-3.49), 
while there were point estimate increases for colorectal, oesophagus, stomach, lung and lip. Further 
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analyses were undertaken, but did not significantly affect the results in relation to the excess in site-
specific mortality experienced by those with diabetes and with and without comorbid CVD.
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Table 8-2: Site-specific cancer mortality ORs among those with diabetes 
Progressive 
Adjustment 
Pancreas Colorectal Bladder Gender-
Specific 
Stomach Liver Lung Lymphatic Kidney Oesophagus Lip Other 
cancer 
Age & sex 1.62 1.14 1.20 1.09 1.54 0.70 1.29 0.93 1.44 1.11 1.12 1.23 
 
(1.08-
2.44) 
(0.80-
1.62) 
(0.66-
2.16) 
(0.82-
1.45) 
(0.95-
2.52 
(0.22-
2.23) 
(1.04-
1.61) 
(0.58-
1.48) 
(0.77-
2.68 
(0.65-1.88) (0.35-
3.60) 
(0.95-
1.59) 
+ Smoking 1.58 1.11 1.16 1.06 1.50 0.67 1.23 0.91 1.41 1.07 1.08 1.21 
 
(1.05-
2.38) 
(0.78-
1.58) 
(0.64-
2.09) 
(0.80-
1.42) 
(0.92-
2.44) 
(0.21-
2.14) 
(0.98-
1.53) 
(0.57-
1.45) 
(0.76-
2.64) 
(0.64-1.82) (0.34-
3.48) 
(0.94-
1.56) 
+ BMI 1.76 1.18 1.19 1.05 1.57 0.70 1.26 1.01 1.39 1.11 1.86 1.27 
 
(1.14-
2.70) 
(0.82-
1.70) 
(0.62-
2.29) 
(0.77-
1.44) 
(0.94-
2.60) 
(0.22-
2.28) 
(0.99-
1.62) 
(0.62-
1.64) 
(0.72-
2.67) 
(0.63-1.95) (0.57-
6.11) 
(0.97-
1.67) 
Addition adjustment (Advanced model + the following variables) 
+ CVD 1.62 1.11 1.10 1.03 1.48 0.61 1.18 1.01 1.32 1.10 1.91 1.22 
 
(1.06-
2.50) 
(0.77-
1.61) 
(0.57-
2.12) 
(0.75-
1.41) 
(0.89-
2.46) 
(0.19-
1.97) 
(0.92-
1.52) 
(0.62-
1.64) 
(0.68-
2.57) 
(0.62-1.95) (0.58-
6.33) 
(0.93-
1.61) 
+ 
Education 
1.71 1.14 1.15 1.02 1.40 0.70 1.19 0.97 1.36 1.07 1.68 1.23 
 
(1.12-
2.62) 
(0.79-
1.64) 
(0.60-
2.19) 
(0.75-
1.40) 
(0.83-
2.35) 
(0.22-
2.24) 
(0.93-
1.52) 
(0.60-
1.58) 
(0.70-
2.62) 
(0.60-1.86) (0.51-
5.51) 
(0.94-
1.61) 
+Social 
class 
1.76 1.18 1.18 1.05 1.53 0.71 1.24 1.01 1.38 1.10 1.80 1.27 
 
(1.15-
2.70) 
(0.82-
1.70) 
(0.62-
2.26) 
(0.77-
1.44) 
(0.92-
2.54) 
(0.22-
2.28) 
(0.97-
1.59) 
(0.62-
1.63) 
(0.72-
2.66) 
(0.62-1.95) (0.55-
5.93) 
(0.97-
1.66) 
+ Region 1.76 1.19 1.20 1.04 1.58 0.73 1.27 1.01 1.39 1.02 1.23 1.28 
 
(1.15-2.70 (0.82-
1.71) 
(0.63-
2.29) 
(0.76-
1.42) 
(0.95-
2.62) 
(0.23-
2.35) 
(0.99-
1.62) 
(0.63-
1.64) 
(0.72-
2.68) 
(0.56-1.83) (0.29-
5.14) 
(0.97-
1.68) 
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Table 8-3: Site-specific cancer deaths by sex, HSE and SHeS 
 
No 
Diabetes Diabetes Total 
Male Alive 78,816 2,768 81,584 
Pancreatic 138 15 153 
Colorectal 264 20 284 
Bladder 102 12 114 
Stomach 114 13 127 
Liver 43 2 45 
Lung 691 57 748 
Lymphoid  198 10 208 
Kidney 79 7 86 
Prostate 326 20 346 
Oesophagus 150 10 160 
Lip 46 1 47 
Other cancer 498 33 531 
Total cancers 2,649 200 2,849 
Female Alive 100,247 2,648 102,895 
Pancreatic 157 11 168 
Colorectal 254 14 268 
Bladder 54 0 54 
Breast 331 22 353 
Cervix 78 3 81 
Stomach 78 5 83 
Liver 36 1 37 
Lung 516 31 547 
Lymphoid 155 9 164 
Ovarian 159 6 165 
Kidney 50 4 54 
Oesophagus 96 5 101 
Lip 16 2 18 
Other cancer 472 32 504 
Total cancers 2,452 145 2,597 
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Table 8-4: Site-specific cancer mortality ORs (men) 
Progressive 
adjustment 
Pancreatic Colorectal Bladder Stomach Liver Lung Lymphatic Kidney Prostate Oesophagus Lip Other 
Cancer 
Age  1.69 1.16 1.67 1.74 0.74 1.26 0.76 1.32 0.80 1.18 0.56 1.09 
 
(0.99-
2.91) 
(0.73-
1.84) 
(0.91-
3.06) 
(0.97-
3.11) 
(0.18-
3.08) 
(0.95-
1.66) 
(0.40-
1.43) 
(0.60-
2.89) 
(0.51-
1.27) 
(0.62-2.26) (0.08-
4.13) 
(0.76-
1.56) 
+ Smoking 1.64 1.12 1.59 1.69 0.69 1.20 0.74 1.29 0.79 1.14 0.52 1.06 
 
(0.95-
2.82) 
(0.71-
1.78) 
(0.87-
2.92) 
(0.94-
3.02) 
(0.17-
2.88) 
(0.91-
1.59) 
(0.39-
1.40) 
(0.59-
2.82) 
(0.50-
1.24) 
(0.60-2.18) (0.07-
3.82) 
(0.74-
1.52) 
+ BMI 1.97 1.19 1.67 1.82 0.77 1.25 0.85 1.25 0.85 1.16 1.10 1.12 
 
(1.14-
3.42) 
(0.74-
1.92) 
(0.86-
3.25) 
(1.01-
3.28) 
(0.18-
3.23) 
(0.93-
1.70) 
(0.44-
1.61) 
(0.54-
2.91) 
(0.52-
1.37) 
(0.58-2.30) (0.15-
8.18) 
(0.76-
1.65) 
+ CVD 1.81 1.10 1.48 1.72 0.68 1.15 0.86 1.22 0.84 1.14 1.09 1.35 
 
(1.04-
3.51) 
(0.68-
1.78) 
(0.76-
2.88) 
(0.95-
3.11) 
(0.16-
2.86) 
(0.85-
1.57) 
(0.45-
1.64) 
(0.52-
2.86) 
(0.52-
1.36) 
(0.57-2.28) (0.15-
8.15) 
(1.07-
1.71) 
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Table 8-5: Site-specific cancer mortality ORs (women)a 
Progressive 
adjustment 
Pancreas Colorectal Breast Cervix 
etc 
Stomach Liver Lung Lymphatic Ovarian Kidney Oesophagus Lip Other 
cancer 
Age 1.52 1.11 1.59 0.98 1.21 0.63 1.34 1.21 0.94 1.68 1.01 2.42 1.42 
(0.82-
2.82) 
(0.65-
1.91) 
(1.02-
2.46) 
(0.31-
3.14) 
(0.49-
3.01) 
(0.09-
4.60) 
(0.92-
1.93) 
(0.62-
2.39) 
(0.41-
2.13) 
(0.60-
4.69) 
(0.41-2.50) (0.55-
10.69) 
(0.98-
2.04) 
+ Smoking 1.50 1.09 1.56 0.97 1.18 0.61 1.28 1.20 0.94 1.66 0.99 2.41 1.41 
(0.81-
2.78) 
(0.63-
1.88) 
(1.01-
2.42) 
(0.30-
3.10) 
(0.48-
2.94) 
(0.08-
4.52) 
(0.89-
1.86) 
(0.61-
2.37) 
(0.41-
2.13) 
(0.60-
4.66) 
(0.40-2.45) (0.55-
10.66) 
(0.98-
2.02) 
+ 
BMI 
1.47 1.17 1.62 1.08 1.13 0.61 1.29 1.30 0.49 1.64 1.06 3.13 1.46 
(0.74-
2.92) 
(0.66-
2.07) 
(1.01-
2.61) 
(0.33-
3.48) 
(0.41-
3.12) 
(0.08-
4.49) 
(0.85-
1.97) 
(0.63-
2.69) 
(0.16-
1.55) 
(0.58-
4.64) 
(0.38-2.92) (0.67-
14.55) 
(1.00-
2.13) 
+ 
CVD 
1.37 1.12 1.57 1.05 1.06 0.51 1.24 1.27 0.48 1.49 1.07 3.41 1.43 
(0.68-
2.73) 
(0.64-
2.00) 
(0.97-
2.53) 
(0.32-
3.42) 
(0.38-
2.95) 
(0.07-
3.80) 
(0.81-
1.90) 
(0.61-
2.63) 
(0.15-
1.51) 
(0.52-
4.25) 
(0.39-2.98) (0.73-
16.04) 
(0.97-
2.09) 
a
 There were no cases of bladder cancer among women with diabetes 
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Table 8-6: Site-specific cancer mortality by CVD status 
  No Diabetes Diabetes All 
No CVD reported at baseline Alive 164,573 3,498 168,071 
Pancreas 235 11 246 
Colorectal 408 16 424 
Bladder 117 8 125 
Gender-specific cancers 743 29 772 
Stomach 147 13 160 
Liver 57 <5 58 
Lung 959 47 1,006 
Lymphatic 292 15 307 
Kidney 101 8 109 
Oesophagus 205 8 213 
Lip 57 <5 59 
Other cancer 794 43 837 
Total cancers 4,115 201 4,316 
CVD reported at baseline Alive 14,595 1,921 16,516 
Pancreas 60 15 75 
Colorectal 110 18 128 
Bladder 39 <5 43 
Gender-specific cancers 153 22 175 
Stomach 45 6 51 
Liver 22 <5 24 
Lung 250 41 291 
Lymphatic 62 <5 66 
Kidney 28 <5 31 
Oesophagus 41 7 48 
Lip 5 <5 6 
Other cancer 179 22 201 
Total cancers 994 145 1,139 
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Table 8-7: Site-specific cancer mortality ORs among those without comorbid CVD 
Progressive 
adjustment 
Pancreas Colorectal Bladder Sex- 
specific 
Stomach Liver Lung Lymphatic Kidney Oesophagus Lip  Other 
cancers 
Age & sex 1.20 0.93 1.43 1.02 1.79 0.46 1.18 1.19 1.76 0.96 1.06 1.35 
(0.65-
2.22) 
(0.56-
1.53) 
(0.70-
2.96) 
(0.70-
1.49) 
(0.99-
3.25) 
(0.06-
3.31) 
(0.87-
1.59) 
(0.70-
2.01) 
(0.85-
3.65) 
(0.47-1.95) (0.26-
4.38) 
(0.99-
1.85) 
+ Smoking 1.19 0.91 1.39 1.00 1.75 0.43 1.16 1.17 1.75 0.93 1.03 1.34 
(0.64-
2.18) 
(0.55-
1.50) 
(0.67-
2,86) 
(0.69-
1.46) 
(0.96-
3.17) 
(0.06-
3.14) 
(0.69-
1.97) 
(0.69-
1.97) 
(0.84-
3.62) 
(0.46-1.91) (0.25-
4.26) 
(0.98-
1.83) 
+ BMI 1.42 0.98 1.55 0.92 1.76 0.47 1.14 1.28 1.71 1.10 1.83 1.42 
(0.77-
2.63) 
(0.58-
1.65) 
(0.71-
3.37) 
(0.61-
1.41) 
(0.94-
3.29) 
(0.06-
3.40) 
(0.82-
1.60) 
(0.74-
2.21) 
(0.78-
3.74) 
(0.54-2.26) (0.44-
7.70) 
(1.02-
1.98) 
 
Table 8-8: ORs site-specific cancer among those with comorbid CVD 
Progressive 
adjustment 
Pancreas Colorectal Bladder Sex- 
specific 
Stomach Liver Lung Lymphatic Kidney Oesophagus Lip  Other 
cancers 
Age & sex 1.77 1.18 0.69 1.08 0.95 0.67 1.15 0.47 0.77 1.22 1.50 0.88 
(1.00-
3.13) 
(0.71-
1.94) 
(0.24-
1.92) 
(0.69-
1.70) 
(0.40-
2.23) 
(0.16-
2.85) 
(0.82-
1.60) 
(0.17-
1.30) 
(0.23-
2.52) 
(0.55-2.73) (0.17-
12.86) 
(0.57-
1.38) 
+ Smoking 1.74 1.16 0.68 1.07 0.93 0.66 1.10 0.46 0.75 1.20 1.46 0.88 
(0.98-
3.07) 
(0.70-
1.91) 
(0.24-
1.91) 
(0.68-
1.69) 
(0.40-
2.19) 
(0.16-
2.83) 
(0.79-
1.54) 
(0.17-
1.28) 
(0.23-
2.46) 
(0.54-2.69) (0.17-
12.57) 
(0.56-
1.37) 
+ BMI 1.88 1.23 0.6 1.25 1.13 0.75 1.23 0.57 0.79 1.09 1.84 0.95 
(1.02-
3.49) 
(0.73-
2.08) 
(0.19-
1.97) 
(0.77-
2.02) 
(0.47-
2.69) 
(0.17-
3.23) 
(0.85-
1.79) 
(0.21-
1.59) 
(0.24-
2.65) 
(0.42-2.82) (0.20-
16.90) 
(0.59-
1.52) 
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Analyses were then performed using Cox regression. Unlike the multinomial regression above, this 
compared those who had died from the site-specific cancer of interest with the rest of the study 
population (those still alive at the end of the follow-up period, plus those who died of another 
cause). Table 8-9 gives the results of these analyses. Those with diabetes had a consistently 
increased risk of mortality from pancreatic cancer; this increase remained after adjustment for the 
full range of covariates, apart from HbA1C. Women with diabetes were found to have an increased 
risk of mortality from breast cancer; this remained statistically significant within the advanced model 
(1.61, CI 1.01-2.59), but not within the further analyses. The Hazard Ratios (HRs) were increased at 
the point estimate for mortality from cancers of the colorectum, bladder, lip, stomach, kidney, and 
‘other’ cancers but the increase was not statistically significant. The results suggest that those with 
diabetes do not have an increased risk of mortality from ovarian, prostate and liver cancer, while the 
results were inconsistent for cancers of the cervix and oesophagus. For lung cancer mortality there 
was a statistically significant increased risk of mortality among those with diabetes within the basic 
but not advanced models. 
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Table 8-9: HRs for site-specific cancers among those with diabetes compared with those without diabetes 
Progressive 
Adjustment 
Pancreatic Colorectal Bladder Breast Cervix Ovarian Stomach Lymphatic 
Age & sex 1.59 
(1.06-2.38) 
1.09 
(0.77-1.55) 
1.12 
(0.62-2.03) 
1.58 
(1.02-2.45) 
1.02 
(0.32-3.26) 
0.96 
(0.42-2.19) 
1.47 
(0.90-2.39) 
0.90 
(0.57-1.43) 
+ 
smoking 
1.58 
(1.06-2.38) 
1.08 
(0.76-1.53) 
1.12 
(0.62-2.03) 
1.59 
(1.03-2.46) 
1.02 
(0.32-3.27) 
0.96 
(0.42-2.19) 
1.47 
(0.90-2.40) 
0.90 
(0.56-1.43) 
 
+ BMI 
1.67 
(1.09-2.55) 
1.11 
(0.77-1.59) 
1.08 
(0.57-2.07) 
1.61 
(1.01-2.59) 
1.13 
(0.35-3.66) 
0.50 
(0.16-1.58) 
1.47 
(0.88-2.43) 
0.96 
(0.60-1.55) 
+ CVD 1.56 
(1.02-2.40) 
1.06 
(0.74-1.53) 
1.02 
(0.53-1.95) 
1.57 
(0.98-2.53) 
1.11 
(0.34-3.61) 
0.49 
(0.16-1.56) 
1.40 
(0.84-2.34) 
0.98 
(0.60-1.58) 
Advanced + 
Education 
1.65 
(1.08-2.53) 
1.08 
(0.75-1.55) 
1.05 
(0.55-2.01) 
1.57 
(0.98-2.52) 
1.11 
(0.35-3.60) 
0.49 
(0.16-1.56) 
1.32 
(0.78-2.21) 
0.94 
(0.58-1.52) 
Advanced +  
Social class 
1.68 
(1.10-2.57) 
1.11 
(0.77-1.60) 
1.07 
(0.56-2.05) 
1.69 
(1.05-2.72) 
1.12 
(0.35-3.62) 
0.53 
(0.17-1.69) 
1.44 
(0.87-2.38) 
0.94 
(0.58-1.52) 
Advanced +  
Region 
1.68 
(1.10-2.57) 
1.12 
(0.78-1.61) 
1.09 
(0.57-2.08) 
1.55 
(0.96-2.52) 
1.16 
(0.36-3.75) 
0.50 
(0.16-1.59) 
1.49 
(0.90-2.47) 
0.94 
(0.58-1.52) 
Advanced +  
HbA1c 
0.85 
(0.13-5.53) 
2.79 
(0.91-8.65) 
1.12 
(0.99-12.83) 
2.74 
(0.45-16.57) 
N/A 2.33 
(0.13-41.14) 
0.26 
(0.03-2.52) 
0.69 
(0.07-6.62) 
Basic +  
WC 
1.79 
(1.05-3.01) 
1.23 
(0.79-1.91) 
0.89 
(0.36-2.22) 
1.36 
(0.73-2.54) 
0.35 
(0.05-2.58) 
0.42 
(0.10-1.73) 
1.80 
(1.02-3.18) 
1.25 
(0.72-2.17) 
Basic +  
WHR 
1.81 
(1.07-3.07) 
1.23 
(0.79-1.91) 
0.87 
(0.35-2.16) 
1.42 
(0.76-2.64) 
0.40 
(0.06-2.97) 
0.44 
(0.11-1.82) 
1.73 
(0.98-3.05) 
1.26 
(0.72-2.19) 
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Table 8-9: continued 
Progressive 
Adjustment 
Prostate Lung Liver Kidney Oesophagus Lip  Other 
Age & sex 0.74 
(0.45-1.16) 
1.25 
(1.00-1.55) 
0.70 
(0.22-2.23) 
1.42 
(0.76-2.65) 
1.06 
(0.63-1.80) 
1.10 
(0.34-3.55) 
1.17 
(0.91-1.51) 
+ smoking 0.73 
(0.46-1.15) 
1.31 
(1.05-1.64) 
0.70 
(0.21-2.17) 
1.42 
(0.76-2.65) 
1.06 
(0.63-1.80) 
1.16 
(0.36-3.75) 
1.18 
(0.92-1.52) 
+ BMI 0.75 
(0.46-1.20) 
1.22 
(0.96-1.56) 
0.69 
(0.22-2.22) 
1.34 
(0.69-2.57) 
1.05 
(0.59-1.85) 
1.83 
(0.56-6.04) 
1.18 
(0.91-1.55) 
+ CVD 0.76 
(0.47-1.23) 
1.15 
(0.90-1.47) 
0.60 
(0.19-1.94) 
1.29 
(0.67-2.50) 
1.06 
(0.60-1.88) 
1.89 
(0.57-6.28) 
1.15 
(0.89-1.51) 
Advanced + 
Education 
0.74 
(0.46-1.20) 
1.17 
(0.92-1.50) 
0.70 
(0.22-2.25) 
1.33 
(0.69-2.57) 
1.01 
(0.57-1.79) 
1.68 
(0.51-5.53) 
1.16 
(0.89-1.51) 
Advanced +  
Social class 
0.75 
(0.46-1.21) 
1.21 
(0.95-1.55) 
0.70 
(0.22-2.24) 
1.33 
(0.69-2.56) 
0.96 
(0.53-1.74) 
1.80 
(0.55-5.94) 
1.18 
(0.91-1.55) 
Advanced +  
Region 
0.76 
(0.47-1.23) 
1.23 
(0.97-1.57) 
0.72 
(0.22-2.30) 
1.35 
(0.70-2.60) 
0.96 
(0.53-1.73) 
1.23 
(0.29-5.17) 
1.20 
(0.91-1.57) 
Advanced +  
HbA1c 
0.69 
(0.15-3.23) 
1.40 
(0.63-3.10) 
N/A 5.03 
(0.60-42.12) 
1.25 
(0.22-7.26) 
N/A 0.30 
(0.06-1.42) 
Basic +  
WC 
0.82 
(0.47-1.45) 
1.17 
(0.88-1.57) 
0.33 
(0.05-2.43) 
0.90 
(0.33-2.51) 
0.80 
(0.37-1.72) 
0.88 
(0.12-6.64) 
1.32 
(0.97-1.81) 
Basic +  
WHR 
0.82 
(0.47-1.45) 
1.14 
(0.85-1.52) 
0.34 
(0.05-2.48) 
1.00 
(0.36-2.79) 
0.76 
(0.35-1.65) 
0.90 
(0.12-6.81) 
1.34 
(0.98-1.84) 
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The above analyses were then re-run excluding deaths within the first year following participation in 
the HSE and SHeS. This enabled an assessment of the issue of reverse causality for the association of 
diabetes with mortality from pancreatic, as well as the other, cancer mortality. Specifically for 
mortality from cancer of the pancreas, within all of the models the HRs were not significantly 
attenuated (Basic: 1.57, 1.04-2.38; Advanced: 1.66, 1.07-2.56; CVD 1.54, 1.00-2.39).The results for 
mortality from other site-specific cancers also remained unchanged (results not shown). 
 
The next chapter details the results of the analyses related to the association between glycated 
haemoglobin and mortality. 
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9. Chapter 9: Results – glycated haemoglobin and mortality 
within the HSE and SHeS 
Within the HSE and SHeS, some participants had a measurement of glycated haemoglobin, a 
measurement of longer term blood glucose levels that can be used to detect uncontrolled or 
undiagnosed diabetes. This allowed analyses to be performed which assessed the strength of the 
association between this variable and all-cause and cause-specific mortality. 
 
9.1 Glycated haemoglobin: descriptive analysis 
 
9.2 HbA1C and cause-specific mortality 
Within the HbA1C sample there were a total of 1,362 deaths, of which 449 were caused by cancer, 
471 by cardiovascular disease (CVD), 173 by respiratory disease, and 269 by other causes. Within the 
CVD category, 84 were from stroke and 263 from ischaemic heart disease (IHD). Multinomial 
regression was used to investigate whether HbA1C was associated with specific causes of death. 
 
Those with an HbA1C measurement ≥6.5% had statistically significant increased odds of cancer 
mortality within the basic model (1.44, CI 1.05-1.97) but not in the advanced or CVD models, 
although there were point estimate increases within each model, including the one which contained 
diabetes (Table 9-1). Among those with a raised HbA1C measurement there were point estimate 
increases in risk of mortality from respiratory disease and statistically significant increases for other 
causes within each model. The risk of mortality from CVD was close to doubled among those with a 
raised HbA1C measurement compared with those with a lower measurement. 
Table 9-1: Raised glycated haemoglobin and cause-specific mortality (ORs and 95% CI)  
Progressive 
adjustment 
Cancer Respiratory CVD Other 
Age, sex 1.47 1.35 2.02 1.59 
(1.07-2.01) (0.83-2.19) (1.55-2.64) (1.07-2.36) 
& Smoking 1.44 1.33 2.02 1.57 
(1.05-1.97) (0.81-2.16) (1.54-2.63) (1.06-2.34) 
& BMI 1.38 1.52 1.94 1.70 
(0.98-1.95) (0.89-2.61) (1.45-2.60) (1.11-2.60) 
Additional adjustment (Advanced model + the following variables 
+ CVD 1.34 1.44 1.73 1.56 
(0.95-1.90) (0.84-2.48) (1.29-2.33) (1.02-2.39) 
+ Education 1.31 1.34 1.85 1.58 
170 
 
(0.93-1.85) (0.77-2.33) (1.38-2.48) (1.03-2.42) 
+ Social 
Class 
1.36 1.45 1.92 1.65 
(0.96-1.91) (0.85-2.50) (1.43-2.57) (1.07-2.52) 
+ Region 1.40 1.53 2.00 1.66 
(0.99-1.97) (0.89-2.62) (1.49-2.67) (1.09-2.53) 
+ Diabetes 1.26 1.23 1.19 0.79 
(0.82-1.94) (0.62-2.44) (0.81-1.75) (0.45-1.37) 
 
When the multinomial logistic regression models included alternate measures of adiposity the odds 
ratios were found to be similar to those found when adjustment included BMI. For cancer the ORs 
were: BMI 1.38, CI 0.98-1.95; WHR 1.35, 0.97-1.88 and WC 1.42, 1.02-1.97. The ORs also remained 
consistent for respiratory disease, CVD and other causes of mortality (Table 9-2). Further to this, 
removing all of the measurement of overweight and obesity did little to alter the ORs for each cause 
of mortality (Table 9-3). The same results were found when a number of additional independent 
variables were included within the model (results not shown). 
 
Table 9-2: Raised HbA1C and cause-specific mortality adjusting for alternative measures of 
overweight and obesity)  
Further 
adjustment 
Cancer Respiratory CVD Other 
Basic 1.38 1.52 1.94 1.70 
& BMI (0.98-1.95) (0.89-2.61) (1.45-2.60) (1.11-2.60) 
Basic 
&WHR 
1.35 1.26 2.04 1.64 
(0.97-1.88) (0.75-2.13) (1.55-2.70) (1.07-2.52) 
Basic 
& WC 
1.42 
(1.02-1.97) 
1.33 
(0.79-2.24) 
2.08 
(1.57-2.74) 
1.65 
(1.08-2.52) 
Additional adjustment for baseline CVD status 
Basic + 
WHR & CVD 
1.32 
(0.95-1.84) 
1.23 
(0.73-2.07) 
1.86 
(1.40-2.46) 
1.55 
(1.01-2.38) 
Basic + 
WC & CVD 
1.39 
(1.00-1.93) 
1.29 
(0.77-2.18) 
1.88 
(1.42-2.49) 
1.55 
(1.02-2.38) 
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Table 9-3: All-cause mortality ORs among diabetic cases (without adjustment for overweight and 
obesity) HbA1C ≥6.5% 
Further 
adjustment 
Cancer Respiratory CVD Other 
Basic & 
Education 
1.35 1.18 1.91 1.46 
(0.99-1.85) (0.71-1.95) (1.46-2.49) (0.98-2.17) 
Basic & 
Social Class 
1.41 1.28 2.00 1.52 
(1.03-1.93) (0.79-2.10) (1.53-2.61) (1.02-2.27) 
Basic & 
Region 
1.48 1.37 2.12 1.60 
(1.08-2.03) (0.84-2.23) (1.62-2.77) (1.08-2.38) 
Basic & 
Diabetes 
1.30 1.17 1.19 0.73 
(0.87-1.95) (0.63-2.16) (0.83-1.70) (0.44-1.23) 
 
The data were then stratified by CVD status and the above analyses re-run. As can be seen from 
Table 9-4, there were point estimate increases for all of the causes under investigation; only for 
mortality from CVD were the increases consistently statistically significant among those with and 
without comorbid CVD. The addition of other covariates did not impact upon these results. Table 9-5 
details the results of the analyses stratified by sex. For women raised HbA1C appeared to be 
associated with an increased risk of mortality from cancer at the point estimate and statistically 
significant increases for respiratory disease, CVD and other causes within each of the models. 
Somewhat contradicting this result, men were found to have statistically significant increased ORs 
for cancer (basic: 1.55, CI 1.05-2.27 and advanced: 1.55, 1.04-2.39), but not for respiratory disease, 
CVD or other causes. The results remained statistically unchanged when a range of covariates were 
added to the regression model. Among those who indicated that they had never been a regular 
smoker, those with a raised measurement for HbA1c there were point estimate increases in risk for 
all of the causes of mortality under investigation; although these were only statistically significant for 
mortality from CVD (advanced: 2.38, 1.50-3.79). Results of these analyses are given in Table 9-6.  
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Table 9-4: Cause-specific mortality odds ratios (and 95% CI) among those with raised HbA1C stratified by CVD status 
Progressive 
adjustment 
CVD as a comorbidity (CVD removed from the model) 
NO YES 
Cancer Respiratory CVD Other Cancer Respiratory CVD Other 
Age & sex 1.48 1.32 2.11 1.68 1.34 1.23 1.51 1.21 
(1.00-2.20) (0.70-2.48) (1.47-3.03) (1.02-2.77) (0.79-2.26) (0.57-2.66) (1.02-2.23) (0.63-2.33) 
& Smoking 1.45 1.30 2.12 1.67 1.30 1.21 1.49 1.17 
(0.98-2.15) (0.70-2.46) (1.46-3.01) (1.01-2.75) (0.77-2.21) (0.56-2.62) (1.00-2.20) (0.61-2.27) 
& BMI 1.35 1.33 1.94 1.73 1.34 1.58 1.52 1.34 
(0.88-2.09) (0.63-2.81) (1.30-2.90) (1.00-3.00) (0.76-2.36) (0.72-3.50) (0.99-2.34) (0.68-2.63) 
Advanced adjustment (Advanced model + the following variables) 
+ Education 1.30 1.28 1.87 1.63 1.31 1.26 1.50 1.27 
(0.84-2.00) (0.60-2.70) (1.25-2.79) (0.94-2.82) (0.74-2.30) (0.54-2.91) (0.98-2.31) (0.65-2.50) 
+ Social Class 1.34 1.25 1.92 1.67 1.31 1.54 1.53 1.31 
(0.86-2.07) (0.59-2.64) (1.29-2.87) (0.96-2.90) (0.74-2.31) (0.70-3.42) (0.99-2.35) (0.67-2.57) 
+ Region 1.31 1.28 1.91 1.58 1.67 1.74 1.91 1.55 
(0.85-2.01) (0.61-2.69) (1.28-2.85) (0.92-2.73) (0.94-2.97) (0.78-3.87) (1.23-2.98) (0.78-3.10) 
+ Diabetes 1.34 0.88 1.08 0.97 1.11 1.88 1.22 0.57 
(0.79-2.27) (0.35-2.23) (0.64-1.83) (0.47-1.97) (0.53-2.35) (0.69-5.16) (0.69-2.15) (0.24-1.32) 
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Table 9-5: Cause-specific mortality odds ratios (and 95% CI) among those with raised HbA1C stratified by sex 
 
Progressive adjustment Sex (sex removed from the models) 
WOMEN MEN 
Cancer Respiratory CVD Other Cancer Respiratory CVD Other 
Age & sex 1.24 2.17 2.93 1.96 1.57 0.80 1.53 1.35 
(0.71-2.16) (1.16-4.06) (1.99-4.31) (1.10-3.48) (1.07-2.30) (0.36-1.75) (1.06-2.20) (0.78-2.34) 
& Smoking 1.23 2.11 2.91 1.93 1.55 0.81 1.52 1.35 
(0.70-2.15) (1.12-3.96) (1.97-4.30) (1.09-3.44) (1.05-2.27) (0.37-1.78) (1.06-2.20) (0.78-2.34) 
& BMI 1.04 2.62 3.02 2.09 1.58 0.88 1.40 1.50 
(0.56-1.96) (1.29-5.30) (1.97-4.62) (1.08-4.04) (1.04-2.39) (0.37-2.07) (0.93-2.10) (0.86-2.62) 
& CVD 1.02 2.45 2.70 1.98 1.52 0.84 1.25 1.34 
(0.54-1.93) (1.20-4.99) (1.76-4.16) (1.02-3.84) (1.00-2.31) (0.36-1.98) (0.83-1.88) (0.77-2.36) 
Further adjustment (Advanced model + the following variables) 
+ Education 0.95 2.35 2.85 1.93 1.53 0.69 1.34 1.40 
(0.51-1.79) (1.16-4.75) (1.86-4.36) (1.00-3.72) (1.01-2.31) (0.27-1.76) (0.89-2.01) (0.80-2.45) 
+ Social Class 1.01 2.38 2.97 2.01 1.56 0.86 1.39 1.47 
(0.53-1.89) (1.17-4.83) (1.94-4.56) (1.04-3.89) (1.03-2.36) (0.37-2.03) (0.93-2.09) (0.84-2.57) 
+ Region 1.02 2.58 3.01 1.93 1.64 0.88 1.47 1.51 
(0.55-1.92) (1.28-5.20) (1.97-4.60) (1.00-3.71) (1.09-2.48) (0.37-2.07) (0.98-2.20) (0.87-2.64) 
+ Diabetes 0.61 2.04 2.07 1.22 1.88 0.71 0.76 0.59 
(0.28-1.33) (0.83-5.02) (1.18-3.62) (0.52-2.84) (1.12-3.16) (0.24-2.06) (0.44-1.30) (0.29-1.22) 
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Table 9-6: Cause-specific mortality odds ratios (and 95% CI) among those with raised HbA1C among never smokers
Progressive 
adjustment 
Cause of mortality 
Cancer Respiratory CVD Other 
Age & sex 1.52 
(0.84-2.74) 
1.49 
(0.58-3.87) 
2.34 
(1.53-3.57) 
1.76 
(0.92-3.38) 
& BMI 1.44 
(0.75-2.74) 
2.13 
(0.79-5.75) 
2.38 
(1.50-3.79) 
2.06 
(1.02-4.15) 
& CVD 1.39 
(0.73-2.66) 
1.97 
(0.73-5.32) 
2.22 
(1.39-3.53) 
2.00 
(0.99-4.03) 
Further adjustment (Advanced model + the following variables) 
+ Education 1.38 
(0.73-2.64) 
2.05 
(0.76-5.53) 
2.32 
(1.46-3.68) 
1.96 
(0.97-3.94) 
+ Social Class 1.40 
(0.73-2.69) 
2.09 
(0.78-5.64) 
2.39 
(1.50-3.80) 
1.97 
(0.98-3.99) 
+ Region 1.42 
(0.75-2.70) 
2.13 
(0.79-5.74) 
2.39 
(1.51-3.79) 
1.97 
(0.98-3.95) 
+ Diabetes 1.59 
(0.71-3.58) 
1.99 
(0.56-7.12) 
1.93 
(1.05-3.56) 
0.91 
(0.36-2.31) 
175 
 
The continuous HbA1C variable was then used within the regression models. For cancer and 
respiratory disease, there were small point estimate increases in odds ratios, while for CVD the 
increase was statistically significant. There appeared to be no association between the continuous 
HbA1C variable and the combined ‘other’ causes of mortality. Each of these results remained 
unchanged following the inclusion of further covariates (results not shown). Further analyses were 
then performed using tertiles of HbA1C (using data from the whole sample as well as stratified by 
CVD status and sex); none of these analyses showed an association between this variable and cause-
specific mortality (results not shown). 
 
Table 9-7: Cause-specific mortality odds ratios (and 95% CI) continuous HbA1C variable 
Progressive 
adjustment 
Cause of mortality 
Cancer Respiratory CVD Other 
Age, sex 1.05 1.07 1.21 0.96 
(0.94-1.18) (0.89-1.28) (1.10-1.33) (0.81-1.14) 
& Smoking 1.03 1.05 1.20 0.94 
(0.92-1.16) (0.87-1.26) (1.09-1.31) (0.79-1.12) 
& BMI 1.02 1.17 1.17 0.99 
(0.89-1.16) (0.97-1.40) (1.05-1.30) (0.82-1.18) 
Additional adjustment (advanced model + the following variables) 
+ CVD 1.01 1.14 1.12 0.95 
(0.88-1.15) (0.95-1.38 (1.00-1.25) (0.79-1.14) 
+ Education 0.99 1.08 1.14 0.95 
(0.87-1.13) (0.89-1.32) (1.02-1.27) (0.79-1.14) 
 + Social Class 1.01 1.14 1.16 0.97 
0.88-1.15) (0.95-1.38) (1.04-1.29) (0.81-1.16) 
+ Region 1.07 1.2 1.21 1.04 
(0.94-1.21) (1.00-1.43) (1.10-1.34) (0.88-1.23) 
+ Diabetes 0.95 1.1 0.97 0.72 
(0.82-1.11) (0.88-1.37) (0.85-1.12) (0.58-0.90) 
  
9.3 Site-specific cancer mortality and HbA1C 
There was found to be a relatively small number of site-specific cancer deaths within the sample 
with a valid glycated haemoglobin measurement, with an even smaller number of deaths among 
those with raised HbA1C. Table 9-8 demonstrates the number of cases within the sample; as can be 
seen, there were no deaths among those with raised HbA1C from cancers of the cervix, kidney and 
lip. Therefore analyses of the association between HbA1C and these cancers were not performed. 
The ORs were raised at the point estimate for cancers of the pancreas, liver, colorectum, stomach, 
oesophagus, lung and other cancers; while for mortality from sex-specific cancers there appeared to 
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be a statistically significant increase in risk among those with a raised HbA1C. Because of the small 
number of cancer cases, no further covariates were added to the model. 
 
Table 9-8: Site-specific cancer mortality among the HbA1C sample 
Site-specific cancer deaths Glycated 
haemoglobin level 
 
 Normal Raised Total 
Alive 26,117 1,291 27,408 
Lung 111 12 123 
Colorectal 41 <5 44 
Oesophagus 25 <5 28 
Lymphatic 27 <5 28 
Prostate 16 5 21 
Stomach 16 <5 20 
Pancreatic 15 <5 19 
Breast 16 <5 19 
Bladder 14 <5 15 
Liver 10 <5 11 
Ovarian 10 <5 11 
Kidney 8 0 8 
Cervix <5 0 <5 
Lip <5 0 <5 
Other cancer 72 8 80 
Death unrelated to cancer 789 122 911 
TOTAL 27,295 1,459 28,754 
 
 
The data were then stratified by sex, in order to explore whether or not there were differences in 
risk between men and women. This also enabled an exploration of the sex-specific cancers and their 
associations with raised HbA1C. In the instances when there were not deaths from a specific cancer 
among those with a raised glycated haemoglobin measurement, analyses were not performed. 
Among men there was a significant association between HbA1C and mortality from stomach cancer, 
as well as point estimate increases for cancers of the liver, lung, prostate, oesophagus, pancreas, 
colorectum, bladder and ‘other’ cancers. There were point estimate increases in risk of mortality 
from cancers of the pancreas, lung, lymphatic system, breast and ovary among women, none of 
these were statistically significant. As above, the small number of site-specific cancer deaths 
prevented the inclusion of further variables within the regression model. Table 9-10 details the 
number of site-specific cancers by sex and HbA1C (normal/≥6.5%).
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Table 9-9: Site-specific cancer mortality ORs among those with HbA1C ≥6.5%  
 
Table 9-10: Site-specific cancer mortality by sex and HbA1C 
Sex Pancreas Colorectal Bladder Cervix Stomach Liver Lung Lymphatic Ovarian Kidney Prostate Oesophagus Lip Other  
cancer 
Male               
Normal  8 25 8 N/A 9 5 61 17 N/A <5 16 17 <5 40 
Raised <5 <5 <5 N/A <5 <5 8 0 N/A 0 5 <5 0 5 
Female               
Normal 7 16 6 <5 7 5 50 10 10 5 N/A 8 <5 32 
Raised <5 0 0 0 0 0 <5 <5 <5 0 N/A 0 0 <5 
Progressive 
adjustment 
Site-specific cancers 
 Pancreas Colorectal Bladder Gender-
specific 
Stomach Liver Lung Lymphatic Oesophagus Other 
cancer 
Age & sex 2.94 1.00 0.83 2.52 2.38 1.36 1.41 0.46 1.50 1.31 
 (0.96-9.01) (0.31-3.28) (0.11-6.43) (1.21-5.22) (0.79-7.19) (0.17-10.87) (0.77-2.59) (0.06-3.44) (0.45-5.06) (0.62-2.74) 
& Smoking 2.87 1.00 0.82 2.50 2.32 1.27 1.36 0.45 1.47 1.29 
 (0.94-8.82) (0.31-3.27) (0.11-6.31) (1.20-5.19) (0.77-7.03) (0.16-10.17) (0.74-2.50) (0.06-3.36) (0.44-4.96) (0.62-2.72) 
& BMI 2.37 1.10 0.96 2.85 2.05 N/A 1.74 0.51 1.18 0.96 
 (0.66-8.57) (0.33-3.64) (0.12-7.56) (1.35-6.02) (0.57-7.36)  (0.94-3.23) (0.07-3.81) (0.27-5.19) (0.38-2.42) 
& CVD 0.90 1.17 1.21 1.54 2.69 N/A 1.68 0.71 1.47 1.16 
 (0.11-7.25) (0.35-3.96) (0.14-10.08) (0.52-4.54) (0.52-13.90)  (0.84-3.33) (0.09-5.52) (0.33-6.60) (0.45-2.97) 
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Table 9-11: ORs for site-specific cancer mortality among men with raised HbA1C 
a There were no deaths from kidney, lymphatic or lip cancers found among men with a raised HbA1C measurement. 
 
 
 
 
 
 
 
 
PROGRESSIVE 
ADJUSTMENT 
Site-specific cancersa 
 Pancreas Colorectal Bladder Stomach Liver Lung Prostate Oesophagus Other 
cancers 
Age 2.10 1.43 1.13 3.85 2.06 1.43 2.75 2.02 1.26 
 (0.44-10.01) (0.42-4.85) (0.14-9.16) (1.16-12.77 (0.23-18.24) (0.67-3.03) (0.99-7.62) (0.58-7.08) (0.49-3.24) 
& Smoking 2.13 1.43 1.09 3.95 1.92 1.39 2.72 2.02 1.25 
 (0.45-10.17) (0.42-4.84) (0.13-8.86) (1.19-13.13) (0.22-17.06) (0.65-2.95) (0.98-7.55) (0.58-7.10) (0.49-3.23) 
& BMI 2.20 1.56 1.58 4.94 N/A 1.74 3.02 1.65 1.31 
 (0.44-11.03) (0.45-5.38) (0.19-13.36) (1.21-20.20)  (0.80-3.75) (1.06-8.58) (0.36-7.50) (0.45-3.79) 
& CVD 1.20 1.70 2.18 6.88 N/A 1.64 1.47 2.25 1.47 
 (0.14-10.59) (0.48-6.05) (0.23-21.04) (1.05-45.07)  (0.72-3.77) (0.32-6.87) (0.47-10.71) (0.50-4.34) 
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Table 9-12: Site-specific cancer mortality ORs among women with raised HbA1C 
 
 
 
 
 
 
 
 
 
 
a There were no deaths from cancers of the colorectum, bladder, cervix, stomach, 
 liver, kidney, oesophagus or lip among women with raised HbA1C. 
 
 
 
 
 
 
Progressive 
adjustment 
Site-specific cancersa 
Pancreas Lung Lymphatic Breast Ovarian Other 
cancers 
Age 4.38 1.34 1.55 3.12 1.68 1.36 
 (0.88-21.82) (0.48-3.76) (0.20-12.39) (0.89-10.97) (0.21-13.48) (0.41-4.49) 
& Smoking 6.58 1.18 1.38 3.33 1.51 1.22 
 (1.78-24-25) (0.39-3.56) (0.14-13.37) (0.94-11.80) (0.97-2.35) (0.35-4.31) 
& BMI 2.28 1.43 1.85 4.11 2.44 0.59 
 (0.23-22.43) (0.45-4.52) (0.17-20.31) (1.15-14.66) (1.70-3.49) (0.10-3.50) 
& CVD 0.67 1.24 1.50 1.15 2.19 0.83 
 (0.01-49.37) (0.30-5.05) (0.10-23.26) (0.09-14.37) (0.89-5.39) (0.12-5.71) 
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Within the current study HbA1C was found to be significantly associated with mortality from CVD 
and the group of ‘other’ causes, as well as being associated with mortality from cancer and 
respiratory disease at the point estimate. For cause-specific mortality there appeared to be 
differences in risk when the analyses were stratified either by sex or the presence of comorbid CVD. 
 
Although limited by the number of deaths from site-specific cancers, the results above are also 
indicative of an association between HbA1C and some site-specific cancers as well as the potential 
for there being differences in risk between the sexes.  
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10. Chapter 10: Diabetes and all-cause mortality 
As with the analyses which explored the associations between diabetes, raised HbA1C and mortality 
from CVD, respiratory disease and other causes, the following analyses sought to examine the 
strength of the association between diabetes and all-cause mortality within a recent, general 
population cohort. Through the use of data from the HSE/SHeS and Whitehall I it was also possible 
to compare results from analyses of two different datasets – one of which had relatively recently 
collected baseline data and the other having a 40 year follow-up period. 
 
10.1 All-cause mortality: HSE and SHeS 
Within the analyses of the appended HSE/SHeS dataset, the all-cause mortality variable (deadalive) 
was binary (0=alive and 1=died) and those whose death had been registered within UK mortality 
records during the follow-up period were included in the ‘died’ category. 
 
In total, 20,051 cases were identified as having died during the follow-up period, with 1,814 deaths 
among those with diagnosed diabetes. Table 10-1 
 
Table 10-1 details the results related to the increased risk of all-cause mortality among those with 
diabetes compared with the general study population. Among the whole sample, those with 
diabetes had an increased odds for all-cause mortality that ranged from 1.68 (95% CI 1.57-1.79) 
within the basic model (adjusted for age-group, sex and smoking status) which was attenuated to 
1.56 (CI 1.45-1.68) when adjustment included age-group, sex, smoking status, BMI (categorical) and 
CVD as a baseline comorbidity. When the analyses were stratified by baseline CVD status, those with 
diabetes and either with or without comorbid CVD had increased odds of all-cause mortality 
compared with those without diabetes. These increases remained statistically significant after 
adjustment for a range of confounding factors. 
 
When the analyses were stratified by sex, and analyses compared the risk of all-cause mortality 
among those with and without diabetes, both men and women with diabetes appeared to be at 
increased risk. Men with diabetes had an increased risk at the point estimate compared with women 
with diabetes, but this was not statistically significant. Sensitivity analysis, which included only those 
who indicated that they had never been a regular smoker, was then performed. This indicated that 
never smokers with diabetes had increased odds of all-cause mortality of 1.63 (CI 1.44-1.83) within 
the CVD model which was similar to the raised odds among diabetics in the whole study population. 
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Table 10-1: All-cause mortality odds ratios (and 95% CI) among those with diabetes 
PROGRESSIVE 
ADJUSTMENT 
WHOLE 
SAMPLE STRATIFIED BY CVDa 
STRATIFIED BY 
GENDERb 
NEVER 
SMOKERS 
ONLY 
  
  n=98,107 
NO YES WOMEN MEN 
 Age, sex 1.61 1.58 1.29 1.58 1.64 1.72 
 
(1.51-1.72) (1.45-1.72) (1.18-1.42) (1.44-1.73) (1.50-1.79) (1.55-1.92) 
& Smokingc 1.68 1.66 1.33 1.67 1.69 N/A 
 
(1.57-1.79) (1.52-1.81) (1.20-1.46) (1.51-1.83) (1.54-1.84)  
& BMId 1.69 1.68 1.38 1.63 1.74 1.71 
 
(1.57-1.82) (1.53-1.85) (1.24-1.54) (1.46-1.81) (1.58-1.92) (1.51-1.92) 
Basic + 
CVD status 
1.55 
(1.46-1.66) N/A N/A 
1.57 
(1.43-1.73) 
1.54 
(1.41-1.68) 
1.65 
(1.48-1.84) 
Additional adjustment (Advanced model + the following variables) 
+ CVDe 1.56 N/A N/A 1.52 1.59 1.63 
 
(1.45-1.68) 
  
(1.37-1.70) (1.44-1.75) (1.44-1.83) 
+ Education 1.64 1.64 1.36 1.58 1.69 1.67 
 (1.53-1.76) (1.49-1.80) (1.22-1.51) (1.42-1.76) (1.54-1.86) (1.48-1.88) 
+ Social Class 1.66 1.65 1.35 1.57 1.73 1.65 
 (1.54-1.78) (1.50-1.82) (1.22-1.51) (1.41-1.75) (1.57-1.90) (1.47-1.86) 
+ Region 1.69 1.68 1.37 1.62 1.74 1.70 
 (1.57-1.81) (1.53-1.85) (1.23-1.52) (1.45-1.80) (1.58-1.91) (1.51-1.92) 
+ HbA1c 1.93 1.95 1.57 2.12 1.84 1.49 
 (1.49-2.49) (1.39-2.74) (1.06-2.31) (1.43-3.14) (1.31-2.58) (0.95-2.35) 
a CVD removed from the model when analyses stratified by baseline CVD. 
b Sex removed from the model when analyses stratified by sex. 
c Referred to as the ‘basic’ model. 
d Referred to as the ‘advanced’ model. 
e Referred to as the ‘CVD’ model. 
 
Additional adjustment was made which included the variables related to education, social class, 
region and glycated haemoglobin (HbA1C). Within all of these models, participant with diabetes 
remained at an increased risk for all-cause mortality (at the point estimate). The lack of statistical 
significance found within the sensitivity analysis which adjusted for HbA1C may relate to the small 
number of participants within this group who also had a valid measurement for this variable. 
 
As can be seen from Table 10-2, an excess risk of all-cause mortality remained among those with 
diabetes compared with the reference group after adjustment for either waist-to-hip ratio (WHR) or 
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waist circumference (WC). These increases were statistically similar to those found within the 
advanced model (which adjusted for BMI). 
 
Table 10-2: All-cause mortality ORs (adjusting for alternative measures of overweight and obesity) 
Additional 
adjustment 
WHOLE 
SAMPLE STRATIFIED BY CVD STRATIFIED BY GENDER 
NEVER 
SMOKERS 
ONLY 
 
 
(CVD removed from 
model) 
(Sex removed from 
model) n=98,107 
NO YES WOMEN MEN 
 
Basic + 
BMI 
1.69 1.68 1.38 1.63 1.74 1.71 
(1.57-1.82) (1.53-1.85) (1.24-1.54) (1.46-1.81) (1.58-1.92) (1.51-1.92) 
Basic +  
WHRa 
1.56 
(1.43-1.70) 
1.50 
(1.34-1.68) 
1.35 
(1.19-1.53) 
1.59 
(1.40-1.81) 
1.53 
(1.36-1.72) 
1.64 
(1.41-1.89) 
Basic +  
WCb 
1.59 
(1.46-1.73) 
1.54 
(1.37-1.72) 
1.35 
(1.19-1.54) 
1.60 
(1.41-1.83) 
1.57 
(1.40-1.76) 
1.62 
(1.40-1.87) 
Basic + 
WHRa & CVDc 
1.45 
(1.33-1.58) N/A N/A 
1.50 
(1.32-1.71) 
1.42 
(1.26-1.59) 
1.56 
(1.35-1.81) 
Basic +  
WCb & CVDc 
1.48 
(1.36-1.61) N/A N/A 
1.51 
(1.33-1.72) 
1.44 
(1.29-1.62) 
1.55 
(1.34-1.79) 
a
 WHR – Waist-to-hip ratio 
b
 WC – Waist circumference 
c
 CVD – Cardiovascular disease 
 
Table 10-2 and Table 10-3 demonstrate that the ORs for all-cause mortality remained statistically 
similar among those with diabetes whether or not the model included a measurement related to 
overweight and obesity. For example, analyses of the whole sample found a raised OR among those 
with diabetes of 1.93 (CI 1.52-2.45) when adjustment did not include BMI compared with 1.93 (CI 
1.49-2.49) when it did. 
 
Table 10-3: All-cause mortality ORs among diabetic cases (without adjustment for overweight and 
obesity) 
Additional 
adjustment 
WHOLE 
SAMPLE STRATIFIED BY CVD STRATIFIED BY GENDER 
NEVER 
SMOKERS 
ONLY 
  
(CVD removed from the 
model) 
(Sex removed from the 
model) n=98,107 
NO YES WOMEN MEN 
 Basic + 
Education 
1.62 
(1.52-1.73) 
1.61 
(1.47-1.75) 
1.31 
(1.19-1.44) 
1.61 
(1.46-1.77) 
1.63 
(1.49-1.78) 
1.68 
(1.51-1.87) 
Basic +  
Social Class 
1.64 
(1.54-1.75) 
1.63 
(1.49-1.77) 
1.30 
(1.18-1.43) 
1.60 
(1.45-1.76) 
1.67 
(1.53-1.82) 
1.66 
(1.49-1.85) 
Basic +  1.69 1.70 1.32 1.68 1.69 1.74 
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Region (1.58-1.80) (1.53-1.82) (1.20-1.45) (1.53-1.85) (1.54-1.84) (1.56-1.94) 
Basic +  
HbA1c 
1.93 
(1.52-2.45) 
1.95 
(1.43-2.67) 
1.58 
(1.10-2.27) 
2.05 
(1.43-2.93) 
1.87 
(1.36-2.58) 
1.65 
(1.09-2.51) 
 
Further analyses included a combination of the above variables. Table 10-5 demonstrates that the 
increased risk of all-cause mortality remained among those with diabetes, even after adjusting for 
combination of a number of confounding factors. Only within the sensitivity analysis, and when 
HbA1C was adjusted for, did the association between diabetes and all-cause mortality become non-
significant (1.47, CI 0.96-2.24). A power calculation undertaken for this group suggested that the 
analysis was underpowered; among those who had indicated that they had never been a regular 
smoker there were only 3,023 cases with diabetes and among this group only 532 had a valid 
measurement for HbA1C. Within this additional adjustment, the majority of the excess in all-cause 
mortality remained. When the analyses were stratified by CVD status, only those without CVD at 
baseline had consistently statistically significant increased ORs; for those with comorbid CVD the 
inclusion of HbA1C produced point estimate increased ORs that were not statistically significant. 
These analyses were then repeated, without adjustment for CVD (Table 10-6): as can be seen, the 
removal of this variable had very little impact upon the increased risk of all-cause mortality found 
among those with diabetes compared with the general population. 
 
10.1.1 Diabetes and all-cause mortality: further analyses 
Similarly for the cox regression undertaken to explore the associations between diabetes and cancer 
mortality, variables were derived within the Health Survey for England and Scottish Health Survey 
dataset which included the following information: 
 All-cause mortality/Everyone else. 
 A censor date variable (this either contained information about date of death or the end of 
the follow-up period). 
 A duration of time in study variable (derived from the baseline interview date and censor 
date). 
As can been seen from the table below, those with diabetes had a substantially increased HRs 
compared with those in the general population. This remained unchanged after adjustment for a 
range of covariates. 
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Table 10-4: HRs all-cause mortality among those with diabetes 
 
Progressive adjustment All cause 
 1.68 
Age & sex (1.60-1.76) 
 1.74 
Age, sex & smoking (1.66-1.83) 
 1.76 
Age, sex, smoking & BMI (1.67-1.86) 
 1.64 
Age, sex, smoking, BMI & 
CVD 
(1.55-1.73) 
Further adjustment 
Further adjustment 1.73 
Age, sex, smoking, BMI & 
Education group 
(1.64-1.82) 
 1.74 
Age, sex, smoking, BMI & 
social class 
(1.65-1.83) 
 1.77 
Age, sex, smoking, BMI & 
Region 
(1.67-1.87) 
 1.84 
Age, sex, smoking, BMI & 
Hba1c 
(1.47-2.30) 
 1.70 
Age, sex, smoking & waist 
raised 
(1.59-1.82) 
 1.66 
Age, sex, smoking & waist-
hip-ratio 
(1.55-1.78) 
 
 
10.1.2 Survival curves (all-cause mortality) 
Survival curves were also produced for mortality from all-causes and, as can be seen below, they 
indicate that the diabetic cohort were found to have substantially increased all-cause mortality 
compared with those without diabetes.  
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Figure 10-1: All-cause mortality: HSE/SHeS (age and sex) 
 
 
These analyses suggest that the diabetic cohort has an increased risk of all-cause mortality even 
after adjustment for a range of factors. Further to this, after adjusting for measurements of 
overweight and obesity (BMI, waist-to-hip ratio and waist circumference) this increased risk remains. 
One issue of particular note is that after adjusting for glycated haemoglobin the excess in all-cause 
mortality remains amongst those with diabetes. The next section explores the associations between 
HbA1C and all-cause mortality.
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Table 10-5: All-cause mortality ORs among cases with diabetes (further adjustment) 
Further adjustment WHOLE SAMPLE STRATIFIED BY GENDER 
NEVER 
SMOKERS ONLY 
  WOMEN MEN n=98,107 
Advanced Model + Sclass, Region & CVD 1.52 
(1.42-1.64) 
1.47 
(1.31-1.64) 
1.57 
(1.42-1.73) 
1.56 
(1.39-1.77) 
Advanced Model + Sclass, Region, CVD & HbA1c 1.76 
(1.37-2.26) 
2.13 
(1.46-3.11) 
1.57 
(1.13-2.18) 
1.45 
(0.93-2.25) 
Advanced Model + Education, Region & CVD 1.51 
(1.41-1.63) 
1.48 
(1.33-1.65) 
1.54 
(1.39-1.69) 
1.59 
(1.41-1.79) 
Advanced Model + Education, Region, CVD & HbA1c 1.72 
(1.34-2.20) 
2.07 
(1.42-3.02) 
1.54 
(1.11-2.13) 
1.42 
(0.92-2.21) 
Basic Model + Waist/Hip, Sclass, Region & CVD 1.42 
(1.30-1.55) 
1.44 
(1.26-1.64) 
1.41 
(1.26-1.59) 
1.49 
(1.28-1.73) 
Basic Model + Waist/Hip, Sclass, Region, CVD & HbA1c 1.63 
(1.28-2.08) 
1.81 
(1.26-2.61) 
1.53 
(1.10-2.11) 
1.49 
(0.98-2.29) 
Basic Model + Waist/Hip, Education, Region & CVD 1.44 
(1.32-1.57) 
1.48 1.40 1.56 
(1.30-1.69) (1.25-1.58) (1.34-1.80) 
Basic Model + Waist/Hip, Education, Region, CVD & HbA1c 1.60 1.78 1.50 1.49 
(1.25-2.04) (1.24-2.56) (1.08-2.07) (0.98-2.29) 
Basic Model + Waist Circ, Sclass, Region & CVD 1.44 1.45 1.43 1.47 
(1.32-1.57) (1.27-1.65) (1.27-1.61) (1.27-1.71) 
Basic Model + Waist Circ, Sclass, Region, CVD & HbA1c 1.62 1.82 1.51 1.47 
(1.27-2.07) (1.26-2.63) (1.09-2.09) (0.96-2.25) 
Basic Model + Waist Circ, Education, Region & CVD 1.45 1.49 1.42 1.54 
(1.33-1.59) (1.31-1.70) (1.27-1.60) (1.33-1.78) 
Basic Model + Waist Circ, Education, Region, CVD & HbA1c 1.59 1.79 1.48 1.47 
(1.25-2.03) (1.24-2.58 (1.07-2.05) (0.96-2.24) 
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Table 10-6: All-cause mortality ORs (no adjustment for CVD at baseline) 
Additional adjustment WHOLE SAMPLE STRATIFIED BY CVD STRATIFIED BY GENDER 
NEVER 
SMOKERS ONLY 
  NO YES WOMEN MEN  
Advanced model + 
 Sclass & Region 
1.65 
(1.54-1.78) 
1.66 
(1.50-1.82) 
1.34 
(1.20-1.49) 
1.57 
(1.40-1.75) 
1.72 
(1.57-1.90) 
1.65 
1.46-1.86) 
Advanced model + 
Sclass, Region & HbA1c 
1.92 1.97 
(1.42-2.72) 
1.43 
(0.97-2.09) 
2.24 1.77 1.54 
(1.50-2.46) (1.53-3.27) (1.28-2.45) (0.99-2.40) 
Advanced model + Education, Region 
1.64 1.64 1.35 1.58 1.69 1.67 
(1.52-1.76) (1.49-1.80) (1.21-1.50) (1.41-1.76) (1.53-1.86) (1.48-1.88) 
Advanced model + Education, Region 
& HbA1c 
1.88 1.93 1.41 2.17 1.73 1.52 
(1.47-2.40) (1.39-2.67) (0.96-2.06) (1.49-3.17) (1.25-2.39) (0.98-2.35) 
Basic model + 
WHR, Sclass & Region 
1.52 1.48 1.32 1.52 1.52 1.56 
(1.40-1.66) (1.31-1.66) (1.16-1.50) (1.34-1.74) (1.36-1.71) (1.35-1.8) 
Basic model + WHR, Sclass, Region & 
HbA1c 
1.75 1.78 1.39 1.89 1.68 1.56 
(1.37-2.23) (1.30-2.45) (0.95-2.02) (1.31-2.73) (1.22-2.32) (1.03-2.4) 
Basic model +  
WHR, Education & Region 
1.53 1.48 1.35 1.57 1.51 1.63 
(1.41-1.67) (1.32-1.66) (1.19-1.53) (1.38-1.79) (1.35-1.70) (1.41-1.88) 
Basic model + WHR, Education, 
Region & HbA1c 
1.72 1.77 1.36 1.86 1.65 1.57 
(1.35-2.19) (1.29-2.43) (0.94-1.98) (1.29-2.68) (1.19-2.27) (1.03-2.40) 
Basic model + WC, Sclass, Region 
1.55 1.50 1.32 1.53 1.55 1.54 
(1.42-1.69) (1.34-1.69) (1.16-1.50) (1.34-1.75) (1.38-1.74) (1.33-1.78) 
Basic model + WC, Sclass, Region & 
HbA1c 
1.75 1.77 1.39 1.90 1.67 1.55 
(1.37-2.22) (1.29-2.43) 0.95-2.02) (1.32-2.75) (1.21-2.30) (1.01-2.36) 
Basic model + WC, Education & 
Region 
1.56 1.51 1.35 1.57 1.54 1.61 
(1.43-1.70) (1.34-1.69) (1.19-1.53) (1.38-1.79) (1.37-1.73) (1.39-1.86) 
Basic model + WC, Education, Region 
& HbA1c 
1.71 
(1.34-2.18) 
1.75 1.36 1.87 1.63 1.54 
(1.28-2.41) (0.93-1.97) (1.30-2.69) (1.18-2.25) (1.01-2.36) 
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10.2 HbA1C and all-cause mortality 
There were a total of 1,362 deaths among those with a valid HbA1C measurement (5% of those with 
HbA1C data); this compared with 1,814 deaths among the diabetic sample within the whole 
combined HSE and SHeS dataset. Among those with raised HbA1C, 28% of deaths were caused by 
cancer, 11% by respiratory and 43% by cardiovascular disease. This compared with 34%, 13% and 
33% among those with an HbA1C <6.5%.  
 
The results given in Table 10-7 demonstrate that, those with a raised HbA1C measurement, had an 
increased odds ratio (OR) in relation to all-cause mortality within the basic (OR 1.65, CI 1.38-1.98), 
advanced (1.66, CI 1.36-2.02) and CVD models (1.54, CI 1.26-1.88). When the data were stratified by 
CVD status, the increased risk for those with raised HbA1C for all-cause mortality remained. The 
increased risk appeared greater among those without comorbid CVD compared with those with CVD, 
at the point estimate, although was not statistically significant. There was a statistically significant 
increased  risk of all-cause mortality in both men and women with a raised glycated haemoglobin 
measurement. The odds were doubled amongst women, with this increase remaining within each of 
the models, while for men the OR was around 1.42. Finally, the ORs were also doubled among those 
who indicated that they had never been a regular smoker. These increases remained when 
covariates related to education, social class and region were added to the models. The only variable 
to impact upon the statistical significance of the association was the presence of diabetes; only 
among the ‘never smokers’ group did the increased risk of all-cause mortality among those with a 
raised HbA1C remain statistically significant after adjustment for this variable. 
 
Table 10-7: Mortality odds ratios (and 95% CI) among those with a raised HbA1C measurement 
(≥6.5%) 
Progressive 
adjustment 
WHOLE 
SAMPLE 
STRATIFIED BY CVDa STRATIFIED BY GENDERb NEVER 
SMOKERS 
ONLY 
 
NO YES WOMEN MEN 
Age, sex 1.67 1.69 1.38 2.07 1.42 1.90 
 
(1.39-2.00) (1.34-2.14) (1.03-1.83) (1.58-2.72) (1.11-1.81) (1.40-2.58) 
& Smoking 1.65 1.67 1.35 2.05 1.41 N/A 
 
(1.38-1.98) (1.32-2.12) (1.01-1.80) (1.56-2.70) (1.10-1.80) 
 & BMI 1.66 1.61 1.45 2.08 1.42 2.00 
 
(1.36-2.02) (1.24-2.09) (1.07-1.97) (1.54-2.81) (1.09-1.84) (1.44-2.79) 
Additional adjustment (Advanced model + the following variables) 
+ CVD 1.54 N/A N/A 1.94 1.31 1.90 
 
(1.26-1.88) 
  
(1.43-2.63) (1.00-1.71) (1.36-2.65) 
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+ Education 1.56 1.54 1.38 1.92 1.34 1.93 
 
(1.27-1.90) (1.19-2.01) (1.01-1.88) (1.42-2.60) (1.02-1.75) (1.39-2.70) 
+ Social Class 1.62 1.56 1.44 1.98 1.40 2.00 
 
(1.32-1.98) (1.20-2.03) (1.10-1.96) (1.46-2.69) (1.08-1.83) (1.43-2.79) 
+ Region 1.67 1.55 1.76 2.02 1.46 1.97 
 
(1.37-2.04) (1.20-2.01) (1.28-2.42) (1.50-2.73) (1.12-1.91) (1.42-2.75) 
+ DMc 1.12 1.11 1.08 1.35 0.97 1.58 
(0.87-1.45) (0.80-1.55) (0.73-1.62) (0.92-2.00) (0.69-1.38) (1.02-2.44) 
a CVD was removed from the models when the analyses were stratified by CVD. 
b Sex was removed from the models when the analyses were stratified by sex. 
c 
DM: Diagnosed diabetes. 
 
The use of models which included different measurements of overweight and obesity (waist-to-hip 
ratio (WHR) and waist circumference (WC)) had little impact upon the increased risk of all-cause 
mortality among those with an HbA1c measurement ≥6.5% compared with those with a 
measurement below this threshold. The results of these analyses can be found in Table 10-8. 
 
Table 10-8: Mortality ORs (adjusting for measures of overweight and obesity) 
Progressive 
adjustment 
WHOLE 
SAMPLE 
STRATIFIED BY CVD STRATIFIED BY GENDER NEVER 
SMOKERS 
ONLY NO YES WOMEN MEN 
Basic  
& BMI 
1.66 1.61 1.45 2.08 1.42 2.00 
(1.36-2.02) (1.24-2.09) (1.07-1.97) (1.54-2.81) (1.09-1.84) (1.44-2.79) 
Basic 
& WHRa 
1.63 1.64 1.40 2.05 1.38 1.96 
(1.35-1.98) (1.28-2.10) (1.04-1.89) (1.54-2.73) (1.06-1.79) (1.42-2.69) 
Basic  
& WCb 
1.68 1.69 1.45 2.09 1.42 1.95 
(1.39-2.03) (1.32-2.16) (1.07-1.96) (1.57-2.78) (1.10-1.84) (1.42-2.68) 
Additional adjustment for baseline CVD status 
Basic &  
WHR &CVD 
1.54 N/A N/A 1.95 1.30 1.88 
(1.27-1.87) 
  
(1.46-2.60) (1.00-1.68) (1.36-2.59) 
Basic &  
WC & CVD 
1.58 N/A N/A 1.99 1.33 1.86 
(1.31-1.92) 
  
(1.49-2.66) (1.03-1.72) (1.35-2.57) 
a
 WHR: Waist-to-hip ratio 
b
 WC: Waist circumference 
 
In order to assess the impact that the inclusion of a variable related to overweight and obesity had 
upon the association between glycated haemoglobin and all-cause mortality, analyses were then 
performed with these variables removed. As can be seen from Table 10-9, the inclusion of these 
variables had very little impact upon the increased risk of all-cause mortality among this group when 
compared with the basic model. The results contained in Table 10-10 and Table 10-11 demonstrate 
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that only when adjustment included diabetes was the association between an HbA1C ≥6.5% and all-
cause mortality significantly attenuated.  
 
Table 10-9: All-cause mortality ORs among those with raised HbA1C (without adjustment for 
overweight and obesity) 
Further 
adjustment 
WHOLE 
SAMPLE 
STRATIFIED BY CVD STRATIFIED BY GENDER NEVER 
SMOKERS 
ONLY NO YES WOMEN MEN 
Basic 
& Education 
1.54 1.58 1.28 1.89 1.32 1.81 
(1.28-1.85) (1.25-2.00) (0.96-1.71) (1.44-2.49) (1.03-1.69) (1.33-2.47) 
Basic 
 & Social Class 
1.61 1.61 1.34 1.95 1.39 1.88 
(1.34-1.94) (1.27-2.05) (1.00-1.79) (1.48-2.58) (1.09-1.78) (1.38-2.56) 
Basic 
& Region 
1.71 1.66 1.61 2.05 1.49 1.90 
(1.42-2.05) (1.31-2.10) (1.20-2.17) (1.56-2.69) (1.16-1.91) (1.39-2.58) 
Basic 
& Diabetes 
1.11 1.15 1.00 1.36 0.95 1.39 
(0.87-1.41) (0.85-1.56) (0.68-1.46) (0.96-1.94) (0.68-1.32) (0.92-2.10) 
 
Table 10-10: All-cause mortality ORs among those with raised HbA1C (further adjustment) 
Additional adjustment WHOLE 
SAMPLE 
STRATIFIED BY GENDER NEVER 
SMOKERS 
ONLY WOMEN MEN 
Advanced model 1.66 1.61 1.45 2.08 
(1.36-2.02) (1.24-2.09) (1.07-1.97) (1.54-2.81) 
Advanced + Sclassa, Region & 
CVD 
1.55 1.84 1.37 1.89 
(1.26-1.89) (1.35-2.49) (1.05-1.78) (1.35-2.63 
Advanced + Education, 
Region & CVD 
1.50 1.80 1.32 1.83 
(1.23-1.84) (1.33-2.43) (1.01-1.72) (1.31-2.55) 
Advanced & WHRc, Sclass, 
Region & CVD 
1.56 1.85 1.36 1.86 
(1.28-1.89) (1.39-2.48) (1.05-1.77) (1.35-2.56) 
Basic + WHR, Education, 
Region & CVD 
1.53 1.84 1.32 1.82 
(1.26-1.86) (1.38-2.45) (1.01-1.72) (1.32-2.50) 
Basic + WCd, Sclass, Region & 
CVD 
1.58 1.89 1.38 1.83 
(1.30-1.92) (1.41-2.53) (1.06-1.79) (1.33-2.53) 
Basic + WC, Education, 
Region & CVD 
1.55 1.87 1.33 1.79 
(1.27-1.88) (1.40-2.50) (1.03-1.73) (1.29-2.46) 
Additional analyses with DM included 
Advanced + Sclass, Region, 
CVD & DM 
1.14 1.25 1.06 1.54 
(0.89-1.46) (0.86-1.82) (0.77-1.48) (1.01-2.34) 
Advanced + Education, 
Region, CVD & DMb 
1.13 1.25 1.04 1.50 
(0.88-1.44) (0.86-1.81) (0.75-1.45) (0.99-2.29) 
Basic + WHR, Sclass, Region, 
CVD & DM 
1.20 1.38 1.07 1.48 
(0.94-1.52) (0.97-1.96) (0.77-1.48) (0.98-2.23) 
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Basic + WHR, Education, 
Region, CVD & DM 
1.19 1.38 1.05 1.45 
(0.94-1.51) (0.97-1.96) (0.76-1.45) (0.96-2.18) 
Basic + WC, Sclass, Region, 
CVD & DM 
1.22 1.40 1.09 1.47 
(0.96-1.55) (0.99-1.99) (0.79-1.51) (0.98-2.22) 
Basic + WC, Education, 
Region, CVD & DM 
1.21 1.41 1.07 1.44 
(0.95-1.53) (0.99-1.99) (0.77-1.48) (0.96-2.16) 
a
 Sclass – Social Class 
b 
DM – Diabetes 
c 
WHR – Waist-to-hip ratio 
d 
WC – Waist circumference
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Table 10-11: Raised HbA1C and all-cause mortality (no adjustment for CVD at baseline) 
Further adjustment WHOLE 
SAMPLE 
STRATIFIED BY CVD STRATIFIED BY GENDER NEVER 
SMOKERS ONLY 
NO YES WOMEN MEN 
Advanced + 
 Sclass & Region 
1.65 1.52 1.76 1.52 1.76 1.98 
(1.35-2.01) (1.17-1.97) (1.28-2.42) (1.17-1.97) (1.28-2.42) (1.42-2.76) 
Advanced + Sclass, Region & DM 1.16 1.09 1.41 1.09 1.41 1.56 
(0.91-1.49) (0.80-1.50) (0.94-2.10) (0.80-1.50) (0.94-2.10) (1.02-2.37) 
Advanced + Education, Region 1.60 1.52 1.69 1.91 1.41 1.93 
(1.31-1.96) (1.17-1.97) (1.22-2.33) (1.42-2.58) (1.08-1.84) (1.39-2.69) 
Advanced + Education, Region & DM 1.15 1.11 1.37 1.29 1.04 1.53 
(0.90-1.47) (0.81-1.52) (0.92-2.04) (0.89-1.87) (0.75-1.45) (1.01-2.33) 
Advanced + WHR, Sclass & Region 1.64 1.57 1.62 1.93 1.44 1.93 
(1.35-1.98) (1.23-2.02) (1.18-2.20) (1.44-2.57) (1.11-1.86) (1.40-2.66) 
Basic + WHR, Sclass, Region & DM 1.20 1.18 1.32 1.40 1.06 1.49 
(0.95-1.53) (0.87-1.60) (0.89-1.95) (0.98-1.99) (0.77-1.48) (0.99-2.25) 
Basic + WHR, Education & Region 1.61 1.58 1.57 1.92 1.39 1.90 
(1.32-1.95) (1.23-2.03) (1.15-2.15) (1.44-2.55) (1.07-1.81) (1.38-2.61) 
Basic + WHR, Education, Region & DM 1.20 1.19 1.30 1.41 1.05 1.47 
(0.94-1.52) (0.88-1.61) (0.88-1.92) (0.99-1.99) (0.76-1.45) (0.98-2.20) 
Age, Sex, Smoking, WC, Sclass, Region 1.67 1.61 1.65 1.96 1.47 1.91 
(1.37-2.02) (1.25-2.06) (1.21-2.26) (1.47-2.62) (1.13-1.90) (1.39-2.63) 
Basic, WC, Sclass, Region & DM 1.23 1.21 1.35 1.42 1.09 1.49 
(0.97-1.56) (0.89-1.64) (0.91-2.00) (1.00-2.02) (0.79-1.51) (0.99-2.24) 
Basic + WC, Education & Region 1.63 1.60 1.61 1.95 1.41 1.87 
(1.34-1.97) (1.25-2.05) (1.18-2.20) (1.46-2.60) (1.09-1.83) (1.35-2.57) 
Basic + WC, Education, Region & DM 1.22 1.22 1.34 1.43 1.07 1.46 
(0.96-1.55) (0.90-1.64) (0.90-1.98) (1.01-2.03) (0.77-1.48) (0.97-2.19) 
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10.3 HbA1C (continuous and tertiles) and all-cause mortality 
Using data from all participants with a valid HbA1C measurement, an assessment of the association 
between HbA1C and all-cause mortality was also undertaken using a continuous variable and then 
using tertiles of HbA1C. The analyses which included the continuous variable demonstrated that 
there was a small increase in risk of all-cause mortality with each unit increase in HbA1C. This 
increase remained statistically significant in both the basic and advanced models, but not when CVD, 
education or diabetes were included in the model (Table 10-12). When alternative measurements of 
overweight and obesity were included, the increase remained statistically significant, although the 
increase remained only at the point estimate when CVD was added to the model. Further analyses 
included a range of these covariates, but did not significantly alter the results shown below. 
 
Table 10-12: All-cause mortality ORs (and 95% CI) and HbA1C (continuous variable) 
Progressive adjustment All-cause mortality 
Age, sex 1.10 
(1.03-1.17) 
& Smoking 1.08 
(1.01-1.16) 
& BMI 1.09 
(1.01-1.17) 
Basic & CVD Status 1.05 
(0.98-1.13) 
Additional adjustment (advanced + the following variables) 
+ CVD 1.06 
(0.98-1.14) 
+ Education 1.05 
(0.97-1.13) 
+ Social Class 1.07 
(1.00-1.16) 
+ Region 1.13 
(1.06-1.22) 
+ Diabetes 0.93 
(0.85-1.02) 
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Table 10-13: All-cause mortality ORs (adjusting for alternative measures of overweight and 
obesity) and HbA1C (continuous variable) 
Further adjustment All-cause mortality 
Basic + BMI 1.09 
(1.01-1.17) 
Basic & WHR 1.08 
 (1.01-1.16) 
Basic & WC 1.09 
(1.02-1.18) 
Basic + WHR & CVD 1.06 
 (0.88-1.14) 
Basic + WC & CVD 1.07 
 (0.99-1.15) 
 
A variable was then derived to categorise HbA1C into tertiles; within the analyses the lowest tertile 
was used as the reference category. As can be seen in Table 10-14, those with an HbA1C 
measurement in the middle tertile had a substantial and statistically significant increase in odds of 
all-cause mortality (basic model: 1.38, CI 1.19-1.61, advanced: 1.36, 1.15-1.59). However, those in 
the top tertile had only a small increase at the point estimate (basic: 1.05, 0.91-1.21, advanced: 1.04, 
0.90-1.21). Both of these increases remained unchanged after adjustment for a range of covariates, 
when different measurements of overweight and obesity were included in the model, and when a 
combination of variables were also included (data not shown). 
 
Table 10-14: All-cause mortality odds ratios (HbA1C tertiles) 
Progressive adjustment All-cause mortality 
 Tertile 2 Tertile 3 
Age & sex 1.32 1.02 
(1.13-1.54) (0.89-1.18) 
& Smoking 1.38 1.05 
(1.19-1.61) (0.91-1.21) 
& BMI 1.36 1.04 
 (1.15-1.59) (0.90-1.21) 
Additional adjustment (Advanced + the following variables) 
+ CVD 1.42 1.08 
 (1.21-1.66) (0.92-1.26) 
+ Education 1.44 1.09 
 (1.22-1.69) (0.94-1.27) 
+ Social class 1.38 1.04 
 (1.17-1.62) (0.90-1.22) 
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+ Region 1.09 0.98 
 (0.93-1.29) (0.84-1.14) 
+ DM 1.51 1.17 
 (1.28-1.78) (1.00-1.37) 
 
Table 10-15: All-cause mortality ORs (HbA1C tertiles) including measurements of 
overweight/obesity 
Alternative measurements of overweight and obesity All-cause mortality 
Tertile 2 Tertile 3 
  WC 1.37 
(1.16-1.60) 
1.01 
(0.87-1.17) 
 WHR 1.39 
(1.19-1.63) 
1.03 
(0.88-1.19) 
Additional adjustment for baseline CVD status 
WC & CVD 1.42 
(1.21-1.67) 
1.04 
(0.90-1.22) 
WHR & CVD 1.45 
(1.23-1.70) 
1.06 
(0.91-1.23) 
 
The analyses above demonstrate an association between raised HbA1C and all-cause mortality. Of 
particular note is the result that those in the middle tertile appear to have substantially and 
statistically significant increased odds of all-cause mortality compared with those with a lower 
measurement, while those in the top tertile have a small increase at the point estimate only. 
 
In order to further test the hypotheses of the current study, and examine how the associations 
between diabetes and mortality from cancer and other causes may have changed over time, 
analyses were also performed using data from Whitehall I linked to mortality data. The following 
chapter details these results.  
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11. Chapter 11: Results: Whitehall I 
11.1 Whitehall I: Further analyses of the associations between diabetes and 
mortality 
11.1.1 Whitehall I: descriptive statistics 
As detailed previously, health-related information was collected from 19,019 men working within 
the Civil Service for the Whitehall I study. Within the dataset there were 237 men who indicated 
doctor-diagnosed diabetes at baseline (>1% of the total study population). At baseline, the majority 
of participants were between the ages 46 and 64 years (78%). 15,214 died during the follow-up 
period (81%), 4,076 from cancer (27%). Table 11-1 gives further information about the study cohort. 
 
Table 11-1: Whitehall I descriptive statistics 
Variable No. (%) Variable No. (%) 
Age Social class 
Age-grouped   Administrative 967 (5) 
16-64 18,404 (97) Professional/Exec 12,350 (65) 
65-74 615 (3) Clerical 3,007 (16) 
Diabetes Other 1,809 (10) 
Yes 237 (>1) BCDS 886 (5) 
No 18,648 (>98) Blood glucose 
Overweight/obesity Normal glucose 17,574 (94) 
BMI  Impaired glucose 
tolerance 
1,074 (6) 
<20kg/m2 950 (5) 
20-24.99kg/m2 9,490 (50) New diabetes 56 (<1) 
25-29.99kg/m2 7,764 (41) Insulin dependent DM 48 (<1) 
≥30kg/m2 812 (4) Non-insulin 
dependent diabetes 
132 (<1) 
Smoking status 
Never smoker 3,502 (18) Unknown IDD/NIDDM 1 (<1) 
Ex-smoker 6,934 (36) 
Pipe/cigar smoker 657 (3) Cause-specific mortality 
Current smoker 7,921 (42) Cancer 4,076 (27) 
Mortality status CVD  7,105 (47) 
Alive 3,664 (19) Within CVD: CHD 4,346 (29) 
Dead 15,214 (81) Within CVD: Stroke 1,415 (9) 
 
11.1.2 All-cause and cause-specific mortality 
Within the Whitehall I dataset, binary variables had already been created for mortality from all 
causes, cancer, CVD, coronary heart disease (CHD) and stroke. Within this section of the analyses, 
logistic regression models were developed to explore the association between diabetes and 
mortality from these causes. The table below indicates the number of deaths from these causes by 
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diabetes status. In total 219 of the 237 (92%) cases with diabetes at baseline had died within the 
study follow-up period. This compared with 14,887 of the 18,646 (80%) who did not answer the 
diabetes-specific question positively. For cancer only 12% of those with diabetes had died from this 
cause, compared with 22% of those without diabetes. For both CVD and coronary heart disease 
(CHD), a higher percentage of those with diabetes were recorded as having died from these causes, 
while 7% of each group had died from stroke. 
 
Table 11-2: Deaths within Whitehall I by diabetes status 
Cause of death Diabetes at baseline Did not indicate diabetes TOTAL 
All-cause 219 (92) 14,887 (80) 15,106 (79) 
Cancer 29 (12) 4,018 (22) 4,047 (27) 
CVD 120 (51) 6,935 (37) 7,055 (47) 
CHD 87 (37) 4,240 (23) 4,327 (29) 
Stroke 16 (7) 1,381 (7) 1,397 (9) 
 
As can be seen from Table 11-3, those who indicated diabetes at baseline had an increased risk of 
all-cause mortality; the greatest excess was found within the ‘basic’ model (age and smoking) which 
gave an OR of 3.39, CI 2.03-5.66. Within all of the models, those with diabetes experienced at least a 
doubling in odds for all-cause mortality. Unlike the results found within the analyses of Health 
Survey for England and Scottish Health Survey data, those with diabetes within Whitehall I were 
found to have a lower risk of dying from cancer compared with those who did not indicate the 
presence of diabetes. This result remained unchanged within all the models developed (‘basic’ 
model: 0.51, CI 0.35-0.75 and ‘advanced’: 0.51, 0.35-0.76). When the variable related to blood 
glucose group was added to the model, collinearity was achieved and diabetes was removed by 
Stata from the model. Therefore this model was dropped from the analyses undertaken for this 
section of the thesis. 
 
For CVD and CHD increased odds ratios were found for those with diabetes within each of the 
models. For CVD the ORs ranged from 1.47 (CI 1.13-1.91) within the analysis which only adjusted for 
age (continuous) to 1.72 (1.33-2.23) for the ‘basic’ model. Within the analyses focused upon CHD the 
model which included social class gave an OR of 1.90 (1.45-2.49), while the basic model gave a 
substantially increased OR of 2.70 (2.18-3.34). Those with diabetes appeared to not have an 
increased risk of mortality from stroke, within all of the logistic regression models, compared with 
those without diabetes. 
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Table 11-3: All-cause and cause-specific mortality among the diabetic cohort within Whitehall I 
 
 
 
11.2 Whitehall I resurvey: all-cause and cause-specific mortality  
11.2.1 Whitehall I resurvey: descriptive statistics 
In 1997 a second survey utilising a sub-set of participants from Whitehall I occurred (n=7,035). 
Within this survey, similar health-related questions were asked, as well as lifestyle questions related 
to behaviours such as smoking and alcohol consumption and socio-economic/demographic factors. 
Within the resurvey dataset there was information pertaining to the presence of CVD-related 
comorbidities; this enabled models to be developed, for the purposes of this research, within this 
section of the analyses which were not possible with the baseline Whitehall I data. 
 
PROGRESSIVE ADJUSTMENT All-cause Cancer CVD CHD Stroke 
Age (continuous) 2.22 0.47 1.47 2.28 0.79 
 (1.29-3.80) (0.32-0.69) (1.13-1.91) (1.84-2.82) (0.54-1.49) 
Age (grouped) 3.27 0.51 1.72 2.69 0.89 
 (1.96-5.44) (0.34-0.75) (1.33-2.22) (2.18-3.34) (0.54-1.49) 
Age (grouped) & Smoking 3.39 0.51 1.72 2.70 0.89 
 (2.03-5.66) (0.35-0.75) (1.33-2.23) (2.18-3.34) (0.53-1.48) 
Age (grouped) + Smoking & 
BMI (grouped) 
3.32 
(1.99-5.54) 
0.51 
(0.35-0.76) 
1.69 
(1.31-2.20) 
2.67 
(2.16-3.31) 
0.89 
(0.53-1.48) 
Age (grouped) + Smoking & 
BMI (continuous) 
3.34 0.50 1.67 2.63 0.89 
(1.99-5.58) (0.34-0.74) (1.29-2.17) (2.12-3.25) (0.53-1.47) 
Additional adjustment (Basic model + the following variables) 
+ Social class 2.99 0.50 1.68 1.90 0.89 
 (1.79-5.00) (0.34-0.74) (1.30-2.17) (1.45-2.49) (0.54-1.50) 
+ Blood glucose N/A N/A N/A N/A N/A 
      
Further adjustment (Advanced model + the following variables) 
+ Social class 2.99 0.50 1.66 1.88 0.90 
 (1.77-4.96) (0.34-0.75) (1.28-2.15) (1.43-2.46) (0.54-1.50) 
+ Blood glucose N/A N/A N/A N/A N/A 
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Table 11-4: Whitehall I resurvey descriptive statistics 
Variable No. (%) Variable No. (%) 
Age Smoking status 
Age-grouped   Current smoker 803 (12) 
65-74 2,532 (36) Ex-smoker 3,731 (57) 
75+ 4,503 (64) Never smoker 2,011 (31) 
Diabetes Mortality status 
Yes 446 (6) Alive 2,695 (38) 
No 6,566 (94) Dead 4,333 (62) 
Overweight/obesity Cause-specific  
BMI  Cancer 1,038 (15) 
<20 258 (4) CVD  1,816 (26) 
20-24.99 2,860 (47) Within CVD: CHD 889 (13) 
25-29.99 2,525 (42) Within CVD: Stroke 504 (7) 
≥30 441 (4)   
CVD at baseline    
Heart attack 825 (11)   
Stroke 579 (8)   
Angina 1,019 (14)   
 
Table 11-5: Deaths within Whitehall I resurvey by diabetes status 
Cause of death Diabetes at baseline Did not indicate 
diabetes 
All-cause 337 (76) 3,996 (61) 
Cancer 60 (14) 978 (15) 
CVD 140 (32) 1,676 (25) 
CHD 72 (16) 817 (12) 
Stroke 43 (10) 461 (7) 
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Table 11-6: All-cause and cause-specific mortality among the diabetic cohort within Whitehall I 
 
Within this logistic regression analysis of data from Whitehall I it appears that those with diabetes 
are at a decreased risk of mortality from cancer and have similar risks of dying of stroke as those 
without diabetes. For the former, this result contradicts that found within the analyses which 
utilised data from the Health Survey for England and Scottish Health Survey. At the same time this 
analyses confirms the substantially increased odds of mortality from CVD found amongst those with 
diabetes within the earlier analyses. The following section details the results related to the 
associations between diabetes and all-cause and cancer mortality assessed using Cox 
regression/survival analysis and Whitehall I data. 
11.3 Whitehall I: All-cause and cancer specific mortality (Cox regression) 
Cox regression models were developed which analysed the association between diabetes and all-
cause and cancer-specific mortality. For all-cause mortality, the HRs were significantly raised within 
each stage of the analyses, and remained statistically unchanged throughout the analyses. The HRs 
were 1.88 (CI 1.88-2.45) and 2.15 (1.88-2.45) for the ‘basic’ and ‘advanced’ models, respectively. 
Those with diabetes were found to have no increased risk of cancer mortality. The ‘basic’ model 
produced an HR of 1.01 (CI 0.70-1.46), while the HR for the ‘advanced’ model was 1.01 (CI 0.70-
1.46). When analyses were run that adjusted for blood glucose level, Stata automatically removed 
PROGRESSIVE 
ADJUSTMENT 
All-cause Cancer CVD CHD Stroke 
DM 2.06 0.90 1.35 1.37 1.43 
 (1.65-2.58) (0.68-1.19) (1.10-1.66) (1.05-1.78) (1.03-1.98) 
Age (continuous) 2.37 
(1.86-3.02) 
0.90 
(0.68-1.19) 
1.36 
(1.10-1.69) 
1.37 
(1.05-1.78) 
1.42 
(1.02-1.98) 
Age (grouped) 2.26 0.90 1.37 1.38 1.44 
 (1.79-2.86) (0.68-1.19) (1.11-1.70) (1.06-1.80) (1.04-2.00) 
Age (grouped) & Smoking 2.19 0.81 1.37 1.37 1.50 
 (1.71-2.79) (0.59-1.10) (1.11-1.73) (1.04-1.81) (1.06-2.11) 
Basic + Smoking & BMI 
(grouped) 
2.10 
(1.61-2.74) 
0.80 
(0.57-1.12) 
1.36 
(1.06-1.74) 
1.44 
(1.07-1.95) 
1.44 
(0.98-2.12) 
Basic & BMI (continuous) 2.14 
(1.64-2.78) 
0.79 
(0.57-1.11) 
1.36 
(1.06-1.74) 
1.43 
(1.06-1.94) 
1.45 
(0.98-2.14) 
Basic + CVD 1.93 0.82 1.19 1.08 1.45 
 (1.51-2.48) (0.60-1.12) (0.94-1.49) (0.81-1.44) (1.02-2.06) 
Advanced + CVD 1.84 0.81 1.16 1.13 1.38 
 (1.40-2.40) (0.58-1.14) (0.89-1.49) (0.83-1.55) (0.93-2.04) 
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diabetes from the model because collinearity had been achieved. Table 11-7 details the HRs 
produced within the Cox regression related to the associations between all-cause and cancer-specific 
mortality found among those with diabetes compared with those who did not indicate the disease at 
baseline. 
 
Table 11-7: All-cause and cancer-specific mortality HRs among those with diabetes 
 
PROGRESSIVE ADJUSTMENT  All cause Cancer 
DM 
  
2.20 
(1.93-2.52) 
1.03 
(0.72-1.49) 
+ age (continuous) 1.82 0.88 
  (1.59-2.08) (0.61-1.26) 
DM + age (grouped) 
  
2.14 
(1.88-2.45) 
1.01 
(0.70-1.45) 
DM + age (grouped) & smokinga 
  
2.14 
(1.88-2.45) 
1.01 
(0.70-1.46) 
DM + age (grouped) + smoking & BMI (grouped)b 2.15 
(1.88-2.45) 
1.01 
(0.70-1.46) 
DM + age (grouped) + smoking & BMI (continous) 2.12 
(1.86-2.42) 
1.01 
0.70-1.46) 
Further adjustment 
Basic & social class 2.05 
(1.79-2.34) 
0.97 
0.68-1.41 
Basic & Blood glucose N/A N/A 
Advanced & social class 2.05 
(1.79-2.34) 
0.98 
(0.68-1.41) 
Advanced & Blood glucose N/A N/A 
a Within this analyses adjustment for age and smoking is referred to as the ‘basic’ model. 
b Within this analyses adjustment for age, smoking and BMI (grouped) is referred to as the ‘advanced’ model. 
 
 
The following survival curves were produced for the models above for all-cause and cancer-specific 
mortality. The inclusion of a range of covariates did little to alter the results and thus only the 
survival curve which adjusted for age is shown below. 
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11.3.1 All-cause mortality survival curves 
Figure 11-1: All-cause mortality: Whitehall I (age) 
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11.3.2 Cancer-specific survival curves 
Figure 11-2: Cancer mortality: Whitehall I (age) 
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11.4 All-cause and cancer-specific mortality: Whitehall I resurvey 
Within the Whitehall I resurvey data there were binary mortality variables related to all causes and 
cancer. Using these variables Cox regression analyses were performed which explored the 
associations between diabetes and mortality from these causes. Among those with diabetes there 
was found to be an excess in all-cause mortality which remained statistically significant at each stage 
of the regression modelling. However, there was no association with cancer within any models. 
 
Table 11-8: All-cause and cancer mortality HRs among those with diabetes (Whitehall I resurvey) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
11.5 Diabetes and site-specific cancer mortality: Whitehall I 
To further explore the association between diabetes and site-specific cancers, analyses of the 
Whitehall I data were undertaken using Cox regression. Table 11-9 details the number of cancers 
within the dataset for which there was available information related to diabetes status (in 
descending order by number of deaths). For the site-specific cancers, only a small number of cases 
with diabetes died of each cause; for cancers of the kidney, lymphoid leukaemia, lymphoma and 
rectum/sigmoid junction/anus no one who had indicated diabetes at baseline had died from these 
causes by the end of the follow-up period. 
 
PROGRESSIVE ADJUSTMENT  All-cause Cancer 
DM 
  
1.55 
(1.39-1.74) 
1.12 
(0.86-1.46) 
+ age (continuous) 1.58 1.13 
 (1.42-1.77) (0.87-1.47) 
DM + age (grouped) 
  
1.57 
(1.40-1.75) 
1.13 
(0.87-1.46) 
DM + age (grouped) & smokinga 
  
1.53 
(1.36-1.72) 
1.01 
(0.76-1.34) 
DM + age (grouped) + smoking & BMI (grouped)b 1.51 
(1.32-1.72) 
0.98 
(0.72-1.34) 
DM + age (grouped) + smoking & BMI (continuous) 1.51 
(1.33-1.72) 
0.98 
(0.72-1.34) 
Further adjustment 
Basic & CVD 1.36 
(1.21-1.53) 
1.02 
(0.76-1.32) 
Advanced & CVD 1.30 
(1.14-1.49) 
0.97 
(0.71-1.33) 
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Despite the small number of cases among those with diabetes, the association between diabetes 
and site-specific cancer mortality was assessed using models within Cox regression. Similarly to the 
results found within the analysis of HSE and SHeS data, the results indicate that the only cancer with 
a consistent association with diabetes was pancreatic cancer. Contradicting the earlier results, this 
analysis undertaken using data from Whitehall I suggests that those with diabetes also had a 
consistently increased risk of mortality from cancer of the liver. This increase also remained 
throughout the basic, advanced models and further adjustment. Within the Whitehall I data there 
were binary variables associated with a number of site-specific cancers not available within the HSE 
and SHeS dataset. For mortality from melanoma and skin cancer, those with diabetes appeared to 
have a substantial increase in risk, although caution should be taken when exploring these results as 
only two cases with diabetes died of these causes. The diabetic cohort participants also appeared to 
have a non-significant increase in mortality from brain tumours compared with those without 
diabetes. For myeloid leukaemia and cancers of the oesophagus and stomach there were non-
significant increases in the HRs. The results for cancers of the colon, prostate, lung and bladder were 
suggestive of a possible protective effect of diabetes upon site-specific cancer mortality. A power 
calculation undertaken using the total number of cases with diabetes, within the Whitehall I dataset, 
and the small number of deaths from some of the site-specific cancers suggested that the analyses 
were under-powered.  
 
Table 11-9: Site-specific cancer mortality by diabetes status (Whitehall I) 
Site-specific cancer Diabetes No Diabetes Total 
Lung <5 975 979 
Prostate <5 631 632 
Colon <5 350 351 
Stomach <5 230 234 
Lymphoma 0 215 215 
Pancreas 6 198 204 
Bladder <5 193 194 
Oesophagus <5 163 166 
Leukaemia <5 145 146 
Rectum, sigmoid junction & anus 0 136 136 
Kidney 0 88 88 
Myeloid leukaemia <5 81 82 
Skin <5 65 67 
Brain <5 64 65 
Liver <5 61 64 
Melanoma <5 46 48 
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Lymphoid leukaemia 0 53 53 
TOTAL 30 3,694 3,724 
 
Table 11-10: Site-specific cancer mortality HRs among those with diabetes (Whitehall I) 
 
Progressive 
adjustment Pancreas Liver Colon Lung Melanoma Skin Oesophagus 
DM 4.50 7.10 0.40 0.51 7.26 5.13 2.95 
(1.99-10.16) (2.22-22.72) (0.06-2.87) (0.19-1.37) (1.75-30.08) (1.25-21.02) (0.94-9.24) 
+Age 
(cont) 
3.94 6.81 0.35 0.41 7.07 4.69 2.64 
(1.74-8.91) (2.12-21.87) (0.05-2.49) (0.15-1.09) (1.70-29.34) (1.14-19.26) (0.84-8.30) 
+ Age 
(grouped) 
4.48 7.18 0.40 0.50 7.30 5.03 2.91 
(1.99-10.13 (2.24-22.99) (0.06-2.83) (0.19-1.34) (1.76-30.24) (1.23-20.65) (0.93-9.12) 
+Smoking 4.45 0.40 0.40 0.52 7.30 5.02 2.82 
(1.97-10.05) (0.06-2.83) (0.06-2.83) (0.19-1.39) 1.76-30.24) (1.22-20.61) (0.90-8.84) 
+ BMI 
(grouped) 
4.48 7.35 0.40 0.53 7.38 5.04 2.82 
(1.98-10.12) (2.29-23.58) (0.06-2.83) (0.20-1.42) (1.78-30.54) (1.23-20.67) (0.90-8.86) 
+BMI 
(cont) 
4.43 7.31 0.39 0.53 7.30 5.03 2.79 
(1.96-10.01) (2.28-23.42) (0.06-2.81) (0.20-1.41) (1.76-30.26) (1.23-20.62) (0.89-8.76) 
Basic  
+ Social class  
4.29 7.21 0.39 0.48 7.41 5.11 2.82 
(1.90-9.70) (2.24-23.14 (0.05-2.78) (0.18-1.29) (1.79-30.80) (1.24-21.02) (0.90-8.86) 
Advanced  
+ Social class 
4.32 7.19 0.39 0.49 7.36 5.10 2.83 
(1.91-9.77) (2.23-23.16) (0.05-2.77) (0.19-1.32) (1.77-30.55) (1.24-20.97) (0.90-8.90) 
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Table 11-11: Site-specific cancer mortality HRs among those with diabetes (Whitehall I)(continued) 
 
 
11.6 Site-specific cancer mortality (Whitehall I resurvey) 
Within the Whitehall I resurvey dataset, there was a limited amount of information related to site-
specific cancers. Table 11-12 details the cancers for which there was available information; only 
three of the cancers had caused deaths among the diabetic cohort, therefore regression models 
were developed only for these sites. 
 
Table 11-12: Number of site-specific cancers (Whitehall I resurvey) 
Site-specific cancer Diabetes Did not indicate 
Diabetes 
Total 
Lung 8 146 154 
Oesophagus 0 57 57 
Pancreas 7 49 56 
Rectum etc <5 33 37 
Stomach 0 36 36 
TOTAL 19 321 340 
 
Those with diabetes were found to have an excess risk of mortality from pancreatic cancer which 
was significant within the basic (2.39, CI 1.02-5.61) but not advanced (2.43, 0.96-6.17) models (at 
 Bladder Brain Leukaemia Myeloid 
Leukaemia 
Prostate Stomach 
DM 0.77 1.73 1.03 1.93 0.27 2.22 
 (0.11-5.53) (0.24-12.46) (0.14-7.35) (0.27-13.90) (0.04-1.91) (0.82-5.97) 
+Age  0.64 1.62 0.91 1.77 0.23 1.85 
(cont) (0.09-4.56) (0.22-11.72) (0.13-6.52) (0.25-12.79) (0.03-1.63) (0.69-4.98) 
+ Age 
(grouped) 
0.74 1.68 1.02 1.90 0.26 2.18 
(0.10-5.31) (0.23-12.16) (0.14-7.32) (0.26-13.72) (0.37-1.86) (0.81-5.87) 
+Smoking 0.74 1.69 1.00 1.84 0.26 2.23 
 (0.10-5.29) (0.23-12.24) (0.14-7.14) (0.26-13.26) (0.04-1.85) (0.83-6.01) 
+ BMI 
(grouped) 
0.75 1.70 0.99 1.82 0.26 2.24 
(0.11-5.38) (0.23-12.27) (0.14-7.10) (0.25-13.11) (0.04-1.85) (0.83-6.02) 
+BMI  0.74 1.69 1.00 1.84 0.26 2.23 
(cont) (0.10-5.25) (0.23-12.19) (0.14-7.12) (0.26-13.28) (0.04-1.85) (0.83-5.99) 
Basic  
+ Social class  
0.73 1.73 1.01 1.92 0.26 2.10 
(0.10-5.19) (0.24-12.54) (0.14-7.21) (0.27-13.84) (0.05-1.84) (0.79-5.65) 
Advanced  
+ Social class 
0.74 1.73 1.00 1.90 0.26 2.09 
(0.10-5.32) (0.24-12.54) (0.14-7.18) (0.26-13.66) (0.04-1.84) (0.78-5.64) 
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each step of the analyses the point estimate was raised for those with diabetes compared with those 
without the disease). The HRs were also increased for mortality from cancers of the rectum (and 
surrounding sites), but the increase was non-significant. For lung cancer those with diabetes 
appeared to have no excess in mortality risk compared with those without diabetes. 
 
Table 11-13: HRs for those with diabetes (Whitehall I resurvey) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The results presented in this section suggest that those with diabetes have an increased risk of 
mortality from a number of the site-specific cancers under investigation. Within both the analyses of 
the HSE and SHeS (combined) and Whitehall I datasets, it appears that the strongest association is 
between diabetes and cancer of the pancreas. This association was present within both the 
multinomial logistic regression and Cox regression and remained after adjustment for a range of 
covariates. The point estimate increases for a number of the site-specific cancers suggests that there 
may be an association between diabetes and these cancers that requires further analysis with 
datasets with sufficient numbers and the power to fully assess the association between the two 
diseases. 
 
Progressive 
adjustment 
Pancreas Lung Rectum 
DM 2.61 0.97 2.17 
(1.18-5.68) (0.48-1.98) (0.77-6.14) 
+Age (cont) 2.62 0.98 2.20 
(1.18-5.79) (0.48-2.00) (0.78-6.22) 
+ Age 
(grouped) 
2.62 0.97 2.18 
(1.18-5.79) (0.48-1.99) (0.77-6.16) 
+Smoking 2.39 0.88 1.75 
(1.02-5.61) (0.41-1.89) (0.53-5.75) 
+ BMI 
(grouped) 
2.43 0.93 1.42 
(0.96-6.17) (0.41-2.12) (0.34-6.02) 
+BMI (cont) 2.39 0.94 1.38 
(0.94-6.06) (0.41-2.13) (0.32-5.86) 
Basic  
+ CVD 
2.45 0.92 1.67 
(1.04-5.79) (0.43-1.96) (0.50-5.55) 
Advanced  
+ CVD 
2.33 0.97 1.30 
(0.91-6.00) (0.42-2.12) (0.30-5.59) 
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The chapters above detailed the associations between diabetes, HbA1C and incidence of and 
mortality from cancer (both all-cause and site-specific) as well as all-cause and cause-specific 
mortality. The results suggest that there are differences in the excess mortality experienced by those 
with diabetes dependent upon the group being investigated (in terms of the study cohort, sex, 
whether or not comorbid CVD is present and whether the participants were smokers). Within the 
Health Survey for England and Scottish Health Survey dataset, which includes >204,000 participants 
aged 16 and over, followed from 1994-2008 to 2011 (England) or from 1995-2003 to 2008 
(Scotland), it appears that those with diabetes have an excess of cancer mortality (compared with 
the general public) which is little attenuated by the inclusion of potential confounding factors within 
the regression models. The results from analysing Whitehall I participants, at baseline and resurvey, 
contradict this result and find that those with diabetes have similar cancer mortality risk when 
compared with those without diabetes. The reasons for these differences in results are explored in 
the discussion chapter below. 
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12. Chapter 12: Discussion 
12.1 Key findings of the current study 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
The literature review undertaken as part of this thesis suggested that there were still a number of 
unanswered questions in relation to the associations between diabetes and cancer. One of these 
questions related to whether it was the presence of diabetes (via hyperglycaemia and/or  
hyperinsulinaemia and the other consequences of the condition) or underlying factors present at a 
What is already known 
 Diabetes is associated with an excess in mortality from all-causes and CVD. 
 The biological cause of this excess is thought to relate primarily to the biological impact that 
hyperglycaemia has upon the body. 
 There is heterogeneity within study results related to the associations between diabetes and cancer 
incidence and mortality. 
 Hyperinsulinaemia and hyperglycaemia are thought to increase the risk of cancer among those with 
diabetes, although related factors (such as overweight and obesity) may also play a role. 
 The most consistent evidence of an association relates to cancers of the liver, pancreas and 
endometrium, as well as less consistent results relating to those of the colorectum, breast and 
bladder. There also appears to be some evidence that those with diabetes have a reduced risk of 
mortality from cancers of the lung and prostate.   
 
What this study adds: 
 Evidence of associations between diabetes and incidence of and mortality from cancer, within a 
recent, nationally representative general population sample, that remains after adjustment for a 
range of confounding factors. Of particular interest is the persistence of the association after 
inclusion of different measures of overweight and obesity and the presence of comorbid CVD within 
the regression models. 
 Support for there being an association between raised HbA1C and cancer incidence and mortality, 
and mortality from other causes. 
 Evidence of diabetes and HbA1C being associated with increased site-specific cancer incidence and 
mortality. 
 Results suggestive of differences in cancer risk dependent upon sex and comorbid CVD status. 
 Evidence of increased risk of developing and dying from a range of cancers, 
 Support for diabetes, rather than related factors such as overweight and obesity, being associated 
with cancer incidence and mortality and mortality from other causes.  
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high rate among people with diabetes (for example overweight and obesity) that increased an 
individual’s risk of developing or dying from cancer. The results of the current study suggest that the 
presence of overweight and obesity has little impact upon the excess mortality and incidence of 
cancer among those with diabetes compared with the general population. This finding lends support 
to diabetes, in and of itself, being the cause of the excess in cancer among those with diabetes. The 
key hypotheses at the heart of this study, that ‘the specifics of having diabetes directly increase the 
risk of an individual developing cancer. This increase in cancer incidence is above that caused by 
related factors such as adiposity.’ and ‘individuals with diabetes are more likely to die of cancer than 
individuals who do not have diabetes’, are supported by the following results:  
 
 Diabetes was associated with an increased risk of cancer incidence and mortality, which 
remained after adjustment for a range of confounding factors including overweight and 
obesity and socioeconomic and demographic status. 
 Adjusting for BMI, waist-to-hip ratio or waist circumference had little impact upon the 
associations between diabetes and cancer incidence and mortality. 
 
The literature review also demonstrated a lack of evidence related to the associations between 
HbA1C and cancer incidence and mortality, as well as mortality from other causes. In this regard the 
study produced a number of novel findings, including evidence of: 
 
 HbA1C being associated with an excess in cancer mortality and incidence within a nationally 
representative UK sample linked to up-to-date mortality and Cancer Registry data.  
 HbA1C being associated with an increased risk of dying from all-causes and causes other than 
cancer. 
 Differences in cancer incidence and mortality between those with diabetes but with or 
without comorbid CVD.  
 Comorbid CVD altering the all-cause and cause-specific mortality risk among those with 
diabetes. 
 
There was also a limited amount of evidence related to the impact comorbid CVD might have upon 
the associations between diabetes, HbA1C and cancer incidence and mortality. A further hypothesis, 
developed in light of the results of the literature review, that ‘comorbid CVD alters the strength of 
the association between diabetes and incidence of and mortality from cancer’ was also supported by 
the results of this research. 
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 Those with diabetes and comorbid CVD had differences in their cancer mortality risk 
compared with those with diabetes but without CVD. 
 Only those with diabetes but without comorbid CVD at baseline had an increased risk of 
cancer incidence. 
 There were differences in the risk of all-cause and cause-specific mortality between those 
with diabetes and comorbid CVD and those with only diabetes. 
 
One of the key weaknesses of previous studies, which sought to explore the associations between 
diabetes, HbA1C and site-specific cancer incidence and mortality, was the small number of site-
specific cancer events within study follow-up periods. This issue was also relevant to the current 
study, but the consistency within results – in finding point estimate increases in site-specific cancer 
risk among those with diabetes when compared with the general population – are indicative of an 
association and add further evidence to the results of earlier studies. The strength of the results 
related to HbA1C are hindered by a lack of power, but again, many of them suggest an association 
between raised HbA1C and incidence and mortality from a number of site-specific cancers. 
 
12.2 Diabetes and cancer mortality 
Two hypotheses were explored within the literature review carried out for this study, which seek to 
explain the current evidence related to the biological plausibility of a causal relationship between 
diabetes and cancer (Section 2.6). The first of these suggests that the proliferative (encourages cell 
growth and multiplication), mitogenic (triggers mitosis) and anti-apoptotic (reduces cell suicide) 
effects of hyperinsulinaemia (increased insulin in the blood often in response to reduced insulin 
sensitivity within the body) and increased levels of Insulin-like Growth Factor-1 (IGF-1) are the main 
cause of the relationship.(207–209) There is also a limited amount of evidence that some cancer 
cells produce, and may even over-produce, receptors for IGF-1 and insulin.(214) Hypothesis two 
takes into account a more diverse range of factors, related to diabetes itself as well as confounding 
factors such as obesity, which may explain the association between diabetes and cancer. The earliest 
finding in this area was made by Warburg, who found that cancer cells utilised insulin at higher rates 
than normal cells and could survive without oxygen if they were in a glucose-containing serum.(99) 
Following this finding it has been postulated that inducing hypoglycaemia could cause cancer 
remission, although because cancer cells utilise glucose at near full-capacity regardless of 
environment, this has been disputed and the evidence is limited.(215)  
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An element of the second hypothesis also relates to the increased risk of cancer incidence and 
mortality among those who are overweight/obese. (216,217) Overweight and obesity are associated 
with increased levels of adipose tissue which are, in turn, associated with altering the levels of 
cytokines such as Inter-leukin-6 and leptin (which may reduce cell apoptosis and encourage insulin 
sensitivity and cell metastases) and adiponectin (an insulin sensitiser) within the body.(216,220,221) 
In short, the second hypothesis supports the view that the increase in cancer mortality found among 
those with diabetes is due to factors related to diabetes, as well as factors related to the body being 
in a state of overweight/obesity. 
 
The detailed literature review presented in chapter 2 outlines the history of studies investigating 
suggested associations between diabetes and cancer. During the 1980s studies began to be 
undertaken which overcame some of the weaknesses of earlier studies, although there was still 
heterogeneity within study results and a number of studies still had small numbers of concurrent 
diabetes and cancer or failed to adjust for confounding factors.(75,302) Perhaps as a consequence of 
this, a number of studies found lower cancer mortality among those with diabetes,(109) some found 
rates similar to the general population,(75) while others found increased risk.(84) 
Within the HSE and SHeS combined dataset, a total of 5,571 cases died of cancer during the follow-
up period, including 355 who had indicated diabetes at baseline. The results of the analyses of the 
HSE and SHeS combined dataset are in agreement with the Emerging Risk Factors Collaboration 
(ERFC) study which utilised pooled data from 97 prospective studies and a recent meta-analysis 
which included 12 studies.(84,110) The adjusted (age, sex, smoking and BMI) all-cause cancer 
mortality HR found within the ERFC study was 1.27, 95%CI 1.20-1.34, while the RR within the meta-
analysis was 1.16, 1.03-1.30. Within this HSE/SHeS study the adjusted (age, sex, smoking and BMI) 
OR for those with diabetes was 1.27, 1.12-1.43. Across the various HSE/SHeS models, the increased 
odds of dying of cancer among those with diabetes compared with the general population changed 
little and were indicative of around a 20% increased odds of dying of cancer among those with 
diabetes. Of particular note is the finding that, whether a measurement of overweight and obesity 
was adjusted for or not, and whichever anthropometric measurement was included within the 
regression model, the increase in odds of dying of cancer was unchanged and remained statistically 
significant among those with diabetes. This suggests that the association between diabetes and 
cancer mortality may relate to the specifics of having diabetes, and goes some way to refuting the 
conclusions of earlier commentators that the association was caused by the confounding factors 
which accompany diabetes, particularly obesity.(303) The result also differs from those found for the 
association between diabetes and mortality from respiratory disease among men, which was 
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indicative of overweight/obesity being the underlying mechanism. The only covariate which reduced 
the statistical significance of the association between diabetes and mortality from cancer was 
HbA1C; as with the results related to respiratory disease, this may relate to the small number of 
deaths from this cause among the substantially smaller number of participants with both diabetes 
and a valid HbA1C measurement.  
Within the Whitehall I dataset there were 4,047 deaths from cancer, including 29 among those who 
indicated diabetes at baseline. When the binary cancer death variable (death from cancer  vs. alive 
or other cause of death) was used within logistic regression models, those with diabetes were found 
to have a lower risk of dying of cancer compared with those without diabetes (OR adjusted for age, 
smoking status and BMI at baseline 0.51, 0.35-0.76 and at resurvey 0.80, 0.57-1.12). However, when 
Cox regression models were developed, those with diabetes, within the advanced model, were 
found to have the same cancer mortality as those without diabetes (baseline 1.01, 0.70-1.46; 
resurvey 0.98, 0.72-1.34). The differences in these results are probably caused by the inclusion of 
time to event within the Cox regression models. An earlier study, that utilised the same Whitehall I 
data with a follow-up period of 25 years rather than the 40 years available for this study, found that 
those with Non-Insulin Dependent Diabetes (NIDDM) had an HR of 0.73 (0.44-1.19) compared with 
those without diabetes.(89)  
The Whitehall results appear to contradict the findings of the analyses of the HSE and SHeS data. 
This discrepancy is likely to be a result of the provision of a binary variable which categorises cases 
into either 1) those who are still alive or have died of any cause other than cancer (including CVD 
which those with diabetes were found to have a substantially increased risk of dying from within the 
analyses of both Whitehall I and HSE/SHeS datasets) or 2) those who have died of cancer, rather 
than having a variable which allows for competing causes of death to be considered. Because of this, 
the multinomial logistic regression used with the HSE and SHeS combined dataset, which does utilise 
the competing cause of death technique, was considered to be more accurately representative of 
the risk of dying of cancer among those with diabetes compared with those without diabetes. 
Another explanation, the issue of possible changes in cancer mortality risk over time among people 
with diabetes, is discussed in more detail below. 
Two recent studies explored the associations between diabetes and cancer mortality among men 
and women. The first used data from the Cancer Prevention Study-II (CPS-II) in America, mentioned 
previously, and found an increased relative risk of mortality from cancer among those with diabetes 
(men 1.07, 1.04-1.11 and women 1.11, 1.06-1.15).(110) The second used data from 17 population-
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based or occupational cohorts from Europe and found HRs of 1.71, 1.35-2.17 among men with 
known diabetes and 1.27, 1.02-1.57 for men with undiagnosed diabetes; the corresponding HRs for 
women were 1.43, 1.01-2.02 and 1.31, 1.00-1.70, respectively.(80) The use of occupational cohorts 
may be different to those from the general population due to the ‘healthy worker effect’ wherein 
those in work are found to have lower overall mortality compared with the general population 
because those who are too ill to work are not included within the cohort.(304) Despite this, both of 
these results are in agreement with the results of this current HSE/SHeS study, which found adjusted 
ORs of 1.27, 1.05-1.54 and 1.25, 1.10-1.47 among men and women, respectively. The results of these 
three studies demonstrate that there may be country differences in the magnitude of the effect that 
diabetes has upon cancer mortality, although the differences may be a chance finding and the 
confidence intervals indicate that there may not be a difference.  Although future studies could 
explore whether or not there are differences in diabetes treatment regimens administered and the 
severity of diabetes within countries, further research might also wish to consider whether or not 
those with diabetes are offered different cancer-related treatments once they are diagnosed with 
the disease (affecting mortality but not incidence).(276,305) 
An intriguing finding of the stratified analyses was that when HbA1C was included within the 
HSE/SHeS model, the OR for women increased substantially (2.45, 1.24-4.86) while for men the 
same analyses produced a non-significant reduction in risk of mortality from cancer among those 
with diabetes (0.73, 0.39-1.35). This result will be further explored within the discussion related to 
HbA1C and cancer mortality (below), but it appears that further studies could be undertaken which 
clarify this potential difference in risk between the sexes and establish whether this was a chance or 
substantive finding. Further to this, although adjusting for BMI did not significantly alter the 
increased odds of dying from cancer among those with diabetes compared with the general 
population, when the abdominal obesity measurements (waist-to-hip ratio and waist circumference) 
were included, the association among both men and women became non-significant but remained 
raised at the point estimate. This lack of significance may relate to the number of participants who 
had valid measurement for these variables: within the whole sample 89% had a measurement 
related to BMI compared with 56% for waist-to-hip ratio and waist circumference. 
Those who had diabetes but did not indicate CVD at baseline were found to have statistically 
significant increased odds of mortality from cancer, while those with diabetes and comorbid CVD 
had an increase at the point estimate, but the result was not significant. It may be that those with 
diabetes and comorbid CVD are diagnosed with cancer earlier than those with only diabetes because 
the former make more visits to their healthcare providers. Those with diabetes and CVD may also 
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have their insulin and glycaemic levels under tighter control compared with those with only 
diabetes, which may increase cancer cell apoptosis, while reducing the ability of a developing cancer 
to proliferate. Those with diabetes and CVD may also be taking CVD-related medications which alter 
their cancer risk – although whether there is a biological plausible relationship between these 
medications and increased cancer risk has yet to be confirmed or refuted. Finally, cases are at risk of 
experiencing morbidity from a number of different causes simultaneously, but can only experience 
death from one. Those with diabetes and comorbid CVD were found to have age-standardised 
mortality that was above those with only diabetes. Among women 12% of those with diabetes had 
died, compared with 16% of those with diabetes and comorbid CVD. The corresponding figures were 
14% and 17% among men, respectively. Among women and men who had neither diabetes nor CVD 
the figure was 9% and for only CVD 11% and 13%, respectively. It could therefore be postulated that 
those with diabetes, but not comorbid CVD, are living longer and therefore have the opportunity to 
live to an age within which the risk of developing and dying from cancer are raised. 
Because those with diabetes have lower smoking rates, and when they do smoke are more likely to 
attempt to quit,(306) it would be expected that those without diabetes would have higher mortality 
than those with diabetes from cancer if it were caused by residual confounding from smoking. In 
analysis restricted to  those who indicated that they had never been a regular smoker, the results 
within the basic (age and sex) and advanced (basic + BMI) models demonstrated an increase in risk 
of dying of cancer; this persisted but the confidence intervals were indicative of a non-significant 
association when alternative measures of overweight and obesity were included. Similarly to the 
results for CVD, those for cancer mortality suggest that the increase in cancer mortality may be due 
to the presence of diabetes itself and not confounding from related factors. However, the small 
number of those within the non-smoking group who indicated having diabetes means that caution 
should be taken when drawing conclusions from these results. 
One explanation for the increased risk of mortality from cancer among HSE and SHeS participants 
with diabetes may relate to those with diabetes being diagnosed with cancer at a later stage of the 
disease. Within a recent study focussed upon women over the age of 66, those with diabetes had a 
19% increased odds of being diagnosed with late-stage breast cancer compared with those without a 
comorbidity.(307) In contrast some earlier research, particularly the work of Berkson, suggests that 
those with diabetes may be more likely to be diagnosed with other diseases because they come into 
regular contact with healthcare services.(103) Other reasons for such an increase in cancer mortality 
may be the biological impact that hyperinsulinaemia and hyperglycaemia have upon the whether or 
not cancers proliferate and metastasize within the body,(308) the differences in the cancer 
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treatments offered to those with and without diabetes,(305) and the reduction in the effectiveness 
of chemotherapy upon cancer within the body of someone with diabetes.(309) There is also some 
evidence that treatments for cancer have higher rates of toxicity in people with diabetes and may 
increase the risk of mortality from other causes, and that this group may be more likely to be 
unsuitable for cancer-related surgery.(310) A study by Renehan et al. concluded that diabetes 
increases mortality from cancer because of delays in cancer diagnosis, differences in cancer 
treatment, and differences in outcomes related to specific cancer types between those with and 
without diabetes.(311) Finally, if those with diabetes have increased cancer incidence compared 
with the population without diabetes (discussed in the next section), then the increased mortality 
from cancer may have more to do with factors which produce this increased incidence rather than 
those which occur post-diagnosis. 
 
Within the Whitehall I baseline and resurvey data analyses it appeared that those with diabetes had 
a similar risk of cancer mortality compared with people without diabetes, or even a substantially 
reduced risk using the baseline data. This result may be a statistical artefact related to the use of a 
binary variable within the analyses or the impact of the ‘healthy worker effect’ mentioned above. 
Those with diabetes in Whitehall I had a substantially increased risk of mortality from CVD. 
Therefore if the risk of cancer mortality is analysed in comparison with those with diabetes who had 
died of CVD, then it is likely that the outcome will be an apparent reduced risk of cancer mortality. 
Binary logistic regression was also used in a number of the earlier studies focused upon diabetes and 
cancer and may explain why they also found a reduced cancer risk among those with diabetes. 
The next section considers the results for diabetes and cancer incidence, in the context of these 
findings on cancer mortality. 
12.3 Diabetes and cancer incidence 
While mortality from a particular cause is a combined measure of the development of disease and 
deaths from it, incidence enables a more detailed explanation of the former. Understanding whether 
those with diabetes develop cancer at an increased rate compared with the general population can 
inform our knowledge related to the underlying causes of the associations between the two diseases 
and enable the development of measures and treatments to reduce the excess. If an association 
were to be found, programmes which sought to address the increasing prevalence of diabetes could 
also be considered in the context of cancer prevention.  Within the literature review it was observed 
that the majority of studies were focussed upon mortality from cancer. The cause of this may be the 
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availability of mortality data compared with that for cancer incidence: within this current study, 
mortality data were more easily accessible than that for the Cancer Registry.  
Among studies which were focussed upon the associations between diabetes and cancer incidence, 
the results were heterogeneous. A 1997 study found a marginally increased incidence of cancer 
among those with diabetes compared with the general population, although their use of data from 
patients who had been hospitalised makes the extrapolation of their results to the general 
population problematic.(172) Zendehdel found that those with type-1 diabetes also had an 
increased risk of developing cancer (standardized incidence ratio: 1.2, CI 1.0 to 1.3).(173) A number 
found similar incidence among those with diabetes compared with the general population.(168) Gu 
et al. found similar cancer incidence among those with type-2 diabetes whether or not they were 
being treated with insulin.(312) A number of studies focussed upon site-specific cancer incidence 
and these results will be discussed in the appropriate sections below. 
Within the current study those with diabetes were found to have an increased odds of developing 
cancer compared with the general population of over 10%; this increase remained within the basic 
(adjusted for age, sex and smoking status), the advanced model (basic + BMI) and when alternative 
measurements of overweight and obesity were included within the model. The biological plausibility 
of such an association was discussed extensively within the literature review above, related to 
cancer mortality. Specifically to cancer incidence, it appears that the state of hyperinsulinaemia, 
which occurs in the initial stages of diabetes (and may start during the pre-diabetes state), IGF-1 and 
hyperglycaemia facilitate the proliferation of cancer cells and reduce the occurrence of cell 
apoptosis. It therefore appears that those with diabetes are more likely to develop cancer and are 
consequently more likely to die of the disease compared with the general population. As mentioned 
previously, those with diabetes may come into contact with health care services more regularly than 
those without diabetes, so may be more likely to be diagnosed with other conditions, including 
cancer. At the same there is some evidence that women with diabetes are less likely to take up 
cancer screening for breast and cervical cancer; the reasons for this are complex and may relate to 
the complex healthcare needs of those with diabetes leaving less time for services related to disease 
prevention, the age of those with diabetes compared with the general population and the 
perception of reduced survival among those with diabetes among their healthcare providers.(313) 
One issue that was not addressed within this current study was the influence that diabetes 
medications have upon an individual’s risk of developing and dying from cancer. There is a growing 
body of evidence suggesting that metformin reduces cancer risk (in terms of incidence and 
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mortality) compared with other diabetes medications.(314,315) This reduced risk appears to relate 
to the pro-apoptotic and anti-mitogenic nature of metformin; rosiglitazone, another drug used to 
treat diabetes, was also found to have the same properties.(316) If the alterations in insulin levels 
which define diabetes are a causal factor within the increase in cancer incidence among those with 
diabetes, then the use of exogeneous insulin could also be altering cancer risk. Insulin has been 
found to encourage cell proliferation and chemoresistance; the latter may contribute to the excess 
in cancer mortality found among those with diabetes.(316) Additionally, as the disease progresses 
individuals with type-2 diabetes may be prescribed a plethora of different oral medications as well as 
exogeneous insulin. The changing drug regimens administered to those with diabetes means that 
unravelling the impact of one medication (over the confounding caused by the other medications 
that an individual may be taking) upon cancer risk is beyond the scope of a study of this nature. 
Future randomised controlled trials could be undertaken which would enable an effective 
exploration of the impact of individual diabetes treatments upon the association between diabetes 
and cancer. 
An American study used data from the National Institutes of Health - American Association of 
Retired Persons Diet and Health Study and found that cancer incidence among women with diabetes 
was raised (HR 1.07, CI 1.02-1.12) but that among men, the inverse was true (HR 0.96, 0.93-
0.98).(317) A 2006 study from Japan contradicts this result, and found that men with diabetes had 
an increased risk in relation to cancer incidence while women did not.(318) A contributing factor to 
this may be the differing CHD risk among these populations – the mortality rate for CHD in Japan is 
the lowest in the developing world and has been estimated to be between one-third to one-fifth 
that of America.(319)  For a middle-aged Japanese man, the incidence rate for CHD was found to be 
≤2 per 1000 compared with 5 to 6 per 1000 for an American man, while for women the equivalent 
figures were ≤1  and 2 to 3 per 1000, respectively.  Adding further inconsistency to the results of 
previous studies, a Korean study found that both men (HR 1.24, 1.20-1.8) and women (1.33, 1.25-
1.41) with diabetes had increased risk of cancer incidence.(320)  The result of this current study 
support those of the first study: women had a statistically significant increased odds of developing 
cancer (after adjusting for age, sex, smoking and BMI the OR was 1.16, 1.02-1.33) while for men the 
OR was indicative of similar risk to those found among the general population (1.03, 0.91-1.17). The 
reason for these similarities, and differences, in results may be the make-up of the study samples. 
The cohort from the US and current study were made up of samples taken from the diverse 
populations of these countries, while the populations of Japan and Korea are relatively 
homogeneous, genetically. There are also differences in the baseline CHD risk (including when CHD 
develops and sex differences in risk) between the countries within the studies. 
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The results of analyses related to diabetes and cancer incidence which utilise a grouped variable (all 
site-specific cancers) are likely to be altered by the site-specific cancers which make up the variable. 
If, within a study cohort, there are more cases of a cancer for which those with diabetes have a 
reduced incidence, compared with the general population, then analyses are likely to produce 
results which show a decrease or no increase in incidence. Correspondingly, if the variable includes a 
large number of cases of cancers for which those with diabetes have an increased incidence, then 
the result is likely to be contradictory. Within the current study, a large number of deaths were from 
lung cancer, and as shown below, those with diabetes were found to have an increased incidence of 
this cancer.  The American study, mentioned above, suggested that the reduced risk of cancer 
incidence among men may be driven by the reduced risk of prostate cancer incidence found among 
men with diabetes; once they excluded this cancer site from their analyses men with diabetes were 
also found to have an increased risk of cancer incidence.(317) The key difference between that study 
and the current one is that 43% of incident cancers were from prostate cancer in the former, while 
in this study it only accounted for 13%. Further to this, as can be seen from the results given in the 
section related to prostate cancer within the current study (Section 12.4), men with diabetes were 
found to have similar cancer incidence to the general population for a number of site-specific 
cancers. Future studies should be aware of the rates of each site-specific cancer making up the 
overall cancer incidence variable and may conclude that analyses of such a variable is not advisable. 
When the analyses were stratified by CVD status, those with diabetes but without comorbid CVD 
were found to have a statistically significant increased incidence of cancer, while those with diabetes 
and CVD had a non-significant reduced odds. As with cancer mortality, the reasons for this are 
unclear but could be a result of the increased mortality from other causes among those with 
diabetes and CVD. In essence, that those with both diabetes and CVD die of another cause before 
reaching an age where cancer incidence is more likely. The sensitivity analysis, performed using data 
only from those who indicated that they had never been a regular smoker, indicates that those with 
diabetes do not have an increased incidence of cancer compared with the general population. If this 
result is not a chance finding, in collaboration with those for cancer mortality, it indicates that those 
with diabetes do not have an increased incidence of cancer but are more likely to die of the disease 
than their non-diabetic counterparts. The reasons for this increased mortality are discussed in the 
previous section. 
Because of the differing aetiologies and incidence of site-specific cancers a number of commentators 
suggest analysing the associations between individual cancers rather than cancer overall.(303,321) 
In order to assess the associations between diabetes and site-specific cancer incidence and 
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mortality, analyses were then performed for a number of specific cancers. The next section details 
these results within the context of earlier studies and explores the biological reasons why these 
associations may exist.  
12.4 Site-specific cancer incidence and mortality 
Lung cancer 
Lung cancer causes the greatest number of site-specific cancer deaths within the UK (around one in 
five cancers among men and women combined).(111) None of the studies which explored the 
association between diabetes and cancer commented upon the specific biological mechanism that 
may underpin an association between the two conditions.   
 
Incidence 
Within the HSE and SHeS dataset there were 1,373 incident cases of lung cancer, including 96 among 
those with diabetes. Within the basic model (adjusted for age, sex and smoking status) there was a 
statistically significant increased OR, which became marginally non-significant when BMI was added 
to the model. This result is supported by earlier research by Steenland et al.(322) and a second study 
found an adjusted HR of 1.05, 0.96-1.26.(113)  Contradicting this, Hall et al. used data from the UK’s 
General Practice Research Database (their sample included over 66,000 individuals with diabetes as 
well as age, sex and GP practice matched controls) and found a decrease in HR for incidence of lung 
cancer among those with diabetes of 0.88, 0.79-0.97,(112) Some studies did not adjust for smoking 
and considering the impact that this factor has upon lung cancer incidence the relevance of their 
results are difficult to assess.(172) Two recent meta-analyses also demonstrated conflicting results. 
The first demonstrated lower incidence of lung cancer, concluding that the disease may be 
protective against lung cancer.(323) The second found that women with diabetes had a statistically 
significant increased risk, while men did not.(116) The results of the analyses when split by sex were 
raised at the point estimate within each of the models for both men and women; but statistical 
significance was not maintained across all of the models. For example for men the association only 
became statistically significant within the advanced model (age, sex, smoking status and BMI), while 
for women the association became non-significant when this covariate was included.  
The small number of studies investigating the associations between diabetes and incident lung 
cancer and the mixed results found within this, and previous studies, suggests the need for further 
research in this regard.  It is also worth noting that survival for lung cancer is consistently low and 
those with diabetes, once diagnosed with lung cancer, appear to have shorter survival times than 
the general population.(324) 
222 
 
Mortality 
Within the current study 1,297 participants died of the disease (including 88 who indicated diabetes 
at baseline). Within the literature review only a small number of studies were found which had 
explored the potential association between diabetes and mortality from lung cancer and their 
results had been inconsistent. A study of lung cancer mortality risk among post-menopausal women 
with and without diabetes found that the former had an increased HR of 1.27, 1.02-1.59(114); the 
ERFC study found an HR of 1.27, 1.13-1.43 among those with diabetes (86); and a meta-analysis 
found a RR of 1.11, CI 1.02-1.20 among those with diabetes.(116) The results of the multinomial 
logistic regression undertaken within the current study support the result of these studies. Within 
the basic and advanced models those with diabetes had substantially increased odds of dying of lung 
cancer at the point estimate, but the association was marginally non-significant. Within the Cox 
regression the increase at the point estimate was increased even further within the basic model (HR: 
1.31, 1.05-1.64) but became non-significant when BMI was added to the model (1.22, 0.96-1.56). 
This lack of association supports the results of an earlier study undertaken among a Hong Kong 
cohort (≥65 years of age) which found that obesity was associated with reduced mortality from lung 
cancer; the researchers also suggested that genes which predispose individuals to being 
overweight/obese may be protective against lung cancer.(325) A meta-analysis also found that 
overweight/obesity was associated with a reduced risk of developing lung cancer, given the short 
life-expectancy for those diagnosed with the disease it is likely that any reduction in risk of 
developing lung cancer would also impact upon mortality risk.(323)  
The results of the analyses of the Whitehall I data are in agreement with an earlier study which 
utilised the same data but had a shorter follow-up period: both were indicative of those with 
diabetes having a reduced risk of mortality from lung cancer.(89) As with the results related to 
overall cancer and respiratory disease mortality, it is likely that the differing smoking rates found 
among those with diabetes compared with the general public mean that the former would have a 
lower risk of developing, and therefore dying, of lung cancer. Within the current study a categorical 
variable related to smoking was used within the analyses; this variable categorised cases into three 
groups (current smokers; ex-regular smokers and never-regular smokers). Although a similar variable 
is used within the majority of recent studies that explore the associations between diabetes and 
cancer, further analyses could be undertaken that uses more detailed smoking related information, 
which would allow for an assessment of whether or not cigarette consumption differs between 
those with and without diabetes, and the impact that this residual confounding may have upon 
differences in cancer mortality.  
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A 2010 study found that diabetes was not associated with a  risk of dying of lung cancer among 
either men or women with diabetes.(80) The results of this current study are indicative of an 
association between diabetes and lung cancer mortality; although for neither men nor women were 
the results statistically significant. The point estimates were raised among those with diabetes and 
without comorbid CVD and were similar for those with diabetes and comorbid CVD. This result 
implies that there is no difference in risk between the two groups; while the results of earlier studies 
suggest that the obesity which often accompanies type-2 diabetes may protect those with the 
disease against developing and consequently dying of lung cancer. 
Colorectal cancer  
Colorectal cancer includes those of the colon and rectum and is the second largest site-specific cause 
of cancer mortality in the UK, killing over 16,000 individuals in 2008.(117) Globally, 1.28 million 
individuals were diagnosed with the disease in 2008.(118) Although the biological plausibility of a 
causal relationship between diabetes and colorectal cancer is poorly understood, there is a limited 
amount of evidence that the increased presence of conditions such as autonomic neuropathy among 
those with diabetes may slow the movement of faecal matter within the colon and increase the risk 
of developing colon cancer.(222,326) 
 
Incidence 
Within the HSE and SHeS dataset there were 989 cases of colorectal cancer within 68 of these 
occurring among those with diabetes at baseline. While the results of the current study were 
inconclusive, although the point estimate was raised the confidence intervals were indicative of a 
non-significant association, those of earlier studies demonstrated an increased risk of developing 
colorectal cancer among those with diabetes. A case-control study found that those in the highest 
quintile in relation to c-peptide, an indicator of the insulin level within the blood, were at an 
increased risk of developing colorectal cancer.(119) One of the reasons for these differing results 
may be the study samples: in the earlier study the sample was made up of 14,916 male doctors, 
while the current study uses a sample made up from the general population. 
 
The results in relation to the associations between diabetes and incident colorectal cancer when the 
dataset was stratified by CVD appear to indicate no difference in risk among either group. Similarly, 
for both men and women, although the point estimate was raised the association appeared non-
significant. These results could be down to chance and require further analyses using data with a 
greater number of outcomes of interest. 
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Mortality 
Within the current study there were 552 deaths from cancers of the colorectum, with 34 of these 
being among those with diabetes. Although consensus has not been reached as to the association 
between diabetes and mortality from colorectal cancer, the majority of studies found within this 
study’s literature review did support an association – including a meta-analysis which utilised data 
from over 2.5 million study participants.(86,87,121) Those with diabetes who are then diagnosed 
with colorectal cancer also have a higher risk of all-cause mortality compared with those without 
diabetes.(120)  
Within the multinomial and Cox regression analyses there was found to be point estimate increases 
within each of the models. These results are compatible with an earlier study which found non-
significant increases for risk of dying from this cause.(80,327) The latter study concluded that, 
although the result appeared non-significant, there was enough evidence to suggest that there 
appeared to be an association between diabetes and colorectal cancer mortality. The study then 
went on to stratify their analyses by sex, and found that the association became statistically 
significant for men, while among women those with diabetes appeared to have a lower risk than 
women without diabetes. Within the current study, both men and women with diabetes were found 
to have a non-significant increase in risk of mortality from colorectal cancer compared with those 
without diabetes. When stratification occurred based upon CVD status, those with diabetes but 
without CVD did not appear to have an increased risk of mortality. For those with CVD the point 
estimate was higher but the association was not significant: for the latter group the OR increased to 
1.23, 0.73-2.08 when adjusted for age, sex, smoking status and BMI. If a future study, able to explore 
the associations between diabetes and mortality from colorectal cancer within a sample that 
included a larger number of cancer endpoints, were to find that those with diabetes did have around 
a 20% increased risk of dying from this cause then this could result in a significant excess of mortality  
among those with diabetes and comorbid CVD. The results of the analyses of the Whitehall I data 
suggested that those with diabetes were at a reduced risk of mortality from cancer of the colon; this 
result is consistent with that of the earlier study which utilised the same Whitehall I data.(89) The 
results of both studies should be treated with caution as only a small number of cancers of the colon 
were found among those with diabetes. 
Pancreatic cancer  
Pancreatic cancer causes around 7,000 deaths in the UK per year and the disease has one of the 
lowest median survival times of any site-specific cancers.(117,328) As early as 1934, studies had 
begun to note the association between diabetes and cancer and in 1971 Kessler undertook an 
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extensive literature review of all of the research exploring diabetes and cancer and concluded that 
only for pancreatic did the evidence consistently demonstrate an association.(72,100) The issue for 
many commentators has been whether it is the diabetes or cancer that comes first, with some 
concluding that the development of diabetes among lean individuals between the ages of 45 and 50 
should be considered an indicator of the presence of pancreatic cancer.(123,124) This finding is 
supported by an increased incidence of the cancer among those who have had diabetes for the 
shortest amount of time. For example within the meta-analysis by Huxley et al., those who had had 
diabetes for less than 4 years were twice as likely to get pancreatic cancer, while those who had the 
disease for longer had an excess risk of 50% compared with those without diabetes. 
 
Incidence 
Two meta-analyses, focussed upon diabetes and the risk of developing pancreatic cancer, were 
found within the literature review and both of these supported an association between the two 
diseases. The first, by Huxley mentioned above, included 36 cohort and case-control studies and 
found an odds ratio of 1.8 (CI 1.7-1.9)  among those with diabetes compared with the general 
population.(122,329) Within the current study, those with diabetes had a substantially increased risk 
of developing pancreatic cancer which remained unaltered following adjustment for BMI (basic 
model: 1.58, 1.04-2.40; advanced model: 1.60, 1.02-2.50). When the data were stratified by either 
sex or CVD status, only men were found to have statistically significant increased odds of developing 
pancreatic cancer; although for women, and those with and without comorbid CVD, there were 
increases at the point estimate. The issue of reverse causality between diabetes and pancreatic is 
addressed within the section related to mortality (below).   
 
Mortality 
Within the Cox regression analyses of the HSE and SHeS dataset those with diabetes were found to 
be at a substantially increased risk of dying of pancreatic cancer compared with the general 
population. When adjusted for age, sex, smoking and BMI they were found to have odds that were 
increased by nearly 70%. Within all of the analyses undertaken to assess the association between 
diabetes and pancreatic mortality the inclusion of a range of covariates had little impact upon the 
excess found among those with the former. This result is similar to those of previous research, for 
example an earlier study from the UK found a rate ratio among those with diabetes of 2.2, 1.8-
2.7.(330) The increase within the results related to Whitehall I were even more substantial: among 
those with diabetes, the HR within the advanced model showed a substantially increased risk of 
pancreatic cancer mortality for this group compared with those without diabetes (around 4.5).  
226 
 
 
The sex-stratified analyses indicated that men and women with diabetes have similar odds of 
pancreatic cancer mortality, increased at the point estimate. When the analyses were stratified by 
CVD status, those with diabetes and comorbid CVD had an excess risk of nearly 90% compared with 
the general population, while those without comorbid CVD had only non-significant increases within 
each model. The small number of deaths among those with concurrent diabetes and CVD suggests 
that future studies should be undertaken which analyse data with a greater number of cases with 
both conditions. In vivo and In vitro studies could explore whether or not there is a multiplicative 
association between diabetes and cardiovascular disease and mortality from pancreatic cancer. 
Future epidemiological studies might also explore the factors which reduce the risk of pancreatic 
cancer among those with diabetes. The consistency of the excess in pancreatic cancer mortality 
among those with diabetes suggests that health education programmes, for those with diabetes and 
their healthcare providers, should be developed which enable both groups to have a better 
understanding of the associations between the two diseases.  
 
The issue of reverse causality has been addressed within studies by excluding deaths which occurred 
within a certain number of years (either after diabetes diagnosis or within the follow-up period); an 
earlier study using Whitehall I data found that the exclusion of deaths within the first ten years of 
follow-up had little impact upon the excess in death from this cause among those with diabetes.(89) 
Within the Cox regression, further analyses were undertaken which excluded deaths within the first 
year. Given the short survival time amongst those with pancreatic cancer it was felt that a year 
would be enough to address the issue, while maintaining an adequate number of deaths from this 
cause among those with diabetes. The result supports those of earlier studies in finding that 
excluding such deaths had little impact upon the excess mortality experienced by those with 
diabetes. 
 
Oesophageal cancer 
Oesophageal cancer causes around 5,000 cancer deaths each year within the UK. The biological 
plausibility of an association is as yet unconfirmed; one contributing factor may relate to the impact 
that overweight and obesity have upon an individual’s risk of developing diabetes and oesophageal 
cancer.(331) Another may be the increased risk of Barrett’s oesophagus - a condition which causes 
abnormal cells within the oesophagus and increases the risk of oesophageal cancer - among those 
with diabetes.(332) 
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Incidence 
A 2012 meta-analysis included 17 studies which sought to assess the associations between diabetes 
and oesophageal cancer incidence and found a statistically significant summary relative risks for men 
of 1.28 (1.10-1.49), while for women the corresponding rate was non-significant (1.07, 0.71-
1.62).(333) Within the HSE and SHeS dataset there were 262 cases of oesophageal cancer including 
16 among those with diabetes and although the point estimates were increased within each model, 
the association was non-significant within each of the regression models or when the analyses were 
stratified by sex or baseline CVD status. The small number of cases among those with diabetes 
indicates that further studies are needed which are able to utilise datasets with a larger number of 
incident cases of oesophageal cancer. 
 
Mortality 
The results of earlier studies are mixed in relation to the association between diabetes and mortality 
from oesophageal cancer with some finding no association,(131) while others found substantially 
increased odds.(130) Within the HSE and SHeS dataset there were 261 deaths from this cause, 
including 15 among those with diabetes. The corresponding figures within the Whitehall I data were 
166 and 3, respectively. Within the analyses of the HSE and SHeS dataset, the adjusted ORs for risk 
of oesophageal cancer mortality among those with diabetes were raised at the point estimate by 
around 10%. This increase remained after adjustment for a range of covariates. The Cox regression 
also found similar point estimate results accompanied by confidence intervals suggestive of a non-
significant association. Further to this, the results of the Cox regression undertaken using data from 
Whitehall I found a non-significant nearly 3-fold increase in risk of mortality from oesophageal 
cancer among those with diabetes, a resulted supported by the earlier Whitehall I study mentioned 
previously.(89) However, the small number of cases among those with diabetes (n=3) indicates that 
the study was under-powered. Because of the small number, the results of the stratified analyses 
will not be discussed. 
 
Stomach cancer 
There is a growing body of evidence suggestive of a dose-response effect in relation to increasing 
adiposity and the risk of developing stomach cancer.(334) The cancer causes around 5,000 deaths in 
England and Wales each year.(335) Although substantive evidence related to the biological 
mechanisms behind an association between diabetes and stomach cancer has yet to be compiled, 
one contributing factor may be the increased stomach cancer risk posed by helicobacter pylori – a 
bacteria which causes stomach ulcers and evidence suggests is associated with hyperglycaemia.(336) 
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Incidence 
A meta-analyses published in 2013 found that those with diabetes were at an increased risk of 
developing stomach cancer compared with the general population, with the excess being around  
40%.(247) A cohort study from Taiwan found that the risk of developing stomach cancer was lower 
among those who had had diabetes for a short time compared with the general population, but then 
increased with the duration of diabetes. After living with diabetes for over for years the HR was 1.76, 
(1.06-2.91), before this time those with diabetes were at a reduced risk of developing stomach 
cancer.(129) It is unclear why this might be the case, but a potential contributing factor may be the 
latency period between infection with helicobacter pylori and its impact upon cancer development. 
The impact that obesity has upon cancer development is also likely to increase with the number of 
years that an individual is obese. Interestingly within the current study, those with diabetes were 
found to have a reduced, although non-significant, risk of developing stomach cancer. This is unlikely 
to relate to the length of time that participants were in the study as 75% of the sample had been 
followed for at least four years, the cut-off point mentioned in the earlier study. The location of the 
study sample may also contribute to these differences in results, the earlier studies were undertaken 
within Asian populations, a high risk area in relation to stomach cancer incidence and mortality, 
while the current study was undertaken within a population with relatively low risk.(337,338) The 
results of the stratified analyses differ in relation to CVD status, those with comorbid CVD had a non-
significant reduced risk, while those without comorbid CVD had a non-significant increased risk. The 
results of the sex-stratified analyses were also ORs that were raised at the point estimate only. These 
results should be treated with caution and both the underlying biological mechanism and the 
potential associations between diabetes and incident stomach cancer require further investigation. 
Mortality 
In total there were 262 deaths from this cause in the HSE and SHeS dataset including 15 among 
those with diabetes at baseline. Within the Whitehall I sample there were 234 deaths from stomach 
cancer, of which four were among those with diabetes. A 2012 meta-analysis included 25 studies 
and found that those with diabetes had nearly a 30% increased risk of mortality from stomach 
cancer compared with those without the disease and a large cohort study supported this result,(128) 
although some other studies have indicate no increased risk among those with diabetes.(125) Two 
large, recent studies both found non-significant increases in risk of mortality from stomach cancer 
among those with diabetes, although the latter found men to have a statistically significant 
increased risk.(80,86)  
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The results of the Cox regression, multinomial logistic regression and the analyses of the Whitehall I 
data undertaken within this study support the results of earlier research. Men had a substantially 
increased risk of mortality from stomach cancer at the point estimate (consistently above 70%) but 
only within the advanced model was the association statistically significant. Women with diabetes 
had an increase at the point estimate, but the confidence interval suggested that the association was 
not statistically significant. None of these results were altered by the inclusion of a variety of 
covariates within the model. Of particular note is that the increase was not attenuated by the 
inclusion of the various measurements of overweight and obesity, suggestive of an association 
between diabetes and stomach cancer, rather than via confounding factors as suggested by some 
commentators.(303) The ORs for those with diabetes and without comorbid CVD were indicative of a 
substantial increased odds of dying from stomach cancer among this group compared with the 
general population, while for those with diabetes and comorbid CVD there appeared to be no 
association with mortality from stomach cancer. No explanation for these differences in risk were 
found within the literature review and further studies (both epidemiological and biological in nature) 
are required to establish whether this result is consistently found and what factors form the 
foundations of this difference in stomach cancer mortality risk. 
Kidney cancer 
Around 3,500 deaths are caused by kidney cancer each year in England and Wales. Diabetes is the 
major factor related to the development of nephropathy and chronic kidney disease.(339) There is 
also a growing body of evidence suggesting that kidney disease may encourage the development of 
kidney cancer.(340) Overweight and obesity, found at increased rates among those with diabetes, 
are also associated with an increased risk of developing kidney cancer.(219) 
 
Incidence 
A 2013 meta-analysis found uniformity within 24 studies, all of which found an increased incidence 
of kidney cancer among those with diabetes compared with the general population. The RR for 
those with diabetes was 1.40 (CI 1.16-1.69).(136) A Swedish cohort study found a 70% increased risk 
of renal cell cancer among women with diabetes, for men the corresponding figure was 30%.(132) 
Within the current study there were 261 incident cases of kidney cancer among the HSE/SHeS 
cohort, including 22 among those with diabetes and those with diabetes were found to have a 
significantly increased odds of developing kidney cancer. The excess remained within the basic 
model, but became marginally non-significant when BMI was added to the model. Although the 
stratified analyses gave increased point estimates within each of the regression models, it was only 
for men that the association approached statistical significance. As with other cancer sites future 
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studies could be undertaken which allow a greater exploration of the associations between diabetes 
and incident kidney cancer; particularly when these results are considered in unison with those 
related to the risk of kidney cancer mortality among those with diabetes. 
 
Mortality 
Despite the relatively strong evidence related to a biologically plausible association between 
diabetes and kidney cancer, there are mixed results in relation to mortality from the latter. A 2013 
meta-analysis found an increased (although marginally non-significant) risk ratio among those with 
diabetes compared with the general population (1.12, 0.99-1.20).(136) One of the key issues, even 
among more recent studies investigating the associations between diabetes and kidney cancer 
mortality, is that they have lacked a large enough number of deaths among those with diabetes. For 
example a 2007 study found only eight deaths from this cause among their diabetic participants 
within a total sample of over 100,000.(135) Perhaps because of this a joint consensus report by the 
American Diabetes Association and the American Cancer Society concluded that there was 
insufficient evidence to draw any robust conclusions related to whether or not there was an 
association between diabetes and kidney cancer.(303) 
 
Within the HSE and SHeS dataset there were 140 deaths from kidney cancer, including 11 within the 
diabetic group. The odds ratios were indicative of a non-significant excess in mortality from kidney 
cancer. The same result was found within the Cox regression, although the point estimate was 
substantially raised. This finding mirrors that of an earlier study.(80) An issue of particular note is the 
attenuation of risk among those with diabetes and comorbid CVD; the reasons for this reduced risk 
are unclear and not addressed within currently published in vivo and in vitro studies – possible 
causes could relate to the differing treatment regimens offered to individuals with diabetes and 
those with diabetes as well as CVD and the increased mortality from other causes among the latter 
group.(341) This result is particularly surprising considering the inter-related nature of the 
associations between diabetes and renal disease and diabetes and CVD. Future studies could explore 
this finding further. There were no cases of kidney cancer among the diabetic cohort within the 
Whitehall I data so analyses were not performed. 
 
Liver cancer 
Globally, around 9% of all cancer deaths are from liver cancer, equating to over 650,000 deaths each 
year.(342) The biological plausibility of an association between the two diseases related to the 
carcinogenic properties of cirrhosis of the liver and non-alcoholic fatty liver disease – both of which 
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are found at increased rates among those with diabetes.(343) 80-90% of primary liver cancers are 
diagnosed among those with cirrhosis of the liver.(224) 
 
Incidence 
A number of systematic reviews were found within the literature that were focussed upon the 
association between diabetes and incidence of liver cancer and all of them found a substantial 
increase in the latter amongst those with diabetes.(344–346) A 2013 cohort study using population-
based cohorts from China found that those with diabetes had a significant increase in risk in relation 
to liver cancer incidence (men: HR 1.63, 1.06–2.51, women: 1.64, 1.03–2.61).(138) A case-control 
study which included 420 patients with liver cancer and 1,104 controls found an increased 
prevalence diabetes among the cases which gave an OR of 4.2 (CI 3.0-5.9).(137) A second study 
found that men and women with diabetes were more likely to develop liver cancer than individuals 
without (men: 1.63, CI 1.06-2.51, women: 1.64, 1.03-2.61). (138) Finally, a study assessing the impact 
that insulin use had upon the risk of developing liver cancer among those with diabetes found that 
those with type-2 diabetes who used insulin were more likely to develop the cancer than those who 
did not.(RR 2.84, 1.12-7.17).(312) The results of the current study are hindered by the small number 
of incident liver cancers found within the sample; in total there were 81, with four among those with 
diabetes. Because of this the models produced ORs indicative of a similar cancer risk among those 
with and without diabetes when the analyses utilised data from the whole sample and inconsistent 
results within the stratified analyses.  
 
Mortality 
The Cancer Prevention Study-II found that both men and women with diabetes had an increased risk 
of mortality from the liver cancer.(83) This finding was also supported by an earlier study which used 
data from the Whitehall I cohort,(89) as well as a number of other large recent 
studies.(80,110,330,347) As with the incidence data related to liver cancer, only a small number of 
deaths from this cause were found among those with diabetes within the current study, and as such 
these results should be treated with caution. 
 
The analyses of the HSE and SHeS dataset suggest that those with diabetes are at a reduced risk of 
mortality from liver cancer, although the association was not significant. The reduction in risk among 
those with diabetes remained after stratification for sex and for comorbid CVD. None of these 
results were substantially altered by the inclusion of covariates. Contradicting these findings were 
those of the analyses of the Whitehall I data; these found that those with diabetes had over a seven-
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fold increased risk of mortality from liver cancer. The small number of deaths from this cause within 
the data was likely to be the explanation for the wide confidence intervals (advanced model HR: 
7.35, 2.29-23.58). Given the large number of cancer deaths caused by those of the liver, if an 
association between the two conditions were to be found it could result in a large number of excess 
cancer deaths. At the same time, if those with diabetes were found to have a reduced risk of 
developing liver cancer then knowledge of this attenuated risk may enable a greater understanding 
of the factors which underpin the development of this specific cancer and concurrently the 
development of treatments to address it. 
Haematopoietic cancers 
 This group of cancers consists of non-Hodgkins lymphoma (NHL), leukaemia and multiple myeloma 
and are cancers of the blood. To data only a few studies have investigated whether diabetes is 
associated with any of these cancers and even less is known about the biological cause of any 
potential associations. A number of studies have demonstrated that BMI is associated with an 
increased risk of developing and/ or dying of leukaemia, non-Hodgkins lymphoma or Hodgkins 
lymphoma,(348) with one demonstrating that diabetes was not associated with leukaemia.(349)  
 
Incidence 
The 2012 meta-analysis investigated the association between type-2 diabetes and non-Hodgkins 
lymphoma, leukaemia and myeloma and found 26 studies in total.(143) The majority of the studies 
which met the inclusion criteria supported an association between diabetes and cancers of this type. 
The ORs given were 1.22 (1.07-1.39) for non-Hodgkins lymphoma; 1.22 (1.03-1.44) for leukaemia; 
and 1.22 (0.98-1.53) for myeloma. A note of caution is needed in relation to the results of this meta-
analysis as only 50% of the studies included adjusted or matched for age and only 15% adjusted for 
BMI. The authors themselves noted that future studies should consider the impact of these 
confounders upon the associations between diabetes and incidence of haematopoietic cancers. A 
second meta-analysis focussed upon the risk of non-Hodgkins lymphoma among those with diabetes 
found an increased risk ratio of 1.19 (1.04-1.35).(142) Within the HSE and SHeS cohort there were 
875 cases of haematopoietic cancer, of which 39 were among those with diabetes. All of the 
analyses resulted in non-significant reduced odds among those with diabetes in relation to incident 
cancers of this type; the small number of cases lends the result to being one of chance. There were 
also no cases among diabetic men, which prevented the undertaking of this analysis. 
 
Mortality 
233 
 
The results of an earlier study indicated that men with diabetes had nearly a three-fold increased 
hazard ratio related to mortality from non-Hodgkins lymphoma, while women with diabetes were 
found not to have an increased risk of mortality from this cause.(141) Tseng found that those with 
diabetes were at an increased risk of mortality from non-Hodgkins lymphoma, but also concluded 
that more studies were required which included greater numbers of concurrent diabetes and deaths 
from NHL.(151) Within the HSE and SHeS data there were a total of 373 deaths from haematopoietic 
cancers, including 19 among those with diabetes. The results of the analyses of Whitehall I data 
should be treated with caution as there were only a small number of deaths from this cause among 
those with diabetes. 
The results of the Cox regression and multinomial logistic regression indicate that different groups 
have different risks in relation to mortality from haematopoietic cancers; although, similarly with 
incidence of this specific cancer, the small number of cases makes it likely that these results are a 
chance finding. The result with which we can be most confident is that which is based upon data 
from the whole sample, within these analyses there appeared to be no association between 
diabetes and mortality from haematopoietic cancers. The paucity of evidence related to 
haematopoietic cancers and their association with diabetes calls for further research to be 
undertaken that is both biological and epidemiological in nature. 
Bladder Cancer 
Mortality from bladder cancer is the eighth leading cause of cancer death within the UK, equating to 
around 8,000 deaths in England and Wales in 2012.(335) The biological plausibility of an association 
between diabetes and cancer appears to be supported by the increased incidence of urinary and 
bladder infections among those with diabetes – both of which are associated with an increased risk 
of bladder cancer.(147) 
 
Incidence 
A 2013 meta-analysis found consistency within the results of 23 studies investigating the 
associations between diabetes and the risk of developing bladder cancer, overall the OR was 1.68 
(1.32-2.13).(350) The study also investigated regional and sex differences and found that the 
increase was only present within the diabetic populations of America and Asia, not Europe, and that 
there were no differences in risk between the sexes.  A second meta-analysis (which included only 
cohort studies) published in 2013 found an increase in bladder cancer risk among those with 
diabetes, but when the analyses were stratified by sex the increase only remained among men.(351) 
A cohort study found that those with diabetes had around  a 25% increased risk of developing 
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cancers of the urothelial, the majority being cancers of the bladder – the study adjusted for 
confounders, such as obesity, and concluded that these did not explain the association between 
diabetes and bladder cancer.(148)   
Within the current study 516 participants within the HSE/SHeS sample were registered as having 
bladder cancer, with 46 of those also having indicated the presence of diabetes at baseline. Within 
each of the multinomial logistic regression models there were point estimate increases, that were 
marginally non-significant, for those with diabetes compared with the general population. Those 
with diabetes but without comorbid CVD were found to have a statistically significant increased risk 
of bladder cancer, while those with comorbid CVD appeared to have a non-significant reduced risk. 
Again the latter result may relate to the increased mortality, within this group, from other causes. As 
with the results of a previous study, when the analyses were stratified by sex, only men with 
diabetes were found to have an increased risk in relation to bladder cancer. The reasons for this are 
unclear within the current literature, but may relate to the impact that testosterone and other sex-
hormones have upon the development of cancer. An in vivo study found that androgens – 
compounds related to male characteristic – and their receptors were associated with the 
development of bladder cancer and were found at higher rates among wild type male mice 
compared with wild-type female mice.(352) 
Mortality 
Earlier studies suggest that those with diabetes have over double the increased risk of mortality 
from bladder cancer compared with the general population.(145,146) The results of the analyses of 
the HSE and SHeS dataset were that those with diabetes had an increased risk at the point estimate, 
but the association was not found to be statistically significant. Among men with diabetes there was 
a substantially raised point estimate (>60%) but this was not statistically significant; no women with 
diabetes died of bladder cancer so this analysis was not performed. Those with diabetes and 
comorbid CVD had a non-significant lowered risk of mortality from bladder cancer, while those with 
diabetes but without CVD had a non-significant increased risk. As with haematopoietic cancer 
mortality, the reasons for this are yet to be clarified and require further investigation. The results for 
Whitehall I were also contradictory, in finding that those with diabetes were at a lower risk of 
mortality from bladder cancer compared with their non-diabetic counterparts. However, the small 
number of deaths from this cause among those with diabetes means that the results of this analyses 
should be treated with caution. 
 
Breast cancer 
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Over 10,000 women in England and Wales died of breast cancer in 2012, with the disease being rare 
among men.(335) Postmenopausal breast cancer is associated with overweight and obesity and 
women diagnosed with breast cancer who are overweight or obese have poorer prognosis than 
those who are of normal weight.(353)  
 
Incidence 
A meta-analysis found 20 studies which explored whether or not those with diabetes had an 
increased risk of developing breast cancer; within the meta-analysis the relative risk was found to be 
1.20 (1.12-1.28).(153) The meta-analysis found no difference between the results of cohort and 
case-control studies. A cohort study using data from 1,248 Asian-American women indicated that 
diabetes was associated with an adjusted increased risk of developing breast cancer of nearly 
70%.(151) The study also found that the association was strongest among women who were lean, 
compared to those with a BMI above 22.7. The ORs for the two groups were 3.50 (1.32-9.24) and 
1.39 (0.81-2.36), respectively.(152) Within the current study women with diabetes were found to 
have an increased risk of incident breast cancer compared with their non-diabetic counterparts, this 
increase became marginally non-significant when BMI was added to the model. The reason for this 
may relate to the positive association between increasing BMI and risk of breast cancer found 
among some groups of women.(354) Whether or not the result related to adjusting for CVD, as well 
as age, smoking and BMI, was by chance is unclear and requires further exploration. 
 
Mortality 
A meta-analysis which explored the association between diabetes and cancer incidence and 
mortality found five studies focussed upon breast cancer mortality.(149) Within the meta-analysis 
women with diabetes had over a 20% increased risk of mortality from breast cancer, although the 
lower confidence interval fell just below one. Within the current study, women with diabetes were 
found to have a substantially increased risk of mortality from breast cancer. Two results are 
particularly comment worthy. First, that adjusting for glycated haemoglobin increased the point 
estimate for mortality for breast cancer among those with diabetes to nearly a three-fold increase. A 
note of caution: the small number of deaths from this cause among those with a measure for 
glycated haemoglobin and who indicated that they had diabetes at baseline produced a wide 
confidence interval – so could still be a chance finding. Secondly, within the Cox regression the 
increase odds remained after adjustment for BMI, but not for the other measurements of 
overweight and obesity. The reasons for this are unclear but may relate to the different types of 
adiposity that BMI, waist circumference (WC) and waist-to-hip ratio (WHR) are measuring. BMI uses 
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height and weight to give an indicator of whether or not a person is a healthy weight for their height, 
while WC and WHR are indicators of central adiposity. There is some evidence that the latter are 
better predictors of risk of overweight and obesity related conditions such as diabetes and 
CVD.(355,356) It may be the case that the increased risk of breast cancer among women with 
diabetes is a spurious association, the actual cause of which is centralised adiposity. The Whitehall I 
sample included only men and there were no cases of breast cancer within the sample. 
 
Cervical, endometrial and ovarian cancer 
Over 1,900 women each year die of cervical and endometrial cancer in the UK, with similar numbers 
newly diagnosed.(154) This current study grouped cancers of the cervix, uterus/endometrium into a 
single category. The reason for this was to ensure that the dataset was not disclosive in nature.  
Ovarian cancer has a high case-fatality rate, with the majority of diagnoses occurring at a later stage 
of the disease.(357) Whether or not diabetes is associated with an increased incidence of ovarian 
cancer, and the biological mechanisms that might underpin such an association, are yet to be 
established. 
Incidence 
 As with breast cancer, women with diabetes were found to have an increased risk of developing 
cervical/endometrial cancer with the association becoming non-significant when BMI was added to 
the regression model. The small number of cases among those with diabetes (n=38) demonstrates 
the need for further research which can utilise data with a larger number of cancer cases. 
In terms of the associations between diabetes and incident ovarian cancer, a 2013 meta-analysis 
found an increased RR of 1.55 (1.11-2.19) among those with diabetes compared with the general 
population.(250) This increase was found after adjusting for a range of confounding factors including 
BMI. The small number of incident ovarian cancers among those with diabetes, meant that this 
group was added to the ‘other cancers’ category and the analyses related to diabetes and incident 
ovarian cancer was not performed. 
Mortality 
Previous studies suggest that women with diabetes are at an increased risk of mortality from these 
cancers and that, once diagnosed with cervical cancer, they are more likely to die compared with 
those without diabetes.(358) The ORs and HRs within the multinomial and Cox regression analyses, 
respectively were indicative of similar risks among those with and without diabetes but the small 
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number of deaths from these cancers, among those with diabetes, within this study makes the 
drawing of firm conclusions difficult. 
A small number of studies were found within the literature review which focussed upon the 
associations between diabetes and mortality from ovarian cancer. One study found that women 
with ovarian cancer who also had diabetes had higher mortality than women with ovarian cancer 
alone.(161) As with cervical/endometrial cancer, the small number of cases of mortality from 
ovarian cancer with diabetes meant that the analyses within the current study was likely under-
powered. When adjustment included a measurement of overweight and obesity the risk of mortality 
from this cause was reduced, at the point estimate, among women with diabetes compared with 
women without diabetes. Further analyses could be undertaken, utilising datasets with larger 
numbers of deaths from this cause. 
Lip, oral cavity and pharynx cancer 
There was found to be a lack of research related to the associations between diabetes and mortality 
from oral cancer. One study did not find an association between diabetes and oral cancer, instead 
calling for more research to be undertaken to determine whether there is an association between 
diabetes and site-specific cancers of this nature.(160)  
 
Incidence 
There were only six cases of cancers of the lip, oral cavity and pharynx among those with diabetes; 
within the whole sample there were 225 cases. The results of the multinomial logistic regression 
were that those with diabetes had a non-significant reduced risk of developing cancers within this 
category; although the small number of incident cancer among those with diabetes means that the 
analyses were likely under-powered and should be treated with caution. 
 
Mortality 
Only three cases of lip, oral and cavity cancer were found among those with diabetes within the HSE 
and SHeS dataset, and the ORs and HRs were indicative of no increased risk among those with 
diabetes compared with the general population. 
 
Prostate cancer 
Around 10,000 men die of prostate cancer each year in England and Wales.(335) Although there is a 
limited amount of evidence of a biologically plausible causal association between diabetes and 
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prostate cancer, current research suggests that it is related to differing levels of testosterone and 
circulating sex hormone.(359) 
 
Incidence 
Prostate cancer is the only cancer for which the results of previous studies are indicative of a 
reduced risk of developing the disease among those with diabetes compared with the general 
population. The results of two meta-analyses demonstrated a negative association; the first found 
an RR of 0.91 (0.86-0.96) and the second an RR of 0.84, 0.76-0.93.(157,158) The reduced risk was 
consistent across the results of both cohort and case control studies. Within the data of the current 
study there were 1,362 incident cases of prostate cancer among men, with 75 among those with 
diabetes at baseline. The ORs were indicative of a reduced risk, although the confidence intervals 
were marginally non-significant within a number of the regression models.  
 
Mortality 
A meta-analysis involving 11 studies focussing specifically upon prostate cancer mortality found a 
substantial increase in prostate cancer mortality among those with diabetes; compared with those 
without diabetes, the pooled hazard ratio was 1.57 (CI 1.12-2.20).(159) Within the HSE and SHeS 
dataset 347 men died of prostate cancer, including 20 deaths among men who had indicated 
diabetes at baseline. Other studies have found a reduced risk of prostate cancer among those with 
diabetes.(110,330) At the same time, other studies have found non-significant increased point 
estimate for prostate cancer mortality among those with diabetes compared with those without the 
disease.(80,347) The results of the current study are consistent in finding reduced point estimates 
that are non-significant; this result was found within the analyses of both the HSE and SHeS and 
Whitehall I datasets. Understanding whether or not there is a reduced risk of mortality from 
prostate cancer among those with diabetes and the underlying biology of the reduction - for 
example, the link between testosterone and the development of prostate cancer is an area that 
requires further research(360) – is an area that requires further exploration, the results of which 
may reveal novel ways of preventing and treating the disease. 
 
The above sections demonstrate differences in the associations between diabetes and site-specific 
cancer incidence and mortality. For cancer incidence the most consistent increased risk among those 
with diabetes, compared with the general population, was found for cancers of the pancreas; while 
there were some differences in risk between the sexes and when analyses were stratified by 
baseline CVD. In terms of mortality, the most consistent associations were found for cancers of the 
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pancreas and for breast cancer among women. These results suggest that these differing rates of 
excess mortality for site-specific cancer may, in part explain the differences in international study 
results focused upon total cancer mortality. If there are differences in the mix and frequency of the  
different cancers within the study population examined, this will impact upon whether or not the 
study finds differences in overall cancer mortality risk between those with and without diabetes. 
 
It appears that, because adjusting for overweight and obesity had little impact upon the OR and HRs 
found within this study, diabetes does have an impact upon cancer mortality that is separate from 
and additional to the presence of adiposity. At the same time, for some site-specific cancers the 
inclusion of measures of overweight and obesity did impact upon the risk of mortality among those 
with diabetes. Further research is needed to fully understand the impact that diabetes has upon site-
specific cancer incidence and mortality among those with and without diabetes. 
  
The results of this study suggest that there are still many questions left unanswered in terms of the 
associations between diabetes and site-specific cancer mortality. The small number of incident 
cancers and deaths from some of the site-specific cancers is a consequence of the study’s use of 
general population data. This issue will need to be addressed through the undertaking of further 
analyses which are able to utilise datasets which contain a greater number of cases who had 
diabetes and either developed or died of site-specific cancers. The following section discusses the 
potential associations between glycated haemoglobin and all-cause and cause-specific mortality. 
 
12.5 Glycated haemoglobin and cancer mortality and incidence 
Cancer mortality 
Glycated haemoglobin (HbA1C) is caused by the chemical reaction of glucose meeting haemoglobin 
in the blood and its measurement offers an accurate assessment of uncontrolled or undiagnosed 
diabetes within the previous three months.(361) Within the literature review only a small number of 
papers were found that specifically reported upon the associations between HbA1C and cancer 
incidence and mortality; this may be due to a publication bias in favour of studies which show 
positive associations or because this area of research is relatively new. The World Health 
Organisation only supported the use of HbA1C as a diagnosis tool for diabetes in 2011.(11) Perhaps 
because of this, and the small sample sizes of some of the studies, the results were mixed. 
Silbernagel et al. found a J-shaped association between HbA1C and cancer mortality, although the 
association was not statistically significant in the majority of the regression models used within the 
study and the sample included only those without diabetes who were undergoing coronary 
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angiography.(362) A 2012 study counted a measurement ≥ 5.7% as being indicative of raised HbA1C, 
the results of the study suggested that women in this group were at an increased risk of mortality 
from cancer (HR 1.58, 1.23,2.05), while men were not.(363) This result again suggests that the 
impact of HbA1C begins within the normoglycaemic range and continues as duration of exposure to 
increase blood glucose and the HbA1C level increases. A third study found a non-significant 
association between a 1% increase in HbA1C and cancer mortality was found among 4,345 
participants with diabetes within the European Prospective Investigation of Cancer and 
Nutrition.(364)  
 
Within the current study 449 participants with a valid measurement for HbA1C had died of cancer, 
including 47 with a raised measurement. There was a statistically significant increased risk of cancer 
mortality among those with a measurement of HbA1C ≥6.5% within the basic model (OR 1.44, 1.05-
1.97) which became marginally non-significant when BMI was added to the model (1.38, 0.98-1.95). 
Because of the inter-play between overweight and obesity and blood glucose it may be the case that 
the association between the latter and cancer mortality is not significant when the former is 
adjusted for. Alternatively the lack of significance may have been caused by the small number of 
cases within the HbA1C sample who died of cancer. 
 
The stratified analyses produced mixed results. When stratified by CVD status neither group with 
raised HbA1C had a statistically significant increased risk of cancer mortality; although perhaps the 
product of chance the results for those with raised HbA1C but no CVD did almost reach significance 
within the basic model. For women within raised HbA1C there appeared to be no difference in 
cancer mortality risk compared with those with a lower measurement, while for men in this group 
there was a statistically significant increased odds. The reasons for this are unclear, but may relate to 
the site-specific cancers that are making up the overall cancer mortality variable. This issue will be 
addressed in more detail within the section related to the associations between HbA1C and mortality 
from site-specific cancers. The small number of cases who indicated that they had never been a 
regular smoker within the group with a valid HbA1c measurement means that the results of this 
analysis should be treated with caution; other than to say that there was a point estimate increase 
which could be further explored in future studies. 
 
Incidence 
Jonasson et al. used data from over more than 25,000 Swedish residents with diabetes and found 
that HbA1c was not associated with either overall cancer incidence or incidence of any of the site-
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specific cancers under investigation.(192) The study also used quartiles to assess the associations 
between HbA1c and cancer incidence and found no association; the HR was also not significantly 
raised when a continuous HbA1c variable was used within the regression models (1.01, 0.98-1.04). 
The HbA1C sample within the HSE and SHeS dataset included 1,137 registered cases of cancer, within 
this 103 were among those with HbA1C ≥ 6.5%. Within each regression model there was a point 
estimate increased risk of incident cancer among those with raised HbA1C compared with those in 
the normoglycaemic category; although the association was only statistically significant within the 
basic (age, sex and smoking) model. The point estimate also remained raised when the analyses 
were stratified by CVD status and sex, and when sensitivity analysis was carried out using data from 
those who indicated that they had never been a regular smoker. The reason for this increase, from 
the biological perspective, is likely to be rooted in the mitogenic and proliferative properties of 
hyperglycaemia. Another factor may also be the hyperinsulinaemia that those with pre-diabetes or 
the metabolic syndrome may experience before they encounter hyperglycaemia. At the very early 
stages of diabetes insulin resistance occurs within the insulin sensitive tissue of the body, in order to 
combat this resistance the body releases ever increasing amounts of insulin which results in 
hyperinsulinaemia. This continues until insulin secretion becomes restricted and hyperglycaemia 
occurs. It is possible that this earlier hyperinsulinaemia is the actual cause of the increased risk of 
cancer incidence among those with hyperglycaemia, and that the latter is just a marker of the 
occurrence of the former within the body. At present whether or not it is hyperglycaemia or 
hyperinsulinaemia, or a combination of the two, which is altering the risk of cancer incidence among 
those with raised HbA1C has yet to be established. Further in vivo and in vitro studies could begin to 
unravel this issue. Epidemiological research is also required to elucidate the magnitude of the effect 
that each factor has upon cancer incidence and mortality. 
 
12.6 Glycated haemoglobin and site-specific cancer incidence and mortality 
There was found to be a dearth of prior evidence related to the associations between HbA1C and 
site-specific cancer incidence and mortality. Within the studies that were found within the literature 
review, the cancers for which there was any epidemiological evidence of an association included 
colorectal,(365) respiratory and endometrial (evidence for both cancers comes from one 
study),(366) and pancreatic.(367) Concurrently, other studies have found no increased risk of 
developing site-specific cancers among those with raised blood glucose.(192) The biological 
plausibility of an association between hyperglycaemia and cancer incidence has been discussed in 
detail in earlier sections of this thesis. 
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Mortality 
As with diabetes, there was a substantial excess in mortality from pancreatic cancer among those 
with raised HbA1C, although unlike the results for diabetes the confidence intervals were suggestive 
of a non-significant association. Despite this, the consistency of this finding, within both the current 
study and the results of earlier investigations, indicates that those with either uncontrolled or 
undiagnosed diabetes are at an increased risk of dying from pancreatic cancer compared with the 
general population. The issue of reverse causality has also been addressed within the current study 
and the results indicate that diabetes is the antecedent followed by pancreatic cancer. Considering 
the short life expectancy once pancreatic cancer has been diagnosed, if mortality is to be reduced 
then interventions must be focussed upon preventing the disease occurring. For a number of the 
other site-specific cancers there were consistently, and substantially, raised point estimates redolent 
of excess mortality among those with hyperglycaemia. If these results were to be confirmed within 
larger population-based studies they could signify a substantial number of excess deaths among 
those with diabetes/raised glycated haemoglobin. 
 
Incidence 
Within the current study a small number of site-specific incident cancers were found among those 
with a raised measurement related to HbA1C and this significantly hindered the undertaking of 
extensive analyses in this area of the study. Within the basic and advanced models there were raised 
ORs, at the point estimate for cancers of the lip, stomach, colon, liver, pancreas, lung, kidney, ‘other’ 
cancers. There were also non-significant increased ORs for cancers of the prostate among men and 
cervix/endometrium among women. Only for cancers of the stomach and lung were the associations 
statistically significant; although the consistency of the results, for each site-specific cancer, suggests 
that, if data were to become available with an appropriate number of cancer end-points, other 
associations might also be found to be statistically significant.  
 
To conclude this section, although the current study lacked the power required to effectively assess 
the potential excess in site-specific cancer incidence and mortality among those with 
hyperglycaemia, the consistency in results within the analyses of HbA1c and diabetes for a number of 
the site-specific cancers investigated alludes to an association that requires further investigation. 
 
12.7 Diabetes and all-cause and CVD-related mortality 
Studies which sought to assess the associations between diabetes and all-cause and CVD-related 
mortality have a long history; for the latter cause of death, one of the earliest studies from the 1960s 
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observed that the increased life expectancy experienced by those with diabetes, due to 
improvements in treatments, corresponded with an increase in mortality from CVD.(270) All the 
studies found within the literature review undertaken as part of this thesis, found an increase in all-
cause mortality among those with diabetes, and the majority concluded that this was being driven 
by increases in mortality from CVD among those with diabetes compared with the general 
population.(273,277) 
 
Within the HSE and SHeS combined dataset of 204,533 participants, a total of 20,051 had died and 
of these 1,814 were among participants who had indicated the presence of doctor-diagnosed 
diabetes. The results of this analyses support those of earlier studies in finding a substantial increase 
in the risk of all-cause mortality among those with diabetes compared with the general population. 
Previous studies found between a 50% and 150% increased risk of all-cause mortality among those 
with diabetes,(159,238,269) while the logistic regression (detailed in section 0) which utilised data 
from the whole HSE and SHeS dataset and adjusted for age, sex and smoking status found a 68% 
increase (CI 57%-79%) among those with diabetes. When the same model was used within Cox 
regression, to enable a consideration of the participants’ time within the study, the Hazard Ratio 
(HR) was 1.74, 1.66-1.83. The findings of earlier research, that adjusting for overweight and obesity 
did not significantly attenuate the association between diabetes and all-cause mortality,(272) was 
also supported by the logistic and Cox regression analyses undertaken within this current study 
which adjusted for one of three measurements of overweight and obesity (BMI, waist-to-hip ratio or 
waist circumference) undertaken within this study.  
Although previous studies have adjusted for CVD within their analyses, and others have sought to 
understand the impact of cancer treatments upon the risk of diabetes and CVD(368) only a few 
found within the literature stratified the sample by CVD status at baseline; one undertook sensitivity 
analyses among those with CVD at baseline and found an HR of 1.65, 1.56-1.75.(86) Within the 
analyses of the HSE/SHeS dataset, those with diabetes but without comorbid CVD had a higher point 
estimate increase in all-cause mortality risk compared with the risk for those with CVD, but this was 
statistically significant only within the model which adjusted for age, sex and smoking (ORs 1.66, 
1.52-1.81 vs. 1.33, 1.20-1.46) not when more advanced models were used which included 
measurements of overweight/obesity, socio-economic/demographic covariates or raised glycated 
haemoglobin.  
The results of earlier studies related to the associations between diabetes and all-cause mortality 
have been suggestive of differences in the excess among men and women. A large study using data 
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from 97 prospective studies undertaken as part of the Emerging Risk Factors Collaboration found 
that women with diabetes had increased mortality compared with their male counterparts,(86) 
although the results of other studies have been inconsistent and contradictory in relation to the 
direction of the difference.(185,277) An important issue for earlier studies has been that stratifying 
analyses by sex had reduced the power of the study making the results uncertain.(269) The size of 
the HSE and SHeS sample allowed for stratification by sex and the results indicated that the excess in 
mortality experienced by people with diabetes when compared with those in the general population 
was found for both men and women. For example the ORs within the advanced model (age, sex, 
smoking status and BMI) were 1.74, 1.58-1.92 for men and 1.63, 1.46-1.81 for women. This lack of 
difference remained when a variety of covariates were included in the models, both consecutively 
and concurrently. 
The number of never regular-smokers within the HSE/SHeS dataset enabled the undertaking of 
sensitivity analysis using data from only these cases. The results of these analyses were still 
indicative of a substantial excess in all-cause mortality among those with diabetes, which was not 
due to residual confounding caused by the consumption of tobacco.  
Within the Whitehall I sample there were 19,019 male civil servants, including 237 who indicated 
diabetes at baseline. The long follow-up period (40 years) gave near complete mortality data; in total 
15,214, including 219 deaths among the diabetic cohort (81% of the total sample and 92% of those 
with diabetes). Similarly to the logistic regression models used within the analyses of the HSE and 
SHeS data the basic model used with the Whitehall I data adjusted for age and smoking (sex was not 
required as all the cases were male): for all-cause mortality those with diabetes had over a tripling in 
the odds compared with those without diabetes. Supporting the results of this and earlier studies, 
the excess in all-cause mortality among those with diabetes remained after adjustment for BMI, 
social class and blood glucose. A substantial, but smaller, excess was also found when analyses 
utilised data from a sub-set of the Whitehall I sample who had participated in a re-survey (basic: 
2.19, 1.71-2.79; advanced: 2.10, 1.61-2.74).  
 
The results from analyses of the HSE and SHeS dataset, in relation to diabetes and all-cause 
mortality, are lower than those from Whitehall I. Factors which may explain this are related to the 
date at which the baseline data were collected, the consequent longer follow-up period available for 
the latter and the nature of the samples. In recent years there has been a reduction in the excess in 
mortality among those with diabetes compared with the general population; analyses undertaken as 
part of the Framingham Heart Study found that excess mortality had reduced from 2.44 in the years 
245 
 
1950-75 to 1.91 in the years 1976-2001 (p<0.01).(281) One of the reasons for this reduction may be 
the increasing availability and use of preventative medications related to cardiovascular disease and 
hypertension, such as statins, which have had a clinically important impact upon mortality among 
those with and without diabetes.(369,370) There is also evidence that the use of lipid lowering 
treatments, and subsequent improvements in cholesterol levels, have increased more among those 
with diabetes than the general population.(371) The contrasting results from the two datasets 
analysed within this study may be indicative of this recent reduction in excess. Further to this, 
mortality from CVD has fallen within the general population and there is some evidence that the 
excess all-cause and CVD mortality among those with diabetes compared with the general 
population has also fallen.(372–375) This, when combined with the increasing absolute risk, but 
falling relative risk associated with most risk factors may explain the differences between the results 
from the two different Whitehall I datasets. 
 
The HSE and SHeS dataset represents a nationally representative sample, while the Whitehall I 
sample is taken only from civil servants working in offices in London. Therefore caution should be 
taken when extrapolating the results from the latter to the wider, diverse population of the UK.  
 
The associations between diabetes and mortality from CVD are well established although, similarly 
to the reductions in all-cause mortality experienced by those with and without diabetes, there has 
been a reduction in the excess over time.(281,376,377) Previous studies have found that the risk of 
mortality from CVD among those with diabetes ranged from double to over a four-fold increase; 
with the excess in CVD mortality decreasing among more recent studies. Within the current analyses 
there was a total of 7,489 deaths from CVD, including 819 among those with diabetes. The results of 
the analyses of the HSE and SHeS indicate a substantial excess in the odds of dying of CVD among 
those with diabetes compared with the general population (after adjustment for a range of 
covariates), are in keeping with those of more recent studies. Those for CHD within Whitehall I 
indicate a similar excess to studies undertaken which used data from the same time period. As with 
the results related to all-cause mortality, the association between diabetes and CVD mortality was 
little altered after adjustment for a range of confounding factors. 
 
The results of the analyses of the baseline Whitehall I data also found a substantial increase in 
mortality from CVD among those with diabetes, although this increase was found for all-CVD deaths 
and coronary heart disease (CHD) but not stroke. The known biological mechanisms which underpin 
the associations between diabetes and stroke make it unlikely that those with diabetes are at a 
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reduced risk of mortality from this cause. More likely, because the relative death rate for CHD 
declines with age, while for stroke it increases, this result is more likely the due to the age of the 
study sample at baseline and then resurvey. This also explains why, within the resurvey data those 
with diabetes were at an increased risk of stroke and CHD, but their risk of the latter was lower than 
it was within analyses of the baseline data. In other words, because the excess death rate from CHD 
and renal and other complications of diabetes was so high at the time of the baseline survey, fewer 
individuals with diabetes were surviving to an age where they were at substantial risk of developing 
a stroke. The results from analyses of Whitehall I data (baseline and resurvey) suggests that the 
excess in CVD mortality among those with diabetes may be substantially driven by CHD. 
 
Earlier studies have suggested that the risk of cardiovascular events among men and women with 
diabetes differs, with women experiencing increased excess mortality compared with men.(378) The 
risk differs dependent upon whether or not CVD as a comorbidity is present at baseline.(379) The 
results of this study contradict this: when analyses were stratified by sex, men and women with 
diabetes were found to have similar (increased) odds of dying of CVD compared with their 
counterparts who did not have diabetes. Adjusting for CVD at baseline reduced the excess at the 
point estimate, but this reduction was not statistically significant. The inclusion of other confounding 
factors also had little impact upon the excess in CVD-related mortality experienced by men and 
women with diabetes. 
 
When analyses were stratified by CVD at baseline status, those with diabetes but without CVD had 
around an 80% increased odds of dying of CVD compared with those with neither disease at 
baseline. Among those with diabetes and comorbid CVD there was an excess in CVD mortality, but it 
was less than that found among those with diabetes but no baseline CVD. Earlier studies show that 
those with diabetes who have experienced a CVD event are the group most likely to die of CVD.(278) 
The analyses undertaken within this current study demonstrate that, although that is probably true 
in terms of absolute death rates, the relative excess among those with diabetes is greater among 
those without baseline CVD. The reasons for the results of this study are unclear but may relate to 
those with CVD having more regular contact with health professionals and taking medications that 
prevent CVD-related events; as mentioned previously those with diabetes are taking medications for 
CVD at increased rates compared with the general public. It may also be the case that those who 
survive the first event have other traits which reduce their risk of dying of CVD, although an 
assessment of this was not taken as part of this study. The age of those with diabetes, and with and 
without comorbid CVD, may also impact upon mortality from CVD: 53% of those without CVD, 
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compared with 39% with CVD were in the age group 16-64. Age was adjusted for within all of the 
models with a categorical (16-64, 65-74 and 75+) variable; a continuous variable (which was 
unavailable within this study due to issues of disclosivity) may have revealed more about this 
association. There is some evidence that the excess risk of mortality among those with diabetes 
compared with the general population is at its greatest amongst those newly diagnosed with 
diabetes and is inversely correlated with age.(274,275,380) At the same time those with diabetes 
but without having experienced a CVD event are at similar risk of experiencing one as those without 
diabetes who have.(279) Future research could explore in greater detail the impact that diabetes 
and comorbid CVD has upon an individual’s risk of dying of CVD, and whether those with diabetes 
who survive their first incidence of CVD are different, in terms of biology and other confounding 
factors, to those who do not. 
 
A key consequence of diabetes, and one specifically related to hyperglycaemia, is the increased risk 
of atherosclerosis- a well-established cause of CVD. The results of this study, and those of earlier 
research, demonstrate a substantial increase in all-cause mortality which is driven primarily by the 
substantial increase in CVD-related mortality among those with diabetes compared with the general 
population. The results of the analyses of data from HSE and SHeS, compared with Whitehall I and 
earlier studies, suggests that this increase has continued to decline in recent years; within the 
English and Scottish population the odds of dying of CVD are currently around 70% higher among 
those with diabetes. There did not appear to be any sex differences in risk of all-cause or CVD-
related mortality, but the issue of whether or not comorbid CVD alters an individual’s risk of dying 
from this cause requires further exploration. 
 
CVD mortality among those with diabetes is the key cause of the excess in mortality found among 
this group compared with those without diabetes. The results of the analyses of the HSE/SHeS and 
Whitehall I data is that the excess mortality from CVD among those with diabetes is reducing; a 
result which is supported by earlier studies. In order to reduce their risk of all-cause and CVD-related 
mortality, those with diabetes are often encouraged to make changes in modifiable risk factors 
related to mortality – for example through weight loss and smoking cessation programmes. 
Understanding the influence that these factors have upon the excess all-cause and CVD-related 
mortality experienced by those with diabetes compared with the general population enables the 
provision of appropriate health care services for those with diabetes. The results of this study 
suggest that currently those with diabetes have a substantial excess in all-cause and CVD-related 
mortality which are unrelated to confounding factors and, although the results of the Whitehall I 
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analyses and previous studies suggests is in decline, require the implementation of further health 
interventions to reduce it. 
 
12.8 Diabetes and mortality from respiratory disease 
Only a small number of studies have focussed upon the impact that diabetes, and its accompanying 
factors, have upon mortality from respiratory disease.(78,86,110,381) In terms of in vivo and in vitro 
studies the current hypothesis which explains a potential causal association between the two 
diseases relates to the impact that overweight and obesity have upon inflammation within the body 
and conditions (such as Chronic Obstructive Pulmonary Disease and asthma) which contribute to an 
individual’s risk of dying of a respiratory-related disease.(282) Similarly to CVD, cytokines related to 
adiposity may also increase the risk of respiratory disease, although the biological mechanism is yet 
to be established.(382) Studies also suggest that weight loss is an effective tool in improving the 
severity of pre-existing respiratory conditions and reducing an individual’s risk of developing 
respiratory disease.(383) It is also noteworthy that men with diabetes and good or moderate cardio-
respiratory fitness were found to have reduced risks of dying of respiratory disease when compared 
with those with diabetes but poor cardio-respiratory fitness; suggesting a cumulative effect of both 
diabetes and respiratory disease upon cancer mortality.(384) 
Within the HSE and SHeS sample there were a total of 2,828 deaths from respiratory disease, 212 of 
which were among those who indicated diabetes at baseline (this amounted to 24% of all deaths 
among those with diabetes and 20% among those who did not have diabetes). The results of this 
study support those of the small number of earlier studies which investigated the associations 
between diabetes and mortality from respiratory disease, in finding that those with diabetes were at 
an increased risk of mortality from this disease. A prospective study utilising data from >1million 
American adults within the Cancer Prevention Study-II found an increased relative risk (RR) for 
mortality from respiratory disease of 1.27 (CI 1.19-1.36) among women and 1.13 (CI 1.06-1.19) 
among men with diabetes after adjustment for a range of confounding factors.(110) These results 
are comparable with those of the current study, which found increased ORs of 1.34 (1.13-1.58) 
among those with diabetes compared with the general population. This increase remained 
statistically significant after adjustment for a range of confounders related to overweight and 
obesity and socio-economic and demographic factors, although the increase became statistically 
non-significant when glycated haemoglobin (HbA1C) was added to the model and the analysis was 
restricted to those with a valid HbA1C measurement. That result may be due to the small number of 
those within the overall sample with a valid measurement for HbA1C (28,754) than with the 
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association between diabetes and mortality from respiratory disease; the OR remained increased, 
but was not statistically significant (1.46, 0.72-2.95). It may also be due to the characteristics of 
those who gave a blood sample being different to those who did not; although there weren’t found 
to be differences in age, sex, BMI, region, educational level or socio-economic status (p<0.05).  
When the current analyses were stratified by sex, men with diabetes were found to have increased 
odds of dying of respiratory disease compared with their non-diabetic counterparts. A similar excess 
was found for women with diabetes when they were compared with women without diabetes. For 
example, when the analyses adjusted for age, smoking status and BMI women had an OR of 1.41 
(1.09-1.82) while for men the corresponding figures were 1.25 (1.10-1.47), a similar difference by sex 
to that found in the Cancer Prevention Study-II.(110) Dawson et al. explored the association of 
diabetes with mortality from respiratory disease among those with insulin-treated diabetes. Their 
sample included 966 participants who had diabetes and were  found to have an increased SMRs for 
respiratory disease (women: SMR 3.31, CI 1.98-4.63; men: 2.32, CI 1.41-3.23).(78) The diabetic group 
within the current study were made up of those with both type-1 and type-2 diabetes; as with many 
studies of this type it was not possible to differentiate between the diabetes types, although it is 
likely that around 90-95% of this group will be type-2 based on figures from the general 
population.(16) Because of this it is likely that these results will most closely match the increased risk 
of mortality from respiratory disease among those with type-2 diabetes, rather than those with 
type-1. 
It is noteworthy that when alternative measurements of overweight and obesity were included 
(waist-to-hip ratio and waist circumference), the increased risk remained significant for women but 
not for men. This may be due to the biological processes underlying the association between 
centralised adiposity, found more frequently among men compared with women (women tending to 
develop peripheral adiposity more than men), and respiratory disease.(282) A number of earlier 
studies also suggested that most of the apparent association between conditions related to 
metabolism, such as diabetes, and respiratory disease may be caused by centralised 
adiposity.(385,386) If the excess in mortality were entirely down to the impact that centralised 
adiposity had upon respiratory disease risk, then adjusting for it should have also impacted upon the 
odds found among women with diabetes. It may be the case that the way in which diabetes and 
adiposity interact to increase an individual’s risk of mortality from respiratory disease differs 
between the sexes. Future epidemiological and biological studies could explore this in more detail.   
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In order to understand the impact that comorbid CVD had upon the association between diabetes 
and mortality from respiratory disease, the analyses were then stratified by CVD. The result 
indicated that those with diabetes but without comorbid CVD had a significantly increased risk of 
mortality from respiratory disease, which remained unchanged after adjusting for many covariates. 
Among those with diabetes and CVD there was a consistent, non-significant point estimate increase 
in odds within each of the models utilised. The only exception was when HbA1C was added to the 
model, this group had reduced odds of dying of respiratory disease, although this could be a chance 
finding due to the small number of cases within this group. Within the sensitivity analyses, using 
data from those participants who identified themselves as having never been a regular smoker, the 
increased odds of dying of respiratory disease was still found among those with diabetes compared 
with the general population. As with the results discussed above, it was only the inclusion of HbA1C 
which significantly altered this result.  
The results presented above indicate that those with diabetes have an increased risk of mortality 
from respiratory disease compared with people without diabetes. This study supports the assertion 
that this increase is related at least in part to the presence of diabetes, although the reduction in 
excess risk among men, when centralised adiposity was adjusted for, suggests that it may be the 
accompanying adiposity that is the principal cause of the excess. The sensitivity analysis, among 
never-regular smokers, supports the hypothesis that there is an increased risk of mortality from 
respiratory disease among those with diabetes that is not caused by residual confounding of 
cigarette use. The small number of cases with both diabetes and a measurement related to glycated 
haemoglobin, and who died of respiratory disease, makes the results of the analyses uncertain in 
relation to assessing the impact that HbA1C had upon mortality from respiratory disease among 
those with diabetes. Future studies which are able to utilise datasets with a large number of cases 
with valid HbA1C measurements should further explore this issue. In vivo and in vitro studies could 
also explore whether or not there are key differences between the sexes in relation to how diabetes, 
adiposity and other confound factors interact to alter the risk of dying of respiratory disease. 
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12.9 HbA1C and all-cause and cardiovascular disease 
The majority of studies aiming to explore the associations between HbA1C and all-cause mortality 
have found HbA1c to be positively associated with mortality. A 2001 study found that a 1% increase 
in HbA1C was associated with a 28% increase in all-cause mortality risk(387), while a more recent 
study found an HR of 1.11 ( CI 1.06, 1.17) for each 1% increase in HbA1c, perhaps indicative of a 
reduction in excess all-cause mortality among those with a raised HbA1C measurement compared 
with the general population in more recent years.(388) Contradicting these findings, a J-shaped 
association between HbA1C and all-cause mortality has also been found among a white German 
cohort,(362) and no association was found among an older non-diabetic population.(389) One key 
issue is that a number of the previous studies have used relatively small samples or used data from a 
defined group, limiting their power and making the extrapolation of their results to the general 
population difficult.(200,362,364,387,390)  
 
As with the biological plausibility of the associations between diabetes and all-cause and cause-
specific mortality, the majority of the excess in mortality among those with raised glycated 
haemoglobin appears to be related to the consequences of hyperglycaemia and its impact upon CVD 
occurrence and mortality. For example, raised HbA1C has been found to be strongly associated with 
carotid intima-media thickness, a marker of atherosclerosis.(136,391) The use of medications which 
reduce blood glucose, either within the general population or the early stages along the diabetic 
pathway, has also been suggested as an effective way of reducing the cardiovascular consequences 
of raised HbA1C.(392) 
 
Within the current study sample, 28,754 participants had a valid sample related to HbA1C. Among 
those with a raised measurement the mean value was 7.81 (SD ±1.46), the corresponding figure for 
those in the normoglycaemic group was 5.37 (0.40). 1,459 participants had a measurement of 
≥6.5%. In terms of age, more of those in the raised HbA1C group were found in the oldest age group 
(≥75) compared with those in the normoglycaemic group (20% vs. 9%). Unlike among those with 
diabetes, a similar percentage of those with raised HbA1C were current smokers when compared 
with those in the normoglycaemic group (19% vs. 23%). For all three measurements related to 
adiposity (BMI, waist circumference and waist-to-hip ratio) more of those with an HbA1C ≥6.5% had 
measurements that were in the overweight and obese category. There were no differences in the 
regions that the two groups resided in, but those with raised blood glucose were more likely to 
indicate that they had no qualifications compared with those in the normoglycaemic group (49% vs. 
28%) – although this did not appear to impact upon socio-economic status, with similar percentages 
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indicating being in either a professional or managerial occupation within each group. 12% of those 
with a raised HbA1C measurement had died compared with 4% of those in the normoglycaemic 
group. In relation to cause of death among those with and without raised glycated haemoglobin 28% 
vs. 34% had died of cancer; 11% vs. 13% from respiratory disease; 43% vs. 33% of CVD and 17% vs. 
20% of other causes, respectively. 
 
Those with raised HbA1C had an increased risk of all-cause mortality of around 60% in both the basic 
(age, sex and smoking) and advanced (basic + BMI) models. This increase was little altered by the 
inclusion of other covariates related to socio-economic/demographic factors or those related to 
alternative measurements of overweight and obesity. The only models within which the association 
became non-significant were those which adjusted for diabetes. When a continuous variable was 
used within the analyses, a 10% increase in all-cause mortality risk was found with each step 
increase in HbA1C, although the increase did not remain statistically significant when the model 
included comorbid CVD. This suggests that comorbid CVD may, in part, explain the increased all-
cause mortality among those with raised glycated haemoglobin. This result is unsurprising if we 
consider the inter-related nature of the associations between increased blood glucose and mortality 
from CVD – and the associated complications such as atherosclerosis. 
 
The analyses then utilised tertiles and compared the odds of all-cause mortality among those in the 
second and third (highest) tertiles with that of those in the lowest tertile. The results indicated that 
those in the middle tertile had a statistically significant increased risk of mortality from all causes 
compared with those in the lowest tertile, while those in the top tertile appeared to have similar 
risks to those in the bottom tertile. This result suggests a tipping point above which HbA1C is not 
associated with mortality. The reasons for this are unclear, but could relate to the aetiologies of the 
diseases which are causing the mortality. This issue will be discussed in further detail within the 
section related to HbA1C and mortality from CVD (below). Evidence also suggests that the impact of 
raised blood glucose upon health outcomes (particularly those related to CVD) begins at a level 
within a normoglycaemic range.(393) This points to the need for health interventions which aim to 
reduce glycated haemoglobin with the entire population and not just those already diagnosed with 
diabetes; programmes could include reducing calorie intake and increasing regular exercise, both of 
which have been found to reduce HbA1C, adiposity and the amount of exogenous insulin required by 
those with diabetes.(394,395) 
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The two groups made up of those with diabetes and without comorbid and those with diabetes and 
CVD both had increased ORs in relation to all-cause mortality. Within the former the increase was 
67% in the basic and 61% in the advanced models, while the corresponding figures for the latter 
were 35% and 45%, respectively. These results support those found for increased mortality among 
those with diabetes (and with and without CVD) and similarly suggests that the presence of CVD is 
altering the impact of HbA1C upon mortality. 
 
Research by Action to Control Cardiovascular Risk in Diabetes Study (ACCORD) was ended early 
because the diabetic group who were tasked with achieving tight glycaemic control (below 6.0%) 
were found to have an increased HR of 1.22 (CI 1.01-1.46) for all-cause mortality compared with 
those who were aiming for a higher HbA1C measurement (7.0-7.9%).(396) It was felt unethical to ask 
those with diabetes to maintain strict control of their blood glucose, when doing so could increase 
their risk of mortality. Analyses of data from the United Kingdom Prospective Diabetes Study found 
that tight glycaemic control (through the use of medications) reduced relative all-cause mortality 
among those with diabetes by 13% compared with those who only received dietary advice.(397) One 
of the key differences in the samples of these two studies was that the latter only included those 
who did not have comorbid CVD, while the former included both those with and without CVD. A 
2012 study utilised data from over 100,000 participants from the UK General Practice Research 
Database with newly diagnosed diabetes and stratified their analyses by CVD status.(398) They 
found that for those with diabetes, but not comorbid CVD, an HbA1C of around 6.5-6.99% was 
associated with increased all-cause mortality, while for those with diabetes and CVD only above 8% 
was there a statistically significant association. A 2013 study also concluded that glycaemic targets 
should be set on an individual basis and should take into account factors such as age and the 
presence of comorbidities.(205) All of these results suggest that tight glycaemic control may be 
beneficial to those with diabetes, but without CVD, but the same would not be the case for those 
with diabetes and CVD. The reason for this may be the impact that the latter disease has upon 
mortality compared with that from raised HbA1C. 
 
The OR for women with diabetes was substantially increased within the basic and advanced models 
(2.05, 1.56-2.70 and 2.08, 1.54-2.81, respectively) as it was for men (1.41, 1.10-1.80 and 1.42, 1.09-
1.84, respectively). This excess remained for both sexes after adjustment for a range of covariates 
and suggests that there are no sex differences in the impact that HbA1C has upon all-cause mortality. 
Among those with diabetes, who indicated that they had never been a regular smoker, there were 
also increased ORs compared with those without diabetes. As with the results for diabetes, this 
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suggests that the increase in all-cause mortality is not related to potentially reduced rates of 
smoking among those with diabetes/residual confounding caused by smoking.  
 
The results of the current study, and those of earlier epidemiological and biological research, suggest 
that HbA1C is associated most strongly with incidence and mortality from CVD but that those with 
raised blood glucose may also be at risk of mortality from cancer. This area of research is relatively 
new, with a measure of HbA1C only beginning to be considered a diagnostic tool for diabetes in 
2011. This absence of available evidence demonstrates the need for further research which 
investigates these associations. Should a consistent and clinically important association be found the 
development of public health programmes and medications may also be required; particularly within 
those populations within which obesity and an ageing population are increasing the number of 
individuals living with raised HbA1C. The finding that the impact that raised HbA1C has upon excess 
mortality begins at a level within the normoglycaemic range is also suggestive of the need for 
interventions which reduce its level not only among those with diagnosed diabetes but among the 
general population. 
 
The biological plausibility of an association between raised HbA1C and CVD incidence and mortality 
has been discussed above. The majority of studies that investigated the associations between HbA1C 
and incidence of and mortality from disease have been focussed upon cardiovascular 
disease.(200,392,399) Myint et al. found a threshold above which risk of stroke was increased,(400) 
suggestive of a tipping point rather than a continuous association. The results of the current study 
related to HbA1C and all-cause mortality, which utilised tertiles, is also suggestive of a threshold 
relationship. The large number of deaths within the all-cause mortality category which were caused 
by CVD within the current study (35% of total deaths among those with a valid HbA1C measurement) 
may explain why the results of the Myint et al. and current study are in agreement. There was a 
substantially (around 200%) increased odds of dying of CVD among those with HbA1C ≥6.5% 
compared with those with a measurement below this. It is this increase that is likely to be driving the 
excess in all-cause mortality. Within the current study, analyses were not performed with a variable 
which included the sub-categories of mortality from CVD. Using the current HSE and SHeS dataset 
future research could explore this issue in more detail. 
 
When the analyses were stratified by CVD status, only those with diabetes but without comorbid 
CVD had a consistently statistically significant increased risk of mortality from CVD, while those with 
comorbid CVD did not. As with diabetes this is likely to be a consequence of the impact that the 
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presence of a comorbidity has upon health service usage and the medications and treatments that 
are used by those with CVD compared with those without the disease. For women with diabetes the 
OR exceeded 3 within the advanced model (3.02, 1.97-4.62) and did not fall below two even when 
adjustment included diabetes. For men the association was not as statistically significant, and the 
point estimate was reduced (although not significantly) when diabetes was included in the model. If 
this finding were to be extrapolated out to the general population then it indicates that men and 
women have differing risks related to HbA1C and mortality from CVD and health care providers and 
patients should be made aware of this when making decisions about levels of glycaemic control.  
 
12.10 HbA1C and respiratory disease and other causes of mortality 
As with the associations between diabetes and respiratory disease, there was found to be a very 
limited amount of evidence related to HbA1C and mortality from respiratory disease. A small study 
which included 60 diabetic and 60 healthy male participants found that HbA1C was not associated 
with poorer respiratory function.(401) As detailed in Section 12.8 the biological plausibility of an 
association between diabetes and/or raised glycated haemoglobin is yet to be fully understood, but 
current evidence suggests that localised and systemic inflammation may be a contributory factor.  
 
Only a small number of deaths from respiratory disease occurred among those with raised HbA1C 
within the current study (n=19 out of a total of 173 within the HbA1C sample).When the regression 
models were used with data from all those with a valid measurement for glycated haemoglobin 
those with a raised measure had an increase at the point estimate within each of the models; 
although the association never achieved statistical significance. Within the stratified analyses 
women with raised HbA1c were found to have an increased risk of mortality from respiratory 
disease, while men in this group were found to have a non-significant reduced risk. As mentioned 
previously, women and men store adipose tissue in different regions of the body and this may alter 
their risk of respiratory disease. 
 
For ‘other’ causes of death those with raised HbA1C had an excess risk compared with those in the 
normoglycaemic group (basic model: OR 1.57, 1.06-2.34; advanced model: 1.70, 1.11-2.60). This 
category of mortality is likely to include a diverse range of causes of death such as renal disease, a 
condition found at low rates among the general population but high rates among those with 
hyperglycaemia and diabetes,(9,283) as well as accidents and suicide. As such, further analyses are 
required which can utilise data with more detailed information about cause of death. Analyses could 
be undertaken using the current HSE and SHeS dataset linked to more recent mortality data, and so 
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a greater number of deaths from each specific cause, this will in turn address some of the issues 
related to the disclosive nature of the data. 
 
12.11 Strengths and limitations of the study 
The current study utilised three datasets from England and Scotland (the Health Survey for England, 
Scottish Health Survey and Whitehall I). The HSE and SHeS allowed for an assessment of the excess 
in incidence of and mortality from cancer among those with diabetes compared with the general 
population. Therefore, unlike those of some of the previous studies which utilised data from a 
defined homogeneous cohort, the results of this study are generalisable to the population of the UK. 
Comparing the results of the analyses of the HSE/SHeS with those found for the diabetic cohort 
within Whitehall I also enabled a comparison to be made between the excess found among a cohort 
for whom their baseline data had been collected 40 years ago and the more up-to-date data from 
the HSE and SHeS. Complementing this, the use of Whitehall I also enabled analyses of a dataset 
with near complete mortality records and a comparison of previous research which had been 
undertaken using the same data but with a 27 year follow-up.  
 
The large number of cases who had indicated cardiovascular disease at baseline enabled an 
exploration of the impact that this comorbidity had upon the associations between diabetes and 
cancer incidence and mortality. Before the current study only a limited number of studies had 
explored this issue in detail and their results were often contradictory. The current study, in finding 
differences in disease incidence and mortality furthers our knowledge in this regard. 
The majority of previous research which explored the associations between diabetes and cancer 
incidence and mortality, as well as published papers detailing the impact that diabetes had upon 
incidence and mortality from other diseases, used self-report to identify the diabetic cohort. Within 
the current study, self-reported diabetes was combined with the use of diabetes-related 
medications (recorded during the nurse visit element of the HSE and SHeS survey process); within 
Whitehall I self-reported diabetes was also used. In an earlier study, when the specificity (those 
correctly identified as not having diabetes) and sensitivity (those correctly identified as having 
diabetes) of this method was compared with those that used Fasting Plasma Glucose levels or 
medication use it was found to have a specificity ranging from 84% to 97% and a sensitivity ranging 
from 55% to 80%, over time it was found to be 92% reliable,(402) while Molenaar et al. found 
specificity of 99.4% and sensitivity of 58.9%.(403) A third study found that 99.9% of those who did 
not report diagnosed diabetes did not have any medically recorded use of diabetes medications and 
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concluded that self-reported diabetes was an appropriate method for identifying individuals with 
diabetes within epidemiological studies.(404) Sensitivity and specificity analyses undertaken within 
the current study found that the diabetes specific question (which was only asked in some of the 
years of the HSE but all years of the SHeS) had a sensitivity of 90% across all study years, while the 
use of the longstanding illness variable and medication variable combined had a sensitivity of 94%. 
Specificity across survey years was also found to be >99%. This suggests that only a small number of 
those with diabetes were categorised as not having diabetes and, correspondingly a small number of 
those without doctor-diagnosed diabetes were identified as having diabetes. The impact of 
misclassification, based upon the results of the current study and previous research, would be to 
underestimate the associations between diabetes and incidence of and mortality from cancer and 
other diseases. Therefore, it is likely that if those with diabetes were to be identified by a more 
stringent method, for example within a study sample with complete data related to HbA1C, the 
magnitude of the effect of diabetes would have been even greater. 
Although the use of diabetic medications was used to identify a participant as having the disease, no 
adjustment was made within the analyses to try and ascertain the impact that the use of such drugs 
might have upon cancer incidence and mortality. The overarching reason for this was the lack of 
information in relation to the medication that participants were taking; within earlier years of the 
HSE it was not possible to differentiate between exogenous insulin use and oral medications. 
Another reason was that those with type-2 diabetes often undergo rapid changes in their drug 
regimens, as their diabetes progresses, and may require insulin injections to control their insulin 
levels in the latter part of the disease progression. Individuals with diabetes may also change the 
oral medications they are on, or take a combination of therapies, in order to control their diabetes; 
this may explain some of the contradictory results of earlier studies, especially if individuals are 
taking multiple drugs (some of which increase, while others decrease, their risk of cancer). Finally, 
within the dataset it was not possible to determine the dose of medication that an individual was 
taking, this prevented analyses of any potential dose-response effect between diabetes treatments 
and disease incidence and mortality. These issues meant that it was beyond the scope of this study 
to attempt analysis of the impact that individual diabetes treatments have upon cancer incidence 
and mortality. A recommendation of this current study is that future randomized controlled trials 
are undertaken which have the ability to assign individuals to specific treatments arms and are 
therefore able to understand the associations between specific diabetes drugs and disease 
outcomes. A cheaper and quicker option would be to ensure that participants in previous 
randomized trials are followed up long-term and that cancer incidence and mortality are included in 
the longer term health outcomes considered. 
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One potential confounding factor that was not included within the analyses was cholesterol. The 
reasons for this relate to the lack of information related to HDL, LDL and the use of cholesterol 
lowering drugs within the HSE. This meant that it would not have been possible to unravel the 
influence that these different types of cholesterol had upon disease occurrence. Current evidence 
suggests the need for analyses, when assessing any potential excess in cancer incidence and/or 
mortality, that is able to differentiate between the two types of cholesterol.(405) Although limited 
by the short duration of follow-up time within many studies, the current evidence suggests that the 
use of lipid-lowering drugs does not influence cancer risk.(406,407) Further research could explore 
this issue in greater detail and in combination with an assessment of the role that diabetes has 
within cancer incidence and mortality. The study did not explore the impact that other confounders, 
such as physical activity, diet and the presence of other comorbidities have upon the associations 
between diabetes, HbA1C and cancer. Their impact may be significant and further research could 
explore the impact that these factors have upon such associations. 
  
The majority of previous studies found within the current literature review did not differentiate 
between type-1 and type-2 diabetes within their analyses. At the same time those which sought to 
analyse the potential differences in incidence and mortality from specific diseases among those with 
the different types of diabetes used a range of measures to determine which type was present; 
these ranged from the use of exogenous insulin to age at onset. One of the issues for the current 
study is that, within the data from the HSE, SHeS and Whitehall I, it was not possible to develop a 
clear picture of the types of diabetes treatments that participants were taking or what age they had 
been diagnosed with diabetes. Because of this, the decision was made to explore the associations 
between diabetes (as a single group) and the outcomes of interest to the study. Only around 5% of 
the diabetic population have type-1 diabetes and, within the literature review, inconsistent results 
were found between this type of diabetes and cancer incidence and mortality. These factors suggest 
that the impact that type-1 diabetes has upon overall results would be minimal, and depending upon 
the outcome investigated would either marginally increase or decrease (within the literature review 
the results of cohort studies investigating the associations between type-1 diabetes and cancer 
incidence and mortality were inconsistent) any potential excess when compared with the general 
population. 
Due to issues of disclosivity and time constraints, analyses were performed only using deaths and 
incidence of a select number of site-specific cancers – for each an adequate number were found 
within the data to guarantee that individual participants could not be identified. Given the lack of 
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power for some of the analyses within the current study, it is likely that separating out the ‘other’ 
category would have further limited power. Another variable that could have elicited more 
information about the excess in mortality among those with diabetes compared with the general 
population was that used within the cause-specific (cancer, respiratory and CVD) analyses. If the 
‘other’ category had been separated out, the current study would have been able to explore this 
issue of diabetes and these other causes of mortality; although this was not the focus of the current 
study and could be undertaken in future studies able to utilise a dataset with a greater number of 
mortality end-points.  
To avoid the issue of the data being disclosive, information related to BMI, age and date of death 
were also only available as categorical variables (for date of death, information was not available 
related to the day of death and the month of death was available only as quarters within the year). 
Although this may not have had a substantial impact upon the study results, the use of continuous 
variables may have elicited a greater understanding of the associations under investigation. 
Although the study was under powered within the analyses related to HbA1C and site-specific cancer 
incidence and mortality, the rest of the study was able to assess the magnitude of the effect that 
diabetes and HbA1C had upon cancer incidence, mortality and the other causes of death under 
investigation. Overwhelmingly the results presented within this thesis, even when non-significant 
statistically, converge and support the hypotheses at the heart of this study – that diabetes and 
HbA1C alter an individual’s risk of developing or dying from cancer- and thus enable more soundly 
based conclusions to be drawn than if the study had been more limited in the scope of its analyses. If 
this had not been the case, the issue of multiple significance tests, the results being difficult to 
interpret due to the large number of tests undertaken, may have arisen. 
 The limited amount of previous research detailing the associations between diabetes and cancer 
incidence give the results of the current study the potential to further our knowledge in an area of 
increasing public health importance. The size of the dataset also allowed for an exploration of the 
role of key confounders within the association between diabetes and/or HbA1C and cancer incidence 
and mortality. The use of COX regression and multinomial logistic regression enabled an assessment 
of the temporality of associations between diabetes and cancer incidence and competing causes of 
death. The large number of deaths from CVD enabled results which further confirm the associations 
between diabetes and CVD, but also detail the magnitude of the effect within a sample of the 
general population of England and Scotland. Finally, the impact that diabetes has upon mortality 
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from respiratory disease is an under researched area. The results of this study are indicative of an 
association which requires further research. 
Because of the categories used to define those with raised blood glucose within the Whitehall I data, 
it was not possible to analyse the impact of this variable upon mortality; although this issue was 
addressed in full using the HSE and SHeS dataset. Given the under- powered nature of the analyses 
using the latter data, it is likely that analyses of the Whitehall I data which used this variable would 
have been even further under powered. If the associations between HbA1C and cancer incidence and 
mortality are to be successfully explored, future studies will have to have access to datasets with 
larger number of cases with valid measurements related to glycated haemoglobin. 
The use of a cohort study design allowed for an exploration of the temporal sequence between 
diabetes and cancer incidence and mortality. Within the HSE/SHeS dataset those with cancer at 
baseline were excluded from the analyses and the exclusion of those who had died of cancer within 
one year of participating in the survey, within the Cox regression analyses, adds further support to 
diabetes increasing the risk of cancer – rather than reverse causality.  A second advantage of the 
study design was that, through the use of multinomial logistic regression, multiple outcomes could 
be assessed at the same time. This was particularly beneficial when the analyses were focussed upon 
competing causes of death and site-specific cancer outcomes. Thirdly, the use of a cohort study 
design enabled the calculation of a cancer event occurring and the development of hazard and odds 
ratios. 
As seen within the analyses which sought to assess the impact of HbA1C upon cancer incidence and 
mortality, the key disadvantages of the cohort study design are the need for a large sample/size and 
/or a long follow-up period in order to collect the necessary number of events to achieve power. At 
the same time, diabetes status was confirmed at baseline only and it was therefore not possible to 
assess whether or not a participant’s disease status had changed during the follow-up period. 
Among those with type-2 diabetes, this is particularly relevant as it can be possible to reverse some 
of the aspects of the disease with changes to lifestyle. A participant’s HbA1C measurement may also 
have changed during follow-up. Future studies could overcome this issue by using longitudinal data 
within which diabetes and HbA1C status are regularly collected for each individual. The English 
Longitudinal Study of Ageing is one such dataset available within the UK, and future studies could 
use different waves of the study to explore how changes in diabetes and or HbA1C impact upon 
cancer risk. 
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Only those who agreed to have their records flagged within mortality data and the Cancer Registry 
were included within the analyses of the current study. It was also not possible to gather this 
information about those who left the UK. This selection bias could have the potential to bias the 
study results, although most of those involved agreed to their data being flagged. 
The analyses of site-specific cancer incidence and mortality demonstrate that diabetes impacts upon 
the risk of each cancer differently. Although the use of the all-cancers variable enabled the study to 
have the power required to analyse the associations between diabetes and cancer over all, it is clear 
that this variable is likely to mask the differences in risk for each site-specific cancer. It may be 
advisable for future studies to avoid the use of an all-cancers variable, although the number of site-
specific cancers will need to be carefully considered before undertaking analyses of this nature. 
Within a large portion of this study, mortality from cancer was the focus of the analyses. Throughout 
the duration of the study a participant could have died of a different cause and this competing cause 
of mortality would therefore exclude the participant from experiencing mortality from cancer. The 
Cox regression undertaken within the current study did not take into account such competing risks 
and this may have produced biased, overestimated, numerical results when compared with those 
produced by analyses which did take such factors into account, particularly given the strong 
associations between diabetes and CVD mortality. It is interesting to note that only a few of the 
earlier studies carried out with the intention of assessing the associations between diabetes and 
cancer mortality undertook analyses which utilised competing risk analysis methods; it appears that 
methods which do take into account competing events have not been fully taken advantage of in 
this field of research. Perhaps as our understanding of the subject evolves, researchers will 
undertakestudies which utilise such methods. 
12.12 Implications for further research 
The current study has demonstrated that those with diabetes have an increased risk of cancer 
incidence and mortality. At the same time the study encountered a number of the weaknesses 
inherent to the use of cohort study methods such as portions of the analyses being underpowered. 
Future studies could utilise data from other sources which may be able to overcome this issue. These 
could include: 
 Primary care data – the majority of those diagnosed with diabetes are likely to receive some 
form of support and/or treatment from their GP. 
 Hospital Episode Statistics –covering the whole of England this data includes records from 
over 125 million patients from A & E, outpatient and those admitted to hospital. 
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 Longitudinal datasets – the English Longitudinal Study of Ageing and the Health and 
Retirement Study (USA) give opportunities to not only explore the impact of diabetes upon 
cancer within a single study with repeat measures but it is also possible to combine and 
compare results from each dataset. 
 
The current study did not explore the role that diabetes treatments had within the associations 
between diabetes and cancer; further research could use RCTs to explore this further. However, the 
requirements of participants to treat their diabetes in the most appropriate way possible will always 
limit the feasibility of RCTs which seek to compare the impact of single treatments upon cancer risk. 
The biological plausibility of an association between diabetes, HbA1C and cancer is yet to be fully 
understood, studies using both in vivo and in vitro studies could play a key role in this regard. At the 
same time, as the measurement of biological biomarkers becomes more reliable and common place, 
this information can also assist in understanding this research area more fully. Finally, the 
prevalence of type-1 diabetes is increasing by around 3% each year, the cause of this is not clear and 
needs to be more widely explored. 
 
12.13 Implications for policy and practice 
Diabetes mellitus is a disease of increasing public health concern in the UK and internationally. The 
incidence and prevalence of the disease is increasing substantially, caused by increases in 
overweight and obesity and the ageing population found within most developed countries. In the UK 
around 2.9 million individuals are currently living with diabetes and this figure is predicted to 
increase to five million by 2025. At the same time the incidence and prevalence of cancer is also 
increasing, with 275,000 new cases in the UK each year. Diabetes and cancer carry a substantial 
emotional, physical and financial cost to the individual, as well as a high financial cost to societies 
aiming to prevent and treat both diseases. The high prevalence of diabetes means that if it were to 
produce even a small excess in cancer incidence and mortality this could equate to a large number of 
cancer cases and deaths within a population. 
 
Overweight and obesity are inextricably linked with diabetes; preventing both conditions is Iikely to 
be more effective and require less resource than treating them. Effective management of diabetes 
has been shown to increase reduce the number of complications experienced. Policy related to 
diabetes and adiposity should be developed which aims to reduce the incidence and prevalence of 
both conditions. This could take the form of policies which seek to decrease calorie consumption 
while increasing exercise uptake.  
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The results of this study suggest that raised HbA1C is associated with an increased risk of mortality 
from and incidence of cancer. Health care provision should therefore seek to enable those with 
diabetes to reduce their blood glucose to a level that does not impact upon their risk of mortality 
from other causes. This requires on-going treatment and an understanding of the particular 
circumstances of each diabetic individual. Health services should also be encouraged to identify 
those who are living with pre-diabetes and support them in making the changes in lifestyle required 
to slow or prevent the occurrence of diabetes. Currently those with diabetes are informed of their 
increased risk of developing complications related to CVD and renal disease. If the results of the 
current study are confirmed then information will need to be disseminated about cancer in much 
the same way that it is about these other conditions. Individuals with diabetes should also be 
encouraged to utilise cancer screening services where available and those who are diagnosed with 
both conditions should receive care which addresses the particular circumstance of having both 
comorbidities. 
As described in chapter 1, diabetes and cancer incidence and prevalence are increasing substantially: 
this has a corresponding impact upon both the health of individuals and communities and the 
financial costs to health care systems of both diseases. Further to this, the results of the current 
study – in finding diabetes to be associated with cancer – suggest that the increase in the number of 
cases of the former will have an impact upon the financial burden of the latter. These associations 
also suggest that the increasing numbers of diabetes cases would result in a substantial increase in 
cancer incidence and/or mortality. Although the results of the current study (within its analyses of 
the HSE and SHeS combined dataset) confirm the associations between diabetes, HbA1C and cancer 
incidence and mortality, the results from Whitehall I did not. There is also heterogeneity within the 
results of previous studies which may relate to differences in study design, the population under 
investigation, the cancer outcome investigated and the confounding factors adjusted for. If the 
results of this current study were to be further confirmed this would enable the development of 
methods to reduce the cancer risk among those with diabetes and evidence-based public health 
messages for those with diabetes. 
12.14 Conclusions 
In relation to the associations between diabetes and incidence of and mortality from cancer the 
results of previous studies have been heterogeneous and often contradictory. Among those which 
have shown a positive association, the strength of the association appeared to be dependent upon 
the population being studied and the methods used within the study. The primary aim of this current 
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study was therefore to explore the associations between diabetes, glycated haemoglobin and cancer 
(both overall and site-specific incidence and mortality) using data from England and Scotland. 
Secondary to this, analyses of the same data also sought to assess the impact that diabetes and 
glycated haemoglobin might have upon mortality from all-causes, cardiovascular and respiratory 
disease and other causes. Finally, the study sought to understand if any of these associations were 
mediated through confounding factors related to adiposity and the impact of the presence of CVD as 
a comorbidity.  
 
Within the current analyses of HSE/SHeS data, those with diabetes were found to have around a 
20% increased odds of dying of cancer compared with the general population; the increase 
remained after adjustment for the various measurements of adiposity. This goes some way to 
supporting the hypothesis that it is the specifics of having diabetes which increases an individual’s 
cancer mortality risk rather than associated factors. Within the stratified analysis men and women 
with diabetes had a similar excess in cancer mortality, while there were differences in the odds of 
dying of cancer between those with diabetes but either with or without comorbid CVD. This latter 
result is novel and suggests the need for the development of health service practice which takes into 
account the underlying characteristics of those with diabetes when considering their disease risk. 
The increased mortality from CVD among those with CVD at baseline may be the underlying cause of 
this difference in cancer risk: those with diabetes and CVD are likely to be dying before the age when 
cancer mortality occurs. Further research exploring whether those with diabetes are at an increased 
risk of developing cancer, are diagnosed with cancer at a later stage of the disease, receive different 
cancer treatments, or have differing  outcomes related to their reactions to chemotherapy and 
radiotherapy compared with those without diabetes is needed. 
 
The excess in the risk of cancer incidence was raised among those with diabetes, compared with the 
general population, by around 10%. Similarly to cancer mortality, this excess remained after 
adjustment for measurements of overweight and obesity again supporting the impact that the 
underlying biology of diabetes impacts upon cancer risk. When stratified by sex only women were 
found to have an increased risk of developing cancer; this may relate to the different rates of CVD 
mortality among men and women with diabetes and is an issue which requires further exploration. 
The results of the current study found raised point estimates for a number of site-specific cancers in 
terms of incidence and mortality; although for the majority the confidence intervals were indicative 
of a non-significant association. The combination of these results with those of earlier studies 
suggest that those with diabetes are at an increased risk of developing and/or dying from a number 
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of site-specific cancers compared with those without diabetes. These associations require further 
analyses within larger studies which would be able to confirm whether these are chance findings or 
indicate true associations that were underpowered within the current study.  One exception is the 
finding that diabetes is associated with pancreatic cancer, and that this increase remains after 
deaths within the first year are excluded, a result which suggests that it is not due to reverse 
causality . If a true understanding of the associations between diabetes and site-specific cancers is to 
be developed, future studies would need to use dataset that include a greater number of cancer 
endpoints. 
 
Prior to this study there was a limited amount of research that had been dedicated to exploring the 
associations between diabetes and respiratory disease. The results of the current study indicate that 
those with diabetes are at an increased risk of mortality from respiratory disease; in vivo and in vitro 
studies have suggested that this is associated with inflammation related to the presence of 
overweight and obesity among those with diabetes. Although the excess in mortality from 
respiratory disease remained among women with diabetes when alternative measurements of 
adiposity were adjusted for, the same was not found for men. Such sex differences call for diabetes-
related services which take into account that those with diabetes may have differing mortality risks 
which are dependent upon their specific circumstances. 
 
Analyses of data from the Health Survey for England, Scottish Health Survey and Whitehall I linked to 
the Cancer Registry and mortality data within the current study demonstrated an excess in all-cause 
mortality, which was predominantly caused by an excess in mortality caused by CVD among those 
with doctor-diagnosed diabetes compared with that found within the general population. Contrary 
to the results of a number of previous studies, this excess was little altered within either the 
multinomial or Cox regression analyses when adjustment was made for confounding factors related 
to adiposity or socio-economic/demographic factors. This result supports the biological relationship 
between diabetes and CVD – focussed upon the impact that the former has upon atherosclerosis – 
and those of some earlier epidemiological studies. By comparing the results of the analyses of the 
HSE and SHeS combined dataset with those of the analyses of Whitehall I it appears that the excess 
in all-cause and CVD mortality found among those with diabetes compared with the general 
population is in decline. This demonstrates that such inequalities in disease risk can be successfully 
addressed if they are fully understood and programmes are developed to combat them. 
 
266 
 
Although the biological plausibility of a relationship between diabetes and cardiovascular disease is 
well established, the potential for a relationship with cancer incidence and mortality has yet to be 
fully established and requires further exploration. This task was beyond the scope of the current 
study, but its results are indicative of an association between diabetes, raised glycated haemoglobin 
and cancer incidence and mortality, as well as mortality from a number of other causes. The 
differences in the excess mortality experienced by those with diabetes who also had comorbid CVD, 
compared with those who did not have CVD calls for personalised healthcare which takes into 
account the underlying health of each diabetic patient. Similarly, the differences in excess mortality 
among men and women with diabetes compared with those without the disease further calls for 
individualised care which takes into account the many facets of an individual’s experience of living 
with diabetes. Only through the provision of such care and services can those with diabetes be 
enabled to live their lives as healthily and free from complications as possible. 
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Appendix One: Syntax for the creation of the site-specific cancer 
variables 
 
For example, the syntax below was used to capture all of those cases who died of cancers of the lip, 
oral cavity and pharynx (it was necessary to write syntax similar to this for each of the grouped 
cancers). 
 
RECODE DRN_or_CS (CONVERT) 
( 'C10'=1)( 'C11'=1)( 'C12'=1)( 'C13'=1)( 'C14'=1) 
( 'C100'=1)( 'C110'=1)( 'C120'=1) ( 'C130'=1)( 'C140'=1) 
( 'C101'=1)( 'C111'=1)( 'C121'=1) ( 'C131'=1)( 'C141'=1) 
( 'C102'=1)( 'C112'=1)( 'C122'=1) ( 'C132'=1)( 'C142'=1) 
( 'C103'=1)( 'C113'=1)( 'C123'=1) ( 'C133'=1)( 'C143'=1) 
( 'C104'=1)( 'C114'=1)( 'C124'=1) ( 'C134'=1)( 'C144'=1) 
( 'C105'=1)( 'C115'=1)( 'C125'=1) ( 'C135'=1)( 'C145'=1) 
( 'C106'=1)( 'C116'=1)( 'C126'=1) ( 'C136'=1)( 'C146'=1) 
( 'C107'=1)( 'C117'=1)( 'C127'=1) ( 'C137'=1)( 'C147'=1) 
( 'C108'=1)( 'C118'=1)( 'C128'=1) ( 'C138'=1)( 'C148'=1) 
( 'C109'=1)( 'C119'=1)( 'C129'=1) ( 'C139'=1)( 'C149'=1) 
INTO ICD10Cancervgd. 
execute. 
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Appendix Two: Lay description of diabetes and glycated 
haemoglobin 
 
The term diabetes mellitus is rooted in the ancient Greek words for ‘siphon’ and ‘sugar’ which 
demonstrates the key symptom of the disease, the passing of urine that contains sugar (glucose) 
caused by too much sugar in the blood. It is called diabetes mellitus (‘sugar’ diabetes) to distinguish 
it from the much rarer condition of diabetes insipidus, a totally unrelated condition in which an 
individual is unable to concentrate the urine and therefore passes copious amounts of dilute urine. 
Because the former is common and the latter is rare, the term diabetes is frequently used by itself to 
refer to diabetes mellitus. 
 
The level of sugar within the body is controlled via the production of insulin which occurs within a 
gland called the pancreas. Within the pancreas there are ducts which contain regions called the 
Islets of Langerhans: within these are the cells which produce insulin (as well as glucagon). Insulin is 
a hormone, a chemical that is released into the blood stream from a particular organ in order to tell 
other areas of the body to react in a particular way. Insulin is secreted directly into the bloodstream 
and acts to control the levels of sugar within the blood.  
 
There are two main types of diabetes mellitus: 
 
Type-1 diabetes 
This form of the disease is caused by the body destroying the cells within the pancreas that produce 
insulin. In most cases the body is left without any of these cells, resulting in a total deficiency of 
insulin. In order for individuals with this form of diabetes to maintain a balanced blood sugar level, 
and good health, it is necessary to replace the insulin via injections. Type-1 diabetes is most 
commonly diagnosed among the young. 
 
Type-2 diabetes 
Type-2 diabetes is defined primarily by insulin resistance (when areas of the body do not react 
effectively to the release of insulin) which is often followed by a reduction in the production of 
insulin. This form of the disease accounts for around 90% of all cases of diabetes and is more 
commonly diagnosed among those in older age groups, although an increasing number of children 
are being diagnosed. Lifestyle factors related to overweight and obesity and excessive calorie intake 
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predispose an individual to developing the disease. Diagnosis of diabetes may occur many years 
after increased levels of sugar have been present in the blood. The progression of the disease can be 
slowed by changes to diet (reduced calorie intake) and weight loss, while tablets can be taken which 
control the level of blood glucose. In the later stages of the disease, insulin injections may also be 
required to prevent high levels of sugar in the blood. 
 
Gestational diabetes 
There is a certain level of glucose intolerance during pregnancy which protects the growing foetus. 
In 2-3% of pregnancies this intolerance is at a level defined as gestational diabetes. The presence of 
the disease may increase an individual’s risk of developing type-2 diabetes in the future; gestational 
diabetes also increases the risk of complications during pregnancy and poorer health outcomes for 
the baby once it is born.  
 
Glycated haemoglobin is the amount of haemoglobin circulating in the blood that has glucose 
attached to it. It is a measurement of blood glucose that gives an indication of the levels of sugar in 
the blood over the preceding two to three months. The more blood sugar present, the higher the 
glycated haemoglobin measurement will be. 
 
Within this study, a boundary of 6.5% is considered to be indicative of diabetes. During the period of 
the study, the International Federation of Clinical Chemistry suggested that glycated haemoglobin 
measurements should be given in mmol/mol. The corresponding values are given in the table below. 
 
% Mmol/mol 
6.0 42 
6.5 48 
7.0 53 
7.5 58 
 
 
309 
 
Appendix Three: Lay description of cancer 
 
Cancer (known medically as malignant neoplasms) is the term used to describe over 200 different 
diseases defined by the abnormal growth and division of cells within the body, and the ability of 
these cells to invade (metastasise) other areas of the body. These cells form when the DNA of a 
normal cell becomes damaged instead of dying the cell may continue to produce new cells which 
form a tumour. Because there are a large number of types of cancer, there are also a diverse range 
of causes of the disease; an increasing age is considered one of the key risk factors for all cancers. 
Other risk factors can relate to lifestyle (smoking, alcohol, diet) and genetic predisposition (for 
example the BRCA1 & 2 genes which increase the risk of developing breast cancer) and the presence 
of some viruses, diseases and carcinogens (Human Papilloma Virus (HPV), increases the risk of 
cervical cancer and may increase the risk of other site-specific cancers). 
 
Cancers are usually named after the organ or cell type in which they originate and can be placed in a 
number of key categories. 
 Carcinoma is a cancer that begins in the lining or covering of organs or the skin. 
 Sarcoma begins in tissue related to a number of areas including bone, muscle, fat and 
connective/supportive tissue. 
 Leukaemia begins in tissue within the body that produces blood and results in abnormal 
blood cells within the body. 
 Cancers of the nervous system originate in either the brain or spinal cord. 
 
There is a further category termed ‘benign’ tumours. Although they form a mass, these cells are 
unable to spread to other areas of the body and can usually be removed via surgery. 
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Appendix Four: Glossary 
 
Name Definition 
Adiponectin Adipokine produced by adipose tissue-
inversely correlated with body fat, may exert a 
protective effect on breast epithelial cells 
through inhibiting proliferation and enhanced 
apoptosis. 
AMPK  Induces glucose uptake by muscles 
Apoptosis Programmed cell death 
Cytokine Regulatory proteins, such as interleukins, TNF 
α and interferons. They act as intercellular 
regulators, have a specific effect on 
communications between cells or on 
behaviour of cells and trigger such things as 
inflammation and responses to infection. Bind 
to a particular receptor. 
IGF-1 (Insulin-like growth factor 1) Endocrine hormone and protein encoded by 
IGF1 gene and produced primarily by the liver. 
Similar to insulin molecularly and can bind to 
the insulin receptor. Potent activator of AKT 
signalling pathway, stimulator of cell growth 
and proliferation, and a potent inhibitor of 
apoptosis. 
IGF1-1 signalling plays a key role in tumour 
progression (cancer promoting factor) and 
glucose homeostatis. 
Leptin Adipocyte derived cytokine-been found to 
promote breast cancer cell proliferation 
LKB1 Tumour suppressor protein 
TNFα (Tumour necrosis factor α) Pro-inflammatory cytokine produced by 
adipose tissue. Induces development and 
progression of many tumours by strongly 
activating nuclear factor-kappa B (NF-kB) 
which mediates the pro-tumoral effects of 
TNFα. 
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Appendix Five: Publications related to thesis 
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Hirani V (Eds). Health Survey for England 2009. Volume 1 Health and Lifestyle. The Health and Social 
Care Information Centre: Leeds(peer-reviewed report chapter, not included at the end of the thesis). 
Available from: http://www.hscic.gov.uk/catalogue/PUB00414/heal-surv-heal-life-eng-2009-rep-
v2.pdf. 
 
Gordon-Dseagu, V. (2011). Diabetes. In M. Stange, C. Oyster, and J. Sloan (Eds.), Encyclopedia of 
women in today’s world. (pp. 386-388). Thousand Oaks, CA: SAGE Publications, Inc. doi: 
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Oyebode, O., Gordon-Dseagu, V., Walker, A. And Mindell, J. Fruit and Vegetable Consumption and 
Mortality: A Cox Regression Analysis (OP57). J Epidemiol Community Health. 2013: 67: A40. 
 
Oyebode, O., Gordon-Dseagu, V., Walker, A. And Mindell, J. Fruit and vegetable consumption and all-
cause, cancer and CVD mortalty: analysis of Health Survey for England data. J Epdemiol Community 
Health. 2014;68:856-862 doi:10.1136/jech-2013-203500 
 
Gordon-Dseagu, V.L.Z., Shelton, N. and Mindell, J. Exploring the Associations between Diabetes and 
Site-Specific cancer Mortality: Evidence from the Health Survey for England and Scottish Health 
Survey linked to Mortality Data (PP28-Poster presentation). J Epidemiol Community Health. 2013: 67: 
A60. 
 
Copies of the papers are available at the end of the thesis. 
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Appendix Six: Focus of the Health Survey for England 1991-2010 
 
Year Specific Issue 
2010 Respiratory disease, sexual health, kidney disease, and wellbeing 
2009 Kidney disease and diabetes 
2008 Physical activity and fitness 
2007 Healthy lifestyles and behaviours 
2006 Cardiovascular disease and obesity in children 
2005 Older People 
2004 Black and minority ethnic communities 
2003 Cardiovascular disease 
2002 Children and young people 
2001 Respiratory and other atopic conditions, accidents and disability 
2000 Older People 
1999 Black and minority ethnic communities 
1998 Cardiovascular disease 
1997 Children and young people 
1996 Respiratory and other atopic conditions, accidents and disability 
1995 Respiratory and other atopic conditions, accidents and disability 
1994 Cardiovascular disease 
1993 Cardiovascular disease 
1992 Cardiovascular disease 
1991 Cardiovascular disease 
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Paper abstracts 
Gordon, V.L.Z., Mindell, J. and Shelton, N. All-Cause and Cause-Specific Mortality among Individuals 
with and without Diabetes in England and Scotland (Oral presentation at SSM: OP57) J Epidemiol 
Community Health 2012; 66: A22 doi:10.1136/jech-2012-201753.057 
 
Abstract 
Background  
Although a growing body of evidence demonstrates an increase in cardiovascular disease (CVD) 
mortality among those with diabetes mellitus, the results related to other causes of death are less 
homogenous. The strength of the association between diabetes and mortality appears to differ by 
geographic location. The role that Body Mass Index (BMI) plays also requires further exploration. In 
the UK, one in 20 individuals is estimated to have diabetes. Therefore, even a small increase in 
mortality risk among those with diabetes, could result in a large number of deaths among those with 
the disease. This large general-population cohort study used data from England and Scotland to 
explore the associations between diabetes and risk of all-cause and cause-specific mortality, and 
examine the extent to which any increase was attributable to raised BMI. 
Methods  
Nationally-representative, cross-sectional data from 15 years of the Health Survey for England (HSE) 
(1994–2005) and Scottish Health Survey (SHeS) (1995, 1998 and 2003) were linked with mortality 
records up to the first quarter of 2011. Odds ratios (OR) and 95% confidence intervals (CI) adjusted 
for age-group and sex (model 1), plus smoking status (model 2) and additionally for BMI category 
(model 3) were estimated using logistic and multinomial logistic regression. Participants mentioning 
cancer at baseline were excluded from the study. 
Results  
Within this sample of 166,600 participants (5,131 with diabetes) there were 19,483 deaths (1,060 
among those with diabetes, 18,423 without diabetes). All-cause mortality was greater among those 
with diabetes when adjusted for age, sex and smoking status (OR 1.52, 95% CI 1.41–1.65), with no 
reduction when adjusting for BMI category (OR 1.49, 1.37–1.64). Cause-specific mortality among 
those with diabetes was raised for CVD (model 2 OR 1.73, 1.55–1.93), cancer (1.24, 1.08–1.43) and 
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‘Other’ (1.77, 1.54–2.04) with a non-significant increase for respiratory diseases (1.21, CI 0.99–1.47). 
Additional adjustment for BMI had a minimal impact upon the excess mortality found among those 
with diabetes: CVD (OR 1.69, 1.49–1.93), cancer (1.24, 1.05–1.45), ‘Other’ causes (1.75, 1.49–2.07), 
and respiratory diseases (1.16, 0.92–1.47). Survival was also lower among those with diabetes 
compared with those without the disease at baseline. 
Conclusion  
Diabetes is associated with an excess of all-cause and cause-specific mortality from CVD, cancer, and 
‘Other’ causes but probably not respiratory diseases. Increased BMI does not appear to be a 
mediating factor within the association between diabetes and cause-specific mortality. 
Oyebode, O., Gordon-Dseagu, V., Walker, A. And Mindell, J. Fruit and Vegetable Consumption and 
Mortality: A Cox Regression Analysis (Oral presentation at SSM: OP57). J Epidemiol Community 
Health. 2013: 67: A40. 
Abstract 
Background  
Following World Health Organisation recommendations, the UK government promotes a daily intake 
of at least five portions of fruit and vegetables. 
Methods  
We used Cox regression to estimate hazard ratios and 95% confidence intervals for an association 
between fruit and vegetable consumption and all-cause, cancer and cardiovascular (CVD) mortality, 
adjusting for age, sex, BMI and social class in data from 85,347 adult participants in the Health 
Survey for England 2001-2008. 
Results  
Fruit and vegetable consumption had a substantial protective effect for all-cause mortality (adjusted 
HR for 6-<7 portions 0·64 (95% CI 0·54–0·76)), stronger when deaths within a year of baseline were 
excluded (HR 0·57 (0·45–0·72) or when fully-adjusting for physical activity (0·48 (0·36–0·66). 
Consumption was significantly associated with reduced cancer (HR for 5- < 7 portions 0·78 (0·63–
0·96) and CVD mortality, with increasing benefits being seen up to more than seven daily portions of 
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fruit and vegetables for CVD (0·69 (0·53–0·89)). Consuming up to three to four portions of fruit daily 
and up to 3 + portions of vegetables a day was associated with decreased mortality. Vegetables had 
a greater effect than fruit (HR for 2- < 3 portions 0·82 (0·74–0·91) and 0·91 (0·83–0·99) respectively). 
Conclusion 
There is no threshold for the association between fruit and vegetable consumption and CVD survival 
up to a total of seven portions daily. Maximal benefit was conferred by six daily portions for all 
deaths and five portions for cancer. Vegetables have greater benefit than fruit. 
Oyebode, O., Gordon-Dseagu, V., Walker, A. And Mindell, J. Fruit and vegetable consumption and all-
cause, cancer and CVD mortality: analysis of Health Survey for England data. J Epidemiol Community 
Health. Doi: 10.1136/jech-2013-203500 
 
Abstract 
Background  
Governments worldwide recommend daily consumption of fruit and vegetables. We examine 
whether this benefits health in the general population of England. 
 
Methods 
Cox regression was used to estimate HRs and 95% CI for an association between fruit and vegetable 
consumption and all-cause, cancer and cardiovascular mortality, adjusting for age, sex, social class, 
education, BMI, alcohol consumption and physical activity, in 65 226 participants aged 35+ years in 
the 2001–2008 Health Surveys for England, annual surveys of nationally representative random 
samples of the non-institutionalised population of England linked to mortality data (median follow-
up: 7.7 years). 
 
Results  
Fruit and vegetable consumption was associated with decreased all-cause mortality (adjusted HR for 
7+ portions 0.67 (95% CI 0.58 to 0.78), reference category <1 portion). This association was more 
pronounced when excluding deaths within a year of baseline (0.58 (0.46 to 0.71)). Fruit and 
vegetable consumption was associated with reduced cancer (0.75 (0.59–0.96)) and cardiovascular 
mortality (0.69 (0.53 to 0.88)). Vegetables may have a stronger association with mortality than fruit 
(HR for 2 to 3 portions 0.81 (0.73 to 0.89) and 0.90 (0.82 to 0.98), respectively). Consumption of 
vegetables (0.85 (0.81 to 0.89) per portion) or salad (0.87 (0.82 to 0.92) per portion) were most 
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protective, while frozen/canned fruit consumption was apparently associated with increased 
mortality (1.17 (1.07 to 1.28) per portion). 
 
Conclusions  
A robust inverse association exists between fruit and vegetable consumption and mortality, with 
benefits seen in up to 7+ portions daily. Further investigations into the effects of different types of 
fruit and vegetables are warranted. 
 
Gordon-Dseagu, V.L.Z., Shelton, N. and Mindell, J. Exploring the Associations between Diabetes and 
Site-Specific cancer Mortality: Evidence from the Health Survey for England and Scottish Health 
Survey linked to Mortality Data (Poster presentation at SSM: PP28). J Epidemiol Community Health. 
2013: 67: A60. 
 
Abstract 
Background  
The associations between diabetes and mortality from a number of causes, such as cardiovascular 
and renal disease, are clearly understood. Concurrently, there is a growing body of evidence 
demonstrating an increase in cancer mortality among those with diabetes, although there is 
heterogeneity regarding the strength of the association and uncertainty around confounding by 
overweight/obesity. Around 2.9 million individuals in the UK are currently living with diabetes; this 
figure is expected to increase to 5 million by 2025, caused by rising rates of obesity and population 
ageing. The high prevalence of diabetes means that even a small increased risk of cancer mortality 
could equate to a large number of deaths among the diabetic population. This large cohort study 
utilised data from the Health Survey for England and the Scottish Health Survey, linked to mortality 
data, to explore overall and site-specific cancer mortality. 
 
Methods  
Nationally-representative, cross-sectional data from the Health Survey for England (HSE: 1994-2008) 
and Scottish Health Survey (SHeS: 1995, 1998 and 2003) linked with mortality records up to the first 
quarter of 2011 and 2008 respectively. Odds ratios (OR) and 95% confidence intervals (CI) adjusted 
for age-group, sex and smoking status and additionally for BMI category were estimated for all and 
site-specific cancer mortality using logistic and multinomial logistic regression respectively. To allow 
for a consideration of the time sequence of any association between the two diseases, individuals 
with cancer at baseline were excluded from the analyses. 
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Results 
 The study sample included 204,537 participants (6,258 with diabetes) and 5,562 cancer deaths. 
After adjustment for age, sex and smoking status, those with diabetes were at greater risk of dying 
from cancer compared with those without diabetes (OR 1.16 (1.02, 1.31)). This increase remained 
after adjustment also included BMI (1.19, 1.04-1.36). For site-specific cancer mortality, there were 
statistically significant increases for pancreatic (1.77 (1.16, 2.72)), breast (1.62 (1.02, 2.65)) and lung 
(1.34 (1.05, 1.72)) cancer when adjustment included age, sex, smoking and BMI; as well as point 
estimate increased risk for cancers of the colorectum, bladder, stomach, lymphoid and 
haematopoietic, kidney and oesophagus. 
 
Conclusion  
The high and rising prevalence of diabetes is of public health concern. Those with diabetes have 
increased overall cancer mortality and site-specific cancers of the pancreas, breast and lung, 
unaffected by measurements of overweight/obesity. Although some cases of pancreatic cancer may 
be reverse causality, health services for people with diabetes need to be aware of the increased 
cancer mortality found among this cohort. 
